

=> fil reg; d stat que l71; fil capl; d que nos l86; d que nos l75; s l86 or l75
FILE=REGISTRY ENTERED AT 14:21:39 ON 06 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JUN 2005 HIGHEST RN 851662-51-6
DICTIONARY FILE UPDATES: 5 JUN 2005 HIGHEST RN 851662-51-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.







*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

L19	1757	SEA FILE=CAPLUS ABB=ON	WAKEFULNESS/BI
L21	13480	SEA FILE=CAPLUS ABB=ON	MEMORY, BIOLOGICAL/CT
L22	7452	SEA FILE=CAPLUS ABB=ON	COGNITION/CW
L23	2672	SEA FILE=CAPLUS ABB=ON	MENTAL/CW(L) ATTENTION/OBI
L24	1385	SEA FILE=CAPLUS ABB=ON	SLEEP/OBI(L) (WAKING/OBI OR WAKE/OBI)
L25	257	SEA FILE=CAPLUS ABB=ON	SLEEPINESS/OBI
L27	2816	SEA FILE=CAPLUS ABB=ON	L19 OR L24 OR L25
L28		TRANSFER L27 1- RN :	8252 TERMS
L29	8252	SEA FILE=REGISTRY ABB=ON	L28
L30		TRANSFER L22 1- RN :	51186 TERMS (TERM LIMIT EXCEEDED)
L31	51186	SEA FILE=REGISTRY ABB=ON	L30
L33	618	SEA FILE=CAPLUS ABB=ON	L21 AND L23
L34		TRANSFER L33 1- RN :	30814 TERMS
L35	30814	SEA FILE=REGISTRY ABB=ON	L34
L36	12862	SEA FILE=CAPLUS ABB=ON	L21 NOT L23
L39	3950	SEA FILE=CAPLUS RAN=(,1992) ABB=ON	L36 NOT (L19 OR L23 OR L24 OR L25)
L40	5462	SEA FILE=CAPLUS RAN=(,2001) ABB=ON	L36 NOT L39
L41	3450	SEA FILE=CAPLUS ABB=ON	L36 NOT (L39 OR L40)
L42		TRANSFER L39 1- RN :	9163 TERMS
L43	9162	SEA FILE=REGISTRY ABB=ON	L42
L44		TRANSFER L40 1- RN :	20267 TERMS
L45	20267	SEA FILE=REGISTRY ABB=ON	L44
L46		TRANSFER L41 1- RN :	42655 TERMS

L47 42655 SEA FILE=REGISTRY ABB=ON L46
 L48 1597 SEA FILE=CAPLUS ABB=ON L23 NOT (L21 OR L19 OR L22 OR (L24 OR L25))
 L49 TRANSFER L48 1- RN : 27797 TERMS
 L50 27797 SEA FILE=REGISTRY ABB=ON L49
 L51 150742 SEA FILE=REGISTRY ABB=ON L29 OR L31 OR L35 OR L43 OR L45 OR L47 OR L50
 L53 STR








*full file search
done on this structure*

VAR G1=3/6/9/14/20
 REP G2=(1-5) C
 REP G3=(1-2) CH
 NODE ATTRIBUTES:
 CONNECT IS E1 RC AT 2
 CONNECT IS E1 RC AT 4
 CONNECT IS E2 RC AT 25
 DEFAULT MLEVEL IS ATOM
 GGCAT IS SAT AT 25
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L55 20417 SEA FILE=REGISTRY SUB=L51 SSS FUL L53
 L66 STR



VAR G1=11/32/36/34

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 13

CONNECT IS E1 RC AT 35

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:



RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 36

STEREO ATTRIBUTES: NONE

L67 STR

*subset search
done looking
for any of the
following 4 structures*



G1 28

VAR G1=9/21

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 11

CONNECT IS E1 RC AT 12

CONNECT IS E1 RC AT 23

CONNECT IS E1 RC AT 24

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 22


STEREO ATTRIBUTES: NONE

```

REP G1=(0-1) C
VAR G2=11/13
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

STEREO ATTRIBUTES: NONE
L69 STR



```
VAR G1=NH2/CY/9/11
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 7
CONNECT IS E2 RC AT 14
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

L71 5921 SEA FILE=REGISTRY SUB=L55 SSS FUL (L66 OR L67 OR L68 OR L69)

```
100.0% PROCESSED 18726 ITERATIONS
SEARCH TIME: 00.00.01
```

5921 ANSWERS

FILE 'CAPLUS' ENTERED AT 14:21:39 ON 06 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Jun 2005 VOL 142 ISS 24
FILE LAST UPDATED: 5 Jun 2005 (20050605/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L19 1757 SEA FILE=CAPLUS ABB=ON WAKEFULNESS/BI
L21 13480 SEA FILE=CAPLUS ABB=ON MEMORY, BIOLOGICAL/CT
L22 7452 SEA FILE=CAPLUS ABB=ON COGNITION/CW
L23 2672 SEA FILE=CAPLUS ABB=ON MENTAL/CW(L)ATTENTION/OBI
L24 1385 SEA FILE=CAPLUS ABB=ON SLEEP/OBI(L) (WAKING/OBI OR WAKE/OBI)
L25 257 SEA FILE=CAPLUS ABB=ON SLEEPINESS/OBI
L27 2816 SEA FILE=CAPLUS ABB=ON L19 OR L24 OR L25
L28 TRANSFER L27 1- RN : 8252 TERMS
L29 8252 SEA FILE=REGISTRY ABB=ON L28
L30 TRANSFER L22 1- RN : 51186 TERMS (TERM LIMIT EXCEEDED)
L31 51186 SEA FILE=REGISTRY ABB=ON L30
L33 618 SEA FILE=CAPLUS ABB=ON L21 AND L23
L34 TRANSFER L33 1- RN : 30814 TERMS
L35 30814 SEA FILE=REGISTRY ABB=ON L34
L36 12862 SEA FILE=CAPLUS ABB=ON L21 NOT L23
L39 3950 SEA FILE=CAPLUS RAN=(,1992) ABB=ON L36 NOT (L19 OR L23 OR L24 OR L25)
L40 5462 SEA FILE=CAPLUS RAN=(,2001) ABB=ON L36 NOT L39
L41 3450 SEA FILE=CAPLUS ABB=ON L36 NOT (L39 OR L40)
L42 TRANSFER L39 1- RN : 9163 TERMS
L43 9162 SEA FILE=REGISTRY ABB=ON L42
L44 TRANSFER L40 1- RN : 20267 TERMS
L45 20267 SEA FILE=REGISTRY ABB=ON L44
L46 TRANSFER L41 1- RN : 42655 TERMS
L47 42655 SEA FILE=REGISTRY ABB=ON L46
L48 1597 SEA FILE=CAPLUS ABB=ON L23 NOT (L21 OR L19 OR L22 OR (L24 OR L25))
L49 TRANSFER L48 1- RN : 27797 TERMS
L50 27797 SEA FILE=REGISTRY ABB=ON L49
L51 150742 SEA FILE=REGISTRY ABB=ON L29 OR L31 OR L35 OR L43 OR L45 OR L47 OR L50
L53 STR
L55 20417 SEA FILE=REGISTRY SUB=L51 SSS FUL L53
L66 STR
L67 STR
L68 STR
L69 STR
L71 5921 SEA FILE=REGISTRY SUB=L55 SSS FUL (L66 OR L67 OR L68 OR L69)
L73 34331 SEA FILE=CAPLUS ABB=ON L71
L75 5 SEA FILE=CAPLUS ABB=ON (L19 OR L24 OR L25) AND L21 AND L22

AND L23
L86 2 SEA FILE=CAPLUS ABB=ON L85 AND L73

L19 1757 SEA FILE=CAPLUS ABB=ON WAKEFULNESS/BI
L21 13480 SEA FILE=CAPLUS ABB=ON MEMORY, BIOLOGICAL/CT
L22 7452 SEA FILE=CAPLUS ABB=ON COGNITION/CW
L23 2672 SEA FILE=CAPLUS ABB=ON MENTAL/CW(L)ATTENTION/OBI
L24 1385 SEA FILE=CAPLUS ABB=ON SLEEP/OBI(L) (WAKING/OBI OR WAKE/OBI)
L25 257 SEA FILE=CAPLUS ABB=ON SLEEPINESS/OBI
L27 2816 SEA FILE=CAPLUS ABB=ON L19 OR L24 OR L25
L28 TRANSFER L27 1- RN : 8252 TERMS
L29 8252 SEA FILE=REGISTRY ABB=ON L28
L30 TRANSFER L22 1- RN : 51186 TERMS (TERM LIMIT EXCEEDED)
L31 51186 SEA FILE=REGISTRY ABB=ON L30
L33 618 SEA FILE=CAPLUS ABB=ON L21 AND L23
L34 TRANSFER L33 1- RN : 30814 TERMS
L35 30814 SEA FILE=REGISTRY ABB=ON L34
L36 12862 SEA FILE=CAPLUS ABB=ON L21 NOT L23
L39 3950 SEA FILE=CAPLUS RAN=(,1992) ABB=ON L36 NOT (L19 OR L23 OR L24 OR L25)
L40 5462 SEA FILE=CAPLUS RAN=(,2001) ABB=ON L36 NOT L39
L41 3450 SEA FILE=CAPLUS ABB=ON L36 NOT (L39 OR L40)
L42 TRANSFER L39 1- RN : 9163 TERMS
L43 9162 SEA FILE=REGISTRY ABB=ON L42
L44 TRANSFER L40 1- RN : 20267 TERMS
L45 20267 SEA FILE=REGISTRY ABB=ON L44
L46 TRANSFER L41 1- RN : 42655 TERMS
L47 42655 SEA FILE=REGISTRY ABB=ON L46
L48 1597 SEA FILE=CAPLUS ABB=ON L23 NOT (L21 OR L19 OR L22 OR (L24 OR L25))
L49 TRANSFER L48 1- RN : 27797 TERMS
L50 27797 SEA FILE=REGISTRY ABB=ON L49
L51 150742 SEA FILE=REGISTRY ABB=ON L29 OR L31 OR L35 OR L43 OR L45 OR L47 OR L50
L53 STR
L55 20417 SEA FILE=REGISTRY SUB=L51 SSS FUL L53
L58 1265 SEA FILE=CAPLUS ABB=ON H3/OBI(L)RECEPTOR#/OBI
L66 STR
L67 STR
L68 STR
L69 STR
L71 5921 SEA FILE=REGISTRY SUB=L55 SSS FUL (L66 OR L67 OR L68 OR L69)
L73 34331 SEA FILE=CAPLUS ABB=ON L71
L74 879 SEA FILE=CAPLUS ABB=ON L73 AND (L19 OR (L21 OR L22 OR L23 OR L24 OR L25))
L75 37 SEA FILE=CAPLUS ABB=ON L74 AND L58

L87 38 L86 OR L75

=> d ibib ed abs hitstr l87 1-38

L87 ANSWER 1 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:283466 CAPLUS
DOCUMENT NUMBER: 142:355171
TITLE: Preparation of piperidine compounds as histamine H3 antagonists or inverse agonists

INVENTOR(S): Ohtake, Norikazu; Mizutani, Sayaka; Yoshimoto, Ryo;
Tokita, Shigeru; Kanatani, Akio
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005028438	A1	20050331	WO 2004-JP13768	20040921
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: JP 2003-330758 A 20030922
ED Entered STN: 01 Apr 2005
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X1, X2 = N, CH; X3 = Os(CH2)m; s = 0, 1; m = an integer that (m+s) is 0 to 4; Y = II; j, k, l = 0, 1; L1 = alkylene, single bond; M = O, NR0; R0 = H, alkyl; Q1 = cyano, etc.] were prepared For example, HBTU mediated acylation of 1-cyclopentyl((3R)-methylamino)pyrrolidine with 4-[(4-piperidin-1-yl)piperidin-1-yl]benzoic acid hydrochloride, e.g., prepared from 4-fluorobenzonitrile in 2 steps, afforded compound III in 44% yield. In histamine analog binding inhibition assays, the IC50 value of compound III was 7.5 (sic). Compds. I are claimed useful for the treatment of obesity, diabetes, etc. Formulations are given.


IT 848822-53-7P 848822-82-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of piperidine compds. as histamine H3 antagonists or inverse agonists for treatment of obesity, diabetes, etc.)

RN 848822-53-7 CAPLUS

CN Benzamide, 4-[1,4'-bipiperidin]-1'-yl-N-[1-(cyclohexylmethyl)-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 848822-82-2 CAPLUS

CN 1,4'-Bipiperidine, 1'-[4-(1-piperidinylmethyl)phenyl]-, dihydrochloride
(9CI) (CA INDEX NAME)

●2 HCl


IT 67149-62-6, 1-Cyclohexylmethyl-4-methylaminopiperidine

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of piperidine compds. as histamine H3 antagonists or inverse agonists for treatment of obesity, diabetes, etc.)

RN 67149-62-6 CAPLUS

CN 4-Piperidinamine, 1-(cyclohexylmethyl)-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

32

THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 2 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:100498 CAPLUS

DOCUMENT NUMBER: 142:336224


TITLE:

4-Phenoxypiperidines: potent, conformationally
restricted, non-imidazole histamine H3 antagonists

AUTHOR(S):

Dvorak, Curt A.; Apodaca, Richard; Barbier, Ann J.;
Berridge, Craig W.; Wilson, Sandy J.; Boggs, Jamin D.;
Xiao, Wei; Lovenberg, Timothy W.; Carruthers, Nicholas

I.
CORPORATE SOURCE: Johnson & Johnson Pharmaceutical Research and
Development, L.L.C., San Diego, CA, 92121, USA
SOURCE: Journal of Medicinal Chemistry (2005), 48(6),
2229-2238
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 06 Feb 2005
GI




I

AB Two series of 4-(1-alkyl-piperidin-4-yloxy)benzonitriles and 4-(1-isopropyl-piperidin-4-yloxy)benzylamines, e.g., I, have been prepared. In vitro activity was determined at the recombinant human H3 receptor and several members of these series were found to be potent H3 antagonists. The present compds. contain a 4-phenoxy-piperidine core, which behaved as a conformationally restricted version of the 3-amino-1-propanol moiety common to the many previously described non-imidazole histamine H3 ligands. One selected member of the series, 4-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-morpholine (I), was found to be a potent, highly selective H3 receptor antagonist with in vivo efficacy in a rat EEG model of **wakefulness** at doses as low as 1 mg/kg s.c.


IT 397275-65-9P 397275-85-3P 397275-97-7P
397276-05-0P 397277-60-0P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, histamine **H3 receptor** binding affinity, and structure-activity relationship of phenoxy-piperidines using reductive amination as the key step)

RN 397275-65-9 CAPLUS
CN Piperidine, 1-(1-methylethyl)-4-[4-(1-piperidinylmethyl)phenoxy]- (9CI)
(CA INDEX NAME)




RN 397275-85-3 CAPLUS

CN 4-Piperidinemethanol, 1-[[4-[[1-(1-methylethyl)-4-piperidinyl]oxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 397275-97-7 CAPLUS

CN 4-Piperidinol, 1-[[4-[[1-(1-methylethyl)-4-piperidinyl]oxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 397276-05-0 CAPLUS

CN Piperidine, 1-(1-methylethyl)-4-[4-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 397277-60-0 CAPLUS

CN Benzonitrile, 4-[[1-(phenylmethyl)-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 3 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:74112 CAPLUS

DOCUMENT NUMBER: 142:176868

TITLE: Preparation of heterocyclic compounds as histamine H3 receptor antagonists/inverse agonists

INVENTOR(S): Ohtake, Norikazu; Naya, Akira; Haga, Yuji; Jitsuoka, Makoto; Suga, Takuya; Yoshimoto, Ryo; Tokita, Shigeru; Kanatani, Akio

PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd, Japan

SOURCE: PCT Int. Appl., 194 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005007644	A1	20050127	WO 2004-JP9272	20040624
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: JP 2003-184879 A 20030627

OTHER SOURCE(S): MARPAT 142:176868

ED Entered STN: 28 Jan 2005

GI



AB The title compds. I [each of X1, X2 and X3 independently represents N or CH; W represents the formula T1, etc.; m = 0 - 3; and Y represents (O)jL1(CO)p(M)iQ1; j, p, i = 0 or 1; L1 = alkylene, single bond; M = O,

etc.; Q1 = cyano, etc; R = cyano, etc.] are prepared Thus, 2-(1-cyclopentylpiperidin-4-yloxy)-5-(4-cyanophenyl)pyrimidine was prepared in a multistep process from 2-chloro-5-bromopyrimidine and 1-tert-butoxycarbonyl-4-hydroxypiperidine. In an in vitro assay for inhibition of a histamine analog binding to the H3 receptors, compds. of this invention showed IC50 values of 0.45 nM to 1.9 nM. Processes for preparing I are disclosed. Formulations are given.


IT 832735-11-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as histamine H3 receptor antagonists/inverse agonists)

RN 832735-11-2 CAPLUS

CN Pyrimidine, 2-[(1-cyclopentyl-4-piperidinyl)oxy]-5-(1-piperidinylmethyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 4 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:589 CAPLUS

DOCUMENT NUMBER: 142:79960

TITLE: New psychiatric drug formulation with an antipsychotic or antidepressant and an histamine H3 receptor antagonist for the prevention of psychotropic adverse effects

INVENTOR(S): Schwartz, Jean Charles; Rousseau Lecomte, Jeanne Marie

PATENT ASSIGNEE(S): Bioprojet, Fr.

SOURCE: Fr. Demande, 32 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2856596	A1	20041231	FR 2003-7836	20030627
WO 2005000315	A1	20050106	WO 2004-FR1628	20040625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: FR 2003-7836 A 20030627

OTHER SOURCE(S): MARPAT 142:79960

ED Entered STN: 31 Dec 2004


AB The invention relates to a drug formulation with an antipsychotic or an antidepressant, which causes adverse effects like body weight gain or sedation when administered, and an histamine H3 receptor antagonist or inverse agonist. The histamine H3 receptor antagonist or inverse agonist should be present in the formulation in therapeutically effective quantities to ensure at least one of the three following effects on the adverse effects induced by the antipsychotic or the antidepressant: suppression or limitation of weight gain, suppression or limitation of the decrease in vigilance, enhancement of the pro-cognitive effect of the treatment.

IT 106266-06-2, Risperidone

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (as antipsychotic or antidepressant; new psychiatric drug formulation with an antipsychotic or antidepressant and an histamine **H3 receptor** antagonist for prevention of psychotropic adverse effects)

RN 106266-06-2 CAPLUS

CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




IT 362665-56-3, 3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(as histamine **H3 receptor** antagonist; new psychiatric drug formulation with an antipsychotic or antidepressant and an histamine **H3 receptor** antagonist for prevention of psychotropic adverse effects)

RN 362665-56-3 CAPLUS

CN Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 5 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1060778 CAPLUS

DOCUMENT NUMBER: 142:38248


TITLE: Preparation of fused bicyclic-substituted amines as histamine-3 receptor ligands

INVENTOR(S): Cowart, Marlon D.; Ku, Yi-Yin; Chang, Sou-Jen;

Fernando, Dilinie P.; Grieme, Timothy A.; Altenbach, Robert J.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 41 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004248899	A1	20041209	US 2004-837162	20040430
PRIORITY APPLN. INFO.:			US 2003-468610P	P 20030507
			US 2003-505790P	P 20030925

OTHER SOURCE(S): MARPAT 142:38248
 ED Entered STN: 10 Dec 2004
 GI



AB Compds. of formula (I), pharmaceutically acceptable salts, esters, amides, or prodrugs thereof [wherein: X = O, S, NH, or N(alkyl); Y, Y1 = CH, CF, or N; Z = C or N, provided that when X is O or S, Z is N; the other of R1 and R2 = aryl, heteroaryl, or heterocyclyl; the other of R1 and R2 = H, alkyl, alkoxy, aryl, cycloalkyl, halo, cyano, or thioalkoxy; R3 is absent when Z is N; when present, R3 = H, Me, alkoxy, halo, or cyano; R4, R5 = alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, or cycloalkylalkyl, or NR4R5 taken together forms a nonarom. ring of the structure Q (wherein R7-R10 = H, hydroxyalkyl, fluoroalkyl, or alkyl; or one of the pair R7 and R8 or the pair R9 and R10 is taken together to form a C3-C6 ring, wherein O, 1, or 2 heteroatoms selected from O, N, or S replace a carbon atom in the ring; R11, R12 = H, HO, hydroxyalkyl, alkyl, or F; R13, R14 = H, alkyl, or F); L = -[C(R15)(R16)]_n; R15, R16 = H, alkyl, alkoxy, or F; m = 0-3; n = 2-3] are prepared These compds. are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands, including acute myocardial infarction, Alzheimer's disease, asthma, attention-deficit hyperactivity disorder, bipolar disorder, cognitive enhancement, cognitive deficits in psychiatric disorders, deficits of memory, deficits of learning, dementia, cutaneous carcinoma, drug abuse, diabetes, type II diabetes, depression, epilepsy, gastrointestinal disorders, inflammation, insulin resistance syndrome, jet lag, medullary thyroid carcinoma, melanoma, Meniere's disease, metabolic syndrome, mild cognitive impairment, migraine, mood and attention alteration, motion sickness, narcolepsy, neurogenic inflammation, obesity, obsessive compulsive disorder, pain, Parkinson's disease, polycystic ovary syndrome, schizophrenia, seizures, septic shock, Syndrome X, Tourette's syndrome, vertigo, and **wakefulness**. Also disclosed are pharmaceutical compns. comprising the histamine-3 receptor ligands and methods for using such compds. and compns. Thus, 4-cyanophenylboronic acid was coupled with


5-bromo-2-[2-(2-methylpyrrolidin-1-yl)ethyl]benzothiazole in the presence of 2-(dicyclohexylphosphino)biphenyl and Pd2(dba)3 in toluene at 90° for 2 h to give, after workup and silica gel chromatog., 31.5% 4-[2-[2-(2-methylpyrrolidin-1-yl)ethyl]benzothiazol-5-yl]benzonitrile. Representative compds. I bound to histamine-3 receptors with binding affinities from .apprx.810 nM to .apprx.0.12 nM.

IT 791614-03-4P, 4-[2-[2-(Piperidin-1-yl)ethyl]benzoxazol-5-yl]benzonitrile 791614-04-5P 791614-11-4P, 4-[2-[2-(2-Hydroxymethylpiperidin-1-yl)ethyl]benzoxazol-5-yl]benzonitrile 791614-12-5P, 4-[2-[2-[2-(2-Hydroxyethyl)piperidin-1-yl]ethyl]benzoxazol-5-yl]benzonitrile 804518-41-0P, 4-[2-[2-(cis-2,6-Dimethylpiperidin-1-yl)ethyl]benzoxazol-5-yl]benzonitrile
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused bicyclic-substituted amines as histamine-3 receptor ligands for treating conditions or disorders prevented or ameliorated by histamine-3 receptor ligands)

RN 791614-03-4 CAPLUS


CN Benzonitrile, 4-[2-[2-(1-piperidinyl)ethyl]-5-benzoxazolyl]- (9CI) (CA INDEX NAME)



RN 791614-04-5 CAPLUS


CN Benzonitrile, 4-[2-[2-[(2R)-2-methyl-1-piperidinyl]ethyl]-5-benzoxazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 791614-11-4 CAPLUS

CN Benzonitrile, 4-[2-[2-[2-(hydroxymethyl)-1-piperidinyl]ethyl]-5-benzoxazolyl]- (9CI) (CA INDEX NAME)



RN 791614-12-5 CAPLUS


CN Benzonitrile, 4-[2-[2-(2-hydroxyethyl)-1-piperidinyl]ethyl]-5-benzoxazolyl]- (9CI) (CA INDEX NAME)



RN 804518-41-0 CAPLUS

CN Benzonitrile, 4-[2-[2-[(2R,6R)-2,6-dimethyl-1-piperidinyl]ethyl]-5-benzoxazolyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L87 ANSWER 6 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1060776 CAPLUS

DOCUMENT NUMBER: 142:38266

TITLE: A preparation of (imidazo/pyrazolo)pyridazine derivatives, useful as cannabinoid receptor ligands

INVENTOR(S): Carpino, Philip A.; Sakya, Subas M.

PATENT ASSIGNEE(S): Pfizer Inc, USA

SOURCE: U.S. Pat. Appl. Publ., 54 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004248881	A1	20041209	US 2004-853993	20040525
WO 2004108728	A1	20041216	WO 2004-IB1888	20040603

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2003-476942P

P 20030609

OTHER SOURCE(S): MARPAT 142:38266

ED Entered STN: 10 Dec 2004

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to a preparation of (imidazo/pyrazolo)pyridazine derivs. of formula I [wherein: R1 and R2 are independently selected from (un)substituted (hetero)aryl; R3 is H, haloalkyl, or aryl; R4 is N-containing heterocyclyl or -O-(hetero)cyclyl; X = N, Y = C; or X = C, Y = N], useful as CB1 receptor antagonists. For instance, (piperidin-1-yl)pyrazolo[3,4-d]pyridazine derivative II was prepared via amination of chloropyrazolo[3,4-d]pyridazine derivative III by formic acid salt of 4-carbamoyl-4-(isopropylamino)piperidine with a yield of 30%. The invention compds. were tested in CB-1 receptor binding assay and provided range of binding activities from 0.2 nM to 21 nM.

IT 1031-36-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of (imidazo/pyrazolo)pyridazine derivs. useful as cannabinoid receptor ligands)

RN 1031-36-3 CAPLUS

CN 4-Piperidinecarboxamide, 4-[(1-methylethyl)amino]-1-(phenylmethyl)- (9CI)
(CA INDEX NAME)

L87 ANSWER 7 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1011627 CAPLUS

DOCUMENT NUMBER: 142:16728

TITLE: Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist

AUTHOR(S): Barbier, A. J.; Berridge, C.; Dugovic, C.; Laposky, A. D.; Wilson, S. J.; Boggs, J.; Aluisio, L.; Lord, B.;

CORPORATE SOURCE: Mazur, C.; Pudiak, C. M.; Langlois, X.; Xiao, W.; Apodaca, R.; Carruthers, N. I.; Lovenberg, T. W. LLC, Johnson and Johnson Pharmaceutical Research and Development, San Diego, CA, 92121, USA

SOURCE: British Journal of Pharmacology (2004), 143(5), 649-661
CODEN: BJPCBM; ISSN: 0007-1188

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English


ED Entered STN: 24 Nov 2004

AB 1-[4-(3-Piperidin-1-yl-propoxy)-benzyl]-piperidine (JNJ-5207852) is a novel, nonimidazole histamine H3 receptor antagonist, with high affinity at the rat ($pK_i = 8.9$) and human ($pK_i = 9.24$) H3 receptor. JNJ-5207852 is selective for the H3 receptor, with negligible binding to other receptors, transporters and ion channels at 1 μ M. JNJ-5207852 readily penetrates the brain tissue after s.c. administration, as determined by ex vivo autoradiog. (ED50 of 0.13 mg kg⁻¹ in mice). In vitro autoradiog. with 3H-JNJ-5207852 in mouse brain slices shows a binding pattern identical to that of 3H-R- α -methylhistamine, with high specific binding in the cortex, striatum and hypothalamus. No specific binding of 3H-JNJ-5207852 was observed in brains of H3 receptor knockout mice. In mice and rats, JNJ-5207852 (1-10 mg kg⁻¹ s.c.) increases time spent awake and decreases REM sleep and slow-wave sleep, but fails to have an effect on **wakefulness** or sleep in H3 receptor knockout mice. No rebound hypersomnolence, as measured by slow-wave delta power, is observed. The wake-promoting effects of this H3 receptor antagonist are not associated with hypermotility. A 4-wk daily treatment of mice with JNJ-5207852 (10 mg kg⁻¹ i.p.) did not lead to a change in body weight, possibly due to the compound being a neutral antagonist at the H3 receptor. JNJ-5207852 is extensively absorbed after oral administration and reaches high brain levels. The data indicate that JNJ-5207852 is a novel, potent and selective H3 antagonist with good in vitro and in vivo efficacy, and confirm the wake-promoting effects of H3 receptor antagonists.

IT 398473-34-2, JNJ-5207852
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL (Biological study)
(acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist)

RN 398473-34-2 CAPLUS

CN Piperidine, 1-[3-[4-(1-piperidinylmethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 8 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:964822 CAPLUS

DOCUMENT NUMBER: 141:410925

TITLE: Preparation of bicyclic substituted pyrrolidine derivatives as histamine-3 receptor ligands

INVENTOR(S): Cowart, Marlon D.; Ku, Yi-Yin; Chang, Sou-Jen;


Fernando, Dilinie P.; Grieme, Timothy A.; Altenbach, Robert J.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 431,152.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004224953	A1	20041111	US 2003-670629	20030925
US 2004224952	A1	20041111	US 2003-431152	20030507
WO 2004101559	A1	20041125	WO 2004-US13606	20040503

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-431152 A2 20030507
 US 2003-670629 A 20030925

OTHER SOURCE(S): MARPAT 141:410925
 ED Entered STN: 12 Nov 2004
 GI



AB The title compds. [I; X = O, S, NH, N(alkyl); Y, Y1 = CH, CF, N; Z = C, N (provided that when X = O or S, Z = N); one of R1 and R2 = (hetero)aryl; the other of R1 and R2 = H, alkyl, alkoxy, aryl, etc.; R3 is absent when Z = N and, when present, R3 = H, Me, alkoxy, halo, CN; R4, R5 = alkyl, haloalkyl, hydroxyalkyl, etc.; or NR4R5 = (un)substituted pyrrolidine, piperidine, etc.; L = CH2CH2, etc.] which are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands, were prepared E.g., a multi-step synthesis of 4-{2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzoxazol-5-yl}benzonitrile, starting from 4-bromo-2-nitrophenol, was given. Representative compds. I bound to histamine-3-receptors with binding affinities from about 810 nM to about 0.12 nM. Also disclosed are pharmaceutical compns. comprising the histamine-3 receptor ligands and methods for using such compds. and compns.


IT 791614-03-4P 791614-04-5P 791614-11-4P
 791614-12-5P 791784-76-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic substituted pyrrolidine derivs. as histamine-3 receptor ligands)

RN 791614-03-4 CAPLUS


CN Benzonitrile, 4-[2-[2-(1-piperidinyl)ethyl]-5-benzoxazolyl]- (9CI) (CA INDEX NAME)



RN 791614-04-5 CAPLUS


CN Benzonitrile, 4-[2-[2-[(2R)-2-methyl-1-piperidinyl]ethyl]-5-benzoxazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 791614-11-4 CAPLUS

CN Benzonitrile, 4-[2-[2-[2-(hydroxymethyl)-1-piperidinyl]ethyl]-5-benzoxazolyl]- (9CI) (CA INDEX NAME)



RN 791614-12-5 CAPLUS


CN Benzonitrile, 4-[2-[2-[2-(2-hydroxyethyl)-1-piperidinyl]ethyl]-5-benzoxazolyl]- (9CI) (CA INDEX NAME)



RN 791784-76-4 CAPLUS

CN Benzonitrile, 4-[2-[2-[(2R,6S)-2,6-dimethyl-1-piperidinyl]ethyl]-5-benzoxazolyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L87 ANSWER 9 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:964821 CAPLUS

DOCUMENT NUMBER: 141:410924

TITLE: Preparation of bicyclic substituted pyrrolidine derivatives as histamine-3 receptor ligands

INVENTOR(S): Cowart, Marlon D.; Ku, Yi-yin; Chang, Sou-jen; Fernando, Dilinje P.; Grieme, Timothy A.; Altenbach, Robert J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 52 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004224952	A1	20041111	US 2003-431152	20030507
US 2004224953	A1	20041111	US 2003-670629	20030925
WO 2004101559	A1	20041125	WO 2004-US13606	20040503

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,

SN, TD, TG

PRIORITY APPLN. INFO.:

US 2003-431152

A2 20030507


US 2003-670629

A 20030925

OTHER SOURCE(S): MARPAT 141:410924

ED Entered STN: 12 Nov 2004

GI



AB The title compds. [I; X = O, S, NH, N(alkyl); Y, Y1 = CH, CF, N; Z = C, N (provided that when X = O or S, Z = N); one of R1 and R2 = (hetero)aryl; the other of R1 and R2 = H, alkyl, alkoxy, aryl, etc.; R3 is absent when Z = N and, when present, R3 = H, Me, alkoxy, halo, CN; R4, R5 = alkyl, haloalkyl, hydroxyalkyl, etc.; or NR4R5 = (un)substituted pyrrolidine, piperidine, etc.; L = CH2CH2, etc.] which are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands, were prepared E.g., a multi-step synthesis of 4-{2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzoxazol-5-yl}benzonitrile, starting from 4-bromo-2-nitrophenol, was given. Representative compds. I bound to histamine-3-receptors with binding affinities from about 810 nM to about 0.12 nM. Also disclosed are pharmaceutical compns. comprising the histamine-3 receptor ligands and methods for using such compds. and compns.

IT 791614-03-4P 791614-04-5P 791614-11-4P

791614-12-5P 791614-92-1P, 4-[2-[2-(2,6-

Dimethylpiperidin-1-yl)ethyl]benzoxazol-5-yl]benzonitrile

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of bicyclic substituted pyrrolidine derivs. as histamine-3 receptor ligands)

RN 791614-03-4 CAPLUS


CN Benzonitrile, 4-[2-[2-(1-piperidinyl)ethyl]-5-benzoxazolyl]- (9CI) (CA INDEX NAME)



RN 791614-04-5 CAPLUS


CN Benzonitrile, 4-[2-[2-[(2R)-2-methyl-1-piperidinyl]ethyl]-5-benzoxazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 791614-11-4 CAPLUS

CN Benzonitrile, 4-[2-[2-[2-(hydroxymethyl)-1-piperidinyl]ethyl]-5-benzoxazolyl]- (9CI) (CA INDEX NAME)




RN 791614-12-5 CAPLUS

CN Benzonitrile, 4-[2-[2-[2-(2-hydroxyethyl)-1-piperidinyl]ethyl]-5-benzoxazolyl]- (9CI) (CA INDEX NAME)



RN 791614-92-1 CAPLUS

CN Benzonitrile, 4-[2-[2-(2,6-dimethyl-1-piperidinyl)ethyl]-5-benzoxazolyl]- (9CI) (CA INDEX NAME)



L87 ANSWER 10 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN



ACCESSION NUMBER: 2004:905623 CAPLUS

DOCUMENT NUMBER: 141:379924

TITLE: Preparation of bicyclic pyrazolyl and imidazolyl

compounds as cannabinoid receptor ligands
 INVENTOR(S): Carpino, Philip A.; Dow, Robert L.
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 46 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004214855	A1	20041028	US 2004-823107	20040412
WO 2004094429	A1	20041104	WO 2004-IB1482	20040420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
NL 1026028	A1	20041027	NL 2004-1026028	20040423
PRIORITY APPLN. INFO.:			US 2003-464831P	P 20030423
OTHER SOURCE(S):			MARPAT 141:379924	
ED Entered STN: 29 Oct 2004				
GI				



AB The title compds. I or II [A = N and B = C, or A = C and B = N; R0 =

(un)substituted (hetero)aryl; R1 = (un)substituted (hetero)aryl, CH:CHR1a, CH2CH2R1a (wherein R1a = H, alkyl, (un)saturated carbocyclyl, heterocyclyl, etc.); X = a bond, (un)substituted CH2; R31, R32 = H, alkyl, haloalkyl; R4 = alkyl, aryl, heteroaryl, etc.] that act as cannabinoid receptor ligands and therefore are useful in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, were prepared Thus, reacting 3-bromo-2-(2-chlorophenyl)-5-isopropyl-4,5-dihydro-2H-pyrrolo[3,4-c]pyrazol-6-one (preparation given) with 3,4,5-trifluorophenylboronic acid afforded III. All the exemplified compds. I (over 100) were tested in the CB-1 receptor binding assay and provided a range of binding activities from 0.6 nM - 2500 nM. The pharmaceutical composition comprising the compound

I

or II is claimed.


IT 784180-57-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic pyrazolyl and imidazolyl compds. for treating disorders modulated by a cannabinoid receptor antagonist)

RN 784180-57-0 CAPLUS

CN 7H-Pyrazolo[3,4-c]pyridin-7-one, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-6-(cyclohexylmethyl)-2,4,5,6-tetrahydro- (9CI) (CA INDEX NAME)



L87 ANSWER 11 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:905618 CAPLUS

DOCUMENT NUMBER: 141:379938

TITLE: Preparation of pyrazolo[4,3-d]pyrimidine and pyrazolo[3,4-c]pyridine compounds as cannabinoid receptor ligands

INVENTOR(S): Griffith, David A.; Hammond, Marlys

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 76 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004214837	A1	20041028	US 2004-822975	20040412
WO 2004096801	A1	20041111	WO 2004-IB1418	20040420

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,


CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

NL 1026030 A1 20041101 NL 2004-1026030 20040423
PRIORITY APPLN. INFO.: US 2003-464918P P 20030423
US 2004-540048P P 20040129

OTHER SOURCE(S): MARPAT 141:379938

ED Entered STN: 29 Oct 2004

GI



AB The title compds. I [A = N, CR₂ (wherein R₂ = H, alkyl, haloalkyl, alkoxy); R₀, R₁ = (un)substituted (hetero)aryl; R₃ = H, alkyl, haloalkyl, alkoxy; R₄ = (un)substituted pyrrolidino, piperidino, piperazino, etc.] that act as cannabinoid receptor ligands and therefore are useful in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, were prepared Thus, reacting 7-chloro-3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-2H-pyrazolo[3,4-c]pyridine with 4-ethylaminopiperidine-4-carboxylic acid amide (prepns. given) afforded 78% II. All the exemplified compds. (over 190) were tested in the CB-1 receptor binding assay and showed a range of binding activities from 0.2 nM to 1.6 μ M. The pharmaceutical composition comprising the compound I is claimed.


IT 784206-82-2P 784207-69-8P 784207-74-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[4,3-d]pyrimidine and pyrazolo[3,4-c]pyridine compds. for treating disorders modulated by a cannabinoid receptor antagonist)


RN 784206-82-2 CAPLUS

CN 2H-Pyrazolo[4,3-d]pyrimidine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-[2-(1-piperidinylmethyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 784207-69-8 CAPLUS


CN 2H-Pyrazolo[4,3-d]pyrimidin-7-amine, 2-(2-chlorophenyl)-3-(4-chlorophenyl)-
N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 784207-74-5 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-
2H-pyrazolo[4,3-d]pyrimidin-7-yl]-3-(phenylmethyl)-,
(1 α ,5 α ,6 α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 3612-20-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrazolo[4,3-d]pyrimidine and pyrazolo[3,4-c]pyridine
comps. for treating disorders modulated by a cannabinoid receptor
antagonist)

RN 3612-20-2 CAPLUS


CN 4-Piperidinone, 1-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT 1024-16-4P 1027-91-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)(preparation of pyrazolo[4,3-d]pyrimidine and pyrazolo[3,4-c]pyridine
comps. for treating disorders modulated by a cannabinoid receptor
antagonist)

RN 1024-16-4 CAPLUS

CN 4-Piperidinecarbonitrile, 4-(ethylamino)-1-(phenylmethyl)- (9CI) (CA
INDEX NAME)




RN 1027-91-4 CAPLUS

CN 4-Piperidinecarboxamide, 4-(ethylamino)-1-(phenylmethyl)- (9CI) (CA INDEX
NAME)



L87 ANSWER 12 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:654773 CAPLUS
DOCUMENT NUMBER: 141:190806
TITLE: Preparation of pyrazolotriazines as cannabinoid CB1
receptor antagonists
INVENTOR(S): Griffith, David A.
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S. Pat. Appl. Publ., 72 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004157839	A1	20040812	US 2004-763105	20040121
WO 2004069837	A1	20040819	WO 2004-IB269	20040126
W:	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
NL 1025404	A1	20040809	NL 2004-1025404	20040204
NL 1025404	C2	20050314		
PRIORITY APPLN. INFO.:			US 2003-445728P	P 20030206
OTHER SOURCE(S):	MARPAT 141:190806			
ED	Entered STN: 13 Aug 2004			
GI				




AB Title compds. [I; R1, R2 = (substituted) aryl, heteroaryl; R3 = H, alkyl, haloalkyl, alkoxy; R4 = Q1, Q2; R41 = H, alkyl; R42, R43 = H, cyano, OH, amino, H2NCO, (substituted) alkyl, alkoxy, acyloxy, acyl, aryl, heteroaryl, etc.; R44, R45 = H, cyano, OH, amino, H2NCO, (substituted) alkyl, aryl, heteroaryl, heterocyclyl, etc.; pairs of R41-R45 may form bonds, methylene, ethylene bridges; X = bond, CH2CH2, etc.; Y = O, S, CO, etc.; Z = bond, CH2CH2, etc.], were prepared for treatment of weight loss, obesity, bulimia, depression, drug abuse, etc. (no data). Thus, 1-[7-(2-chlorophenyl)-8-iodo-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-ethylaminopiperidine-4-carboxamide (preparation given), 4-fluorophenylboronic acid, (Ph3P)4Pd, and Na2CO3 were heated in EtOH/PhMe/H2O at 80° for 5 h to give 58% 1-[7-(2-chlorophenyl)-8-(4-fluorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-ethylaminopiperidine-4-carboxamide.

IT **3612-20-2**, N-Benzyl-4-piperidone
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrazolotriazines as cannabinoid CB1 receptor antagonists)

RN 3612-20-2 CAPLUS


CN 4-Piperidinone, 1-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **1024-16-4P 1027-91-4P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazolotriazines as cannabinoid CB1 receptor antagonists)


RN 1024-16-4 CAPLUS

CN 4-Piperidinecarbonitrile, 4-(ethylamino)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 1027-91-4 CAPLUS

CN 4-Piperidinecarboxamide, 4-(ethylamino)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



L87 ANSWER 13 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:534172 CAPLUS

DOCUMENT NUMBER: 141:89090

TITLE: Preparation of aryloxadiazols and related compounds as histamine **H3 receptor** antagonist.

INVENTOR(S): Sorensen, Jan Lindy; Andersen, Knud Erik; Pettersson, Ingrid

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054973	A2	20040701	WO 2003-DK897	20031218
WO 2004054973	A3	20040819		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005107434	A1	20050519	US 2003-735963	20031215
PRIORITY APPLN. INFO.:			DK 2002-1932	A 20021218
			DK 2003-484	A 20030331

US 2002-434253P

P 20021218


US 2003-460777P

P 20030404


OTHER SOURCE(S): MARPAT 141:89090

ED Entered STN: 02 Jul 2004


GI



I



II



III

AB Title compds. I [A = (CH₂)_r; r = 0-2; Z = (CH₂)_s-X-(CH₂)_t-Y-R₄; s = 0-3; T = 0-3; X = CO, CHOH, CR₂R₃, etc.; R₂, R₃ = H, alkyl; Y = (un)substituted heteroaryl R₁ = (un)substituted alkyl, alkenyl, alkynyl;] and their formulations and pharmaceutically acceptable salts were prepared For example, condensation of 4-methanesulfonylbenzoyl chloride and N-hydroxypropionamidine II, e.g., prepared from 4-piperidineethanol in 3-steps, afforded the hydrochloride of piperidinyloxadiazol III. In human histamine H₃ receptor binding assays, compds. I generally show a high binding affinity to the histamine H₃ receptor. Of note, compds. I possess histamine H₃ receptor antagonistic activity and are useful in the treatment of disorders in which a histamine H₃ receptor blockade is beneficial.


IT 713146-84-0P 713146-89-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryloxadiazols and related compds. as histamine H₃ receptor antagonist.)

RN 713146-84-0 CAPLUS


CN Piperidine, 1-(1-ethylpropyl)-4-[[5-[4-(1-piperidinylmethyl)phenyl]-1,2,4-oxadiazol-3-yl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 713146-89-5 CAPLUS

CN Piperidine, 1-cyclopentyl-4-[[5-[4-(1-piperidinylmethyl)phenyl]-1,2,4-oxadiazol-3-yl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L87 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:430743 CAPLUS

DOCUMENT NUMBER: 141:7138

TITLE: Preparation of bicyclic-substituted amines as histamine-3 receptor ligands

INVENTOR(S): Altenbach, Robert J.; Black, Lawrence A.; Chang, Sou-Jen; Cowart, Marlon D.; Faghih, Ramin; Gfesser, Gregory A.; Ku, Yi-Yin; Liu, Huaqing; Lukin, Kirill A.; Nersesian, Diana L.; Pu, Yu-Ming; Sharma, Padam N.; Bennani, Youssef L.; Curtis, Michael P.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 229 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043458	A1	20040527	WO 2003-US35365	20031105
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,			


ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2004092521 A1 20040513 US 2002-292422 20021112
US 2004152704 A1 20040805 US 2003-689735 20031022
PRIORITY APPLN. INFO.: US 2002-292422 A 20021112
US 2002-425376P P 20021112
US 2003-689735 A 20031022
OTHER SOURCE(S): MARPAT 141:7138
ED Entered STN: 27 May 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [wherein Y, and B = independently CH, CF, or N; X, A, Z, and C = independently C or N; one of R1 and R2 = halo, CN, aryl, aryloxy, etc.; the other of R1 and R2 = H, cyclo/alkyl, thio/alkoxy, aryl, halo, CN, provided that R2 is absent when C = N; R3 = H, alkyl, alkoxy, absent, etc.; R = absent, H, halo, Me, alkoxy, or CN; R6 = absent, H, alkyl, thio/alkoxy, halo, OH, CN; R4 and R5 = independently alkyl, haloalkyl, hydroxyalkyl, or NR4R5 = (un)1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, etc.; L = (un)substituted alkylene or -alkylene-O-; their pharmaceutically acceptable salts, esters, amides, or prodrugs] were prepared as histamine-3 receptor ligands. For example, quinoxaline II was prepared in 6 steps via cyclocondensation of benzenediamine III with glyoxal in EtOH, followed by reaction with oxo(phenyl)acetaldehyde. Selected I showed binding affinities of 0.12 to 20 nM towards histamine-3 receptors in rats. I are useful for the treatment of memory disorder, cognition disorder, obesity, etc. (no data).

IT **693774-34-4P**, 4-[6-[2-(2-Methylpiperidin-1-yl)ethyl]naphthalen-2-yl]benzonitrile **693774-37-7P**, 2-[6-[2-(Piperidin-1-yl)ethyl]naphthalen-2-yl]-2H-pyridazin-3-one **693774-50-4P**, 2-[6-[2-((2R,6S)-2,6-Dimethylpiperidin-1-yl)ethyl]naphthalen-2-yl]-2H-pyridazin-3-one **693774-51-5P**, 2-[6-[2-((R)-3-Hydroxypiperidin-1-yl)ethyl]naphthalen-2-yl]-2H-pyridazin-3-one **693774-52-6P**, 2-[6-[2-((R)-2-Methylpiperidin-1-yl)ethyl]naphthalen-2-yl]-2H-pyridazin-3-one **693774-81-1P**, 3-Bromo-7-[2-(piperidin-1-yl)ethyl]-[1,5]naphthyridine **693774-86-6P**, 3-(2,6-Dimethylpyridin-3-yl)-7-[2-(piperidin-1-yl)ethyl]-[1,5]naphthyridine **693774-87-7P**, 3-(2,4-Dimethoxypyrimidin-5-yl)-7-[2-(piperidin-1-yl)ethyl]-[1,5]naphthyridine **693775-06-3P**, 4-[3-[2-(Piperidin-1-yl)ethyl]cinnolin-7-yl]benzonitrile **693775-11-0P**, 4-[3-[2-(4-Methylpiperidin-1-yl)ethyl]cinnolin-7-yl]benzonitrile
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of bicyclic-substituted amines as histamine-3 receptor ligands)

RN **693774-34-4** CAPLUS
CN Benzonitrile, 4-[6-[2-(2-methyl-1-piperidinyl)ethyl]-2-naphthalenyl]-
(9CI) (CA INDEX NAME)




RN 693774-37-7 CAPLUS

CN 3(2H)-Pyridazinone, 2-[6-[2-(1-piperidinyl)ethyl]-2-naphthalenyl]- (9CI)
(CA INDEX NAME)

RN 693774-50-4 CAPLUS

CN 3(2H)-Pyridazinone, 2-[6-[2-[(2R,6S)-2,6-dimethyl-1-piperidinyl]ethyl]-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 693774-51-5 CAPLUS

CN 3(2H)-Pyridazinone, 2-[6-[2-[(3R)-3-hydroxy-1-piperidinyl]ethyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 693774-52-6 CAPLUS


CN 3(2H)-Pyridazinone, 2-[6-[2-[(2R)-2-methyl-1-piperidinyl]ethyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 693774-81-1 CAPLUS

CN 1,5-Naphthyridine, 3-bromo-7-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 693774-86-6 CAPLUS

CN 1,5-Naphthyridine, 3-(2,6-dimethyl-3-pyridinyl)-7-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 693774-87-7 CAPLUS

CN 1,5-Naphthyridine, 3-(2,4-dimethoxy-5-pyrimidinyl)-7-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 693775-06-3 CAPLUS

CN Benzonitrile, 4-[3-[2-(1-piperidinyl)ethyl]-7-cinnolinyl]- (9CI) (CA INDEX NAME)



RN 693775-11-0 CAPLUS

CN Benzonitrile, 4-[3-[2-(4-methyl-1-piperidinyl)ethyl]-7-cinnolinyl]- (9CI)
(CA INDEX NAME)




IT 689291-15-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of bicyclic-substituted derivs. as histamine-3 receptor ligands)

RN 689291-15-4 CAPLUS

CN Benzonitrile, 4-[6-[2-[(2R)-2-methyl-1-piperidinyl]ethyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L87 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:392439 CAPLUS

DOCUMENT NUMBER: 140:400095

TITLE: Stereoisomers of p-hydroxy-milnacipran, and therapeutic use

INVENTOR(S): Rariy, Roman V.; Heffernan, Michael; Buchwald, Stephen L.; Swager, Timothy M.

PATENT ASSIGNEE(S): Collegium Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 163 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039320	A2	20040513	WO 2003-US33681	20031022
WO 2004039320	A3	20040624		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004142904	A1	20040722	US 2003-691465	20031022
PRIORITY APPLN. INFO.:			US 2002-421640P	P 20021025
			US 2002-423062P	P 20021101
			US 2003-445142P	P 20030205

OTHER SOURCE(S): MARPAT 140:400095

ED Entered STN: 14 May 2004

AB The invention relates generally to the enantiomers of p-hydroxymilnacipran or congeners thereof. Biol. assays revealed that racemic p-hydroxymilnacipran is approx. equipotent in inhibiting serotonin and norepinephrine uptake (IC₅₀ = 28.6 nM for norepinephrine, IC₅₀ = 21.7 nM for serotonin). Interestingly, (+)-p-hydroxymilnacipran is a more potent inhibitor of norepinephrine uptake than serotonin uptake (IC₅₀ = 10.3 nM for norepinephrine, IC₅₀ = 22 nM for serotonin). In contrast, (-)-p-hydroxymilnacipran is a more potent inhibitor of serotonin uptake compared to norepinephrine uptake (IC₅₀ = 88.5 nM for norepinephrine, IC₅₀ = 40.3 nM for serotonin). The invention also relates to salts and prodrug forms of the above compds. In certain embodiments, the compds. of the invention and a pharmaceutically acceptable excipient are combined to prepare a formulation for administration to a patient. Finally, the invention relates to methods of treating mammals suffering from various afflictions, e.g., depression, chronic pain, or fibromyalgia, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of the invention. Compound preparation is included.

IT 83-98-7, Orphenadrine 302-40-9, Benactyzine

437-38-7, Fentanyl 36505-84-7, Buspirone

42408-82-2, Butorphanol 52485-79-7, Buprenorphine

74050-98-9, Ketanserin 83928-76-1, Gepirone

87051-43-2, Ritanserin 87691-91-6, Tiaspirone

106266-06-2, Risperidone 120014-06-4, Donepezil


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(p-hydroxymilnacipran stereoisomers, therapeutic use, and use with other agents)


RN 83-98-7 CAPLUS

CN Ethanamine, N,N-dimethyl-2-[(2-methylphenyl)phenylmethoxy]- (9CI) (CA INDEX NAME)




RN 302-40-9 CAPLUS

CN Benzeneacetic acid, α -hydroxy- α -phenyl-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 437-38-7 CAPLUS

CN Propanamide, N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 36505-84-7 CAPLUS


CN 8-Azaspiro[4.5]decane-7,9-dione, 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



RN 42408-82-2 CAPLUS

CN Morphinan-3,14-diol, 17-(cyclobutylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 52485-79-7 CAPLUS


CN 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-, (αS,5α,7α) - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 74050-98-9 CAPLUS

CN 2,4(1H,3H)-Quinazolinedione, 3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 83928-76-1 CAPLUS

CN 2,6-Piperidinedione, 4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)




RN 87051-43-2 CAPLUS

CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-[bis(4-fluorophenyl)methylene]-1-piperidinyl]ethyl]-7-methyl- (9CI) (CA INDEX NAME)




RN 87691-91-6 CAPLUS

CN 8-Azaspiro[4.5]decane-7,9-dione, 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)




RN 106266-06-2 CAPLUS

CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 120014-06-4 CAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



L87 ANSWER 16 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:392320 CAPLUS

DOCUMENT NUMBER: 140:406732

TITLE: Preparation of pyrrolidine derivatives as histamine-3 receptor ligands

INVENTOR(S): Altenbach, Robert J.; Black, Lawrence A.; Chang, Sou-jen; Cowart, Marlon D.; Faghieh, Ramin; Gfesser, Gregory A.; Ku, Yi-yin; Liu, Huaqing; Lukin, Kirill A.; Nersesian, Diana L.; Pu, Yu-ming; Sharma, Padam N.; Bennani, Youssef L.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 55 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004092521	A1	20040513	US 2002-292422	20021112
WO 2004043458	A1	20040527	WO 2003-US35365	20031105
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2002-292422	A 20021112
			US 2002-425376P	P 20021112



OTHER SOURCE(S): MARPAT 140:406732

ED Entered STN: 14 May 2004

GI

US 2003-689735

A 20031022



AB The title compds. I [wherein X, Y, and Y' = independently CH, CF, or N; X', Z, and Z' = independently C or N; R1 and R2 = independently halo, CN, H, alkyl, alkoxy, etc.; R3 = H, alkyl, alkoxy, absent, etc.; R3a = absent, H, halo, Me, alkoxy, or CN; R4 and R5 = independently alkyl, haloalkyl, hydroxyalkyl, etc.; L = (un)substituted alkylene or -alkylene-O-] or pharmaceutically acceptable salts, esters, amides, or prodrugs thereof are prepared as histamine-3 receptor ligands. For example, the compound II was prepared in a multi-step synthesis. Some of compds. I showed binding affinities of 0.12 to 20 nM towards histamine-3 receptors in rat. I are useful for the treatment of memory disorder, cognition disorder, obesity, etc. (no data).

IT 689291-15-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolidine derivs. as histamine-3 receptor ligands)

RN 689291-15-4 CAPLUS

CN Benzonitrile, 4-[6-[2-[(2R)-2-methyl-1-piperidinyl]ethyl]-2-naphthalenyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L87 ANSWER 17 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:372868 CAPLUS

DOCUMENT NUMBER: 140:375080

TITLE: Preparation of phenylpiperidines and phenylpyrrolidines as histamine **H3** receptor inhibitors

INVENTOR(S): Apodaca, Richard L.; Dvorak, Curt A.; Shah, Chandravadan R.; Xiao, Wei

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 47 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004087573	A1	20040506	US 2003-692080	20031023
PRIORITY APPLN. INFO.:			US 2002-420494P	P 20021023


OTHER SOURCE(S): MARPAT 140:375080

ED Entered STN: 07 May 2004

GI



I



II

AB Substituted phenylpiperidines and phenylpyrrolidines of formula I [L = bond, alkylene, etc.; R1,R2 = H, alkyl, cycloalkyl, heterocyclyl, etc.; R1R2 = alkylene, heteroalkylene, etc.; R3-R5 = H, halo, nitro, CF3, Me, alkoxy; R6 = alkyl, CF3; X = (CH2)p; Y = (CH2)q; p = 0-2; q = 1-2; m = 0-3], compns. containing them, and methods of making and using them to treat

histamine-mediated conditions are described. Thus, II was prepared from 1-(4-pyrrolidinomethylphenyl)piperidin-4-carbaldehyde and cyclohexylamine. The K_i value of II was 0.9 nM in $\{^3H\}$ -N-methylhistamine binding assay.


IT 683772-23-8P 683772-29-4P 683772-31-8P
683772-36-3P 683772-39-6P 683772-45-4P
683772-46-5P 683772-54-5P 683772-58-9P
683772-61-4P 683772-62-5P 683772-63-6P
683772-69-2P 683772-70-5P 683772-72-7P
683772-73-8P 683772-76-1P 683772-77-2P
683772-78-3P 683772-79-4P 683772-81-8P
683772-83-0P

RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylpiperidines and phenylpyrrolidines as histamine H_3 receptor inhibitors)


RN 683772-23-8 CAPLUS

CN Morpholine, 4-[[2-[4-(1-piperidinylmethyl)-1-piperidinyl]phenyl]methyl]-(9CI) (CA INDEX NAME)




RN 683772-29-4 CAPLUS

CN 4-Piperidinol, 1-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]-(9CI) (CA INDEX NAME)



RN 683772-31-8 CAPLUS


CN Piperidine, 4-(1-piperidinylmethyl)-1-[4-(1-pyrrolidinylmethyl)phenyl]-(9CI) (CA INDEX NAME)



RN 683772-36-3 CAPLUS


CN Piperidine, 1-[3-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)-

(9CI) (CA INDEX NAME)




RN 683772-39-6 CAPLUS
CN 4-Piperidinol, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 683772-45-4 CAPLUS

CN Morpholine, 4-[[1-[4-(1-piperidinylmethyl)phenyl]-4-piperidinyl]methyl]-(9CI) (CA INDEX NAME)




RN 683772-46-5 CAPLUS

CN Piperidine, 1-[4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)-(9CI) (CA INDEX NAME)




RN 683772-54-5 CAPLUS

CN 1,4'-Bipiperidine, 1'-[4-(1-piperidinylmethyl)phenyl]-(9CI) (CA INDEX NAME)



RN 683772-58-9 CAPLUS


CN Piperidine, 4-(1-piperidinylmethyl)-1-[4-(1-piperidinylmethyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 683772-61-4 CAPLUS

CN Morpholine, 4-[2-[1-[4-(1-piperidinylmethyl)phenyl]-3-pyrrolidinyl]ethyl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 683772-62-5 CAPLUS

CN 3-Pyrrolidineethanamine, N,N-diethyl-1-[4-(1-piperidinylmethyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 683772-63-6 CAPLUS

CN 3-Pyrrolidineethanamine, N-methyl-N-(2-phenylethyl)-1-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 683772-69-2 CAPLUS

CN Piperidine, 1-[4-(1-piperidinylmethyl)-2-(trifluoromethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 683772-70-5 CAPLUS

CN Piperidine, 1-[2-nitro-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 683772-72-7 CAPLUS

CN 4-Piperidinol, 1-[[3-nitro-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 683772-76-1 CAPLUS

CN Piperidine, 1-[2-methyl-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 683772-77-2 CAPLUS

CN Piperidine, 4-(1-pyrrolidinylmethyl)-1-[4-[[4-(1-pyrrolidinyl)-1-piperidinyl]methyl]-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 683772-78-3 CAPLUS
CN Piperidine, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-2-(trifluoromethyl)phenyl]methyl]-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 683772-79-4 CAPLUS
CN Piperidine, 1-[2-fluoro-4-[(4-phenyl-1-piperidinyl)methyl]phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 683772-81-8 CAPLUS
CN Piperidine, 1-[2-fluoro-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 683772-83-0 CAPLUS

CN 4-Piperidinemethanol, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




IT 683772-15-8P 683772-17-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of phenylpiperidines and phenylpyrrolidines as histamine H3 receptor inhibitors)


RN 683772-15-8 CAPLUS

CN 4-Piperidinemethanol, 1-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 683772-17-0 CAPLUS

CN 4-Piperidinecarboxaldehyde, 1-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



L87 ANSWER 18 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:370916 CAPLUS

DOCUMENT NUMBER: 140:391298

TITLE: Preparation of piperazinyl and diazepanyl benzamides and benzothioamides as inhibitors of histamine H3 receptor

INVENTOR(S): Apodaca, Richard L.; Jablonowski, Jill A.; Ly, Kiev S.; Shah, Chandravadan R.; Swanson, Devin M.; Xiao, Wei

PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.

SOURCE: PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037801	A1	20040506	WO 2003-US33343	20031021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,				

LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
 OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004110746

A1

20040610

US 2003-690115

20031021

PRIORITY APPLN. INFO.:

US 2002-420495P


P 20021023

OTHER SOURCE(S):


MARPAT 140:391298

ED Entered STN: 07 May 2004

GI



I



II

AB The title compds. [I; R1 = alkyl, alkenyl, cycloalkyl, etc.; n = 1-2; X = O, S; one of R2-R4 = G and the other two are H, F, Cl, Br, CF3, Me, NO2, alkoxy; G = LQ; L = (CH2)m; m = 1-7; Q = NR8R9 (R8, R9 = H, alkyl, Ph, etc.), (un)substituted saturated 3-12 membered N-linked heterocyclyl], useful for treating histamine-mediated conditions, were prepared Thus, reacting 4-[4-(1-ethylpropyl)piperazine-1-carbonyl]benzaldehyde with PhCH2NH2 in the presence of NaBH(OAc)3 and AcOH afforded II which showed Ki of 2.0 nM against histamine H3 receptor binding. The pharmaceutical compns. comprising the title compds. I are claimed.


IT 686720-80-9P 686720-85-4P 686720-86-5P
 686720-91-2P 686720-94-5P 686720-97-8P
 686720-99-0P 686721-00-6P 686721-07-3P
 686721-08-4P 686721-12-0P 686721-14-2P
 686721-21-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of piperazinyl and diazepanyl benzamides and benzothioamides as inhibitors of histamine H3 receptor)

RN 686720-80-9 CAPLUS


CN Piperazine, 1-(1-ethylpropyl)-4-[4-[(octahydro-2(1H)-isoquinolinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 686720-85-4 CAPLUS

CN Piperazine, 1-(1-ethylpropyl)-4-[4-(1-piperidinylmethyl)benzoyl] - (9CI)
(CA INDEX NAME)

RN 686720-86-5 CAPLUS


CN Piperazine, 1-(1-methylpropyl)-4-[4-(1-piperidinylmethyl)benzoyl] - (9CI)
(CA INDEX NAME)

RN 686720-91-2 CAPLUS


CN Piperazine, 1-(1-methylheptyl)-4-[4-(1-piperidinylmethyl)benzoyl] - (9CI)
(CA INDEX NAME)

RN 686720-94-5 CAPLUS


CN Piperazine, 1-butyl-4-[4-[[3-(trifluoromethyl)-1-piperidinyl]methyl]benzoyl] - (9CI) (CA INDEX NAME)



RN 686720-97-8 CAPLUS


CN Piperazine, 1-(1-methylethyl)-4-[3-(1-piperidinylmethyl)benzoyl] - (9CI)
(CA INDEX NAME)

RN 686720-99-0 CAPLUS

CN Piperazine, 1-(1-methylethyl)-4-[4-(1-piperidinylmethyl)benzoyl] - (9CI)
(CA INDEX NAME)


RN 686721-00-6 CAPLUS

CN Piperazine, 1-methyl-4-[3-[[4-(phenylmethyl)-1-piperidinyl]methyl]benzoyl] - (9CI) (CA INDEX NAME)




RN 686721-07-3 CAPLUS

CN Piperazine, 1-(1-ethylpropyl)-4-[4-[[3-(trifluoromethyl)-1-piperidinyl]methyl]benzoyl] -, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 686721-08-4 CAPLUS
CN Piperazine, 1-(1-methylpropyl)-4-[4-[[3-(trifluoromethyl)-1-piperidinyl]methyl]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 686721-12-0 CAPLUS
CN Piperazine, 1-methyl-4-[4-(1-piperidinylmethyl)benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 686721-14-2 CAPLUS
CN Piperazine, 1-(1-methylethyl)-4-[4-[[3-(trifluoromethyl)-1-piperidinyl]methyl]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 686721-21-1 CAPLUS

CN Piperazine, 1-cyclohexyl-4-[4-(1-piperidinylmethyl)benzoyl]- (9CI) (CA
INDEX NAME)



L87 ANSWER 19 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:368927 CAPLUS

DOCUMENT NUMBER: 140:391199

TITLE: Preparation of phenylpiperidines and
phenylpyrrolidines as histamine **H3**
receptor modulators

INVENTOR(S): Apodaca, Richard L.; Dvorak, Curt A.; Shah,
Chandravadan R.; Xiao, Wei

PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.

SOURCE: PCT Int. Appl., 115 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037257	A1	20040506	WO 2003-US33809	20031023
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2002-420494P P 20021023

OTHER SOURCE(S): MARPAT 140:391199

ED Entered STN: 06 May 2004

GI



AB The title compds. [I; L = a bond, alkylene, alkenylene, etc.; p = 0-2; q = 1-2 (provided that $2 \leq p+q \leq 4$); R1, R2 = H, alkyl, Ph, etc.; or NR1R2 = (un)substituted saturated 3-13 membered heterocyclyl; one R3-R5 = G and the other two = H, F, Cl, Br, NO2, CF3, Me, alkoxy; G = L2Q; L2 = (CH2)n; n = 1-7; Q = NR8R9 (R8, R9 = H, alkyl, Ph, etc.; or NR8R9 = (un)substituted saturated 3-15 membered heterocyclyl); R6 = H, alkyl; CF3; m = 0-3], useful for treating histamine-mediated conditions, were prepared. Thus, 1-[2-(morpholin-4-ylmethyl)phenyl]piperidine-4-carbaldehyde with piperidine in the presence of NaBH(OAc)3 in DCE afforded II which showed Ki of 4500 nM against H3 receptor binding. The pharmaceutical compns. comprising the compds. I are claimed.

IT 683772-23-8P 683772-29-4P 683772-31-8P
 683772-36-3P 683772-39-6P 683772-45-4P
 683772-46-5P 683772-54-5P 683772-58-9P
 683772-61-4P 683772-62-5P 683772-63-6P
 683772-69-2P 683772-70-5P 683772-72-7P
 683772-73-8P 683772-76-1P 683772-77-2P
 683772-78-3P 683772-79-4P 683772-81-8P
 683772-83-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of phenylpiperidines and phenylpyrrolidines as histamine H3 receptor modulators)

RN 683772-23-8 CAPLUS


CN Morpholine, 4-[[2-[4-(1-piperidinylmethyl)-1-piperidinyl]phenyl]methyl]-(9CI) (CA INDEX NAME)

RN 683772-39-6 CAPLUS
 CN 4-Piperidinol, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl] - (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 683772-45-4 CAPLUS
 CN Morpholine, 4-[[1-[4-(1-piperidinylmethyl)phenyl]-4-piperidinyl]methyl] - (9CI) (CA INDEX NAME)




RN 683772-46-5 CAPLUS
 CN Piperidine, 1-[4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl) - (9CI) (CA INDEX NAME)




RN 683772-54-5 CAPLUS

CN 1,4'-Bipiperidine, 1'-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 683772-58-9 CAPLUS


CN Piperidine, 4-(1-piperidinylmethyl)-1-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 683772-61-4 CAPLUS

CN Morpholine, 4-[2-[1-[4-(1-piperidinylmethyl)phenyl]-3-pyrrolidinyl]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 683772-62-5 CAPLUS
CN 3-Pyrrolidineethanamine, N,N-diethyl-1-[4-(1-piperidinylmethyl)phenyl] -
(9CI) (CA INDEX NAME)




RN 683772-63-6 CAPLUS

CN 3-Pyrrolidineethanamine, N-methyl-N-(2-phenylethyl)-1-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 683772-69-2 CAPLUS

CN Piperidine, 1-[4-(1-piperidinylmethyl)-2-(trifluoromethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-70-5 CAPLUS


CN Piperidine, 1-[2-nitro-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 683772-72-7 CAPLUS

CN 4-Piperidinol, 1-[[3-nitro-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 683772-73-8 CAPLUS
CN Piperidine, 1-[4-(1-piperidinylmethyl)-3-(trifluoromethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 683772-76-1 CAPLUS

CN Piperidine, 1-[2-methyl-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-77-2 CAPLUS


CN Piperidine, 4-(1-pyrrolidinylmethyl)-1-[4-[[4-(1-pyrrolidinyl)-1-piperidinyl]methyl]-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 683772-78-3 CAPLUS

CN Piperidine, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-2-(trifluoromethyl)phenyl]methyl]-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 683772-79-4 CAPLUS

CN Piperidine, 1-[2-fluoro-4-[(4-phenyl-1-piperidinyl)methyl]phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 683772-81-8 CAPLUS
CN Piperidine, 1-[2-fluoro-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 683772-83-0 CAPLUS

CN 4-Piperidinemethanol, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




IT 683772-17-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of phenylpiperidines and phenylpyrrolidines as histamine
H3 receptor modulators)

RN 683772-17-0 CAPLUS

CN 4-Piperidinecarboxaldehyde, 1-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA
INDEX NAME)




IT 683772-15-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of phenylpiperidines and phenylpyrrolidines as histamine
H3 receptor modulators)

RN 683772-15-8 CAPLUS

CN 4-Piperidinemethanol, 1-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX
NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 20 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:331785 CAPLUS

DOCUMENT NUMBER: 140:357343

TITLE: Preparation of cannabinoid receptor ligands and uses
thereof

INVENTOR(S): Dow, Robert L.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 24 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004077650	A1	20040422	US 2003-679878	20031006

WO 2004035566 A1 20040429 WO 2003-IB4411 20031006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-419621P P 20021018

OTHER SOURCE(S): MARPAT 140:357343

ED Entered STN: 23 Apr 2004

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. I [X = C, when Y = N; X = N, when Y = C; R1 = lone pair electrons, H, C1-6-alkyl, C3-6-cycloalkyl; R2 = H, C1-6-alkyl, C3-6-cycloalkyl; R3 = H, C1-6-alkyl, 2- to 8-membered carbocycle, 5- to 6-membered heterocycle, aryl, 5- to 9-membered heteroaryl, (C1-6-alkyl)-aryl, (C1-6-alkyl)-heteroaryl, aryloxy-(C1-6-alkyl) (when X = N, R3 = lone pair electrons); R4 = H, C1-6-alkyl, aryl, aryl-(C1-6-alkyl), (when Y = N, R4 = lone pair electrons); Q = Q1, Q2, Q3; Z = N, CR7; R5, R6 = (un)substituted aryl, heteroaryl; R7 = H, halo, CN, C1-6-alkyl] or pharmaceutically acceptable prodrugs and/or their salts, solvates or hydrates, that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the modulation of the cannabinoid receptors in animals are described herein. Thus, imidazolylpyrazole hydrochloride II·HCl was prepared from 5-(4-chlorophenyl)-1-(2-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid Et ester, via reduction with (Me2CHCH2)2AlH, Swern oxidation with oxalyl chloride/dimethyl sulfoxide in CH2Cl2, reaction with HCONH2/4-MeC6H4SO3H in CH2Cl2 containing Me3SiCl, dehydration with POCl3 in THF, and reaction with 2-(CF3)C6H4CH2NH2·HCl.


IT 681178-18-7P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cannabinoid receptor ligands and their uses in the treatment of diseases linked to cannabinoid receptor modulation)

RN 681178-18-7 CAPLUS

CN Piperidine, 4-[4-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]-1H-imidazol-1-yl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



L87 ANSWER 21 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:267327 CAPLUS

DOCUMENT NUMBER: 140:287412

TITLE: Preparation of piperazines as dopamine D2 and serotonin 5HT2A receptors inhibitors for the treatment of central nervous system disorders, in particular schizophrenia

INVENTOR(S): Andreana, Tonja Lynn; Cho, Stephen Sung Yong; Graham, James Michael; Gregory, Tracy Fay; Howard, Harry Ralph, Jr.; Kornberg, Brian Edward; Nikam, Sham Shridhar; Pflum, Derek Andrew

PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA

SOURCE: PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026864	A1	20040401	WO 2003-IB303902	20030905
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004138230	A1	20040715	US 2003-660908	20030912
PRIORITY APPLN. INFO.:			US 2002-411475P	P 20020917
			US 2002-416355P	P 20021004

OTHER SOURCE(S): MARPAT 140:287412

ED Entered STN: 01 Apr 2004

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X =S, O, SO, SO₂, CH₂, NH and derivs.; Y, Z = independently N or CH; A = (CH₂)_mCH₂, (CH₂)_mO, (CH₂)_mNR₉, (CH₂)_mC(R₇R₈); R₇, R₈ = independently (un)substituted alkyl, alkoxy, or CR₇R₈ = carbonyl; m = 1-4; R₄, R₅ = independently H, (un)substituted alkyl, alkoxy, or when X = NR₆ and derivs., CR₄R₅R₆N = 4-7 membered heterocyclyl ring, with the proviso that when R₉R₄ or R₉R₅ = a ring, the other of R₄ and R₅ is absent; R₉ = H, (un)substituted alkyl, alkoxy; R₆ = H, (un)substituted alkyl, alkoxy; R₁ = H, (un)substituted alkyl; R₂, R₃ = independently H, halo, hetero/aryl, (un)substituted aryl/heteroarylalkyl, alkoxy, etc.; V, W = independently CH₂ and derivs. or CH and derivs.; and their pharmaceutically acceptable salts] were prepared s dopamine D₂ and serotonin 5HT_{2A} receptors inhibitors for treating central nervous system disorders, in particular schizophrenia (no data). For example, II•MeSO₃H was prepared by acylation of 3-chloro-2-methylaniline with 3,3-diethylacryloyl chloride, one-pot Friedel-Craft alkylation with chloroacetyl chloride and cyclization in the presence of AlCl₃ to chloroacetylquinoline intermediate, reduction to chloroethylquinoline III, alkylation of 3-(piperazin-1-yl)benzo[d]isothiazole hydrochloride with III, followed by salt formation of II with methanesulfonic acid. II acted as dopamine D₂ and serotonin 5HT_{2A} receptors inhibitors with a K_i value of 0.9 nM and 1 nM, resp. Thus, I and their formulations are useful for treating central nervous system disorders, in particular schizophrenia and depression.


IT 676117-31-0P 676117-32-1P, 6-[2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one 676117-33-2P, 6-[2-[4-(6-Fluoro-benzo[d]isothiazol-3-yl)piperidin-1-yl]ethyl]-(4S)-methyl-3,4-dihydro-1H-quinolin-2-one hydrochloride 676117-34-3P, 6-[2-[4-(6-Fluoro-benzo[d]isothiazol-3-yl)piperidin-1-yl]ethyl]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one 676118-07-3P, 6-[2-[4-(6-Fluoro-benzo[d]isothiazol-3-yl)piperidin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one 676118-08-4P, 6-[2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-3,4-dimethyl-1H-quinolin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of piperazines for treating of central nervous system disorders, in particular schizophrenia)

RN 676117-31-0 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-3,4-dihydro-4,4-dimethyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 676117-32-1 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676117-33-2 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]ethyl]-3,4-dihydro-4-methyl-, monohydrochloride, (4S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 676117-34-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]ethyl]-3,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 676118-07-3 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 676118-08-4 CAPLUS

CN 2(1H)-Quinolinone, 6-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 22 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:2876 CAPLUS

DOCUMENT NUMBER: 140:59522

TITLE: Preparation of indole derivatives as histamine H3 antagonists

INVENTOR(S): Aslanian, Robert G.; Berlin, Michael Y.; Mangiaracina, Pietro; McCormick, Kevin D.; Mutahi, Mwangi W.; Rosenblum, Stuart B.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000831	A1	20031231	WO 2003-US19619	20030620
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2489337	AA	20031231	CA 2003-2489337	20030620
US 2004019099	A1	20040129	US 2003-600674	20030620
PRIORITY APPLN. INFO.:			US 2002-390987P	P 20020624
			WO 2003-US19619	W 20030620

OTHER SOURCE(S): MARPAT 140:59522

ED Entered STN: 02 Jan 2004
GI




AB Title compds. I [wherein R1 = (un)substituted indolyl or an aza derivative thereof; R2 = (un)substituted (hetero)aryl, quinolyl, heterocycloalkyl; R12, R13 = alkyl, hydroxyl, alkoxy, etc., or R13 = O; m = independently 0-3; n = 1-3; p = 1-3; q = 1-5; X = a bond or alkylene; Y = CO, CS, COCH2, etc.; Z = a bond, alkylene, alkenylene, CO, etc.; M1 = CH or N; M2 = CR3 or N; and salts or solvates thereof] were prepared as histamine H3 antagonists in treatment of H3 receptor related diseases. For example, reaction of II with 3-(4-piperidinyl)-2-(2-pyridinyl)indole, followed by deprotection and substitution with 2-chloromethylpyridine gave III, which showed 1.50 nM binding constant with histamine H3. Thus, I and their pharmaceutical compds., as well as in combination with H1 receptor antagonists, are useful as histamine H3 antagonists for the treatment of inflammatory diseases, allergic conditions and central nervous system disorders (no data).


IT 58-73-1, Diphenhydramine 486-16-8, Carbinoxamine
562-10-7 68844-77-9, Astemizole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy agent; preparation of indole derivs. as histamine H3 antagonists)

RN 58-73-1 CAPLUS

CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 486-16-8 CAPLUS
CN Ethanamine, 2-[(4-chlorophenyl)-2-pyridinylmethoxy]-N,N-dimethyl- (9CI)
(CA INDEX NAME)




RN 562-10-7 CAPLUS

CN Butanedioic acid, compd. with N,N-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]ethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 469-21-6


CMF C17 H22 N2 O



CM 2


CRN 110-15-6

CMF C4 H6 O4



RN 68844-77-9 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




IT 639505-55-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of indole derivs. as histamine H3 antagonists)

RN 639505-55-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-

(2-phenyl-1H-indol-3-yl) - (9CI) (CA INDEX NAME)




IT 639505-56-9P 639505-57-0P 639505-58-1P
 639505-59-2P 639505-60-5P 639505-61-6P
 639505-62-7P 639505-63-8P 639505-64-9P
 639505-65-0P 639505-66-1P 639505-67-2P
 639505-68-3P 639505-69-4P 639505-70-7P
 639505-71-8P 639505-72-9P 639505-73-0P
 639505-74-1P 639505-75-2P 639505-76-3P
 639505-77-4P 639505-78-5P 639505-79-6P
 639505-80-9P 639505-81-0P 639505-82-1P
 639505-83-2P 639505-84-3P 639505-85-4P
 639505-86-5P 639505-87-6P 639505-88-7P
 639505-89-8P 639505-90-1P 639505-91-2P
 639505-92-3P 639505-93-4P 639505-94-5P
 639505-95-6P 639505-96-7P 639505-97-8P
 639505-98-9P 639505-99-0P 639506-00-6P
 639506-01-7P 639506-02-8P 639506-03-9P
 639506-04-0P 639506-05-1P 639506-06-2P
 639506-07-3P 639506-08-4P 639506-09-5P
 639506-10-8P 639506-11-9P 639506-12-0P
 639506-13-1P 639506-14-2P 639506-15-3P
 639506-16-4P 639506-17-5P 639506-18-6P
 639506-19-7P 639506-21-1P 639506-23-3P
 639506-24-4P 639506-26-6P 639506-27-7P
 639506-28-8P 639506-29-9P 639506-30-2P
 639506-31-3P 639506-32-4P 639506-33-5P
 639506-34-6P 639506-35-7P 639506-36-8P
 639506-37-9P 639506-38-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(preparation of indole derivs. as histamine H3 antagonists)


RN 639505-56-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-
 (6-fluoro-2-phenyl-3-benzofuranyl) - (9CI) (CA INDEX NAME)




RN 639505-57-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-
 (6-fluoro-2-methyl-3-benzofuranyl) - (9CI) (CA INDEX NAME)




RN 639505-58-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(6-fluoro-2-methylbenzo[b]thien-3-yl)- (9CI) (CA INDEX NAME)




RN 639505-59-2 CAPLUS

CN Benzo[b]thiophene-2-carboxylic acid, 3-[1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-piperidinyl]-6-fluoro-, ethyl ester (9CI) (CA INDEX NAME)




RN 639505-60-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(6-fluoro-3-benzofuranyl)- (9CI) (CA INDEX NAME)




RN 639505-61-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-phenyl-1-(phenylmethyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



RN 639505-62-7 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[1-[(4-fluorophenyl)methyl]-2-phenyl-1H-indol-3-yl]- (9CI) (CA INDEX NAME)




RN 639505-63-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-phenyl-1-(2-pyridinylmethyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 639505-64-9 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[1-[(3,5-difluorophenyl)methyl]-2-phenyl-1H-indol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 639505-65-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-phenyl-1-(3-pyridinylmethyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 639505-66-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[1-[(dimethylamino)sulfonyl]-2-phenyl-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



RN 639505-67-2 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[2-(2-pyridinyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)




RN 639505-68-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1-(2-pyridinylmethyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 639505-69-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[1-(3,5-difluorophenyl)-6-fluoro-2-(2-pyridinyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 639505-70-7 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1-(4,4,4-trifluorobutyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



RN 639505-71-8 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[6-fluoro-2-(2-pyridinyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)




RN 639505-72-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[6-fluoro-2-(2-pyridinyl)-1-(2-pyridinylmethyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 639505-73-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(2-pyridinyl)-1-(4,4,4-trifluorobutyl)-1H-indol-3-yl]- (9CI)
(CA INDEX NAME)

RN 639505-75-2 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[1-[2-(4-morpholinyl)ethyl]-2-(2-pyridinyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 639505-76-3 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1-(2-pyridinylmethyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 639505-77-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-
4-[1-[(4-chlorophenyl)methyl]-2-(2-pyridinyl)-1H-indol-3-yl]- (9CI) (CA
INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 639505-78-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-
[1-[(4-chlorophenyl)methyl]-2-(2-pyridinyl)-1H-indol-3-yl]- (9CI) (CA
INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 639505-79-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[1-(phenylmethyl)-2-(2-pyridinyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)




RN 639505-80-9 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-

4-[1-[(3,5-difluorophenyl)methyl]-2-(2-pyridinyl)-1H-indol-3-yl]- (9CI)
(CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 639505-81-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[1-methyl-2-(2-pyridinyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)




RN 639505-82-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[1-ethyl-2-(2-pyridinyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)




RN 639505-83-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)




RN 639505-84-3 CAPLUS

CN Piperidine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(2-pyridinyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)




RN 639505-85-4 CAPLUS

CN Piperidine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(2-pyridinyl)-1-(2-pyridinylmethyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)




RN 639505-86-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(6-fluoro-1H-indol-3-yl)- (9CI) (CA INDEX NAME)




RN 639505-87-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-3-[2-(2-pyridinyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)




RN 639505-88-7 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 639505-89-8 CAPLUS

CN Pyridine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-1,2,3,6-tetrahydro-4-(2-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)




RN 639505-90-1 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-piperidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 639505-91-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(1H-indol-3-yl)- (9CI) (CA INDEX NAME)




RN 639505-92-3 CAPLUS

CN 1H-Indole-2-carboxamide, N-(1-methylethyl)-3-[1,2,3,6-tetrahydro-1-[[1-[[2-[[[(1-methylethyl)amino]carbonyl]amino]-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 639505-93-4 CAPLUS

CN 1H-Indole-2-carboxamide, 3-[1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 639505-94-5 CAPLUS

CN 1H-Indole-2-carboxamide, N-methyl-N-(1-methyl-4-piperidinyl)-3-[1,2,3,6-tetrahydro-1-[[1-[[2-[[[methyl(1-methyl-4-piperidinyl)amino]carbonyl]amino]-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 639505-95-6 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[1,2,3,6-tetrahydro-1-[[1-[[2-[[2-(4-pyridinylamino)carbonyl]amino]-4-pyridinyl]methyl]-4-piperidiny]carbonyl]-4-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 639505-96-7 CAPLUS

CN Piperidine, 1-[[1-[[2-amino-4-pyridinyl]methyl]-4-piperidiny]carbonyl]-4-[1-(3-pyridinylmethyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 639505-97-8 CAPLUS
CN Piperidine, 1-[[1-[[2-[(3-pyridinylmethyl)amino]-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-[1-(3-pyridinylmethyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)


RN 639505-99-0 CAPLUS

CN 1H-Indole-2-carboxamide, 3-[1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-piperidinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 639506-00-6 CAPLUS

CN 1H-Indole-2-carboxamide, 3-[1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 639506-01-7 CAPLUS

CN 1H-Indole-2-carboxamide, 3-[1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-piperidinyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 639506-02-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[3-[1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-piperidinyl]-1H-indol-2-yl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 639506-03-9 CAPLUS


CN 1H-Indole-2-carboxamide, 3-[1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-piperidinyl]-N-methyl-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 639506-04-0 CAPLUS

CN Pyridine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-1,2,3,6-tetrahydro-4-[2-methyl-1-(2-pyridinylmethyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 639506-05-1 CAPLUS

CN Pyridine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-
1,2,3,6-tetrahydro-4-[2-methyl-1-(phenylmethyl)-1H-indol-3-yl]- (9CI) (CA
INDEX NAME)




RN 639506-06-2 CAPLUS

CN Pyridine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-
1,2,3,6-tetrahydro-4-[2-methyl-1-(4,4,4-trifluorobutyl)-1H-indol-3-yl]-
(9CI) (CA INDEX NAME)



RN 639506-07-3 CAPLUS


CN Pyridine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(1-ethyl-2-methyl-1H-indol-3-yl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 639506-08-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-methyl-1-(2-pyridinylmethyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 639506-09-5 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)




RN 639506-10-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-methyl-1-(3-pyridinylmethyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 639506-11-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3-fluorophenyl)-1-methyl-1H-indol-3-yl]- (9CI) (CA INDEX NAME)




RN 639506-12-0 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-piperidinyl]-1-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 639506-13-1 CAPLUS

CN Pyridine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-1,2,3,6-tetrahydro-4-(2-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)






RN 639506-14-2 CAPLUS

CN Piperidine, 4-(1,2-dimethyl-1H-indol-3-yl)-1-[[1-[[2-(methylamino)-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 639506-15-3 CAPLUS

CN Pyridine, 4-[2-(2-aminophenyl)-1H-indol-3-yl]-1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 639506-16-4 CAPLUS

CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)




RN 639506-17-5 CAPLUS

CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)




RN 639506-18-6 CAPLUS

CN Piperidine, 1-[[1-(3-pyridazinylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)




RN 639506-19-7 CAPLUS

CN Piperidine, 1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)




RN 639506-21-1 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(3-pyridazinylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)




RN 639506-23-3 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)




RN 639506-24-4 CAPLUS

CN Piperidine, 1-[[1-[[2-[(phenylmethyl)amino]-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-[2-phenyl-1-(phenylmethyl)-1H-indol-3-yl]- (9CI)
(CA INDEX NAME)




RN 639506-26-6 CAPLUS

CN Piperidine, 1-[[1-[[2-[[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-[1-[(4-fluorophenyl)methyl]-2-phenyl-1H-indol-3-yl]- (9CI) (CA INDEX NAME)




RN 639506-27-7 CAPLUS

CN Piperidine, 1-[[1-[[2-[[[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]amino]-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-[1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-2-phenyl-1H-indol-3-yl]- (9CI) (CA INDEX NAME)




RN 639506-28-8 CAPLUS

CN 2-Pyridinamine, 4-[[4-(2-phenyl-1H-indol-3-yl)[1,4'-bipiperidin]-1'-yl]methyl]- (9CI) (CA INDEX NAME)



RN 639506-29-9 CAPLUS


CN Piperidine, 1-[[1-[[2-(ethylamino)-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-[1-ethyl-2-(2-pyridinyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)




RN 639506-30-2 CAPLUS

CN Piperidine, 1-[[1-[[2-((2-pyridinylmethyl)amino)-5-pyrimidinyl]methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1-(2-pyridinylmethyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 639506-31-3 CAPLUS
CN Piperidine, 1-[[1-[[2-[bis(phenylmethyl)amino]-5-pyrimidinyl]methyl]-4-piperidinyl]carbonyl]-4-[1-(phenylmethyl)-2-(2-pyridinyl)-1H-indol-3-yl]-(9CI) (CA INDEX NAME)



RN 639506-32-4 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[1-pyrazinyl-2-(2-pyridinyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)




RN 639506-33-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[1-[2-(1-piperidinyl)ethyl]-2-(2-pyridinyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 639506-34-6 CAPLUS
CN Piperidine, 1-[[1-(1H-imidazo[4,5-b]pyridin-7-ylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)




RN 639506-35-7 CAPLUS

CN 1H-Indole-2-carboxamide, 1-[1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidiny]carbonyl]-4-piperidiny]-2,3-dihydro-N-methoxy-N-methyl- (9CI)
(CA INDEX NAME)




RN 639506-36-8 CAPLUS

CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)





RN 639506-37-9 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidiny]carbonyl]-4-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)




RN 639506-38-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-2-(1-oxopropyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



IT 3612-20-2, 1-Benzyl-4-piperidone 639505-35-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indole derivs. as histamine H3 antagonists)
RN 3612-20-2 CAPLUS
CN 4-Piperidinone, 1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 639505-35-4 CAPLUS
CN Carbamic acid, [4-[[4-[[4-[6-fluoro-2-(2-pyridinyl)-1H-indol-3-yl]-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 131587-27-4P 416852-10-3P 416852-11-4P
416852-43-2P 416852-78-3P 639505-31-0P
639505-32-1P 639505-36-5P 639505-38-7P
639505-40-1P 639505-41-2P 639505-42-3P
639505-46-7P 639505-47-8P 639505-48-9P
639505-49-0P 639505-50-3P 639505-52-5P
639505-54-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of indole derivs. as histamine H3 antagonists)


RN 131587-27-4 CAPLUS

CN 4-Piperidinamine, N-(4-fluorophenyl)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 416852-10-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 416852-11-4 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]methyl]-, monolithium salt (9CI) (CA INDEX NAME)



● Li


RN 416852-43-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-[bis[(1,1-dimethylethoxy)carbonyl]amino]-5-pyrimidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 416852-78-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(3-amino-4-pyridinyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 639505-31-0 CAPLUS

CN Carbamic acid, [4-[[4-[[4-(2-phenyl-1H-indol-3-yl)-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 639505-32-1 CAPLUS


CN Carbamic acid, [4-[[4-[[4-[1-[(dimethylamino)sulfonyl]-2-phenyl-1H-indol-3-yl]-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 639505-36-5 CAPLUS

CN Carbamic acid, [4-[[4-[[4-[1-(3,5-difluorophenyl)-6-fluoro-2-(2-pyridinyl)-1H-indol-3-yl]-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 639505-38-7 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[1-[[1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 639505-40-1 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[1-[[1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-piperidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 639505-41-2 CAPLUS

CN Carbamic acid, [4-[[4-[[4-(1H-indol-3-yl)-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 639505-42-3 CAPLUS


CN 1H-Indole-2-carboxylic acid, 3-[1-[[1-[[2-[[1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-piperidinyl]-, monolithium salt (9CI) (CA INDEX NAME)



● Li


RN 639505-46-7 CAPLUS

CN	Carbamic acid, [4-[[4-[[4-(2-methyl-1H-indol-3-yl)-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
----	---




RN 639505-47-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-,
monolithium salt (9CI) (CA INDEX NAME)




● Li


RN 639505-48-9 CAPLUS

CN 4-Piperidinamine, N-(4-fluorophenyl)-N-nitroso-1-(phenylmethyl)- (9CI)
(CA INDEX NAME)


RN 639505-49-0 CAPLUS

CN Piperidine, 4-[1-(4-fluorophenyl)hydrazino]-1-(phenylmethyl)- (9CI) (CA
INDEX NAME)

RN 639505-50-3 CAPLUS


CN Ethanone, 1-(2-pyridinyl)-, (4-fluorophenyl)[1-(phenylmethyl)-4-
piperidinyl]hydrazone (9CI) (CA INDEX NAME)

RN 639505-52-5 CAPLUS

CN 1H-Indole, 5-fluoro-1-[1-(phenylmethyl)-4-piperidinyl]-2-(2-pyridinyl)-
(9CI) (CA INDEX NAME)

RN 639505-54-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-[bis[(1,1-dimethylethoxy)carbonyl]amino]-5-pyrimidinyl]methyl]-, lithium salt (9CI) (CA INDEX NAME)



● Li

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 23 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:991348 CAPLUS

DOCUMENT NUMBER: 140:27826

TITLE: Preparation of 1-(4-piperidiny)benzimidazolones as histamine H3 antagonists

INVENTOR(S): Ting, Pauline C.; Aslanian, Robert G.; Berlin, Michael Y.; Boyce, Christopher W.; Cao, Jianhua; Mangiaracina, Pietro; Mc, Cormick Kevin D.; Mutahi, Mwangi W.; Rosenblum, Stuart B.; Shih, Neng-yang; Solomon, Daniel M.; Tom, Wing C.; Zeng, Qingbei

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003103669	A1	20031218	WO 2003-US11696	20030416
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2482551	AA	20031218	CA 2003-2482551	20030416
US 2004048843	A1	20040311	US 2003-414943	20030416
US 2004097483	A1	20040520	US 2003-417391	20030416
EP 1494671	A1	20050112	EP 2003-719770	20030416
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			US 2002-373467P	P 20020418
			US 2002-373731P	P 20020418

WO 2003-US11696

W 20030416

OTHER SOURCE(S): MARPAT 140:27826

ED Entered STN: 21 Dec 2003

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed are histamine H3 antagonists I [a, b = 0-3; n = 1-3; p = 1-3 (with the proviso that when M2 = N, then p is not 1); r = 1-3 (with the proviso that when r = 2 or 3, then M2 = CR3 and p = 2 or 3); A = a bond, alkylene; M1 = CR3, N; M2 = CR3, N; Y = CO, CS, SO, SO2, etc.; Z = a bond, alkylene, alkenylene, CO, CH(CN), etc.; R1 = (un)substituted benzimidazolone, quinazolone, etc.; R2 = (un)substituted aryl or heteroaryl; R3 = H, halo, alkyl, OH, alkoxy; R12, R13 = alkyl, OH, alkoxy, etc.]. Synthesis of representative compds. I is described. Thus, amidation of the amine II with the acid III (prepns. given) afforded 80% the compound IV. The compds. I showed a Ki within the range of about 0.1 to about 1000 nM in H3-receptor binding assay. Also disclosed are pharmaceutical compns. comprising the compds. I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compds. of I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compds. I in combination with a H1 receptor antagonist.


IT 58-73-1, Diphenhydramine 486-16-8, Carbinoxamine

562-10-7 68844-77-9, Astemizole

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-administration; preparation of 1-(4-piperidinyl)benzimidazolones as histamine H3 antagonists for use in combination with an H1 receptor antagonists)


RN 58-73-1 CAPLUS

CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 486-16-8 CAPLUS

CN Ethanamine, 2-[(4-chlorophenyl)-2-pyridinylmethoxy]-N,N-dimethyl- (9CI)
(CA INDEX NAME)




RN 562-10-7 CAPLUS

CN Butanedioic acid, compd. with N,N-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]ethanamine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 469-21-6
CMF C17 H22 N2 O




CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 68844-77-9 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidiny]- (9CI) (CA INDEX NAME)



IT 633309-68-9P 633309-69-0P 633309-70-3P
633309-71-4P 633309-72-5P 633309-73-6P
633309-74-7P 633309-75-8P 633309-76-9P
633309-77-0P 633309-78-1P 633309-79-2P
633309-80-5P 633309-81-6P 633309-82-7P
633309-83-8P 633309-84-9P 633309-85-0P
633309-86-1P 633309-87-2P 633309-88-3P
633309-89-4P 633309-90-7P 633309-91-8P
633309-92-9P 633309-93-0P 633309-94-1P
633309-95-2P 633309-96-3P 633309-97-4P
633309-98-5P 633309-99-6P 633310-00-6P
633310-01-7P 633310-02-8P 633310-03-9P
633310-04-0P 633310-05-1P 633310-06-2P
633310-07-3P 633310-08-4P 633310-09-5P
633310-11-9P 633310-13-1P 633310-15-3P
633310-17-5P 633310-19-7P 633310-21-1P
633310-23-3P 633310-25-5P 633310-26-6P
633310-27-7P 633310-28-8P 633310-29-9P
633310-30-2P 633310-31-3P 633310-32-4P
633310-33-5P 633310-34-6P 633310-35-7P
633310-36-8P 633310-37-9P 633310-38-0P
633310-39-1P 633310-40-4P 633310-41-5P

633310-42-6P 633310-43-7P 633310-44-8P
633310-45-9P 633310-46-0P 633310-47-1P
633310-48-2P 633310-49-3P 633310-50-6P
633310-51-7P 633310-52-8P 633310-53-9P
633310-54-0P 633310-55-1P 633310-56-2P
633310-57-3P 633310-58-4P 633310-59-5P
633310-60-8P 633310-61-9P 633310-62-0P
633310-63-1P 633310-64-2P 633310-65-3P
633310-66-4P 633310-67-5P 633310-68-6P
633310-69-7P 633310-70-0P 633310-71-1P
633310-72-2P 633310-73-3P 633310-74-4P
633310-75-5P 633310-76-6P 633310-77-7P
633310-81-3P 633310-82-4P 633310-83-5P
633310-84-6P 633310-85-7P 633310-86-8P
633310-87-9P 633310-88-0P 633310-89-1P
633310-90-4P 633310-91-5P 633310-92-6P
633310-93-7P 633310-94-8P 633310-95-9P
633310-96-0P 633310-97-1P 633310-98-2P
633310-99-3P 633311-00-9P 633311-01-0P
633311-03-2P 633311-05-4P 633311-06-5P
633311-07-6P 633311-08-7P 633311-09-8P
633311-10-1P 633311-11-2P 633311-12-3P
633311-13-4P 633311-14-5P 633311-15-6P
633311-16-7P 633311-19-0P 633311-21-4P
633311-22-5P 633311-25-8P 633311-40-7P
633311-41-8P 633311-43-0P 633311-44-1P
633311-45-2P 633311-46-3P 633311-47-4P
633311-48-5P 633311-49-6P 633311-50-9P
633311-52-1P 633311-53-2P 633311-54-3P
633311-55-4P 633311-56-5P 633311-57-6P
633311-58-7P 633311-59-8P 633311-60-1P
633311-61-2P 633311-62-3P 633311-63-4P
633311-64-5P 633311-65-6P 633311-66-7P
633311-67-8P 633311-68-9P 633311-69-0P
633311-70-3P 633311-71-4P 633311-72-5P
633311-73-6P 633311-74-7P 633311-75-8P
633311-76-9P 633311-77-0P 633311-78-1P
633311-79-2P 633311-80-5P 633311-81-6P
633311-82-7P 633311-83-8P 633311-84-9P
633311-85-0P 633311-86-1P 633311-87-2P
633311-88-3P 633311-89-4P 633311-94-1P
633311-98-5P 633312-00-2P 633312-01-3P
633312-02-4P 633312-03-5P 633312-04-6P
633312-05-7P 633312-06-8P 633312-07-9P
633312-08-0P 633312-09-1P 633312-10-4P
633312-11-5P 633312-12-6P 633312-13-7P
633312-14-8P 633312-15-9P 633312-16-0P
633312-17-1P 633312-18-2P 633312-19-3P
633312-20-6P 633312-21-7P 633312-22-8P
633312-23-9P 633312-24-0P 633312-25-1P
633312-26-2P 633312-27-3P 633312-28-4P
633312-29-5P 633312-30-8P 633312-31-9P
633312-32-0P 633312-33-1P 633312-34-2P
633312-35-3P 633312-36-4P 633312-37-5P
633312-38-6P 633312-39-7P 633312-40-0P
633312-41-1P 633312-42-2P 633312-43-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of 1-(4-piperidinyl)benzimidazolones as histamine H3

antagonists)


RN 633309-68-9 CAPLUS

CN Piperidine, 4-(5-chloro-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633309-69-0 CAPLUS

CN Piperidine, 4-[5-chloro-2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633309-70-3 CAPLUS

CN Piperidine, 4-[5-chloro-3-(2-ethoxyethyl)-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633309-71-4 CAPLUS

CN Piperidine, 4-(2,3-dihydro-5-methyl-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633309-72-5 CAPLUS

CN Piperidine, 4-(2,3-dihydro-3,5-dimethyl-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633309-73-6 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633309-74-7 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-methyl-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 633309-75-8 CAPLUS


CN Piperidine, 4-[2,3-dihydro-2-oxo-3-(phenylmethyl)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 633309-76-9 CAPLUS


CN Piperidine, 4-[2,3-dihydro-3-(2-hydroxyethyl)-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-

(9CI) (CA INDEX NAME)




RN 633309-77-0 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-
(9CI) (CA INDEX NAME)




RN 633309-78-1 CAPLUS

CN Piperidine, 4-[3-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633309-79-2 CAPLUS

CN Piperidine, 4-(6-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633309-80-5 CAPLUS

CN Piperidine, 4-(6-chloro-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)-1-
[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633309-81-6 CAPLUS

CN Piperidine, 4-[6-chloro-2,3-dihydro-2-oxo-3-(phenylmethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633309-82-7 CAPLUS

CN Piperidine, 4-(5,6-dichloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 633309-83-8 CAPLUS


CN Piperidine, 4-(5,6-dichloro-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 633309-84-9 CAPLUS


CN Piperidine, 4-[5,6-dichloro-2,3-dihydro-2-oxo-3-(phenylmethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-

(9CI) (CA INDEX NAME)



RN 633309-85-0 CAPLUS


CN Piperidine, 4-[5,6-dichloro-2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-
(9CI) (CA INDEX NAME)




RN 633309-86-1 CAPLUS

CN Piperidine, 4-[5,6-dichloro-2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 633309-87-2 CAPLUS


CN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633309-88-3 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-[(4-methoxyphenyl)methyl]-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633309-89-4 CAPLUS
CN Piperidine, 4-[2,3-dihydro-3-[(3-methoxyphenyl)methyl]-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633309-90-7 CAPLUS
CN Piperidine, 4-[3-[(3,5-dimethoxyphenyl)methyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633309-91-8 CAPLUS
CN Piperidine, 4-[3-[(2-chlorophenyl)methyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633309-92-9 CAPLUS
CN Piperidine, 4-[3-[(3-chlorophenyl)methyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 633309-93-0 CAPLUS


CN Piperidine, 4-[2,3-dihydro-3-(2-hydroxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 633309-94-1 CAPLUS

CN Piperidine, 4-[3-[(4-chlorophenyl)methyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633309-95-2 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633309-96-3 CAPLUS

CN Piperidine, 4-[3-(2-ethoxyethyl)-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633309-97-4 CAPLUS

CN Piperidine, 4-[3-(3-ethoxypropyl)-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633309-98-5 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-[2-(1-methylethoxy)ethyl]-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633309-99-6 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-3-(2-phenoxyethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-00-6 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-[2-(2-methoxyethoxy)ethyl]-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-01-7 CAPLUS

CN Piperidine, 4-[3-[2-(dimethylamino)ethyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)



RN 633310-02-8 CAPLUS


CN Piperidine, 4-[3-[3-(dimethylamino)propyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)




RN 633310-03-9 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-3-[2-(1-piperidinyl)ethyl]-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633310-04-0 CAPLUS
CN Piperidine, 4-[2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633310-05-1 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-3-[2-(1-pyrrolidinyl)ethyl]-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)



RN 633310-06-2 CAPLUS


CN Piperidine, 4-[2,3-dihydro-2-oxo-3-[2-(1H-pyrrol-1-yl)ethyl]-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-
(9CI) (CA INDEX NAME)




RN 633310-07-3 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-3-(2-pyridinylmethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633310-08-4 CAPLUS
CN Piperidine, 4-[2,3-dihydro-2-oxo-3-(3-pyridinylmethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 633310-09-5 CAPLUS
CN 1H-Benzimidazole-1-acetic acid, 2,3-dihydro-2-oxo-3-[1-[[1-(4-pyridinylmethyl)-4-piperidiny]carbonyl]-4-piperidiny]-, methyl ester


(9CI) (CA INDEX NAME)




RN 633310-11-9 CAPLUS

CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-[1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-4-piperidinyl]-1H-benzimidazol-1-yl]acetyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 633310-13-1 CAPLUS


CN Piperidine, 4-[5-chloro-2,3-dihydro-3-[2-(1-methylethoxy)ethyl]-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-

(9CI) (CA INDEX NAME)




RN 633310-15-3 CAPLUS

CN Piperidine, 4-[5-chloro-3-(3-ethoxypropyl)-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-
(9CI) (CA INDEX NAME)




RN 633310-17-5 CAPLUS

CN Piperidine, 4-[3-butyl-2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-
(9CI) (CA INDEX NAME)



RN 633310-19-7 CAPLUS


CN Piperidine, 4-[3-(2-ethoxyethyl)-2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-
(9CI) (CA INDEX NAME)



RN 633310-21-1 CAPLUS


CN Piperidine, 4-[2,3-dihydro-3-[2-(1-methylethoxy)ethyl]-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-

piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-23-3 CAPLUS

CN Piperidine, 4-[3-(3-ethoxypropyl)-2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 633310-25-5 CAPLUS


CN Piperidine, 4-[3-[2-(dimethylamino)ethyl]-2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-26-6 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-3-[2-(1-piperidinyl)ethyl]-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633310-27-7 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633310-28-8 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(methoxymethyl)-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-
(9CI) (CA INDEX NAME)




RN 633310-29-9 CAPLUS


CN 1H-Benzimidazole-1-acetic acid, 2,3-dihydro-2-oxo-3-[1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-4-piperidinyl]-6-(trifluoromethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 633310-30-2 CAPLUS
 CN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[1-[1-(4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-31-3 CAPLUS
 CN Piperidine, 4-[2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-[1-(4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 633310-32-4 CAPLUS
 CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-[1-(4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-33-5 CAPLUS
 CN Piperidine, 4-[5-chloro-2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-[1-(4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-34-6 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]-1-[[1-[1-(4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)




RN 633310-35-7 CAPLUS

CN Piperidine, 4-[5-chloro-2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-[1-(4-pyridinyl)propyl]-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)




RN 633310-36-8 CAPLUS

CN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[4-fluoro-1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)




RN 633310-37-9 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-38-0 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[2-methyl-1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-39-1 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[1-(4-pyridinylmethyl)-4-piperidinyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 633310-40-4 CAPLUS


CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 633310-41-5 CAPLUS


CN Piperidine, 1-[[1-[(3-chloro-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-

(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl) - (9CI) (CA INDEX NAME)




RN 633310-42-6 CAPLUS

CN Piperidine, 4-(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-43-7 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(1-methylethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-44-8 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-3-(phenylmethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-45-9 CAPLUS

CN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[1-[(1-oxido-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-46-0 CAPLUS

CN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(3-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-47-1 CAPLUS

CN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(2-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-48-2 CAPLUS

CN Piperidine, 1-[[1-[(3,5-dichloro-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 633310-49-3 CAPLUS

CN Piperidine, 1-[[1-[(3-bromo-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 633310-50-6 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-[(3-fluoro-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-51-7 CAPLUS

CN Piperidine, 4-[3-[2-(acetyloxy)ethyl]-2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-52-8 CAPLUS

CN Piperidine, 4-[3-[2-(benzoyloxy)ethyl]-2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-53-9 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-3-[2-(phenylmethoxy)ethyl]-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-54-0 CAPLUS

CN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 633310-55-1 CAPLUS

CN Piperidine, 1-[[1-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 633310-56-2 CAPLUS

CN Piperidine, 1-[[1-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-4-pyridinyl]methyl]-4-methyl-4-piperidinyl]carbonyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 633310-57-3 CAPLUS

CN Piperidine, 1-[[1-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633310-58-4 CAPLUS

CN Piperidine, 1-[[1-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633310-59-5 CAPLUS

CN Piperidine, 1-[[1-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-[3-[2-(4-fluorophenoxy)ethyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633310-60-8 CAPLUS

CN Piperidine, 1-[[1-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633310-61-9 CAPLUS

CN Piperidine, 1-[[1-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633310-62-0 CAPLUS

CN Piperidine, 1-[[1-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2,3-dihydro-2-oxo-3-(phenylmethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633310-63-1 CAPLUS

CN Piperidine, 4-[3-[1-(3,4-dichlorophenyl)ethyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[[1-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633310-64-2 CAPLUS

CN Piperidine, 1-[[1-[(2-bromo-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 633310-65-3 CAPLUS

CN Piperidine, 1-[[1-[(2-bromo-4-pyridinyl)methyl]-4-methyl-4-piperidinyl]carbonyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 633310-66-4 CAPLUS

CN Piperidine, 1-[[1-[(2-bromo-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633310-67-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 633310-68-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-methyl-4-piperidinyl]carbonyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 633310-69-7 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633310-70-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633310-71-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[3-[2-(4-fluorophenoxy)ethyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633310-72-2 CAPLUS
CN Piperidine, 1-[[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]]-piperidine] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 633310-73-3 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[5-fluoro-2,3-dihydro-2-oxo-3-(phenylmethyl)-1H-benzimidazol-1-yl] - (9CI)
(CA INDEX NAME)




RN 633310-74-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[3-[1-(3,4-dichlorophenyl)ethyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl] - (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 633310-75-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[3-[1-(4'-fluoro[1,1'-biphenyl]-4-yl)ethyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633310-76-6 CAPLUS
CN Piperidine, 1-[[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[3-[1-(3,4-dichlorophenyl)ethyl]-5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633310-77-7 CAPLUS

CN Piperidine, 1-[[1-[[2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-3-[1-(4'-fluoro[1,1'-biphenyl]-4-yl)ethyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633310-81-3 CAPLUS

CN Piperidine, 1-[[1-[[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633310-82-4 CAPLUS

CN Piperidine, 1-[[1-[[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633310-83-5 CAPLUS

CN Piperidine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633310-84-6 CAPLUS

CN Piperidine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-[3-[1-(3,4-dichlorophenyl)ethyl]-5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633310-85-7 CAPLUS

CN Piperidine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2,3-dihydro-2-oxo-3-(phenylmethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633310-86-8 CAPLUS

CN Piperidine, 1-[[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-methyl-4-piperidinyl]carbonyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)]- (9CI)
(CA INDEX NAME)




RN 633310-87-9 CAPLUS

CN Piperidine, 1-[[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]]- (9CI)
(CA INDEX NAME)




RN 633310-88-0 CAPLUS

CN Piperidine, 1-[[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-[3-[2-(4-fluorophenoxy)ethyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]]- (9CI) (CA INDEX NAME)



RN 633310-89-1 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-2-oxo-3-(4,4,4-trifluorobutyl)-1H-benzimidazol-1-yl]- (9CI)
(CA INDEX NAME)




RN 633310-90-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[3-[(4-chlorophenyl)methyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633310-91-5 CAPLUS

CN Piperidine, 4-[3-[(2-amino-4-pyridinyl)methyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633310-92-6 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633310-93-7 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[5-chloro-2,3-dihydro-2-oxo-3-(3-pyridinyl)-1H-benzimidazol-1-yl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 633310-94-8 CAPLUS


CN Piperidine, 1-[[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[5-fluoro-2,3-dihydro-2-oxo-3-(4,4,4-trifluorobutyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 633310-95-9 CAPLUS

CN Piperidine, 1-[[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[3-(cyclohexylmethyl)-5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 633310-96-0 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(3-cyclopentyl-5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
(CA INDEX NAME)



RN 633310-97-1 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2,3-dihydro-3-(2-methylpropyl)-2-oxo-1H-benzimidazol-1-yl]-

(9CI) (CA INDEX NAME)




RN 633310-98-2 CAPLUS

CN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(4-quinolinylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)



RN 633310-99-3 CAPLUS


CN 1H-Benzimidazole-1-acetic acid, 2,3-dihydro-2-oxo-3-[1-[[1-(4-pyridinylmethyl)-4-piperidiny]carbonyl]-4-piperidiny]- (9CI) (CA INDEX NAME)



RN 633311-00-9 CAPLUS

CN Piperidine, 4-(3-butyl-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[1-[(1R)-1-(4-pyridinyl)ethyl]-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633311-01-0 CAPLUS


CN Piperidine, 4-(3-butyl-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[1-[(1S)-1-(4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633311-03-2 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-[1-methyl-1-(4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-05-4 CAPLUS

CN Piperidine, 4-[5-fluoro-2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 633311-06-5 CAPLUS


CN Piperidine, 4-[5-fluoro-2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-[1-(4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)




RN 633311-07-6 CAPLUS

CN Piperidine, 4-[5-fluoro-2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633311-08-7 CAPLUS

CN Piperidine, 4-[5-fluoro-2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]-1-[[1-[1-(4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-09-8 CAPLUS

CN Piperidine, 4-(5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-10-1 CAPLUS

CN Piperidine, 4-(5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[1-[1-(4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-11-2 CAPLUS

CN Piperidine, 4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-12-3 CAPLUS

CN Piperidine, 4-(5-fluoro-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 633311-13-4 CAPLUS


CN Piperidine, 4-[5-chloro-2,3-dihydro-2-oxo-3-(phenylmethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-14-5 CAPLUS

CN Piperidine, 4-[5-chloro-2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 633311-15-6 CAPLUS

CN Piperidine, 4-[5-chloro-2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]-1-[[1-[(1R)-1-(4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 633311-16-7 CAPLUS


CN Piperidine, 4-[5-chloro-2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]-1-[[1-[(1S)-1-(4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 633311-19-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-N-[1-(4-pyridinylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 633311-21-4 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 633311-22-5 CAPLUS

CN 1-Piperidinecarboximidamide, N-cyano-4-[2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-N'-[1-(4-pyridinylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 633311-25-8 CAPLUS

CN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[1-[2-(4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-40-7 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-[3-(4-pyridinyl)propyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-41-8 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-[3-(3-pyridinyl)propyl]-4-piperidinyl]carbonyl]-
(9CI) (CA INDEX NAME)




RN 633311-43-0 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-[4-(4-pyridinyl)butyl]-4-piperidinyl]carbonyl]-
(9CI) (CA INDEX NAME)




RN 633311-44-1 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-[2-(2-fluoro-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-45-2 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-[4-(2-methyl-4-pyridinyl)butyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-46-3 CAPLUS
 CN Piperidine, 4-[2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]-1-[[1-[(2-fluoro-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 633311-47-4 CAPLUS
 CN Piperidine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 633311-48-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[3-(cyclopropylmethyl)-5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)



RN 633311-49-6 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[3-(3,3-dimethylbutyl)-5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 633311-50-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[3-(4-chlorophenyl)-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633311-52-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidiny]carbonyl]-4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-9-chloro-9H-fluoren-9-ylmethane (9CI) (CA INDEX NAME)




RN 633311-53-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidiny]carbonyl]-4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-9-chloro-9H-fluoren-9-ylmethane (9CI) (CA INDEX NAME)



RN 633311-54-3 CAPLUS


CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633311-55-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2,3-dihydro-2-oxo-3-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633311-56-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[3-(3,5-dichlorophenyl)-5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633311-57-6 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[3-(3,4-difluorophenyl)-5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633311-58-7 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-(5-fluoro-2,3-dihydro-2-oxo-3-pyrazinyl-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633311-59-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2,3-dihydro-2-oxo-3-(2-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633311-60-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[5-fluoro-3-(3-fluorophenyl)-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633311-61-2 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2,3-dihydro-3-(6-methyl-2-pyridinyl)-2-oxo-1H-benzimidazol-1-yl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633311-62-3 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2,3-dihydro-3-(4-methylphenyl)-2-oxo-1H-benzimidazol-1-yl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633311-63-4 CAPLUS

CN Benzoic acid, 3-[3-[1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-piperidinyl]-6-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633311-64-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-(5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 633311-65-6 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[5-fluoro-2,3-dihydro-2-oxo-3-(2,2,2-trifluoroethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633311-66-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[3-(3,5-difluorophenyl)-5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633311-67-8 CAPLUS

CN Piperidine, 4-[5-chloro-3-(3,5-difluorophenyl)-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633311-68-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[5-chloro-3-(3,5-difluorophenyl)-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633311-69-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[5-chloro-3-(3,5-dichlorophenyl)-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 633311-70-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-[5-chloro-3-(3,5-difluorophenyl)-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-9-chloride (CA INDEX NAME)




RN 633311-71-4 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-2-oxo-3-(2-pyridinyl)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-9-chloride

yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633311-72-5 CAPLUS

CN Piperidine, 1-[[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[3-(3,5-difluorophenyl)-2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633311-73-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-2-oxo-3-phenyl-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633311-74-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633311-75-8 CAPLUS

CN Pyridine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1,2,3,6-tetrahydro-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-76-9 CAPLUS

CN Pyridine, 4-[3-[2-(dimethylamino)ethyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1,2,3,6-tetrahydro-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-77-0 CAPLUS

CN Pyridine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1,2,3,6-tetrahydro-1-[[1-[[1-[1-(4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-78-1 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(3-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-79-2 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(2-pyridinylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-80-5 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-[(1-oxido-4-pyridinyl)methyl]-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-81-6 CAPLUS

CN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[4-methyl-1-[1-(4-pyridinyl)ethyl]-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-82-7 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[4-methyl-1-(4-pyridinylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-83-8 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[4-hydroxy-1-(4-pyridinylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-84-9 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-[1-(4-pyridinyl)ethyl]-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-85-0 CAPLUS

CN Piperidine, 4-[5-chloro-2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-[1-(4-pyridinyl)ethyl]-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-86-1 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-3-(3-oxobutyl)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[4-methyl-1-(4-pyridinylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-87-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633311-88-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633311-89-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 633311-94-1 CAPLUS

CN Piperidine, 4-[[4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-piperidinyl]carbonyl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633311-98-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-piperidiny]carbonyl]-N-[1-(4-pyridinylmethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)




RN 633312-00-2 CAPLUS

CN Piperidine, 1-[[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[[4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-01-3 CAPLUS

CN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[1-[[2-[[[4-methoxyphenyl)methyl]amino]-4-pyridinyl]methyl]-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)



RN 633312-02-4 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[1,2-dihydro-2-oxo-1-(4,4,4-trifluorobutyl)-3H-imidazo[4,5-b]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 633312-03-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[1-(3,5-difluorophenyl)-1,2-dihydro-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 633312-04-6 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-c]pyridin-1-yl)- (9CI) (CA INDEX NAME)




RN 633312-05-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[7-(3,5-difluorophenyl)-7,8-dihydro-8-oxo-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633312-06-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[3-(3,5-difluorophenyl)-2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyrazin-1-yl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633312-07-9 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[1,2-dihydro-2-oxo-1-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633312-08-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[7-chloro-1,4-dihydro-1-(2-methoxyethyl)-2-oxo-3(2H)-quinazolinyl]-(9CI) (CA INDEX NAME)




RN 633312-09-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[7-chloro-1,4-dihydro-1-(2-methoxyethyl)-2-oxo-3(2H)-quinazolinyl]-(9CI) (CA INDEX NAME)




RN 633312-10-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[7-chloro-1,4-dihydro-1-(2-methoxyethyl)-2-oxo-3(2H)-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 633312-11-5 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[7-chloro-1,4-dihydro-1-(2-methoxyethyl)-2-oxo-3(2H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 633312-12-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633312-13-7 CAPLUS

CN Piperidine, 4-[(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)methyl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-14-8 CAPLUS

CN Piperidine, 4-(1,2-dihydro-1-methyl-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)-1-[[1-[[5-[(dimethylamino)methyl]-2-furanyl]methyl]-4-fluoro-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-15-9 CAPLUS

CN Piperidine, 1-[[1-[[5-(aminomethyl)-2-furanyl]methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(1,2-dihydro-1-methyl-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 633312-16-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(1,2-dihydro-1-methyl-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 633312-17-1 CAPLUS

CN Piperidine, 4-(1,2-dihydro-1-methyl-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)-1-[[1-(3-furanylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-18-2 CAPLUS

CN Piperidine, 4-(5-fluoro-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-19-3 CAPLUS

CN Piperidine, 4-(5-fluoro-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)-1-
[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA
INDEX NAME)




RN 633312-20-6 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-
1-[[1-(3-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-21-7 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-
1-[[1-(2-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-22-8 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-
1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX
NAME)




RN 633312-23-9 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-[(6-methoxy-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-24-0 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-[(1-methyl-1H-pyrrol-3-yl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-25-1 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(3-furanylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-26-2 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-27-3 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(2-furanylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-28-4 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(2-thienylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-29-5 CAPLUS

CN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(3-furanylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-30-8 CAPLUS

CN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[1-(3-thienylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-31-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-thiazolyl)methyl]-4-piperidinyl]carbonyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 633312-32-0 CAPLUS


CN Piperidine, 1-[[1-[[2-[(aminoiminomethyl)amino]-4-thiazolyl]methyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633312-33-1 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]-1-[[1-[(1,2-dihydro-2-oxo-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633312-34-2 CAPLUS

CN Piperidine, 1-[[1-[[2-(aminomethyl)-4-thiazolyl]methyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633312-35-3 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(1H-pyrrol-2-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-36-4 CAPLUS

CN Piperidine, 1-[[1-[2-(2-amino-4-thiazolyl)ethyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633312-37-5 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(phenylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-38-6 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(phenylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-39-7 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-40-0 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(3-furanylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-41-1 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-42-2 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 633312-43-3 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(2-furanylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




IT 633312-44-4P 633312-45-5P 633312-46-6P
 633312-96-6P 633312-97-7P 633312-98-8P
 633312-99-9P 633313-00-5P 633313-01-6P
 633313-02-7P 633313-03-8P 633313-04-9P
 633313-05-0P 633313-06-1P 633313-07-2P
 633313-08-3P 633313-09-4P 633313-10-7P
 633313-11-8P 633313-66-3P 633313-67-4P
 633313-68-5P 633313-69-6P 633313-70-9P
 633313-71-0P 633313-72-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-(4-piperidinyl)benzimidazolones as histamine H3 antagonists)


RN 633312-44-4 CAPLUS

CN Piperidine, 1-[[1-(cyclohexylmethyl)-4-fluoro-4-piperidinyl]carbonyl]-4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633312-45-5 CAPLUS

CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(2-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 633312-46-6 CAPLUS


CN Piperidine, 4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(2-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633312-96-6 CAPLUS

CN Piperidine, 4-[3-[(2-amino-4-pyridinyl)methyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 633312-97-7 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[3-(cyclopropylmethyl)-5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633312-98-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[3-(3,4-difluorophenyl)-5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633312-99-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-fluoro-2,3-dihydro-2-oxo-3-pyrazinyl-1H-benzimidazol-1-yl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633313-00-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidyl]carbonyl]-
4-[5-fluoro-2,3-dihydro-3-(6-methyl-2-pyridinyl)-2-oxo-1H-benzimidazol-1-
yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633313-01-6 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidiny]carbonyl]-
4-[3-(3,5-difluorophenyl)-5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633313-02-7 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-
4-[2,3-dihydro-2-oxo-3-(2-pyridinyl)-5-(trifluoromethyl)-1H-benzimidazol-1-
yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 633313-03-8 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidiny]carbonyl]-4-[5-fluoro-2,3-dihydro-2-oxo-3-(4,4,4-trifluorobutyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633313-04-9 CAPLUS

CN Piperidine, 4-[3-[(2-amino-4-pyridinyl)methyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 633313-05-0 CAPLUS
CN Piperidine, 4-[3-(cyclopropylmethyl)-5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)




RN 633313-06-1 CAPLUS
CN Piperidine, 4-[3-(3,4-difluorophenyl)-5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl] -

(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633313-07-2 CAPLUS
CN Piperidine, 4-(5-fluoro-2,3-dihydro-2-oxo-3-pyrazinyl-1H-benzimidazol-1-yl)-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633313-08-3 CAPLUS
CN Piperidine, 4-[5-fluoro-2,3-dihydro-3-(6-methyl-2-pyridinyl)-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidiny]carbonyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633313-09-4 CAPLUS
CN Piperidine, 4-[3-(3,5-difluorophenyl)-5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidyl]carbonyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633313-10-7 CAPLUS

CN Piperidine, 4-[2,3-dihydro-2-oxo-3-(2-pyridinyl)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633313-11-8 CAPLUS

CN Piperidine, 4-[5-fluoro-2,3-dihydro-2-oxo-3-(4,4,4-trifluorobutyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 633313-66-3 CAPLUS

CN Piperidine, 1-[[1-[(6-amino-3-pyridinyl)methyl]-4-methyl-4-piperidyl]carbonyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 633313-67-4 CAPLUS


CN Piperidine, 1-[[1-[(6-amino-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 633313-68-5 CAPLUS

CN Piperidine, 1-[[1-[(6-amino-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2,3-dihydro-3-[2-(4-morpholinyl)ethyl]-2-oxo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633313-69-6 CAPLUS
CN Piperidine, 1-[[1-[(6-amino-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[3-[1-(3,4-dichlorophenyl)ethyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 633313-70-9 CAPLUS
CN Piperidine, 1-[[1-[(6-amino-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[3-[2-(4-fluorophenoxy)ethyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)

(9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 633313-71-0 CAPLUS
 CN Piperidine, 1-[[1-[(6-amino-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-
 (9CI) (CA INDEX NAME)



RN 633313-72-1 CAPLUS
 CN Piperidine, 1-[[1-[(6-amino-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[3-[1-(4'-fluoro[1,1'-biphenyl]-4-yl)ethyl]-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl]-
 (9CI) (CA INDEX NAME)




IT 138030-54-3P 416852-10-3P 416852-11-4P
 416852-14-7P 460094-98-8P 633312-47-7P
 633312-48-8P 633312-74-0P 633312-77-3P
 633312-85-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 1-(4-piperidinyl)benzimidazolones as histamine H3
 antagonists)


RN 138030-54-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-(4-pyridinylmethyl)-, ethyl ester (9CI)
 (CA INDEX NAME)




RN 416852-10-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-
 pyridinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 416852-11-4 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]methyl]-, monolithium salt (9CI) (CA INDEX NAME)



● Li

RN 416852-14-7 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-(4-pyridinylmethyl)-, lithium salt (9CI)
(CA INDEX NAME)




● Li

RN 460094-98-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[1-(4-pyridinyl)ethyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 633312-47-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[1-(4-pyridinyl)propyl]-, lithium salt
(9CI) (CA INDEX NAME)


● Li

RN 633312-48-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-fluoro-1-(4-pyridinylmethyl)-, ethyl ester
(9CI) (CA INDEX NAME)


RN 633312-74-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 633312-77-3 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-(4-piperidinylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 633312-85-3 CAPLUS

CN Carbamic acid, [4-[[4-[[4-[2,3-dihydro-2-oxo-3-(4,4,4-trifluorobutyl)-1H-benzimidazol-1-yl]-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 24 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:855801 CAPLUS

DOCUMENT NUMBER: 139:350734

TITLE: Preparation of 1-(4-piperidinyl)benzimidazoles as histamine H3 antagonists

INVENTOR(S): Zeng, Qingbei; Aslanian, Robert G.; Berlin, Michael Y.; Boyce, Christopher W.; Cao, Jianhua; Kozlowski, Joseph A.; Mangiaracina, Pietro; McCormick, Kevin D.; Mutahi, Mwangi W.; Rosenblum, Stuart B.; Shih, Neng-Yang; Solomon, Daniel M.; Tom, Wing C.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 132 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003088967	A1	20031030	WO 2003-US11672	20030416
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2481940	AA	20031030	CA 2003-2481940	20030416
US 2004097483	A1	20040520	US 2003-417391	20030416
EP 1499316	A1	20050126	EP 2003-719766	20030416
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			

BR 2003009348
PRIORITY APPLN. INFO.:

A 20050301



BR 2003-9348
US 2002-373731P
US 2002-373467P
WO 2003-US11672

20030416
P 20020418
P 20020418
W 20030416

OTHER SOURCE(S): MARPAT 139:350734

ED Entered STN: 31 Oct 2003

GI



II

AB The title compds. [I; R1 = (un)substituted benzimidazolyl or a derivative thereof; R2 = (un)substituted aryl or heteroaryl; M1, M2 = CR3, N; X = a bond, alkylene; Y = CO, CS, SO2, etc.; Z = a bond, alkylene, CO, etc.; R3 = H, halo, alkyl, etc.; R12 = alkyl, OH, alkoxy, etc.; R13 = alkyl, alkoxy, OH, etc.; a, b = 0-2; n, p = 1-3; r = 0-3; with the provisos] which are histamine H3 antagonists, were prepared E.g., a multi-step synthesis of II which showed Ki of 1 nM in rHu H3 binding assay, was given. Also disclosed are pharmaceutical compns. comprising the compds. of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compds. I. Also disclosed are methods of treating said diseases or conditions using the compds. of formula I in combination with an H1 receptor antagonist.

IT 58-73-1, Diphenhydramine 486-16-8, Carbinoxamine

562-10-7 68844-77-9, Astemizole

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(H1 **receptor** antagonist; preparation of 1-(4-piperidinyl)benzimidazoles as histamine H3 antagonists for use in combination with an H1 **receptor** antagonist)

RN 58-73-1 CAPLUS

CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)

Ph₂CH-O-CH₂-CH₂-NMe₂

RN 486-16-8 CAPLUS
 CN Ethanamine, 2-[(4-chlorophenyl)-2-pyridinylmethoxy]-N,N-dimethyl- (9CI)
 (CA INDEX NAME)




RN 562-10-7 CAPLUS
 CN Butanedioic acid, compd. with N,N-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]ethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 469-21-6

CMF C17 H22 N2 O




CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 68844-77-9 CAPLUS
 CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



IT 618892-71-0P 618892-72-1P 618892-73-2P
 618892-75-4P 618892-76-5P 618892-77-6P

618892-79-8P 618892-80-1P 618892-81-2P
618892-83-4P 618892-85-6P 618892-87-8P
618892-88-9P 618892-90-3P 618892-92-5P
618892-94-7P 618892-96-9P 618892-98-1P
618893-00-8P 618893-01-9P 618893-02-0P
618893-03-1P 618893-04-2P 618893-06-4P
618893-08-6P 618893-10-0P 618893-12-2P
618893-14-4P 618893-16-6P 618893-18-8P
618893-20-2P 618893-22-4P 618893-24-6P
618893-26-8P 618893-27-9P 618893-29-1P
618893-31-5P 618893-33-7P 618893-35-9P
618893-37-1P 618893-38-2P 618893-40-6P
618893-42-8P 618893-44-0P 618893-46-2P
618893-48-4P 618893-50-8P 618893-52-0P
618893-54-2P 618893-56-4P 618893-59-7P
618893-61-1P 618893-63-3P 618893-65-5P
618893-67-7P 618893-68-8P 618893-69-9P
618893-71-3P 618893-73-5P 618893-75-7P
618893-77-9P 618893-79-1P 618893-81-5P
618893-82-6P 618893-83-7P 618893-85-9P
618893-86-0P 618893-87-1P 618893-89-3P
618893-91-7P 618893-92-8P 618893-93-9P
618893-94-0P 618893-95-1P 618893-96-2P
618893-97-3P 618893-99-5P 618894-00-1P
618894-01-2P 618894-02-3P 618894-04-5P
618894-06-7P 618894-07-8P 618894-09-0P
618894-11-4P 618894-13-6P 618894-15-8P
618894-17-0P 618894-19-2P 618894-21-6P
618894-23-8P 618894-25-0P 618894-27-2P
618894-28-3P 618894-29-4P 618894-30-7P
618894-31-8P 618894-32-9P 618894-33-0P
618894-34-1P 618894-35-2P 618894-36-3P
618894-37-4P 618894-38-5P 618894-39-6P
618894-40-9P 618894-41-0P 618894-42-1P
618894-43-2P 618894-44-3P 618894-45-4P
618894-46-5P 618894-47-6P 618894-48-7P
618894-49-8P 618894-50-1P 618894-51-2P
618894-52-3P 618894-53-4P 618894-54-5P
618894-55-6P 618894-56-7P 618894-57-8P
618894-58-9P 618894-59-0P 618894-60-3P
618894-61-4P 618894-62-5P 618894-63-6P
618894-64-7P 618894-65-8P 618894-66-9P
618894-67-0P 618894-68-1P 618894-69-2P
618894-70-5P 618894-71-6P 618894-72-7P
618894-73-8P 618894-74-9P 618894-75-0P
618894-76-1P 618894-77-2P 618894-78-3P
618894-79-4P 618894-80-7P 618894-81-8P
618894-82-9P 618894-83-0P 618894-84-1P
618894-85-2P 618894-86-3P 618894-87-4P
618894-88-5P 618894-89-6P 618894-90-9P
618894-91-0P 618894-92-1P 618894-93-2P
618894-94-3P 618894-95-4P 618894-96-5P
618894-97-6P 618894-98-7P 618894-99-8P
618895-00-4P 618895-01-5P 618895-02-6P
618895-03-7P 618895-04-8P 618895-05-9P
618895-06-0P 618895-07-1P 618895-08-2P
618895-09-3P 618895-10-6P 618895-11-7P
618895-12-8P 618895-13-9P 618895-14-0P
618895-15-1P 618895-16-2P 618895-17-3P
618895-18-4P 618895-19-5P 618895-20-8P


618895-21-9P 618895-22-0P 618895-23-1P
618895-24-2P 618895-25-3P 618895-26-4P
618895-27-5P 618895-28-6P 618895-29-7P
618895-30-0P 618895-31-1P 618895-32-2P
618895-33-3P 618895-34-4P 618895-35-5P
618895-36-6P 618895-37-7P 618895-38-8P
618895-39-9P 618895-40-2P 618895-41-3P
618895-42-4P 618895-43-5P 618895-44-6P
618895-45-7P 618895-46-8P 618895-47-9P
618895-48-0P 618895-49-1P 618895-50-4P
618895-51-5P 618895-52-6P 618895-53-7P
618895-54-8P 618895-56-0P 618895-57-1P
618895-58-2P 618895-59-3P 618895-60-6P
618895-61-7P 618895-62-8P 618895-63-9P
618895-64-0P 618895-65-1P 618895-66-2P
618895-67-3P 618895-68-4P 618895-69-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of 1-(4-piperidinyl)benzimidazoles as histamine H3 antagonists)


RN 618892-71-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618892-72-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618892-73-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 618892-75-4 CAPLUS

CN 4-Piperidinamine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-[1-(4,4,4-trifluorobutyl)-1H-benzimidazol-2-yl]-(9CI) (CA INDEX NAME)




RN 618892-76-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)




RN 618892-77-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[[[(4-fluorophenyl)amino]carbonyl]amino]-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618892-79-8 CAPLUS

CN Piperidine, 1-[[1-[[2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-methoxy-2-methyl-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618892-80-1 CAPLUS

CN Piperidine, 1-[[1-[[2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(6-chloro-2-methyl-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618892-81-2 CAPLUS

CN Piperidine, 1-[[1-[[2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-bromo-2-methyl-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618892-83-4 CAPLUS

CN Piperidine, 1-[[1-[[2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-bromo-2-methyl-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618892-85-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-chloro-2-cyclohexyl-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618892-87-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(phenylmethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618892-88-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-bromo-2-(1-methylethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618892-90-3 CAPLUS

CN Piperidine, 4-[2-(aminomethyl)-1H-benzimidazol-1-yl]-1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618892-92-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[(methylsulfonyl)amino]methyl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618892-94-7 CAPLUS

CN Acetamide, N-[[1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-piperidinyl]-5-chloro-1H-benzimidazol-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 618892-96-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(methoxymethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618892-98-1 CAPLUS

CN Piperidine, 4-[2-(aminomethyl)-5-chloro-1H-benzimidazol-1-yl]-1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618893-00-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6,7-difluoro-2-(methoxymethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-01-9 CAPLUS



CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(tetrahydro-2H-pyran-4-yl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618893-02-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(tetrahydro-2H-pyran-4-yl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618893-03-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(tetrahydro-2-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618893-04-2 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(5-oxo-2-pyrrolidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618893-06-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-oxo-4-imidazolidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618893-08-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-bromo-2-(tetrahydro-2-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618893-10-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(tetrahydro-3-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)






RN 618893-12-2 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(tetrahydro-2-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618893-14-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2,4-difluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-16-6 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3,5-difluorophenyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-18-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(4-fluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-20-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3,4-difluorophenyl)-6,7-difluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-22-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-chloro-2-(4-fluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-24-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[5-fluoro-2-(4-fluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-26-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[5-chloro-2-(3,5-difluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-27-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[2-(3,4-difluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-29-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[5-chloro-2-(4-fluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-31-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-(5-chloro-2-phenyl-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618893-33-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[2-(1,3-benzodioxol-5-yl)-6-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-35-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-bromo-2-(2-fluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-37-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-bromo-2-(3,4-difluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-38-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-chlorophenyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-40-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-hydroxyphenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-42-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-benzofuranyl)-6-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-44-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(2-quinolinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-46-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-48-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3,5-dichlorophenyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-50-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(4-chlorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-52-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-chloro-2-(4-chlorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-54-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(2-methoxyphenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-56-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-trifluoromethylphenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-59-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(3,5-dichlorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-61-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[5-fluoro-2-(2-(trifluoromethoxy)phenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-63-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[5-bromo-2-(2-methoxyphenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-65-5 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[6-chloro-2-(3,5-dichlorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-67-7 CAPLUS
 CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-ethoxy-3-fluorophenyl)-5-methyl-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618893-68-8 CAPLUS
 CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-69-9 CAPLUS
 CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[3,5-bis(trifluoromethyl)phenyl]-5-bromo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-71-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-ethoxy-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-73-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(1-oxido-2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-75-7 CAPLUS

CN Piperidine, 4-[2-(2-amino-3-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618893-77-9 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618893-79-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-81-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-82-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-83-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(6-fluoro-2-pyrazinyl-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618893-85-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[7-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-86-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-87-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-fluoro-2-pyrazinyl-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618893-89-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-chloro-2-pyrazinyl-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618893-91-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-92-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-93-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-94-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-ethoxy-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-95-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(6-methyl-2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618893-96-2 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618893-97-3 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-

[5-bromo-2-(1-oxido-2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-99-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-00-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(4-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-01-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-chloro-2-pyridinyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-02-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-pyrimidinyl)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-04-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-06-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-chloro-2-pyridinyl)-6,7-difluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-07-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6,7-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-09-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(1,2-dihydro-2-oxo-3-pyridinyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-11-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-chloro-2-pyridinyl)-7-fluoro-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-13-6 CAPLUS

CN Piperidine, 4-[2-(2-amino-4-pyridinyl)-5-fluoro-1H-benzimidazol-1-yl]-1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618894-15-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-17-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidyl]carbonyl]-4-[2-(2-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-19-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(1H-pyrrol-2-yl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-21-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(3-thienyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-23-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(3-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-25-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-27-2 CAPLUS



CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-thienyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618894-28-3 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-29-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-30-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-thienyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-31-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6,7-difluoro-2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-32-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-bromo-2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-33-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-ethoxy-2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-34-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(3-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-35-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-bromo-2-(1H-pyrrol-2-yl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-36-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(1H-pyrrol-2-yl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-37-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-38-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[7-fluoro-2-(5-methyl-3-isoxazolyl)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-39-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[5-(4-fluorophenyl)-3-isoxazolyl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-40-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-methyl-3-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-41-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[5-(1,1-dimethylethyl)-2-methyl-3-furanyl]-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-42-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(3-methyl-2-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-43-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(methylthio)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-44-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(ethylthio)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-45-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(methanesulfonyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-46-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(phenylthio)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-47-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[(1-methylethyl)thio]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-48-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[(2,2,2-trifluoroethyl)thio]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-49-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[[2-(dimethylamino)ethyl]thio]-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-50-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-fluoro-2,3-dihydro-2-thioxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618894-51-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-2-methyl-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(methylthio)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618894-52-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(methylthio)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)



RN 618894-53-4 CAPLUS



CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinylamino)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 618894-54-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-morpholinyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618894-55-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[4-(methylsulfonyl)-1-piperazinyl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-56-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(phenylamino)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-57-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[(2,4-difluorophenyl)amino]-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-58-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[(2,4-difluorophenyl)methylamino]-5-fluoro-1H-benzimidazol-1-yl]- (9CI)
(CA INDEX NAME)




RN 618894-59-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[(4-fluorophenyl)(methylsulfonyl)amino]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-60-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[(4-fluorophenyl)amino]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-61-4 CAPLUS

CN Piperidine, 1-[[1-[[2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[4-[(trifluoromethyl)sulfonyl]-1-piperazinyl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-62-5 CAPLUS

CN Piperidine, 1-[[1-[[2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[(2-methoxyethyl)amino]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-63-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[1-[1-[[1-[[2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-piperidinyl]-5-fluoro-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 618894-64-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(dimethylamino)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-65-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-fluoro-2-methoxy-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618894-66-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-ethoxy-5-fluoro-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618894-67-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-methoxyethoxy)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-68-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(1-methylethoxy)-1H-benzimidazol-1-yl] - (9CI) (CA INDEX NAME)




RN 618894-69-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-fluoro-2-phenoxy-1H-benzimidazol-1-yl) - (9CI) (CA INDEX NAME)



RN 618894-70-5 CAPLUS


CN Piperidine, 4-[2-(6-amino-3-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl] - (9CI) (CA INDEX NAME)



RN 618894-71-6 CAPLUS



CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[7-fluoro-2-(2-pyridinyl)-5-(trifluoromethyl)-1H-benzimidazol-1-yl] - (9CI)

(CA INDEX NAME)




RN 618894-72-7 CAPLUS

CN Piperidine, 1-[[1-[[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-73-8 CAPLUS

CN Piperidine, 1-[[1-[[1-(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-74-9 CAPLUS

CN Piperidine, 1-[[1-[[1-(2-amino-4-pyridinyl)methyl]-4-hydroxy-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-75-0 CAPLUS

CN Piperidine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-76-1 CAPLUS

CN Piperidine, 1-[[1-[1-(2-amino-4-pyridinyl)methyl]-4-methyl-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-77-2 CAPLUS

CN Piperidine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-78-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-(5-fluoro-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 618894-79-4 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[2-(2,5-dimethyl-3-furanyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618894-80-7 CAPLUS



CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-

[2-(4,5-dimethyl-2-furanyl)-5-fluoro-1H-benzimidazol-1-yl] - (9CI) (CA INDEX NAME)





RN 618894-81-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[5-methyl-2-(trifluoromethyl)-3-furanyl]-1H-benzimidazol-1-yl] - (9CI) (CA INDEX NAME)




RN 618894-82-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)-1H-benzimidazol-1-yl] - (9CI) (CA INDEX NAME)




RN 618894-83-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[5-(trifluoromethyl)-2-furanyl]-1H-benzimidazol-1-yl]- (9CI)
(CA INDEX NAME)




RN 618894-84-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-85-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[[2-(dimethylamino)ethyl]amino]-5-fluoro-1H-benzimidazol-1-yl]- (9CI)
(CA INDEX NAME)




RN 618894-86-3 CAPLUS

CN Piperidine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(methylthio)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-87-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-2-methyl-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-88-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(3-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-89-6 CAPLUS


CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-90-9 CAPLUS
 CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-thiomorpholinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618894-91-0 CAPLUS
 CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(1-piperidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-92-1 CAPLUS
 CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(2-ethoxy-5-fluoro-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)





RN 618894-93-2 CAPLUS

CN Piperidine, 1-[[1-[[2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[[2-(dimethylamino)ethyl]methylanino]-5-fluoro-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618894-94-3 CAPLUS

CN Piperidine, 1-[[1-[[2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-methyl-1-piperazinyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618894-95-4 CAPLUS

CN Piperidine, 1-[[1-[[2-amino-4-pyridinyl)methyl]-3-hydroxy-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)





RN 618894-96-5 CAPLUS

CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-
(9CI) (CA INDEX NAME)




RN 618894-97-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-morpholinyl)-1H-benzimidazol-1-yl]-
(9CI) (CA INDEX NAME)




RN 618894-98-7 CAPLUS

CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]-
(9CI) (CA INDEX NAME)




RN 618894-99-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-cyclohexyl-3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 618895-00-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-ethoxy-3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 618895-01-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(tetrahydro-2H-pyran-4-yl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-02-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-cyclopropyl-3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 618895-03-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(1-methylethyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-04-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[(dimethylamino)methyl]-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-05-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-fluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-06-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3,4-difluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-07-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-chlorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-08-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2,4-difluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-09-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(1,3-benzodioxol-5-yl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-10-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3,5-dichlorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-11-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-12-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3-ethoxy-5-fluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-13-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-14-0 CAPLUS

CN Piperidine, 4-[2-(2-amino-3-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618895-15-1 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-chloro-2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-16-2 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-pyrimidinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618895-17-3 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 618895-18-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(6-methyl-2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618895-19-5 CAPLUS
CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618895-20-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618895-21-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-22-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-23-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-benzofuranyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-24-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3-quinolinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618895-25-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-quinolinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 618895-26-4 CAPLUS



CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[5-(1,1-dimethylethyl)-3-isoxazolyl]-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 618895-27-5 CAPLUS



CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-

[2-[5-(4-fluorophenyl)-3-isoxazolyl]-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI)
(CA INDEX NAME)





RN 618895-28-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618895-29-7 CAPLUS

CN Piperidine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618895-30-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-hydroxy-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-31-1 CAPLUS



CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-phenyl-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 618895-32-2 CAPLUS
 CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)




RN 618895-33-3 CAPLUS
 CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(3-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)






RN 618895-34-4 CAPLUS
 CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-

[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-35-5 CAPLUS

CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2,4-difluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 618895-36-6 CAPLUS




CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 618895-37-7 CAPLUS


CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2,4-difluorophenyl)-3H-imidazo[4,5-b]pyridin-3-

yl]- (9CI) (CA INDEX NAME)




RN 618895-38-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)- (9CI) (CA INDEX NAME)




RN 618895-39-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-imidazo[4,5-c]pyridin-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-40-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-41-3 CAPLUS

CN Piperidine, 1-[[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-chlorophenyl)-1H-imidazo[4,5-c]pyridin-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-42-4 CAPLUS

CN Piperidine, 1-[[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-43-5 CAPLUS

CN Piperidine, 1-[[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-44-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-chloro-2-pyrazinyl-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618895-45-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-46-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-cyclohexyl-3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 618895-47-9 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-cyclohexyl-3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 618895-48-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-
4-[2-(1-methylethyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX
NAME)




RN 618895-49-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-
4-[2-(3,4-difluorophenyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX
NAME)



RN 618895-50-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-
4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-51-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-
4-(5-chloro-2-pyrazinyl-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618895-52-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-
4-[6-chloro-2-(4-fluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX
NAME)




RN 618895-53-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-
4-[5-fluoro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX
NAME)




RN 618895-54-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-
4-[6-chloro-2-(3,5-dichlorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX
NAME)




RN 618895-56-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-57-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618895-58-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-pyrimidinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618895-59-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-
4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA
INDEX NAME)




RN 618895-60-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-
4-[2-(2-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-61-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-
4-[2-(2-quinolinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-62-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3-quinoliny)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618895-63-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-pyrimidinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-64-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-65-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-benzofuranyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-66-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3-quinolinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-67-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(1,3-benzodioxol-4-yl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-68-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3-ethoxy-5-fluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 618895-69-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



IT 618895-70-8P 618895-71-9P 618895-72-0P
618895-73-1P 618895-74-2P 618895-75-3P
618895-76-4P 618895-77-5P 618895-78-6P
618895-79-7P 618895-80-0P 618895-81-1P
618895-83-3P 618895-84-4P 618895-85-5P
618895-86-6P 618895-87-7P 618895-88-8P
618895-89-9P 618895-90-2P 618895-91-3P
618895-92-4P 618895-93-5P 618895-94-6P
618895-96-8P 618895-98-0P 618895-99-1P
618896-01-8P 618896-03-0P 618896-05-2P
618896-07-4P 618896-08-5P 618896-09-6P
618896-11-0P 618896-13-2P 618896-15-4P
618896-17-6P 618896-19-8P 618896-21-2P
618896-23-4P 618896-25-6P 618896-27-8P
618896-29-0P 618896-31-4P 618896-33-6P
618896-35-8P 618896-37-0P 618896-39-2P
618896-40-5P 618896-41-6P 618896-42-7P

618896-43-8P 618896-44-9P 618896-45-0P
618896-46-1P 618896-47-2P 618896-48-3P
618896-49-4P 618896-50-7P 618896-51-8P
618896-52-9P 618896-53-0P 618896-54-1P
618896-55-2P 618896-56-3P 618896-57-4P
618896-58-5P 618896-59-6P 618896-60-9P
618896-61-0P 618896-62-1P 618896-63-2P
618896-64-3P 618896-65-4P 618896-66-5P
618896-67-6P 618896-68-7P 618896-69-8P
618896-70-1P 618896-71-2P 618896-72-3P
618896-73-4P 618896-74-5P 618896-75-6P
618896-76-7P 618896-77-8P 618896-78-9P
618896-79-0P 618896-80-3P 618896-81-4P
618896-82-5P 618896-83-6P 618896-84-7P
618896-85-8P 618896-86-9P 618896-87-0P
618896-88-1P 618896-89-2P 618896-90-5P
618896-91-6P 618896-92-7P 618896-94-9P
618896-95-0P 618896-96-1P 618896-97-2P
618896-98-3P 618896-99-4P 618897-00-0P
618897-01-1P 618897-02-2P 618897-03-3P
618897-04-4P 618897-05-5P 618897-06-6P
618897-07-7P 618897-08-8P 618897-09-9P
618897-10-2P 618897-11-3P 618897-12-4P
618897-13-5P 618897-14-6P 618897-15-7P
618897-16-8P 618897-17-9P 618897-18-0P
618897-19-1P 618897-20-4P 618897-21-5P
618897-22-6P 618897-23-7P 618897-24-8P
618897-25-9P 618897-26-0P 618897-27-1P
618897-28-2P 618897-29-3P 618897-30-6P
618897-31-7P 618897-32-8P 618897-33-9P
618897-34-0P 618897-35-1P 618897-37-3P
618897-39-5P 618897-40-8P 618897-41-9P
618897-42-0P 618897-43-1P 618897-44-2P
618897-45-3P 618897-46-4P 618897-47-5P
618897-48-6P 618897-49-7P 618897-50-0P
618897-51-1P 618897-52-2P 618897-53-3P
618897-54-4P 618897-55-5P 618897-56-6P
618897-57-7P 618897-58-8P 618897-59-9P
618897-60-2P 618897-61-3P 618897-62-4P
618897-63-5P 618897-64-6P 618897-65-7P
618897-66-8P 618897-67-9P 618897-68-0P
618897-69-1P 618897-70-4P 618897-71-5P
618897-72-6P 618897-75-9P 618897-77-1P
618897-78-2P 618897-79-3P 618897-80-6P
618897-81-7P 618897-82-8P 618897-83-9P
618897-84-0P 618897-85-1P 618897-86-2P
618897-87-3P 618897-88-4P 618897-89-5P
618897-90-8P 618897-91-9P 618897-92-0P
618897-93-1P 618897-94-2P 618897-95-3P
618897-96-4P 618897-97-5P 618897-99-7P
618898-00-3P 618898-01-4P 618898-02-5P
618898-03-6P 618898-04-7P 618898-05-8P
618898-06-9P 618898-07-0P 618898-08-1P
618898-09-2P 618898-10-5P 618898-12-7P
618898-13-8P 618898-14-9P 618898-15-0P
618898-16-1P 618898-17-2P 618898-18-3P
618898-19-4P 618898-20-7P 618898-21-8P
618898-22-9P 618898-23-0P 618898-24-1P
618898-25-2P 618898-26-3P 618898-27-4P
618898-28-5P 618898-29-6P 618898-31-0P


618898-33-2P 618898-35-4P 618898-37-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-(4-piperidinyl)benzimidazoles as histamine H3 antagonists)




RN 618895-70-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-71-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2,4-difluorophenyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-72-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3,4-difluorophenyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-73-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(3-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-74-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-fluoro-2-pyrazinyl-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618895-75-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618895-76-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[(dimethylamino)methyl]-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618895-77-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618895-78-6 CAPLUS



CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618895-79-7 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5,7-difluoro-2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI)

(CA INDEX NAME)




RN 618895-80-0 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyrimidinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618895-81-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(5,6-difluoro-2-pyrazinyl-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618895-83-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-84-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(5-fluoro-2-pyrazinyl-1H-benzimidazol-1-yl)- (9CI)
(CA INDEX NAME)




RN 618895-85-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-86-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(3-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)






RN 618895-87-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(3,4-difluorophenyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-88-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2,4-difluorophenyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-89-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-90-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-91-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-92-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(3-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618895-93-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(tetrahydro-2H-pyran-4-yl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-94-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-96-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(3-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-98-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(tetrahydro-2H-pyran-4-yl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-99-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-01-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-benzofuranyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618896-03-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-[(dimethylamino)methyl]-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-05-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-07-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-ethoxy-5-fluoro-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618896-08-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(methylthio)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-09-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(2-ethoxy-5-fluoro-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618896-11-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-benzofuranyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-13-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(3-quinolinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-15-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidiny]carbonyl]-4-[2-(3-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618896-17-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidiny]carbonyl]-4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618896-19-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidiny]carbonyl]-4-[5-fluoro-2-(4-morpholinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-21-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidiny]carbonyl]-4-[5-fluoro-2-(4-morpholinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-23-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-3-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618896-25-6 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(1H-imidazo[4,5-b]pyridin-7-yl)methyl]-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)





RN 618896-27-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2,5-dimethyl-3-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618896-29-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3-methyl-2-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-31-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(3-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)



RN 618896-33-6 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(1H-indol-2-yl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)



RN 618896-35-8 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(tetrahydro-2H-pyran-4-yl)-3H-imidazo[4,5-

b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-37-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-3-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)






RN 618896-39-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-40-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2,4-difluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-41-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(4-pyrimidinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)




RN 618896-42-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-quinolinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)




RN 618896-43-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3,4-difluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)




RN 618896-44-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(methylthio)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618896-45-0 CAPLUS

CN Piperidine, 1-[[1-[(6-amino-3-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)




RN 618896-46-1 CAPLUS

CN Piperidine, 1-[[1-[(6-amino-3-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618896-47-2 CAPLUS

CN Piperidine, 1-[[1-[(6-amino-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618896-48-3 CAPLUS

CN Piperidine, 1-[[1-[(6-amino-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl] - (9CI) (CA INDEX NAME)




RN 618896-49-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(dimethylamino)-5-fluoro-1H-benzimidazol-1-yl] - (9CI) (CA INDEX NAME)




RN 618896-50-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(ethylthio)-5-fluoro-1H-benzimidazol-1-yl] - (9CI) (CA INDEX NAME)




RN 618896-51-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(5-fluoro-2-methoxy-1H-benzimidazol-1-yl) - (9CI) (CA INDEX NAME)




RN 618896-52-9 CAPLUS

CN Piperidine, 1-[[1-[(6-methoxy-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-53-0 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-[(6-methoxy-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-54-1 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-[(6-methoxy-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-55-2 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-[(6-methoxy-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618896-56-3 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-[(5-fluoro-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618896-57-4 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-[(5-fluoro-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-58-5 CAPLUS

CN Piperidine, 1-[[1-[(3,6-dichloro-4-pyridazinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-59-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2,4-difluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-60-9 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 618896-61-0 CAPLUS


CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 618896-62-1 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-methyl-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-

(9CI) (CA INDEX NAME)




RN 618896-63-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(diethylamino)-5-fluoro-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618896-64-3 CAPLUS

CN Piperidine, 1-[[1-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)



RN 618896-65-4 CAPLUS


CN Piperidine, 1-[[1-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)



RN 618896-66-5 CAPLUS


CN Piperidine, 1-[[1-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-4-

piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-
(9CI) (CA INDEX NAME)



RN 618896-67-6 CAPLUS


CN Piperidine, 1-[[1-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-
(9CI) (CA INDEX NAME)



RN 618896-68-7 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-5-fluoro-1H-benzimidazol-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 618896-69-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(methylthio)-3H-imidazo[4,5-b]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 618896-70-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(2-ethoxy-3H-imidazo[4,5-b]pyridin-3-yl)-(9CI)
(CA INDEX NAME)





RN 618896-71-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(4-quinolinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)





RN 618896-72-3 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(2-furanylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)





RN 618896-73-4 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(3-furanylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618896-74-5 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(2-thienylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-75-6 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(3-thienylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-76-7 CAPLUS

CN Piperidine, 1-[[1-[(6-amino-4-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)





RN 618896-77-8 CAPLUS

CN Piperidine, 1-[[1-[(6-amino-4-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)





RN 618896-78-9 CAPLUS

CN Piperidine, 4-[2-(2,4-difluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[4-fluoro-1-(3-thienylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)




RN 618896-79-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(4-morpholinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)





RN 618896-80-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(1-methylethoxy)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)





RN 618896-81-4 CAPLUS



CN Piperidine, 1-[[4-fluoro-1-(2-thiazolylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)



RN 618896-82-5 CAPLUS



CN Piperidine, 1-[[4-fluoro-1-(1H-pyrrol-2-ylmethyl)-4-piperidinyl]carbonyl]-
4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)

RN 618896-83-6 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(1H-pyrazol-3-ylmethyl)-4-piperidinyl]carbonyl]-
4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 618896-84-7 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(1,2,3-thiadiazol-4-ylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-
(9CI) (CA INDEX NAME)





RN 618896-85-8 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-[[5-(methylthio)-2-thienyl]methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-
(9CI) (CA INDEX NAME)





RN 618896-86-9 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(4-thiazolylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618896-87-0 CAPLUS

CN Piperidine, 1-[[1-[(3,5-dimethyl-4-isoxazolyl)methyl]-4-fluoro-4-piperidiny]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)




RN 618896-88-1 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-[(5-methyl-3-isoxazolyl)methyl]-4-piperidiny]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)





RN 618896-89-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(2-methoxy-3H-imidazo[4,5-b]pyridin-3-yl)- (9CI)
(CA INDEX NAME)





RN 618896-90-5 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(1,2,4-oxadiazol-3-ylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618896-91-6 CAPLUS

CN Acetamide, N-[4-[[4-fluoro-4-[[4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-thiazolyl]- (9CI)
(CA INDEX NAME)




RN 618896-92-7 CAPLUS

CN Piperidine, 1-[[1-[[5-[(dimethylamino)methyl]-2-furanyl]methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)





RN 618896-94-9 CAPLUS

CN Piperidine, 1-[[1-[(5-aminopyrazinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)





RN 618896-95-0 CAPLUS

CN Piperidine, 1-[[1-[[5-(aminomethyl)-2-furanyl]methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)





RN 618896-96-1 CAPLUS

CN Piperidine, 1-[[1-[[5-(aminomethyl)-2-furanyl]methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618896-97-2 CAPLUS


CN Piperidine, 1-[[4-fluoro-1-[(2-methyl-4-thiazolyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)




RN 618896-98-3 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-(trifluoromethyl)-1H-benzotriazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-99-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-(trifluoromethyl)-1H-benzotriazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618897-00-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-(trifluoromethyl)-1H-benzotriazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618897-01-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-(trifluoromethyl)-1H-benzotriazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618897-02-2 CAPLUS
CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-(trifluoromethyl)-1H-benzotriazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618897-03-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[[2-phenyl-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)




RN 618897-04-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[[2-(2-pyridinyl)-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 618897-05-5 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[[2-(phenylmethyl)-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 618897-06-6 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-

[4,6-difluoro-1-(2-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 618897-07-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[1-(2-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 618897-08-8 CAPLUS

CN 4-Piperidinamine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-[1-(2-ethoxyethyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 618897-09-9 CAPLUS

CN 4-Piperidinamine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 618897-10-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[(5-fluoro-1H-benzimidazol-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 618897-11-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[(2-benzoyl-1H-benzimidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)




RN 618897-12-4 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(1-phenyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 618897-13-5 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-
[1-(2,2,2-trifluoroethyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)

RN 618897-14-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-
[[1-(2-pyridinyl)-1H-benzimidazol-2-yl]methyl]- (9CI) (CA INDEX NAME)


RN 618897-15-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-
4-[[4,6-difluoro-1-(2-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX
NAME)




RN 618897-16-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(1H-imidazo[4,5-b]pyridin-2-yl)- (9CI) (CA INDEX NAME)




RN 618897-17-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-methoxy-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 618897-18-0 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[[1-(2-pyridinyl)-1H-benzimidazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 618897-19-1 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-

[[5-fluoro-1-(2,2,2-trifluoroethyl)-1H-benzimidazol-2-yl)methyl]- (9CI)
(CA INDEX NAME)




RN 618897-20-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(5,6-dichloro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 618897-21-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[(1-phenyl-1H-benzimidazol-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 618897-22-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(1H-benzimidazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 618897-23-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)




RN 618897-24-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-benzothiazolyl)- (9CI) (CA INDEX NAME)




RN 618897-25-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-chloro-2-benzoxazolyl)- (9CI) (CA INDEX NAME)




RN 618897-26-0 CAPLUS

CN Piperidine, 1-[[1-[3-(2-amino-4-pyridinyl)propyl]-4-piperidinyl]carbonyl]-4-(2-benzothiazolyl)- (9CI) (CA INDEX NAME)




RN 618897-27-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[7-chloro-2-(2-pyridinyl)-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)





RN 618897-28-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidiny]carbonyl]-4-[7-chloro-2-(2-pyridinyl)-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)





RN 618897-29-3 CAPLUS

CN 2-Pyridinamine, 4-[[4-[[4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]cyclohexyl]methyl]-1-piperidiny]methyl]- (9CI) (CA INDEX NAME)





RN 618897-30-6 CAPLUS

CN 2-Pyrimidinamine, 5-[[4-[[4-[5-fluoro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]-1-piperidinyl]amino]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 618897-31-7 CAPLUS

CN 2-Pyrimidinamine, 5-[[4-[[4-[5-fluoro-2-(3-furanyl)-1H-benzimidazol-1-yl]-1-piperidinyl]amino]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 618897-32-8 CAPLUS

CN 2-Pyrimidinamine, 5-[[4-[[4-[5-fluoro-2-(tetrahydro-2-furanyl)-1H-benzimidazol-1-yl]-1-piperidinyl]amino]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)





RN 618897-33-9 CAPLUS

CN 2-Pyrimidinamine, 5-[[4-[[4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-piperidinyl]amino]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 618897-34-0 CAPLUS

CN 2-Pyridinamine, 4-[[4-[[4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-piperidinyl]amino]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 618897-35-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 618897-37-3 CAPLUS

CN Piperidine, 1-[[8-[(2-amino-5-pyrimidinyl)methyl]-8-azabicyclo[3.2.1]oct-3-yl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618897-39-5 CAPLUS

CN 2-Pyrimidinamine, 5-[[4-[[4-(2-ethoxy-5-fluoro-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 618897-40-8 CAPLUS

CN Piperidine, 1-[[1-[[5-(aminomethyl)-2-furanyl]methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618897-41-9 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-[[2-[(methylsulfonyl)amino]-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)





RN 618897-42-0 CAPLUS

CN Piperidine, 1-[[1-[[2-[bis(methylsulfonyl)amino]-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)





RN 618897-43-1 CAPLUS

CN Piperidine, 1-[[1-[[5-[(dimethylamino)methyl]-2-furanyl]methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)





RN 618897-44-2 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(1H-tetrazol-5-ylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)





RN 618897-45-3 CAPLUS

CN Piperidine, 4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(1H-pyrrol-2-ylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)





RN 618897-46-4 CAPLUS

CN Piperidine, 4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(2-thiazolylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618897-47-5 CAPLUS

CN Piperidine, 4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618897-48-6 CAPLUS

CN Piperidine, 1-[[1-(2-furanylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618897-49-7 CAPLUS

CN Piperidine, 4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(2-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618897-50-0 CAPLUS

CN Piperidine, 1-[[1-(3-furanylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618897-51-1 CAPLUS

CN Piperidine, 4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(1,2,3-thiadiazol-4-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618897-52-2 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(2-furanylmethyl)-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618897-53-3 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(1H-pyrrol-2-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618897-54-4 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(2-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618897-55-5 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618897-56-6 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(3-furanylmethyl)-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618897-57-7 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(2-thiazolylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-58-8 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(1,2,3-thiadiazol-4-ylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)





RN 618897-59-9 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidiny]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618897-60-2 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(1H-1,2,3-triazol-4-ylmethyl)-4-piperidiny]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618897-61-3 CAPLUS

CN Piperidine, 4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(1H-tetrazol-5-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618897-62-4 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(2-furanylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618897-63-5 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(1H-pyrrol-2-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618897-64-6 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(2-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618897-65-7 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618897-66-8 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-furanylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618897-67-9 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(2-thiazolylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-68-0 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(1,2,3-thiadiazol-4-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-69-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(cyclobutyloxy)-5-fluoro-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618897-70-4 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)





RN 618897-71-5 CAPLUS

CN Piperidine, 1-[[1-[[2-[[[(ethylamino)carbonyl]amino]-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)





RN 618897-72-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-[(methylsulfonyl)amino]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-75-9 CAPLUS

CN Piperidine, 1-[[1-[[5-[(dimethylamino)methyl]-2-furanyl]methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618897-77-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(1-oxido-2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618897-78-2 CAPLUS

CN Piperidine, 1-[[1-[[2-(1-piperidinyl)-5-thiazolyl]methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)



RN 618897-79-3 CAPLUS



CN Piperidine, 1-[[4-fluoro-1-[[2-(1-piperidinyl)-5-thiazolyl]methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)



RN 618897-80-6 CAPLUS



CN Piperidine, 1-[[1-[[2-(4-morpholinyl)-5-thiazolyl]methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)

piperidinyll carbonyll -4- [2- (2-pyridinyl) -3H-imidazo[4,5-b]pyridin-3-yl] -
(9CI) (CA INDEX NAME)




RN 618897-81-7 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-[[2- (4-morpholinyl) -5-thiazolyl]methyl] -4-piperidinyll carbonyll -4- [2- (2-pyridinyl) -3H-imidazo[4,5-b]pyridin-3-yl] -
(9CI) (CA INDEX NAME)




RN 618897-82-8 CAPLUS

CN Piperidine, 1-[[1-[[2-amino-5-pyrimidinyl]methyl] -4-piperidinyll carbonyll -4- [2- (3-methyl-2-pyridinyl) -3H-imidazo[4,5-b]pyridin-3-yl] - (9CI) (CA INDEX NAME)




RN 618897-83-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(3-methyl-2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-84-0 CAPLUS

CN Piperidine, 1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618897-85-1 CAPLUS

CN Piperidine, 1-[[1-[(1-methyl-1H-pyrrol-3-yl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-86-2 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-[(1-methyl-1H-pyrrol-3-yl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618897-87-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(ethylthio)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)





RN 618897-88-4 CAPLUS

CN Piperidine, 1-[[1-(1H-pyrazol-3-ylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)





RN 618897-89-5 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(1H-pyrazol-3-ylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)





RN 618897-90-8 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(1H-pyrazol-3-ylmethyl)-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618897-91-9 CAPLUS

CN Piperidine, 4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(1H-pyrrol-3-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-92-0 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(1H-pyrrol-3-ylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-93-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(2-phenoxy-3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 618897-94-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(2-propoxy-3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 618897-95-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(propylthio)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618897-96-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(5-fluoro-2-phenoxy-1H-benzimidazol-1-yl) - (9CI)
(CA INDEX NAME)





RN 618897-97-5 CAPLUS

CN Piperidine, 1-[[1-[[5-[(dimethylamino)methyl]-2-furanyl]methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl] - (9CI) (CA INDEX NAME)





RN 618897-99-7 CAPLUS

CN Piperidine, 1-[[1-[(5-nitro-3-thienyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl] - (9CI) (CA INDEX NAME)





RN 618898-00-3 CAPLUS

CN Piperidine, 1-[[1-[(5-amino-3-thienyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl] - (9CI) (CA INDEX NAME)





RN 618898-01-4 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-[(5-nitro-3-thienyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)




RN 618898-02-5 CAPLUS

CN Piperidine, 1-[[1-[(5-amino-3-thienyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)




RN 618898-03-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-methoxy-3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 618898-04-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-methoxy-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618898-05-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-[(1-methylethyl)thio]-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-06-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(5-fluoro-2-propoxy-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618898-07-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-fluoro-2-propoxy-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618898-08-1 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(3-furanylmethyl)-4-piperidinyl]carbonyl]-4-(2-methoxy-3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 618898-09-2 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(3-thienylmethyl)-4-piperidinyl]carbonyl]-4-(2-methoxy-3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)





RN 618898-10-5 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(1-methylethoxy)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618898-12-7 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-[(5-nitro-2-furanyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-13-8 CAPLUS

CN Piperidine, 1-[[1-[(5-nitro-2-furanyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-14-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-hydroxy-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-15-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(2-ethyl-5-fluoro-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618898-16-1 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(3-furanylmethyl)-4-piperidinyl]carbonyl]-4-[2-(methylthio)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-17-2 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(3-thienylmethyl)-4-piperidinyl]carbonyl]-4-[2-(methylthio)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-18-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(methylthio)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 618898-19-4 CAPLUS


CN Piperidine, 1-[[1-(3-furanylmethyl)-4-piperidinyl]carbonyl]-4-[2-(methylthio)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 618898-20-7 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-

4-(2-ethoxy-3H-imidazo[4,5-b]pyridin-3-yl)-(9CI) (CA INDEX NAME)




RN 618898-21-8 CAPLUS

CN Piperidine, 1-[[1-(cyclohexylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)




RN 618898-22-9 CAPLUS

CN Piperidine, 1-[[1-(cyclohexylmethyl)-4-fluoro-4-piperidinyl]carbonyl]-4-(2-ethoxy-3H-imidazo[4,5-b]pyridin-3-yl)-(9CI) (CA INDEX NAME)




RN 618898-23-0 CAPLUS

CN Piperidine, 4-(2-ethoxy-3H-imidazo[4,5-b]pyridin-3-yl)-1-[[4-fluoro-1-(phenylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)




RN 618898-24-1 CAPLUS

CN Piperidine, 1-[[1-(cyclohexylmethyl)-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)




RN 618898-25-2 CAPLUS

CN Piperidine, 4-(2-ethoxy-3H-imidazo[4,5-b]pyridin-3-yl)-1-[[4-fluoro-1-(3-furanylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-26-3 CAPLUS

CN Piperidine, 4-(2-ethoxy-3H-imidazo[4,5-b]pyridin-3-yl)-1-[[4-fluoro-1-(2-furanylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-27-4 CAPLUS

CN Piperidine, 1-[[1-[(5-amino-2-furanyl)methyl]-4-fluoro-4-piperidiny]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-28-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-3-hydroxy-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)




RN 618898-29-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-hydroxy-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618898-31-0 CAPLUS

CN Piperidine, 4-(2-ethoxy-3H-imidazo[4,5-b]pyridin-3-yl)-1-[[4-fluoro-1-(3-thienylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)




RN 618898-33-2 CAPLUS

CN Piperidine, 4-(2-ethoxy-3H-imidazo[4,5-b]pyridin-3-yl)-1-[[1-(2-furanylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)




RN 618898-35-4 CAPLUS

CN Piperidine, 4-(2-ethoxy-3H-imidazo[4,5-b]pyridin-3-yl)-1-[[1-(2-furanylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)



RN 618898-37-6 CAPLUS
 CN Piperidine, 4-(2-ethoxy-3H-imidazo[4,5-b]pyridin-3-yl)-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



IT 618898-38-7P 618898-40-1P 618898-42-3P
 618898-43-4P 618898-45-6P 618898-47-8P
 618898-48-9P 618898-50-3P 618898-52-5P
 618898-56-9P 618898-57-0P 618898-59-2P
 618898-60-5P 618898-62-7P 618898-63-8P
 618898-65-0P 618898-66-1P 618898-68-3P
 618898-70-7P 618898-71-8P 618898-72-9P
 618898-73-0P 618898-74-1P 618898-75-2P
 618898-76-3P 618898-77-4P 618898-78-5P
 618898-79-6P 618898-80-9P 618898-81-0P
 618898-82-1P 618898-83-2P 618898-84-3P
 618898-85-4P 618898-86-5P 618898-87-6P
 618898-88-7P 618898-89-8P 618898-90-1P
 618898-91-2P 618898-92-3P 618898-93-4P
 618898-94-5P 618898-95-6P 618898-96-7P
 618898-97-8P 618898-98-9P 618898-99-0P
 618899-00-6P 618899-01-7P 618899-02-8P
 618899-03-9P 618899-04-0P 618899-05-1P
 618899-06-2P 618899-07-3P 618899-08-4P
 618899-09-5P 618899-10-8P 618899-11-9P
 618899-12-0P 618899-13-1P 618899-14-2P
 618899-15-3P 618899-16-4P 618899-17-5P
 618899-18-6P 618899-19-7P 618899-20-0P
 618899-21-1P 618899-22-2P 618899-23-3P
 618899-24-4P 618899-25-5P 618899-26-6P
 618899-27-7P 618899-28-8P 618899-29-9P
 618899-30-2P 618899-31-3P 618899-32-4P
 618899-33-5P 618899-34-6P 618899-35-7P
 618899-36-8P 618899-37-9P 618899-38-0P
 618899-39-1P 618899-40-4P 618899-41-5P
 618899-42-6P 618899-43-7P 618899-44-8P
 618899-45-9P 618899-46-0P 618899-47-1P
 618899-48-2P 618899-49-3P 618899-50-6P
 618899-51-7P 618899-52-8P 618899-53-9P
 618899-54-0P 618899-55-1P 618899-56-2P
 618899-57-3P 618899-58-4P 618899-59-5P
 618899-60-8P 618899-61-9P 618899-62-0P


618899-63-1P 618899-64-2P 618899-65-3P
 618899-66-4P 618899-67-5P 618899-68-6P
 618899-69-7P 618899-70-0P 618899-71-1P
 618899-72-2P 618899-73-3P 618899-74-4P
 618899-75-5P 618899-76-6P 618899-77-7P
 618899-78-8P 618899-79-9P 618899-80-2P
 618899-81-3P 618899-82-4P 618899-83-5P
 618899-84-6P 618899-85-7P 618899-86-8P
 618899-87-9P 618899-88-0P 618899-89-1P
 618899-90-4P 618899-91-5P 618899-92-6P
 618899-93-7P 618899-94-8P 618899-95-9P
 618899-96-0P 618899-97-1P 618899-98-2P
 618899-99-3P 618900-00-8P 618900-01-9P
 618900-02-0P 618900-04-2P 618900-05-3P
 618900-06-4P 618900-07-5P 618900-08-6P
 618900-09-7P 618900-10-0P 618900-11-1P
 618900-12-2P 618900-13-3P 618900-14-4P
 618900-15-5P 618900-16-6P 618900-17-7P
 618900-18-8P 618900-19-9P 618900-20-2P
 618900-21-3P 618900-22-4P 618900-23-5P
 618900-24-6P 618900-25-7P 618900-26-8P
 618900-27-9P 618900-28-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of 1-(4-piperidiny)benzimidazoles as histamine H3 antagonists)



RN 618898-38-7 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidiny]carbonyl]-4-[2-(methylthio)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-40-1 CAPLUS

CN Piperidine, 1-[[1-[(3-amino-2-thienyl)methyl]-4-piperidiny]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-42-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(cyclohexyloxy)-5-fluoro-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)





RN 618898-43-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[(tetrahydro-2H-pyran-4-yl)oxy]-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618898-45-6 CAPLUS

CN Piperidine, 1-[[1-[(3-amino-2-thienyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-(9CI) (CA INDEX NAME)




RN 618898-47-8 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(methylthio)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-48-9 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(methylthio)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-50-3 CAPLUS

CN Piperidine, 1-[[1-(benzo[b]thien-2-ylmethyl)-4-fluoro-4-piperidiny]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618898-52-5 CAPLUS

CN Piperidine, 4-[2-(methylthio)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-56-9 CAPLUS

CN Piperidine, 4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-57-0 CAPLUS

CN Piperidine, 4-(2-methoxy-3H-imidazo[4,5-b]pyridin-3-yl)-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618898-59-2 CAPLUS

CN Piperidine, 1-[[1-(3-furanylmethyl)-4-piperidinyl]carbonyl]-4-(2-methoxy-3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)





RN 618898-60-5 CAPLUS

CN Piperidine, 1-[[1-(3-furanylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618898-62-7 CAPLUS

CN Piperidine, 4-[2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-63-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[(tetrahydro-2-furanyl)methoxy]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618898-65-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(methylthio)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618898-66-1 CAPLUS

CN Piperidine, 4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618898-68-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618898-70-7 CAPLUS

CN Piperidine, 4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-furanylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618898-71-8 CAPLUS

CN Piperidine, 4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-furanylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-72-9 CAPLUS

CN Piperidine, 4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-73-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618898-74-1 CAPLUS

CN Piperidine, 4-[5-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-furanylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-75-2 CAPLUS

CN Piperidine, 4-[5-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-76-3 CAPLUS

CN Piperidine, 4-[2-(methylthio)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-77-4 CAPLUS

CN Piperidine, 4-(2-ethoxy-5-fluoro-1H-benzimidazol-1-yl)-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-78-5 CAPLUS

CN Piperidine, 4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-79-6 CAPLUS

CN Piperidine, 4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(2-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-80-9 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(2-pyridinylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-81-0 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(3-pyridinylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-82-1 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-83-2 CAPLUS

CN Piperidine, 4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(3-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-84-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(ethylthio)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618898-85-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(ethylthio)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-86-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(methylsulfonyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618898-87-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(propylthio)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618898-88-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(propylthio)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-89-8 CAPLUS

CN Piperidine, 1-[[1-[(2-methyl-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(methylsulfonyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-90-1 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(2-pyridinylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-91-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidiny]carbonyl]-4-[5-bromo-2-(ethylthio)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618898-92-3 CAPLUS



CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-pyridinylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)



RN 618898-93-4 CAPLUS



CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-[(1-ethyl-4-piperidyl)carbonyl]-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)

methyl-1H-pyrrol-3-yl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-94-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(methylsulfinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-95-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(butylthio)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618898-96-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(butylthio)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618898-97-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-ethyl-3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 618898-98-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(methylsulfinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618898-99-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[(1-methylethyl)thio]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-00-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[(1-methylethyl)thio]-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618899-01-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-bromo-2-(methylthio)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-02-8 CAPLUS

CN Piperidine, 4-[5-bromo-2-(methylthio)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-03-9 CAPLUS

CN Piperidine, 4-[5-bromo-2-(methylthio)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-04-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-bromo-2-(methylthio)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-05-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-fluoro-2-methoxy-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618899-06-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(cyclopentyloxy)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-07-3 CAPLUS

CN Piperidine, 4-[2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-08-4 CAPLUS

CN Piperidine, 1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-09-5 CAPLUS

CN Piperidine, 4-[5-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-10-8 CAPLUS

CN Piperidine, 4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-11-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[(2-methylpropyl)thio]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-12-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[(phenylmethyl)thio]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-13-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[(1-methylpropyl)thio]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-14-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-ethoxy-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-15-3 CAPLUS

CN Piperidine, 4-[2-ethoxy-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-16-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-ethoxy-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-17-5 CAPLUS

CN Piperidine, 4-(2-propoxy-1H-benzimidazol-1-yl)-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-18-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(ethylthio)-5,6-difluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-19-7 CAPLUS

CN Piperidine, 4-[5,6-difluoro-2-(methylthio)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-20-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5,6-difluoro-2-(methylthio)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-21-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidiny]carbonyl]-4-[2-[(1,1-dimethylethyl)thio]-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-22-2 CAPLUS

CN Piperidine, 4-[5-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-23-3 CAPLUS

CN Piperidine, 4-[5,6-difluoro-2-(methylthio)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-24-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidiny]carbonyl]-4-[5-fluoro-2-(1-methylethoxy)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-25-5 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(1-methylethoxy)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-26-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidiny]carbonyl]-4-[2-(methylthio)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-27-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[5,6-difluoro-2-(methylthio)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-28-8 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridinylmethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-29-9 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(2-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-30-2 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(3-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-31-3 CAPLUS

CN Piperidine, 4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-32-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-piperidine-1-[[4-fluoro-1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-33-5 CAPLUS

CN Piperidine, 4-[2-(methylthio)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-34-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(methylthio)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-35-7 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]-4-[2-(methylthio)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-36-8 CAPLUS

CN Piperidine, 4-(5-fluoro-2-methoxy-1H-benzimidazol-1-yl)-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-37-9 CAPLUS

CN Piperidine, 4-[5,6-difluoro-2-(methylthio)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-38-0 CAPLUS

CN Piperidine, 4-[5,6-difluoro-2-(methylthio)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-39-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5,6-difluoro-2-(methylthio)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-40-4 CAPLUS

CN Piperidine, 4-[5-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-41-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618899-42-6 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(ethylthio)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618899-43-7 CAPLUS

CN Piperidine, 4-[2-(ethylthio)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)




RN 618899-44-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(ethylthio)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618899-45-9 CAPLUS

CN Piperidine, 4-[2-[(aminomethyl)thio]-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI)
(CA INDEX NAME)




RN 618899-46-0 CAPLUS

CN Piperidine, 4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-47-1 CAPLUS

CN Piperidine, 4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-48-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-49-3 CAPLUS

CN Piperidine, 4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-50-6 CAPLUS

CN Piperidine, 4-[2-(ethylthio)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618899-51-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-propoxy-3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 618899-52-8 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(1H-pyrrol-3-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-53-9 CAPLUS

CN Piperidine, 4-[2-(propylthio)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-54-0 CAPLUS

CN Piperidine, 4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-55-1 CAPLUS

CN Piperidine, 4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-56-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-chloro-2-ethoxy-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618899-57-3 CAPLUS

CN Piperidine, 4-(5-chloro-2-ethoxy-1H-benzimidazol-1-yl)-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-58-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-(methylsulfonyl)-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-59-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-60-8 CAPLUS

CN Piperidine, 4-[5-(methylsulfonyl)-2-(methylthio)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-61-9 CAPLUS

CN Piperidine, 1-[[1-(3-furanylmethyl)-4-piperidinyl]carbonyl]-4-[5-(methylsulfonyl)-2-(methylthio)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-62-0 CAPLUS

CN Piperidine, 4-[5-(methylsulfonyl)-2-(methylthio)-1H-benzimidazol-1-yl]-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-63-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-ethyl-5-fluoro-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618899-64-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-fluoro-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618899-65-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 618899-66-4 CAPLUS

CN Piperidine, 4-(5-fluoro-1H-benzimidazol-1-yl)-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-67-5 CAPLUS


CN Piperidine, 4-(3H-imidazo[4,5-b]pyridin-3-yl)-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-68-6 CAPLUS
 CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(5-fluoro-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618899-69-7 CAPLUS
 CN Piperidine, 4-(5-fluoro-1H-benzimidazol-1-yl)-1-[[4-fluoro-1-(4-pyridazinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-70-0 CAPLUS
 CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 618899-71-1 CAPLUS
 CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-imidazo[4,5-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-72-2 CAPLUS
 CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-imidazo[4,5-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-73-3 CAPLUS

CN Piperidine, 1-[[1-[3-(2-amino-4-pyridinyl)propyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618899-74-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(5-chloro-2-ethoxy-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618899-75-5 CAPLUS

CN Piperidine, 4-(5-chloro-2-ethoxy-1H-benzimidazol-1-yl)-1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-76-6 CAPLUS


CN Piperidine, 4-[2-(ethylthio)-5-(methylsulfonyl)-1H-benzimidazol-1-yl]-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-77-7 CAPLUS

CN Piperidine, 4-[2-(ethylthio)-5-(methylsulfonyl)-1H-benzimidazol-1-yl]-1-
[[1-(3-furanylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

RN 618899-78-8 CAPLUS


CN Piperidine, 4-[2-(ethylthio)-5-(methylsulfonyl)-1H-benzimidazol-1-yl]-1-
[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

RN 618899-79-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-
4-[2-(ethylthio)-5-(methylsulfonyl)-1H-benzimidazol-1-yl]- (9CI) (CA
INDEX NAME)


RN 618899-80-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-
4-[5-(methylsulfonyl)-2-(methylthio)-1H-benzimidazol-1-yl]- (9CI) (CA
INDEX NAME)




RN 618899-81-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-fluoro-2-methyl-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618899-82-4 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]-4-(3H-imidazo[4,5-b]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 618899-83-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(5-fluoro-2-propyl-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618899-84-6 CAPLUS

CN Piperidine, 4-(5-fluoro-2-propyl-1H-benzimidazol-1-yl)-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-85-7 CAPLUS

CN Piperidine, 4-[5-(methylsulfonyl)-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-86-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[4-methyl-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-87-9 CAPLUS

CN Piperidine, 4-[4-methyl-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-88-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[4-methyl-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-89-1 CAPLUS

CN Piperidine, 4-[5-chloro-2-(methylthio)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-90-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-chloro-2-(methylthio)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618899-91-5 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-piperidinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-92-6 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(phenylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618899-93-7 CAPLUS

CN Piperidine, 4-[5-chloro-2-(methylthio)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-94-8 CAPLUS

CN Piperidine, 1-[[1-(phenylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618899-95-9 CAPLUS

CN Piperidine, 4-[5-chloro-2-(ethylthio)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-96-0 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(phenylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618899-97-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(ethylthio)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618899-98-2 CAPLUS


CN Piperidine, 4-[5-chloro-2-(ethylthio)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 618899-99-3 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-chloro-2-(ethylthio)-1H-benzimidazol-1-yl]-

(9CI) (CA INDEX NAME)




RN 618900-00-8 CAPLUS

CN Piperidine, 1-[[1-(4-piperidinylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618900-01-9 CAPLUS

CN Piperidine, 4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618900-02-0 CAPLUS

CN Piperidine, 4-(2-ethoxy-5-fluoro-1H-benzimidazol-1-yl)-1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 618900-04-2 CAPLUS

CN Piperidine, 1-[[1-(5-isoxazolylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618900-05-3 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-[(1-methyl-1H-pyrrol-3-yl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-(9CI) (CA INDEX NAME)




RN 618900-06-4 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(1H-pyrrol-3-ylmethyl)-4-piperidinyl]carbonyl]-(9CI) (CA INDEX NAME)





RN 618900-07-5 CAPLUS

CN Piperidine, 4-[5-(methylsulfonyl)-2-(methylthio)-1H-benzimidazol-1-yl]-1-[[1-(1H-pyrrol-3-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618900-08-6 CAPLUS

CN Piperidine, 4-[5-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(1H-pyrrol-3-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618900-09-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[4-fluoro-2-(methylthio)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618900-10-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[4-fluoro-2-(methylthio)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618900-11-1 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(ethylthio)-4-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618900-12-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(ethylthio)-4-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618900-13-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-(4-fluoro-2-methoxy-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618900-14-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-(4-fluoro-2-methoxy-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618900-15-5 CAPLUS

CN Piperidine, 4-[4-fluoro-2-(methylthio)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618900-16-6 CAPLUS

CN Piperidine, 4-[4-fluoro-2-(methylthio)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618900-17-7 CAPLUS

CN Piperidine, 4-[2-(ethylthio)-4-fluoro-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618900-18-8 CAPLUS

CN Piperidine, 4-[2-(ethylthio)-4-fluoro-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618900-19-9 CAPLUS

CN Piperidine, 4-(4-fluoro-2-methoxy-1H-benzimidazol-1-yl)-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618900-20-2 CAPLUS

CN Piperidine, 4-(4-fluoro-2-methoxy-1H-benzimidazol-1-yl)-1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618900-21-3 CAPLUS

CN Piperidine, 4-(2-ethoxy-1H-benzimidazol-1-yl)-1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618900-22-4 CAPLUS

CN Piperidine, 4-(2-ethoxy-1H-benzimidazol-1-yl)-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618900-23-5 CAPLUS

CN Piperidine, 4-[2-(ethylthio)-5-(methylsulfonyl)-1H-benzimidazol-1-yl]-1-[[1-(1H-pyrrol-3-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618900-24-6 CAPLUS

CN 1H-Benzimidazole, 2-ethoxy-5-fluoro-1-[1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 618900-25-7 CAPLUS

CN 2-Pyrimidinamine, 5-[[4-[[4-[5-fluoro-2-(methylthio)-1H-benzimidazol-1-yl]-1-piperidinyl]methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 618900-26-8 CAPLUS

CN 1H-Benzimidazole, 5-fluoro-2-(methylthio)-1-[1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 618900-27-9 CAPLUS

CN Piperidine, 4-[5-fluoro-2-(propylthio)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 618900-28-0 CAPLUS

CN Piperidine, 4-(5-fluoro-2-propoxy-1H-benzimidazol-1-yl)-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




IT 50541-93-0, 1-Benzylpiperidin-4-amine 618900-84-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 1-(4-piperidinyl)benzimidazoles as histamine H3 antagonists)


RN 50541-93-0 CAPLUS

CN 4-Piperidinamine, 1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 618900-84-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



IT 416852-10-3P 416852-11-4P 618900-58-6P

618900-60-0P 618900-61-1P 618900-62-2P

618900-63-3P 618900-64-4P 618900-66-6P

618900-77-9P 618900-80-4P 618900-82-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of 1-(4-piperidiny)benzimidazoles as histamine H3 antagonists)


RN 416852-10-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 416852-11-4 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]methyl]-, monolithium salt (9CI) (CA INDEX NAME)



● Li

RN 618900-58-6 CAPLUS


CN Carbamic acid, [4-[[4-[[4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 618900-60-0 CAPLUS


CN Carbamic acid, [4-[[4-[[4-[2-nitro-4-(trifluoromethyl)phenyl]amino]-1-

piperidinyl]carbonyl]-1-piperidinyl)methyl]-2-pyridinyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 618900-61-1 CAPLUS

CN Carbamic acid, [4-[[4-[[4-[[2-amino-4-(trifluoromethyl)phenyl]amino]-1-piperidinyl]carbonyl]-1-piperidinyl)methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 618900-62-2 CAPLUS

CN Carbamic acid, [4-[[4-[[4-[[2-[(2-pyridinylcarbonyl)amino]-4-(trifluoromethyl)phenyl]amino]-1-piperidinyl]carbonyl]-1-piperidinyl)methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 618900-63-3 CAPLUS

CN Carbamic acid, [4-[[4-[[4-[[5-chloro-1H-benzimidazol-2-yl]-1-piperidinyl]carbonyl]-1-piperidinyl)methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 618900-64-4 CAPLUS

CN 1H-Benzimidazol-2-amine, N-[1-(phenylmethyl)-4-piperidinyl]-1-(4,4,4-trifluorobutyl)- (9CI) (CA INDEX NAME)




RN 618900-66-6 CAPLUS

CN Carbamic acid, [4-[[4-[[4-[[1-(4,4,4-trifluorobutyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 618900-77-9 CAPLUS

CN Carbamic acid, [4-[[4-[[4-[5-fluoro-2-[[[(4-fluorophenyl)amino]carbonyl]amino]-1H-benzimidazol-1-yl]-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 618900-80-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(2-ethoxy-5-fluoro-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 618900-82-6 CAPLUS

CN 1H-Benzimidazole, 2-ethoxy-5-fluoro-1-[1-(4-piperidinylmethyl)-4-piperidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 618900-81-5


CMF C20 H29 F N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS


Searched by Barb O'Bryen, STIC 2-2518

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 25 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:610440 CAPLUS
DOCUMENT NUMBER: 139:164703
TITLE: Preparation of cinnamoylpyrrolidines and related
compounds as histamine **H3 receptor**
antagonists, agonists, or inverse agonists.
INVENTOR(S): Peschke, Bernd; Pettersson, Ingrid
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Boehringer Ingelheim
International G.m.b.H.
SOURCE: PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003064411	A1	20030807	WO 2003-DK48	20030127
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2473468	AA	20030807	CA 2003-2473468	20030127
BR 2003006980	A	20041109	BR 2003-6980	20030127
EP 1474419	A1	20041110	EP 2003-701477	20030127
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 2003195190	A1	20031016	US 2003-354341	20030130
PRIORITY APPLN. INFO.:			DK 2002-160	A 20020201
			DK 2002-1501	A 20021007
			US 2002-354192P	P 20020204
			US 2002-416567P	P 20021007
			WO 2003-DK48	W 20030127

OTHER SOURCE(S): MARPAT 139:164703
ED Entered STN: 08 Aug 2003
GI



AB Title compds. [I; R1, R2 = H, alkyl, alkenyl, alkynyl, which may optionally be substituted with ≥ 1 cycloalkyl, cycloalkenyl, halo, OH, cycloalkyl, cycloalkenyl, which may optionally be substituted with ≥ 1 halo, OH, alkyl, alkenyl, alkynyl; R1R2 = atoms to form a C3-6 alk(en)ylene bridge, which may be substituted with ≥ 1 halo, OH; R11, R12 = H, alkyl, which may be substituted with ≥ 1 C3-8-cycloalkyl, C5-8-cycloalkenyl, halo OH, cycloalkyl, cycloalkenyl, which may optionally be substituted with ≥ 1 halo, OH; R17 = H, alkyl, alkenyl, alkynyl; R18, R19 = H, halo, OH, amino, alkyl, alkenyl, alkynyl; X = (substituted) Ph, naphthyl, pyrrolyl, furyl, thienyl, etc.], were prepared as H3 ligands (no data). At 0°, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride was added to (E)-4-bromocinnamic acid and 3-hydroxy-1,2,3-benzotriazin-4(3H)-one in CH2Cl2/DMF; the mixture was stirred 20 min. at 0° and a solution of (S)-2-[(pyrrolidin-1-yl)methyl]pyrrolidine dihydrochloride (preparation given) in DMF was added. The reaction mixture was stirred for 16 h to give (E)-3-(4-bromophenyl)-1-[(2S)-2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl]propenone. 1 drug formulations are given.

IT 575467-82-2P 575467-84-4P 575467-86-6P
575467-88-8P 575467-90-2P 575467-92-4P
575467-94-6P 575467-96-8P 575468-36-9P
575468-38-1P 575468-40-5P 575468-42-7P
575468-44-9P 575468-46-1P 575468-48-3P
575468-50-7P 575468-72-3P 575468-74-5P
575468-76-7P 575468-84-7P 575468-88-1P
575468-90-5P 575468-98-3P 575469-02-2P
575469-06-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cinnamoylpyrrolidines and related compds. as histamine H3 receptor antagonists, agonists, or inverse agonists)

RN 575467-82-2 CAPLUS

CN Pyrrolidine, 1-[(2E)-3-(4-bromophenyl)-1-oxo-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 575467-84-4 CAPLUS

CN Pyrrolidine, 1-[(2E)-3-(4-chlorophenyl)-1-oxo-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 575467-86-6 CAPLUS

CN Pyrrolidine, 1-[(2E)-1-oxo-3-[4-(trifluoromethyl)phenyl]-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 575467-88-8 CAPLUS

CN Pyrrolidine, 1-[(2E)-3-(3-bromophenyl)-1-oxo-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 575467-90-2 CAPLUS

CN Pyrrolidine, 1-[(2E)-3-(4-methoxyphenyl)-1-oxo-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 575467-92-4 CAPLUS

CN Pyrrolidine, 1-[(2E)-3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 575467-94-6 CAPLUS

CN Pyrrolidine, 1-[(2E)-3-(4-chloro-3-nitrophenyl)-1-oxo-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 575467-96-8 CAPLUS


CN Pyrrolidine, 1-[(2E)-1-oxo-3-[4-(trifluoromethoxy)phenyl]-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 575468-36-9 CAPLUS
CN Pyrrolidine, 1-[(2E)-1-oxo-3-[3-(trifluoromethyl)phenyl]-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 575468-38-1 CAPLUS
CN Pyrrolidine, 1-[(2E)-3-(3-cyanophenyl)-1-oxo-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 575468-40-5 CAPLUS
CN Pyrrolidine, 1-[(2E)-3-(4-cyanophenyl)-1-oxo-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 575468-42-7 CAPLUS
CN Pyrrolidine, 1-[(2E)-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 575468-44-9 CAPLUS
CN Pyrrolidine, 1-[(2E)-3-[4-[(methylsulfonyl)oxy]phenyl]-1-oxo-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 575468-46-1 CAPLUS

CN Methanesulfonic acid, trifluoro-, 4-[(1E)-3-oxo-3-[(2S)-2-(1-piperidinylmethyl)-1-pyrrolidinyl]-1-propenyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 575468-48-3 CAPLUS

CN Pyrrolidine, 1-[(2E)-3-(3-cyano-4-fluorophenyl)-1-oxo-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 575468-50-7 CAPLUS

CN Pyrrolidine, 1-[(2E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]-1-oxo-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 575468-72-3 CAPLUS

CN Pyrrolidine, 1-[(2E)-1-oxo-3-[4-(trifluoromethoxy)phenyl]-2-propenyl]-2-(1-piperidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 575468-74-5 CAPLUS

CN Pyrrolidine, 1-[(2E)-1-oxo-3-[4-(trifluoromethyl)phenyl]-2-propenyl]-2-(1-piperidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 575468-76-7 CAPLUS

CN Pyrrolidine, 2-(1-piperidinylmethyl)-1-[[5-(trifluoromethyl)-2-benzofuranyl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 575468-84-7 CAPLUS

CN Pyrrolidine, 2-(1-piperidinylmethyl)-1-[[6-(trifluoromethyl)-2-benzofuranyl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 575468-88-1 CAPLUS

CN Pyrrolidine, 1-[(2E)-3-[4-chloro-3-(trifluoromethyl)phenyl]-1-oxo-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 575468-90-5 CAPLUS

CN Pyrrolidine, 1-[(2E)-3-[3-fluoro-5-(trifluoromethyl)phenyl]-1-oxo-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 575468-98-3 CAPLUS

CN Pyrrolidine, 1-[(2E)-1-oxo-3-[4-(trifluoromethyl)phenyl]-2-butenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 575469-02-2 CAPLUS

CN Pyrrolidine, 1-[(2E)-3-[4-(2-methylpropyl)phenyl]-1-oxo-2-butenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 575469-06-6 CAPLUS

CN Pyrrolidine, 1-[(2E)-1-oxo-3-[4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propenyl]-2-(1-piperidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 65921-41-7P 575469-26-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of cinnamoylpyrrolidines and related compds. as histamine H3 receptor antagonists, agonists, or inverse agonists)

RN 65921-41-7 CAPLUS

CN Piperidine, 1-[(2S)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 575469-26-0 CAPLUS

CN Piperidine, 1-[(2R)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 26 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:472499 CAPLUS

DOCUMENT NUMBER: 139:53038



TITLE: Preparation of substituted phenylalkynes for use in histamine-mediated disorders

INVENTOR(S): Apodaca, Richard; Xiao, Wei; Jablonoski, Jill A.

PATENT ASSIGNEE(S): Ortho-Mcneil Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 104 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003050099	A1	20030619	WO 2002-US38480	20021202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2469893	AA	20030619	CA 2002-2469893	20021202
EP 1451167	A1	20040901	EP 2002-792315	20021202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014886	A	20041207	BR 2002-14886	20021202
JP 2005511740	T2	20050428	JP 2003-551124	20021202
WO 2004050623	A1	20040617	WO 2003-US19601	20030617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2001-339523P	P 20011210
			WO 2002-US38480	W 20021202
OTHER SOURCE(S): MARPAT 139:53038				
ED Entered STN: 20 Jun 2003				
GI				




AB Title compds. I [n = 0-1; R1-2 = alkyl, cycloalkyl or taken together with the nitrogen to which they are attached form a nonarom. 4-7 membered heterocycle; one of R3-5 = G, one of the remaining two is H and the other = H, F, Cl; G = L2Q; L2 = CH2; Q = (substituted)amino, N-linked heterocycle, etc.] are prepared For instance, 1-(4-bromobenzyl)piperidine (preparation given) was coupled to 1-(but-3-ynyl)piperidine (preparation given; DME/water, K2CO3, CuI, Ph3P, Pd/C) to give II. II had Ki = 1.6 nM for the histamine H3 receptor. I are useful for the treatment of histamine-mediated conditions.

IT **544707-19-9P**, 4-[3-[4-[Piperidinyl]but-1-ynyl]benzyl]morpholine
544707-40-6P, 4-[4-[4-[Piperidinyl]but-1-ynyl]benzyl]piperazine-1-carboxylic acid tert-butyl ester **544707-41-7P**,
 1-[4-[4-[Piperidinyl]but-1-ynyl]benzyl]piperazine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of substituted phenylalkynes for use in histamine-mediated disorders)


RN 544707-19-9 CAPLUS

CN Morpholine, 4-[[3-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 544707-40-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 544707-41-7 CAPLUS

CN Piperazine, 1-[[4-[[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




IT 544707-17-7P, 1-[4-[4-[[Piperidinyl]methyl]phenyl]but-3-ynyl]piperidine 544707-18-8P, 1-[3-[4-[Piperidinyl]but-1-ynyl]benzyl]piperidine 544707-20-2P, 4-[3-[4-[Piperidinyl]but-1-ynyl]benzyl]morpholine dihydrochloride 544707-21-3P, 1-[4-[4-[Pyrrolidinyl]but-1-ynyl]benzyl]piperidine 544707-22-4P, Diethyl 4-[4-[4-[piperidinyl]methyl]phenyl]but-3-ynyl]amine 544707-23-5P, 4-[4-[4-[4-[Piperidinyl]methyl]phenyl]but-3-ynyl]thiomorpholine 544707-24-6P, 4-[4-[4-[4-[Piperidinyl]methyl]phenyl]but-3-ynyl]morpholine 544707-25-7P, 1-Methyl-4-[4-[4-[4-[piperidinyl]methyl]phenyl]but-3-ynyl]piperazine 544707-26-8P, 1-[4-[4-[4-[Pyrrolidinyl]methyl]phenyl]but-3-ynyl]piperidine 544707-27-9P, 4-[4-[4-[4-[Piperidinyl]but-1-ynyl]benzyl]morpholine 544707-28-0P, Diethyl 4-[4-[4-[piperidinyl]but-1-ynyl]benzyl]amine 544707-29-1P, 1-[4-[4-[4-[4-Benzylpiperidin-1-yl]methyl]phenyl]but-3-ynyl]piperidine 544707-30-4P, 1-[4-[4-[4-[Piperidinyl]but-1-ynyl]benzyl]piperidin-4-ol 544707-31-5P, 2-[1-[4-[4-[4-[Piperidinyl]but-1-ynyl]benzyl]piperidin-2-yl]ethanol 544707-32-6P, 1-[4-[4-[4-[Piperidinyl]but-1-ynyl]benzyl]decahydroquinoline 544707-33-7P, 1-[4-[4-[4-[Piperidinyl]but-1-ynyl]benzyl]piperidine-4-carboxylic acid amide 544707-34-8P, 8-[4-[4-[4-[Piperidinyl]but-1-ynyl]benzyl]-1,4-dioxo-8-azaspiro[4.5]decane 544707-35-9P, 1-Methyl-4-[4-[4-[4-[piperidinyl]but-1-ynyl]benzyl]piperazine 544707-38-2P, 1-Phenyl-4-[4-[4-[4-[piperidinyl]but-1-ynyl]benzyl]piperazine 544707-39-3P, 1-Benzyl-4-[4-[4-[4-[piperidinyl]but-1-ynyl]benzyl]piperazine 544707-42-8P, 1-Isopropyl-4-[4-[4-[4-[piperidinyl]but-1-ynyl]benzyl]piperazine 544707-43-9P, 1-Phenyl-8-[3-[4-[4-[piperidinyl]but-1-ynyl]benzyl]-1,3,8-triazaspiro[4.5]decan-4-one 544707-44-0P, 1-[3-[4-[4-[Piperidinyl]but-1-ynyl]benzyl]piperidine-3-carboxylic acid diethylamide 544707-45-1P, 1-[3-[4-[4-[Piperidinyl]but-1-ynyl]benzyl]-1,2,3,4,5,6-hexahydro-[2,3']bipyridinyl 544707-46-2P, 1-[3-[4-[4-[Piperidinyl]but-1-ynyl]benzyl]-4-[3-trifluoromethylphenyl]piperazine 544707-47-3P, 2-[4-[3-[4-[4-[Piperidinyl]but-1-ynyl]benzyl]piperazin-1-yl]pyrimidine 544707-48-4P, 1-[3-[4-[4-[Piperidinyl]but-1-ynyl]benzyl]piperidine-4-carboxylic acid amide 544707-56-4P, 1-[1-[3-[4-[4-[Piperidinyl]but-1-ynyl]benzyl]piperidin-4-yl]-1,3-dihydrobenzimidazol-2-one 544707-58-6P, 1-[4-[3-[4-[Pyrrolidinyl]methyl]phenyl]but-3-

ynyl]piperidine **544707-60-0P**, Dimethyl[4-[4-
 [[piperidinyl)methyl]phenyl]but-3-ynyl]amine **544707-61-1P**,
 Dimethyl[4-[4-[piperidinyl]but-1-ynyl]benzyl]amine **544707-63-3P**,
 1-[4-[3-[4-[piperidinyl]but-3-ynyl]piperidine
544707-64-4P, 2-[1-[3-[4-[piperidinyl]but-1-ynyl]benzyl]piperidin-
 4-yloxy]pyrimidine **544707-65-5P**, [1-[3-[4-[piperidinyl]but-1-
 ynyl]benzyl]piperidin-4-yl] [pyridin-2-yl]amine **544707-72-4P**,
 1-Methyl-4-[3-[4-[piperidinyl]but-1-ynyl]benzyl]piperazine
544707-73-5P, 1-[3-[4-[piperidinyl]but-1-ynyl]benzyl]piperidin-4-
 ol **544707-74-6P**, 1-[3-[4-[morpholinyl]but-1-
 ynyl]benzyl]piperidin-4-ol **544707-75-7P**, 1-[3-[4-[thiomorpholin-4-
 yl]but-1-ynyl]benzyl]piperidin-4-ol **544707-76-8P**,
 1-[4-[3-[4-[4-methoxypiperidin-1-yl]methyl]phenyl]but-3-ynyl]piperidine
544707-77-9P, 4-[4-[3-[4-[4-methoxypiperidin-1-yl]methyl]phenyl]but-
 3-ynyl]morpholine **544707-78-0P**, 4-[4-[3-[4-[4-methoxypiperidin-1-
 yl]methyl]phenyl]but-3-ynyl]thiomorpholine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of substituted phenylalkynes for use in histamine-mediated disorders)


RN 544707-17-7 CAPLUS

CN Piperidine, 1-[[4-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl] - (9CI) (CA INDEX NAME)




RN 544707-18-8 CAPLUS

CN Piperidine, 1-[[3-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl] - (9CI) (CA INDEX NAME)



RN 544707-20-2 CAPLUS


CN Morpholine, 4-[[3-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl] -, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 544707-21-3 CAPLUS

CN Piperidine, 1-[[4-[4-(1-pyrrolidinyl)-1-butynyl]phenyl]methyl] - (9CI) (CA INDEX NAME)




RN 544707-22-4 CAPLUS

CN 3-Butyn-1-amine, N,N-diethyl-4-[4-(1-piperidinylmethyl)phenyl] - (9CI) (CA INDEX NAME)




RN 544707-23-5 CAPLUS

CN Thiomorpholine, 4-[4-[4-(1-piperidinylmethyl)phenyl]-3-butynyl] - (9CI) (CA INDEX NAME)




RN 544707-24-6 CAPLUS

CN Morpholine, 4-[4-[4-(1-piperidinylmethyl)phenyl]-3-butynyl] - (9CI) (CA INDEX NAME)




RN 544707-25-7 CAPLUS

CN Piperazine, 1-methyl-4-[4-[4-(1-piperidinylmethyl)phenyl]-3-butynyl] - (9CI) (CA INDEX NAME)




RN 544707-26-8 CAPLUS

CN Piperidine, 1-[4-[4-(1-pyrrolidinylmethyl)phenyl]-3-butynyl] - (9CI) (CA INDEX NAME)




RN 544707-27-9 CAPLUS

CN Morpholine, 4-[[4-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl] - (9CI) (CA INDEX NAME)




RN 544707-28-0 CAPLUS

CN Benzenemethanamine, N,N-diethyl-4-[4-(1-piperidiny)-1-butynyl]- (9CI)
(CA INDEX NAME)




RN 544707-29-1 CAPLUS

CN Piperidine, 4-(phenylmethyl)-1-[[4-[4-(1-piperidiny)-1-butynyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 544707-30-4 CAPLUS

CN 4-Piperidinol, 1-[[4-[4-(1-piperidiny)-1-butynyl]phenyl]methyl]- (9CI)
(CA INDEX NAME)




RN 544707-31-5 CAPLUS


CN 2-Piperidineethanol, 1-[[4-[4-(1-piperidiny)-1-butynyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 544707-32-6 CAPLUS
 CN Quinoline, decahydro-1-[[4-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]-
 (9CI) (CA INDEX NAME)




RN 544707-33-7 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[[4-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]-
 (9CI) (CA INDEX NAME)




RN 544707-34-8 CAPLUS
 CN 1,4-Dioxaspiro[4.5]decane, 8-[[4-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]-
 (9CI) (CA INDEX NAME)



RN 544707-35-9 CAPLUS
 CN Piperazine, 1-methyl-4-[[4-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]-
 (9CI) (CA INDEX NAME)




RN 544707-38-2 CAPLUS
 CN Piperazine, 1-phenyl-4-[[4-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]-
 (9CI) (CA INDEX NAME)




RN 544707-39-3 CAPLUS

CN Piperazine, 1-(phenylmethyl)-4-[[4-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 544707-42-8 CAPLUS

CN Piperazine, 1-(1-methylethyl)-4-[[4-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 544707-43-9 CAPLUS

CN 1,3,8-Triazaspiro[4.5]decan-4-one, 1-phenyl-8-[[3-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]- (9CI) (CA INDEX NAME)





RN 544707-44-0 CAPLUS


CN 3-Piperidinecarboxamide, N,N-diethyl-1-[[3-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 544707-45-1 CAPLUS
 CN Pyridine, 3-[1-[[3-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]-2-piperidinyl]- (9CI) (CA INDEX NAME)




RN 544707-46-2 CAPLUS
 CN Piperazine, 1-[[3-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 544707-47-3 CAPLUS
 CN Pyrimidine, 2-[4-[[3-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 544707-48-4 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[[3-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 544707-56-4 CAPLUS
 CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[3-[4-(1-piperidinyl)-1-

butynyl]phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 544707-58-6 CAPLUS

CN Piperidine, 1-[4-[3-(1-pyrrolidinylmethyl)phenyl]-3-butynyl]- (9CI) (CA INDEX NAME)




RN 544707-60-0 CAPLUS

CN 3-Butyn-1-amine, N,N-dimethyl-4-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 544707-61-1 CAPLUS

CN Benzenemethanamine, N,N-dimethyl-4-[4-(1-piperidinyl)-1-butynyl]- (9CI) (CA INDEX NAME)




RN 544707-63-3 CAPLUS

CN Piperidine, 1-[4-[3-(1-aziridinylmethyl)phenyl]-3-butynyl]- (9CI) (CA INDEX NAME)




RN 544707-64-4 CAPLUS

CN Pyrimidine, 2-[[1-[[3-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)




RN 544707-65-5 CAPLUS

CN 2-Pyridinamine, N-[1-[[3-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 544707-72-4 CAPLUS

CN Piperazine, 1-methyl-4-[[3-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 544707-73-5 CAPLUS

CN 4-Piperidinol, 1-[[3-[4-(1-piperidinyl)-1-butynyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 544707-74-6 CAPLUS

CN 4-Piperidinol, 1-[[3-[4-(4-morpholinyl)-1-butynyl]phenyl]methyl] - (9CI)
(CA INDEX NAME)


RN 544707-75-7 CAPLUS

CN 4-Piperidinol, 1-[[3-[4-(4-thiomorpholinyl)-1-butynyl]phenyl]methyl] - (9CI) (CA INDEX NAME)




RN 544707-76-8 CAPLUS

CN Piperidine, 4-methoxy-1-[[3-[4-(1-piperidiny)l]-1-butynyl]phenyl]methyl] - (9CI) (CA INDEX NAME)




RN 544707-77-9 CAPLUS

CN Morpholine, 4-[4-[3-[(4-methoxy-1-piperidiny)l]methyl]phenyl]-3-butynyl] - (9CI) (CA INDEX NAME)




RN 544707-78-0 CAPLUS


CN Thiomorpholine, 4-[4-[3-[(4-methoxy-1-piperidiny)l]methyl]phenyl]-3-butynyl] - (9CI) (CA INDEX NAME)



IT 178162-69-1P, 1-[4-Bromobenzyl]piperidine 544707-16-6P,
Toluene-4-sulfonic acid 4-[4-[[piperidinyl]methyl]phenyl]but-3-ynyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of substituted phenylalkynes for use in histamine-mediated
disorders)
RN 178162-69-1 CAPLUS
CN Piperidine, 1-[(4-bromophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 544707-16-6 CAPLUS
CN 3-Butyn-1-ol, 4-[4-(1-piperidinylmethyl)phenyl]-, 4-methylbenzenesulfonate
(ester) (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 27 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:242298 CAPLUS
DOCUMENT NUMBER: 138:271538
TITLE: Novel aminoazetidine, -pyrrolidine and -piperidine
derivatives
INVENTOR(S): Doerwald, Florencio Zaragoza; Hohlweg, Rolf
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Boehringer Ingelheim
International G.m.b.H.
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024928	A2	20030327	WO 2002-DK593	20020911
WO 2003024928	A3	20040304		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				
UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				



KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1430027 A2 20040623 EP 2002-764566 20020911
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

JP 2005510465 T2 20050421 JP 2003-528776 20020911
 US 2003130253 A1 20030710 US 2002-242968 20020912
 US 6673829 B2 20040106
 US 2003186963 A1 20031002 US 2002-245236 20020912
 US 2004248938 A1 20041209 US 2004-891553 20040715

PRIORITY APPLN. INFO.: DK 2001-1344 A 20010914
 DK 2002-750 A 20020516
 US 2001-323004P P 20010918
 US 2002-383418P P 20020521
 WO 2002-DK593 W 20020911
 US 2002-245236 A1 20020912

OTHER SOURCE(S): MARPAT 138:271538
 ED Entered STN: 28 Mar 2003
 GI



AB Title compds. I [R1 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, cycloalkylalkyl, or cycloalkenylalkyl, each optionally substituted with halogens; R2 = alkyl; n = 0-2; X = (CH2)m(Z)p(CH2)q wherein p = 0 or 1 and m or q independently = 0-4 and Z = O, NH, NMe, CO, CHOH, etc.; Y = (un)substituted aryl, heteroaryl, cycloalkyl or cycloalkenyl], use of these compds. as pharmaceutical compns., pharmaceutical compns. comprising the compds., a method of treatment employing these compds. and compns, and preparation of these compds. is disclosed. Thus, II was prepared by condensation of N-(1-ethylpropyl)pyrrolidin-3-ylaminomethane with 4-(3,4-dimethoxyphenyl)-4-oxobutanoic acid. The compds. show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity (no data). As a result, the compds. are useful for the treatment of diseases and disorders related to the histamine H3 receptor.

IT 503067-76-3P 503067-78-5P 503067-80-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amidopyrrolidines and amidopiperidines as ligands for

histamine **H3 receptor** via condensation of
aminopyrrolidines or aminopiperidines with corresponding carboxylic
acids)

RN 503067-76-3 CAPLUS


CN [1,1'-Biphenyl]-4-acetamide, N-[1-(cyclopropylmethyl)-3-piperidiny]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 503067-78-5 CAPLUS


CN Benzamide, N-[1-(cyclopropylmethyl)-3-piperidiny]-N-methyl-3-phenoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 503067-80-9 CAPLUS

CN 2-Propenamide, 3-(1,3-benzodioxol-5-yl)-N-[1-(cyclopropylmethyl)-3-piperidiny]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 503067-88-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amidopyrrolidines and amidopiperidines as ligands for
histamine **H3 receptor** via condensation of
aminopyrrolidines or aminopiperidines with corresponding carboxylic
acids)

RN 503067-88-7 CAPLUS

CN 3-Piperidinamine, 1-(cyclopropylmethyl)-N-methyl- (9CI) (CA INDEX NAME)



L87 ANSWER 28 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:928241 CAPLUS

DOCUMENT NUMBER: 138:14004

TITLE: Preparation of benzofurylbenzonitriles and related compounds as histamine **H3** receptor ligands.

INVENTOR(S): Cowart, Marlon D.; Bennani, Youssef L.; Faghieh, Ramin; Black, Lawrence A.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 810,648.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002183309	A1	20021205	US 2002-44495	20020111
US 2002177589	A1	20021128	US 2001-810648	20010316
CA 2440238	AA	20020926	CA 2002-2440238	20020311
WO 2002074758	A2	20020926	WO 2002-US7107	20020311
WO 2002074758	A3	20030320		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1370546	A2	20031217	EP 2002-715079	20020311
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2005500986	T2	20050113	JP 2002-573767	20020311
BR 2002005829	A	20050308	BR 2002-5829	20020311
PRIORITY APPLN. INFO.:			US 2001-276793P	P 20010316
			US 2001-810648	A2 20010316
			US 2002-44495	A 20020111
			US 2002-81207	A 20020225
			WO 2002-US7107	W 20020311

OTHER SOURCE(S): MARPAT 138:14004

ED Entered STN: 06 Dec 2002

GI




AB Title compds. [I; A = CO, bond; D = O, S; L = CH₂CH₂, CH₂CH₂CH₂; PQ = bond; P, Q = H; R₁, R₂ = H, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclealkyl, hydroxyalkyl, alkenyl, alkynyl; R₁R₂N = heterocycle; R₃, R₄, R₅ = H, alkoxy, alkoxyalkyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, CO₂H, carboxyalkyl, cyano, cyanoalkyl, CHO, halo, haloalkoxy, haloalkyl, OH, hydroxyalkyl, SH, NO₂, NRARB, (NRARB)alkyl, (NRARB)CO, (NRARB)SO₂; R₆, R₇ = H, alkoxy, alkoxyalkyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, aryl, CO₂H, carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, CHO, halo, haloalkoxy, haloalkyl, heterocyclyl, OH, hydroxyalkyl, SH, NO₂, NRARB, (NRARB)alkyl, (NRARB)carbonyl, (NRARB)sulfonyl, L₂R₂₀; L₂ = alkylene, alkenylene, O, S, CO, N(OR₂₁), N(RA); R₂₀ = aryl, heterocyclyl, cycloalkyl; R₂₁ = H alkyl; RA, RB = H, alkyl, alkylcarbonyl, formyl; provided that ≥1, but not both, of R₆, R₇ = aryl, heterocyclyl, cycloalkyl, L₂R₂₀], were prepared. Thus, 4-[2-(2-Et methanesulfonyl)-1-benzofuran-5-yl]benzonitrile (preparation given), 2-(R)-methylpyrrolidine hydrobromide, and Na₂CO₃ were heated in MeCN at 50° for 48 h to give 34% 4-[2-[2-((2R)-2-methylpyrrolidinyl)ethyl]-1-benzofuran-5-yl]benzonitrile. The latter bound to H₃ receptors with K_i = 4.44 nM.

IT **460746-52-5P**, 4-[2-[2-(1-Piperidinyl)ethyl]-1-benzofuran-5-yl]benzonitrile **460746-54-7P**, 4-[2-[2-(2-Methyl-1-piperidinyl)ethyl]-1-benzofuran-5-yl]benzonitrile **460746-62-7P**, 4-[2-[2-(4-Methyl-1-piperidinyl)ethyl]-1-benzofuran-5-yl]benzonitrile **460746-75-2P** **460746-77-4P**, 4-[4-[2-[2-(2-Methyl-1-piperidinyl)ethyl]-1-benzofuran-5-yl]benzoyl]morpholine **460746-82-1P** **460746-95-6P**, 4-[4-Methyl-2-oxo-3-[2-(1-piperidinyl)ethyl]-2H-chromen-6-yl]benzonitrile **460747-09-5P**, 4-[[6-[2-[2-(1-Piperidinyl)ethyl]-1-benzofuran-5-yl]-3-pyridinyl]carbonyl]morpholine **460747-16-4P**, 4-[[6-[2-[2-(4-Methyl-1-piperidinyl)ethyl]-1-benzofuran-5-yl]-3-pyridinyl]carbonyl]morpholine **460747-24-4P** **460749-28-4P** **460749-43-3P** **460749-45-5P**, 4-[[6-[2-[2-((2R,6S)-2,6-Dimethylpiperidinyl)ethyl]-1-benzofuran-5-yl]-3-pyridinyl]carbonyl]morpholine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of benzofurylbenzonitriles and related compds. as histamine H₃ receptor ligands)

RN 460746-52-5 CAPLUS


CN Benzonitrile, 4-[2-[2-(1-piperidinyl)ethyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)




RN 460746-54-7 CAPLUS

CN Benzonitrile, 4-[2-[2-(2-methyl-1-piperidiny)ethyl]-5-benzofuranyl]-
(9CI) (CA INDEX NAME)

RN 460746-62-7 CAPLUS


CN Benzonitrile, 4-[2-[2-(4-methyl-1-piperidiny)ethyl]-5-benzofuranyl]-
(9CI) (CA INDEX NAME)

RN 460746-75-2 CAPLUS

CN Morpholine, 4-[4-[2-[2-(1-piperidiny)ethyl]-5-benzofuranyl]benzoyl]-
(9CI) (CA INDEX NAME)


RN 460746-77-4 CAPLUS

CN Morpholine, 4-[4-[2-[2-(2-methyl-1-piperidiny)ethyl]-5-benzofuranyl]benzoyl]-
(9CI) (CA INDEX NAME)




RN 460746-82-1 CAPLUS

CN Morpholine, 4-[4-[2-[2-(4-methyl-1-piperidinyl)ethyl]-5-benzofuranyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 460746-95-6 CAPLUS

CN Benzonitrile, 4-[4-methyl-2-oxo-3-[2-(1-piperidinyl)ethyl]-2H-1-benzopyran-6-yl]- (9CI) (CA INDEX NAME)




RN 460747-09-5 CAPLUS

CN Morpholine, 4-[[6-[2-[2-(1-piperidinyl)ethyl]-5-benzofuranyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 460747-16-4 CAPLUS

CN Morpholine, 4-[[6-[2-[2-(4-methyl-1-piperidinyl)ethyl]-5-benzofuranyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 460747-24-4 CAPLUS


CN Morpholine, 4-[[6-[[2-[[2-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)ethyl]-5-benzofuranyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 460749-28-4 CAPLUS

CN Benzonitrile, 4-[2-[2-[(2R,6S)-2,6-dimethyl-1-piperidinyl]ethyl]-5-benzofuranyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 460749-43-3 CAPLUS

CN Morpholine, 4-[4-[2-[2-[(2R,6S)-2,6-dimethyl-1-piperidinyl]ethyl]-5-benzofuranyl]benzoyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 460749-45-5 CAPLUS

CN Morpholine, 4-[[6-[2-[2-[(2R,6S)-2,6-dimethyl-1-piperidinyl]ethyl]-5-benzofuranyl]-3-pyridinyl]carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L87 ANSWER 29 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:781497 CAPLUS

DOCUMENT NUMBER: 137:262957

TITLE: Preparation of aryloxyalkylamines as histamine
H3 receptor modulators

INVENTOR(S): Schwartz, Jean-Charles; Arrang, Jean-Michel; Garbarg,
Monique; Lecomte, Jeanne-Marie; Ligneau, Xavier;
Schunack, Walter G.; Stark, Holger; Ganellin, Charon
Robin; Leurquin, Fabien; Sigurd, Elz

PATENT ASSIGNEE(S): Societe Civile Bioprojet, Fr.

SOURCE: PCT Int. Appl., 195 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006254	A2	20000210	WO 1999-EP5744	19990729
WO 2000006254	A3	20000504		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 978512	A1	20000209	EP 1998-401944	19980729
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
EP 982300	A2	20000301	EP 1998-403351	19981231
EP 982300	A3	20000308		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
CA 2321881	AA	20000210	CA 1999-2321881	19990729
AU 9955119	A1	20000221	AU 1999-55119	19990729
EP 1100503	A2	20010523	EP 1999-941543	19990729
EP 1100503	B1	20040922		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			


IE, SI, LT, LV, FI, RO

JP 2002521463	T2	20020716	JP 2000-562103	19990729
AT 276751	E	20041015	AT 1999-941543	19990729
US 2004220225	A1	20041104	US 2004-856838	20040601
PRIORITY APPLN. INFO.:			EP 1998-401944	A 19980729
			EP 1998-403351	A 19981231
			WO 1999-EP5744	W 19990729
			US 2001-622199	A3 20010531

OTHER SOURCE(S): MARPAT 137:262957

ED Entered STN: 14 Oct 2002

GI



AB The title non-imidazole compds. I [wherein n = 2-8; m = 0-5; X = O, S; R¹, R² = alkyl, cycloalkyl; NR¹R² = (unsatd.) N-containing ring, substituted piperazino; R³ = halo, alkyl, cycloalkyl, CF₃, aryl, alkoxy, aryloxy, NO₂, CHO, alkanoyl, aroyl, aralkanoyl, amino, carboxamido, cyano, alkoximino, alkenyl, alkynyl, etc.; and their pharmaceutically acceptable salts, hydrates, polymorphic crystalline structures, optical isomers, racemates, diastereoisomers, and enantiomers] were prepared as antagonists and/or agonists of the histamine H₃-receptors. Thus, 1-[3-(4-cyanophenoxy)propyl]piperidine hydrogen oxalate (general preparation given) increased telemethylhistamine in mice with ED₅₀ = 0.20 mg/kg orally. I are useful for the treatment of central nervous system disorders, in particular Alzheimer's disease, mood and attention alterations, cognitive deficits in psychiatric pathologies, obesity, vertigo, and motion sickness (no data).

IT 27078-39-3P 70403-69-9P, 5-Piperidinopentylamine
 77427-42-0P 99759-00-9P 169815-42-3P,
 7-Chloro-4-(3-piperidinopropylamino)quinoline 172018-41-6P
 199920-60-0P 362665-52-9P 362665-54-1P,
 3-Phenylpropyl 3-piperidinopropyl ether 362665-55-2P
 362665-56-3P, 3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether
 362665-57-4P 362665-63-2P 362665-66-5P,
 N-(6-Phenylhexyl)piperidine 362665-67-6P, N-(6-Phenylhexyl)piperidine hydrogen oxalate 362665-74-5P,
 3-(4-Chlorobenzyl)-5-(2-piperidinoethyl)-1,2,4-oxadiazole hydrogen oxalate
 362665-85-8P 409127-50-0P, 2-Methyl-4-(3-piperidinopropylamino)quinoline 409127-54-4P,
 7-Chloro-4-(4-piperidinobutylamino)quinoline 409127-57-7P,
 4-(6-Piperidinohexylamino)quinoline 409127-58-8P,
 2-Methyl-4-(6-piperidinohexylamino)quinoline 409127-62-4P,
 7-Chloro-4-(8-piperidinooctylamino)quinoline 409127-63-5P,
 7-Chloro-4-(10-piperidinodecylamino)quinoline 409127-84-0P,
 10-Piperidinodecylamine 462114-09-6P 462114-10-9P
 462115-42-0P, 3-Cyclopentyl-N-[3-(1-pyrrolidinyl)propyl]propanamid
 e 462115-43-1P, 3-Cyclopentyl-N-[3-(1-pyrrolidinyl)propyl]propanamide hydrogen oxalate 462115-44-2P
 462115-45-3P 462115-46-4P 462115-47-5P
 462115-50-0P 462115-51-1P 462115-54-4P,
 5-Nitro-2-(6-piperidinohexyl)pyridine hydrogen oxalate
 462115-56-6P, 3-Nitro-2-(6-piperidinohexylamino)pyridine
 462115-57-7P, 3-Nitro-2-(6-piperidinohexylamino)pyridine hydrogen

oxalate 462115-59-9P, 2-(6-Piperidinohexylamino)pyrimidine
 462115-60-2P, 2-(6-Piperidinohexylamino)pyrimidine hydrogen
 oxalate 462115-61-3P 462115-62-4P 462115-63-5P
 462115-64-6P 462115-65-7P 462115-66-8P
 462115-68-0P 462115-69-1P 462115-70-4P
 462115-71-5P 462115-74-8P 462115-75-9P
 462115-76-0P 462115-77-1P 462115-78-2P
 462115-79-3P 462115-80-6P 462115-81-7P
 462115-82-8P 462115-83-9P 462115-84-0P
 462115-85-1P 462115-86-2P 462115-87-3P
 462115-88-4P, 4-(6-Piperidinohexylamino)quinoline dioxalate
 462115-89-5P, 2-Methyl-4-(3-piperidinopropylamino)quinoline
 dioxalate 462115-90-8P, 2-Methyl-4-(6-
 piperidinohexylamino)quinoline dioxalate 462115-91-9P,
 7-Chloro-4-(3-piperidinopropylamino)quinoline dioxalate
 462115-92-0P, 7-Chloro-4-(4-piperidinobutylamino)quinoline
 dioxalate 462115-93-1P, 7-Chloro-4-(8-
 piperidinooctylamino)quinoline dioxalate 462115-94-2P,
 7-Chloro-4-(10-piperidinodecylamino)quinoline dioxalate
 462115-95-3P, 7-Chloro-4-(12-piperidinododecylamino)quinoline
 462115-96-4P, 7-Chloro-4-(12-piperidinododecylamino)quinoline
 dioxalate 462116-03-6P, 5-Nitro-2-(5-
 piperidinopentylamino)pyridine 462116-04-7P,
 5-Nitro-2-(5-piperidinopentylamino)pyridine hydrogen oxalate
 462116-06-9P, 3-Nitro-2-(5-piperidinopentylamino)pyridine hydrogen
 oxalate 462116-07-0P, 5-Amino-2-(5-piperidinopentylamino)pyridin
 e 462116-08-1P, 5-Amino-2-(5-piperidinopentylamino)pyridine
 dioxalate 462116-09-2P, 2-(6-Piperidinohexylamino)quinoline
 462116-10-5P, 2-(6-Piperidinohexylamino)quinoline dioxalate
 462116-12-7P, 2-(6-Piperidinohexylamino)benzothiazole
 462116-13-8P 462116-14-9P, 10-Piperidinodecylamine
 dioxalate 462116-22-9P 462116-23-0P,
 2-[(2-Piperidinoethyl)amino]benzothiazole 462116-24-1P,
 2-Nitro-5-(6-piperidinohexyl)pyridine 462116-25-2P,
 N-Benzyl-N'-(3-piperidinopropyl)guanidine 462116-26-3P,
 N-Cyclohexylmethyl-N'-(3-piperidinopropyl)guanidine 462116-28-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(H3 receptor modulator; preparation of
 aryloxyalkylamines as histamine H3 receptor
 modulators)


RN 27078-39-3 CAPLUS

CN 1-Propanamine, N,N-diethyl-3-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)


Ph-(CH₂)₃-O-(CH₂)₃-NEt₂

RN 70403-69-9 CAPLUS

CN 1-Piperidinepentanamine (9CI) (CA INDEX NAME)




RN 77427-42-0 CAPLUS
CN 2-Benzothiazolamine, N-[2-(1-piperidinyl)ethyl]-, dihydrochloride (9CI)
(CA INDEX NAME)




● 2 HCl


RN 99759-00-9 CAPLUS
CN Urea, N-[3-(diethylamino)propyl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 169815-42-3 CAPLUS
CN 4-Quinolinamine, 7-chloro-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 172018-41-6 CAPLUS
CN 1-Piperidinepropanol, phenylcarbamate (ester) (9CI) (CA INDEX NAME)



RN 199920-60-0 CAPLUS


CN 1-Piperidinepropanol, phenylcarbamate (ester), monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 362665-52-9 CAPLUS


CN 1-Piperidinepentanamine, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 362665-54-1 CAPLUS

CN Piperidine, 1-[3-(3-phenylpropoxy)propyl]- (9CI) (CA INDEX NAME)




RN 362665-55-2 CAPLUS

CN Piperidine, 1-[3-(3-phenylpropoxy)propyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 362665-54-1

CMF C17 H27 N O




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 362665-56-3 CAPLUS
CN Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]- (9CI) (CA INDEX NAME)



RN 362665-57-4 CAPLUS
CN Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 362665-56-3
CMF C17 H26 Cl N O




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 362665-63-2 CAPLUS
CN Carbamic acid, pentyl-, 3-(1-piperidinyl)propyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 362665-66-5 CAPLUS
CN Piperidine, 1-(6-phenylhexyl)- (9CI) (CA INDEX NAME)



RN 362665-67-6 CAPLUS
CN Piperidine, 1-(6-phenylhexyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 362665-66-5
CMF C17 H27 N



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 362665-74-5 CAPLUS
CN Piperidine, 1-[2-[3-[(4-chlorophenyl)methyl]-1,2,4-oxadiazol-5-yl]ethyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 362665-73-4
CMF C16 H20 Cl N3 O



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 362665-85-8 CAPLUS

CN 1-Propanamine, N,N-diethyl-3-(3-phenylpropoxy)-, ethanedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 27078-39-3


CMF C16 H27 N O



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 409127-50-0 CAPLUS

CN 4-Quinolinamine, 2-methyl-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX
NAME)




RN 409127-54-4 CAPLUS

CN 4-Quinolinamine, 7-chloro-N-[4-(1-piperidinyl)butyl]- (9CI) (CA INDEX NAME)




RN 409127-57-7 CAPLUS

CN 4-Quinolinamine, N-[6-(1-piperidinyl)hexyl]- (9CI) (CA INDEX NAME)




RN 409127-58-8 CAPLUS

CN 4-Quinolinamine, 2-methyl-N-[6-(1-piperidinyl)hexyl]- (9CI) (CA INDEX NAME)




RN 409127-62-4 CAPLUS

CN 4-Quinolinamine, 7-chloro-N-[8-(1-piperidinyl)octyl] - (9CI) (CA INDEX NAME)




RN 409127-63-5 CAPLUS

CN 4-Quinolinamine, 7-chloro-N-[10-(1-piperidinyl)decyl] - (9CI) (CA INDEX NAME)



RN 409127-84-0 CAPLUS


CN 1-Piperidinedecanamine (9CI) (CA INDEX NAME)



RN 462114-09-6 CAPLUS

CN Carbamic acid, [(1S)-1,2,2-trimethylpropyl]-, 3-(1-piperidinyl)propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 462114-10-9 CAPLUS


CN Carbamic acid, [(1S)-1,2,2-trimethylpropyl]-, 3-(1-piperidinyl)propyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 462114-09-6

CMF C15 H30 N2 O2


Absolute stereochemistry. Rotation (+).



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 462115-42-0 CAPLUS

CN Cyclopentanepropanamide, N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 462115-43-1 CAPLUS

CN Cyclopentanepropanamide, N-[3-(1-pyrrolidinyl)propyl]-, ethanedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 462115-42-0


CMF C15 H28 N2 O



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 462115-44-2 CAPLUS

CN Urea, N-cyclohexyl-N'-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 462115-45-3 CAPLUS

CN Urea, N-cyclohexyl-N'-[3-(1-pyrrolidinyl)propyl]-, ethanedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 462115-44-2


CMF C14 H27 N3 O



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 462115-46-4 CAPLUS

CN Ethanone, 1-[4-[[4-(1-piperidinylmethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 462115-47-5 CAPLUS

CN Ethanone, 1-[4-[[4-(1-piperidinylmethyl)phenyl]methoxy]phenyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 462115-46-4


CMF C21 H25 N O2



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 462115-50-0 CAPLUS

CN Piperidine, 1-[[4-[(3-phenylpropoxy)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 462115-51-1 CAPLUS

CN Piperidine, 1-[[4-[(3-phenylpropoxy)methyl]phenyl]methyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 462115-50-0


CMF C22 H29 N O



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 462115-54-4 CAPLUS

CN Pyridine, 5-nitro-2-[6-(1-piperidiny)hexyl]-, ethanedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 462115-53-3


CMF C16 H25 N3 O2



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 462115-56-6 CAPLUS

CN 2-Pyridinamine, 3-nitro-N-[6-(1-piperidiny)hexyl]- (9CI) (CA INDEX NAME)




RN 462115-57-7 CAPLUS

CN 2-Pyridinamine, 3-nitro-N-[6-(1-piperidiny)hexyl]-, ethanedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 462115-56-6


CMF C16 H26 N4 O2



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 462115-59-9 CAPLUS

CN 2-Pyrimidinamine, N-[6-(1-piperidinyl)hexyl]- (9CI) (CA INDEX NAME)




RN 462115-60-2 CAPLUS

CN 2-Pyrimidinamine, N-[6-(1-piperidinyl)hexyl]-, ethanedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 462115-59-9


CMF C15 H26 N4



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 462115-61-3 CAPLUS

CN Ethanone, 1-[4-[[4-[(4-methyl-1-piperidinyl)methyl]phenyl]methoxy]phenyl]-
(9CI) (CA INDEX NAME)




RN 462115-62-4 CAPLUS

CN Ethanone, 1-[4-[[4-[(4-methyl-1-piperidinyl)methyl]phenyl]methoxy]phenyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 462115-61-3


CMF C22 H27 N O2



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 462115-63-5 CAPLUS

CN Ethanone, 1-[4-[[4-[[[(3R,5S)-3,5-dimethyl-1-piperidinyl]methyl]phenyl]methoxy]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 462115-64-6 CAPLUS

CN Ethanone, 1-[4-[[4-[[[(3R,5S)-3,5-dimethyl-1-piperidinyl]methyl]phenyl]methoxy]phenyl]-, rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 462115-63-5
CMF C23 H29 N O2

Relative stereochemistry.




CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 462115-65-7 CAPLUS
CN Ethanone, 1-[4-[[4-[[[(3R,5R)-3,5-dimethyl-1-piperidinyl]methyl]phenyl]methoxy]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 462115-66-8 CAPLUS
CN Ethanone, 1-[4-[[4-[[[(3R,5R)-3,5-dimethyl-1-piperidinyl]methyl]phenyl]methoxy]phenyl]-, rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 462115-65-7
CMF C23 H29 N O2


Relative stereochemistry.



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 462115-68-0 CAPLUS

CN Methanone, cyclopropyl[4-[[4-(1-piperidinylmethyl)phenyl]methoxy]phenyl]-(9CI) (CA INDEX NAME)




RN 462115-69-1 CAPLUS

CN Methanone, cyclopropyl[4-[[4-(1-piperidinylmethyl)phenyl]methoxy]phenyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 462115-68-0


CMF C23 H27 N O2



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 462115-70-4 CAPLUS

CN Methanone, cyclopropyl [4-[[4-[(4-methyl-1-piperidinyl)methyl]phenyl]methoxylphenyl]- (9CI) (CA INDEX NAME)




RN 462115-71-5 CAPLUS

CN Methanone, cyclopropyl [4-[[4-[(4-methyl-1-piperidinyl)methyl]phenyl]methoxylphenyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 462115-70-4


CMF C24 H29 N O2



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 462115-74-8 CAPLUS

CN Piperidine, 4-methyl-1-[3-(3-phenylpropoxy)propyl]- (9CI) (CA INDEX NAME)




RN 462115-75-9 CAPLUS

CN Piperidine, 4-methyl-1-[3-(3-phenylpropoxy)propyl]-, ethanedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 462115-74-8


CMF C18 H29 N O



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 462115-76-0 CAPLUS

CN Piperidine, 3,5-dimethyl-1-[3-(3-phenylpropoxy)propyl]-, (3R,5S)-rel-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 462115-77-1 CAPLUS


CN Piperidine, 3,5-dimethyl-1-[3-(3-phenylpropoxy)propyl]-, (3R,5S)-rel-,
ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 462115-76-0

CMF C19 H31 N O


Relative stereochemistry.



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 462115-78-2 CAPLUS

CN Piperidine, 3,5-dimethyl-1-[3-(3-phenylpropoxy)propyl]-, (3R,5R)-rel-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 462115-79-3 CAPLUS


CN Piperidine, 3,5-dimethyl-1-[3-(3-phenylpropoxy)propyl]-, (3R,5R)-rel-,
ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 462115-78-2

CMF C19 H31 N O


Relative stereochemistry.



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 462115-80-6 CAPLUS

CN Piperidine, 3-methyl-1-[3-(3-phenylpropoxy)propyl]- (9CI) (CA INDEX NAME)




RN 462115-81-7 CAPLUS

CN Piperidine, 3-methyl-1-[3-(3-phenylpropoxy)propyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 462115-80-6


CMF C18 H29 N O



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 462115-82-8 CAPLUS


CN Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 462115-83-9 CAPLUS
 CN Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-4-methyl-,
 ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 462115-82-8
 CMF C18 H28 Cl N O




CM 2

CRN 144-62-7
 CMF C2 H2 O4



RN 462115-84-0 CAPLUS
 CN Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-3,5-dimethyl-,
 (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 462115-85-1 CAPLUS
 CN Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-3,5-dimethyl-,
 (3R,5S)-rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 462115-84-0
 CMF C19 H30 Cl N O


Relative stereochemistry.



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 462115-86-2 CAPLUS

CN Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-3,5-dimethyl-,
(3R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 462115-87-3 CAPLUS


CN Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-3,5-dimethyl-,
(3R,5R)-rel-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 462115-86-2


CMF C19 H30 Cl N O

Relative stereochemistry.



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 462115-88-4 CAPLUS
CN 4-Quinolinamine, N-[6-(1-piperidinyl)hexyl]-, ethanedioate (1:2) (9CI)
(CA INDEX NAME)


CM 1

CRN 409127-57-7
CMF C20 H29 N3



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 462115-89-5 CAPLUS
CN 4-Quinolinamine, 2-methyl-N-[3-(1-piperidinyl)propyl]-, ethanedioate (1:2)
(9CI) (CA INDEX NAME)

CM 1


CRN 409127-50-0
CMF C18 H25 N3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 462115-90-8 CAPLUS

CN 4-Quinolinamine, 2-methyl-N-[6-(1-piperidinyl)hexyl]-, ethanedioate (1:2)
(9CI) (CA INDEX NAME)

CM 1

CRN 409127-58-8


CMF C21 H31 N3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 462115-91-9 CAPLUS

CN 4-Quinolinamine, 7-chloro-N-[3-(1-piperidinyl)propyl]-, ethanedioate (1:2)
(9CI) (CA INDEX NAME)

CM 1

CRN 169815-42-3


CMF C17 H22 Cl N3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 462115-92-0 CAPLUS

CN 4-Quinolinamine, 7-chloro-N-[4-(1-piperidinyl)butyl]-, ethanedioate (1:2)
(9CI) (CA INDEX NAME)

CM 1

CRN 409127-54-4


CMF C18 H24 Cl N3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 462115-93-1 CAPLUS

CN 4-Quinolinamine, 7-chloro-N-[8-(1-piperidinyl)octyl]-, ethanedioate (1:2)
(9CI) (CA INDEX NAME)

CM 1

CRN 409127-62-4


CMF C22 H32 Cl N3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 462115-94-2 CAPLUS

CN 4-Quinolinamine, 7-chloro-N-[10-(1-piperidinyl)decyl]-, ethanedioate (1:2)
(9CI) (CA INDEX NAME)

CM 1

CRN 409127-63-5


CMF C24 H36 Cl N3



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 462115-95-3 CAPLUS

CN 4-Quinolinamine, 7-chloro-N-[12-(1-piperidinyl)dodecyl]- (9CI) (CA INDEX NAME)




RN 462115-96-4 CAPLUS

CN 4-Quinolinamine, 7-chloro-N-[12-(1-piperidinyl)dodecyl]-, ethanedioate
(1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 462115-95-3


CMF C26 H40 Cl N3



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 462116-03-6 CAPLUS

CN 2-Pyridinamine, 5-nitro-N-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)




RN 462116-04-7 CAPLUS

CN 2-Pyridinamine, 5-nitro-N-[5-(1-piperidinyl)pentyl]-, ethanedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 462116-03-6


CMF C15 H24 N4 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 462116-06-9 CAPLUS

CN 2-Pyridinamine, 3-nitro-N-[5-(1-piperidinyl)pentyl]-, ethanedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 462116-05-8


CMF C15 H24 N4 O2



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 462116-07-0 CAPLUS

CN 2,5-Pyridinediamine, N2-[5-(1-piperidiny)pentyl]- (9CI) (CA INDEX NAME)




RN 462116-08-1 CAPLUS

CN 2,5-Pyridinediamine, N2-[5-(1-piperidiny)pentyl]-, ethanedioate (1:2)
(9CI) (CA INDEX NAME)

CM 1

CRN 462116-07-0


CMF C15 H26 N4



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 462116-09-2 CAPLUS

CN 2-Quinolinamine, N-[6-(1-piperidiny)hexyl]- (9CI) (CA INDEX NAME)




RN 462116-10-5 CAPLUS

CN 2-Quinolinamine, N-[6-(1-piperidiny)hexyl]-, ethanedioate (1:2) (9CI)
(CA INDEX NAME)


CM 1

CRN 462116-09-2
CMF C20 H29 N3




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 462116-12-7 CAPLUS
CN 2-Benzothiazolamine, N-[6-(1-piperidinyl)hexyl]- (9CI) (CA INDEX NAME)



RN 462116-13-8 CAPLUS
CN 2-Benzothiazolamine, N-[6-(1-piperidinyl)hexyl]-, ethanedioate (10:19) (9CI) (CA INDEX NAME)


CM 1

CRN 462116-12-7
CMF C18 H27 N3 S




CM 2


CRN 144-62-7
CMF C2 H2 O4




RN 462116-14-9 CAPLUS
CN 1-Piperidinedecanamine, ethanedioate (1:2) (9CI) (CA INDEX NAME)
CM 1
CRN 409127-84-0
CMF C15 H32 N2




CM 2
CRN 144-62-7
CMF C2 H2 O4




RN 462116-22-9 CAPLUS
CN Carbamic acid, pentyl-, 3-(1-piperidinyl)propyl ester (9CI) (CA INDEX NAME)



RN 462116-23-0 CAPLUS
CN 2-Benzothiazolamine, N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462116-24-1 CAPLUS
CN Pyridine, 2-nitro-5-[6-(1-piperidinyl)hexyl]- (9CI) (CA INDEX NAME)




RN 462116-25-2 CAPLUS

CN Guanidine, N-(phenylmethyl)-N'-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 462116-26-3 CAPLUS

CN Guanidine, N-(cyclohexylmethyl)-N'-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 462116-28-5 CAPLUS

CN Benzenethanimidamide, N-[(4-chlorophenyl)methyl]-4-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)




IT 462115-52-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of aryloxyalkylamines as histamine H3 receptor modulators)


RN 462115-52-2 CAPLUS

CN Benzenemethanol, 4-(1-piperidinylmethyl)-, sodium salt (9CI) (CA INDEX NAME)




● Na

IT 27578-60-5, 1-Piperidineethanamine 68453-37-2,
4-(Piperidinomethyl)benzoic acid methyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of aryloxyalkylamines as histamine **H3**
receptor modulators)
RN 27578-60-5 CAPLUS
CN 1-Piperidineethanamine (9CI) (CA INDEX NAME)





RN 68453-37-2 CAPLUS
CN Benzoic acid, 4-(1-piperidinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



L87 ANSWER 30 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:777907 CAPLUS
DOCUMENT NUMBER: 137:279192
TITLE: Imidazolyl derivatives useful as histamine **H3**
receptor ligands, and their pharmaceutical
composition, preparation, and use
INVENTOR(S): Bogenstaetter, Michael; Carruthers, Nicholas I.;
Jablonowski, Jill A.; Lovenberg, Timothy W.; Ly, Kiev
S.
PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002079168	A1	20021010	WO 2002-US9026	20020322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2442326	AA	20021010	CA 2002-2442326	20020322
US 2002198237	A1	20021226	US 2002-104283	20020322
EP 1373218	A1	20040102	EP 2002-757803	20020322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004524363	T2	20040812	JP 2002-577795	20020322
US 2004147577	A1	20040729	US 2004-757625	20040114
PRIORITY APPLN. INFO.:			US 2001-279802P	P 20010329
			US 2002-104283	B1 20020322
			WO 2002-US9026	W 20020322
OTHER SOURCE(S): CASREACT 137:279192; MARPAT 137:279192				
ED Entered STN: 11 Oct 2002				
GI				



AB Pharmaceutically useful heterocyclic compds. I, their preparation, compns. containing them, and methods of using them, for example, as histamine H3 receptor mediators, are disclosed. In formula I, Q1 is alkyl, haloalkyl, alkenyl; Q1 may be substituted with one or more of halo, cyano, OH, alkyl, alkenyl, nitro, amino, etc.; M is CH₂RM, CH(OH)RM, CORM, or C(:NOH)RM; RM is selected from alkyl, amino or its (halo)alkyl or alkenyl derivs., cycloalkyl, aryl, biaryl, heterocyclyl, etc.; RM may be substituted with one or more halo, cyano, OH, alkyl, nitro, amino, etc. Furthermore, A3 is NH, NR₃, S, S(O), S(O)₂, or O; R₃ is alkyl; L3 is C1-7 alkyl or alkenyl; L3 may be substituted with one or more halo, OH, OMe, and/or amino; or L3 is absent. Also, Q3 is selected from alkyl, haloalkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, 4-7 membered heterocyclyl, cycloalkyl-heterocyclyl, heterocyclyl-cycloalkyl, bi-(4-7 membered


heterocyclyl), (un)substituted amino, azinoyl, cycloalkylsulfanyl, 4-7 membered heterocyclylsulfanyl, and 4-7 membered heterocyclyloxy. The group Q3 may be substituted with one or more halo, cyano, hydroxy, alkyl, haloalkyl, alkenyl, nitro, (un)substituted amino, amido, cycloalkyl, monocyclic 4-7 membered heterocyclyl, monocyclic 4-7 membered heterocyclylalkyl, etc. Alternatively, A3 and L3 are absent and Q3 is sulfanyl. Included are pharmaceutically acceptable esters, ethers, N-oxides, amides, salts, hydrates, and/or isotopically labeled forms. Approx. 100 compds. I were prepared as drug candidates, as intermediates, or both. For example, lithiation of 2-mercapto-1-methylimidazole with t-BuLi and reaction with 4-chlorobenzaldehyde gave an intermediate invention compound, (4-chlorophenyl)(2-mercapto-3-methyl-3H-imidazol-4-yl)methanol. This alc.-thiol was S-alkylated with Br(CH₂)₃Cl, oxidized to the ketone, and aminated at chloro by HNMe₂.HCl, to give title compound II. In tests for inhibition of [3H]-N-methylhistamine binding to cloned human H₃ histamine receptors expressed in SK-N-MC cells, 27 selected compds. I had typical K_i values in the range of 1.6 to 9 nM, e.g., 2 nM for compound II.

IT **465615-81-0P**, (4-Chlorophenyl)[3-methyl-2-[[3-(piperidin-1-yl)propyl]amino]-3H-imidazol-4-yl]methanone **465616-77-7P**, (4-Chlorophenyl)[3-methyl-2-[4-[(piperidin-1-yl)methyl]phenoxy]-3H-imidazol-4-yl]methanone **465618-07-9P**, [3-Methyl-2-[3-(piperidin-1-yl)propoxy]-3H-imidazol-4-yl]piperidin-1-ylmethane
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazolyl derivs. as histamine H₃ receptor ligands)


RN 465615-81-0 CAPLUS

CN Methanone, (4-chlorophenyl)[1-methyl-2-[[3-(1-piperidiny)lpropyl]amino]-1H-imidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 465616-77-7 CAPLUS

CN Methanone, (4-chlorophenyl)[1-methyl-2-[4-(1-piperidinylmethyl)phenoxy]-1H-imidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 465618-07-9 CAPLUS

CN Piperidine, 1-[3-[[1-methyl-5-(1-piperidinylmethyl)-1H-imidazol-2-yl]oxy]propyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:736244 CAPLUS

DOCUMENT NUMBER: 137:247602

TITLE: Preparation of (pyrrolidinylalkyl)benzofurans and analogs as histamine-3 receptor ligands for treatment of disorders related to CNS neurotransmission

INVENTOR(S): Cowart, Marlon D.; Bennani, Youssef L.; Faghih, Ramin; Gfesser, Gregory A.; Black, Lawrence A.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 268 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074758	A2	20020926	WO 2002-US7107	20020311
WO 2002074758	A3	20030320		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002177589	A1	20021128	US 2001-810648	20010316
US 2002183309	A1	20021205	US 2002-44495	20020111
US 2002169188	A1	20021114	US 2002-81207	20020225
CA 2440238	AA	20020926	CA 2002-2440238	20020311
EP 1370546	A2	20031217	EP 2002-715079	20020311
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2005500986	T2	20050113	JP 2002-573767	20020311
BR 2002005829	A	20050308	BR 2002-5829	20020311
PRIORITY APPLN. INFO.:			US 2001-276793P	P 20010316
			US 2001-810648	A 20010316
			US 2002-44495	A 20020111
			US 2002-81207	A 20020225
			WO 2002-US7107	W 20020311

OTHER SOURCE(S): MARPAT 137:247602

ED Entered STN: 27 Sep 2002

GI



AB Title compds. I [wherein A = CO or covalent bond; D = O or S; L = alkylene, fluoroalkylene, or hydroxyalkylene; P and Q taken together form a covalent bond or are both H; R1 and R2 = independently H, (cyclo)alkyl, aryl(alkyl), cycloalkylalkyl, heterocyclyl(alkyl), hydroxyalkyl, alkenyl, or alkynyl; or NR1R2 = heterocyclyl; R3 = H, alkoxy(carbonyl), (halo)alkyl, alkylcarbonyl(oxy), alkylsulfinyl, alkylsulfonyl, alkylthio, aryl, carboxy(alkyl), cyano(alkyl), formyl, halo(alkoxy), heterocyclyl, hydroxy(alkyl), SH, NO2, or (un)substituted amino(alkyl), carbamoyl, or sulfamoyl; R4-R7 = independently R3 or L2R20 or R20L3R22; L2 = alkylene, alkenylene, O, S, SO, SO2, CO, C:NOR21, or (un)substituted amino; L3 = covalent bond, alkylene, alkenylene, O, S, CO, N:OR21, or (un)substituted amino; R20 and R22 = independently aryl, heterocyclyl, or cycloalkyl; R21 = H or alkyl; or pharmaceutically acceptable salts, esters, amides, or prodrugs thereof] where prepared for modulation of the histamine-3 (H3) receptors. For example, 4-hydroxy-4'-cyanobiphenyl was treated with NaI, NaOH, and NaOCl in MeOH to give 4'-hydroxy-3'-iodo-[1,1'-biphenyl]-4-carbonitrile (53%). Cyclization with 3-butyne-1-ol in DMF in the presence of CuI and Pd(PPh3)2Cl2 afforded 4-[2-(2-hydroxyethyl)-1-benzofuran-5-yl]benzonitrile (95%). Mesylation (89%), followed by addition of (2R)-2-methylpyrrolidine•HBr and Na2CO3 in AcCN (34%), produced II. The latter displayed binding activity to H3 receptors in rat brain cortex tissue with Ki of 4.44 nM. I are H3 receptor ligands that modulate function of the H3 receptor by antagonizing its activity. Thus, I are useful for the treatment of disorders ameliorated by H3 receptor ligands, especially Alzheimer's disease, attention-deficit hyperactivity disorder, epilepsy, narcolepsy, obesity, cognitive impairment, deficits of memory, deficits of learning, and dementia (no data).

IT **460746-52-5P**, 4-[2-[2-(1-Piperidinyl)ethyl]-1-benzofuran-5-yl]benzonitrile **460746-54-7P**, 4-[2-[2-(2-Methyl-1-piperidinyl)ethyl]-1-benzofuran-5-yl]benzonitrile **460746-62-7P**, 4-[2-[2-(4-Methyl-1-piperidinyl)ethyl]-1-benzofuran-5-yl]benzonitrile **460746-75-2P** **460746-77-4P** **460746-82-1P** **460746-95-6P**, 4-[4-Methyl-2-oxo-3-[2-(1-piperidinyl)ethyl]-2H-chromen-6-yl]benzonitrile **460747-09-5P** **460747-16-4P** **460747-24-4P** **460749-28-4P** **460749-43-3P** **460749-45-5P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(H3 receptor ligand; preparation of
(pyrrolidinylalkyl)benzofurans and analogs as histamine-3
receptor ligands for treatment of disorders related to CNS
neurotransmission)


RN 460746-52-5 CAPLUS

CN Benzonitrile, 4-[2-[2-(1-piperidinyl)ethyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)




RN 460746-54-7 CAPLUS

CN Benzonitrile, 4-[2-[2-(2-methyl-1-piperidinyl)ethyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)




RN 460746-62-7 CAPLUS

CN Benzonitrile, 4-[2-[2-(4-methyl-1-piperidinyl)ethyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)




RN 460746-75-2 CAPLUS

CN Morpholine, 4-[4-[2-[2-(1-piperidinyl)ethyl]-5-benzofuranyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 460746-77-4 CAPLUS

CN Morpholine, 4-[4-[2-[2-(2-methyl-1-piperidinyl)ethyl]-5-benzofuranyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 460746-82-1 CAPLUS

CN Morpholine, 4-[4-[2-[2-(4-methyl-1-piperidinyl)ethyl]-5-benzofuranyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 460746-95-6 CAPLUS

CN Benzonitrile, 4-[4-methyl-2-oxo-3-[2-(1-piperidinyl)ethyl]-2H-1-benzopyran-6-yl]- (9CI) (CA INDEX NAME)




RN 460747-09-5 CAPLUS

CN Morpholine, 4-[[6-[2-[2-(1-piperidinyl)ethyl]-5-benzofuranyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 460747-16-4 CAPLUS

CN Morpholine, 4-[[6-[2-[2-(4-methyl-1-piperidinyl)ethyl]-5-benzofuranyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 460747-24-4 CAPLUS


CN Morpholine, 4-[[6-[2-[2-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)ethyl]-5-benzofuranyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 460749-28-4 CAPLUS

CN Benzonitrile, 4-[2-[2-[(2R,6S)-2,6-dimethyl-1-piperidinyl]ethyl]-5-benzofuranyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 460749-43-3 CAPLUS

CN Morpholine, 4-[4-[2-[2-[(2R,6S)-2,6-dimethyl-1-piperidinyl]ethyl]-5-benzofuranyl]benzoyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 460749-45-5 CAPLUS

CN Morpholine, 4-[[6-[2-[2-[(2R,6S)-2,6-dimethyl-1-piperidinyl]ethyl]-5-benzofuranyl]-3-pyridinyl]carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L87 ANSWER 32 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:485906 CAPLUS

DOCUMENT NUMBER: 137:211210

TITLE: Activation of central histaminergic system induced by histamine **H3-receptor** antagonists on anxiety and learning in mice

AUTHOR(S): Onodera, K.; Imaizumi, M.; Miyazaki, S.; Sogawa, N.; Furuta, H.

CORPORATE SOURCE: Department of Dental Pharmacology, Okayama University Dental School, Okayama, 700-8525, Japan

SOURCE: International Congress Series (2001), 1224 (Histamine Research in the New Millennium), 273-278
CODEN: EXMDA4; ISSN: 0531-5131

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 28 Jun 2002


AB We studied that effects of H3 antagonists which could enhance release of histamine from presynaptic terminals on anxiety, and learning, and memory in mice. Thioperamide, an H3 antagonist, significantly decreased the locomotion and time spent in a light zone, and shuttle crossing, which means anxiogenic effects in a light/dark test, only when the animals were pretreated with zolantidine, an H2 antagonist. The decreased parameters induced by the combination of thioperamide and zolantidine were reversed by pretreatment with pyrilamine, an H1 antagonist. Further, thioperamide significantly ameliorated learning deficits induced by scopolamine when mice were pretreated with zolantidine in an elevated plus-maze test. The ameliorating effects of thioperamide plus zolantidine were also antagonized by pyrilamine. These results suggest that thioperamide induces the release of neuronal histamine, which produces the anxiogenic effect and the ameliorating effect on scopolamine-induced learning deficits via H1-receptors. The other H3 antagonists, clobenpropit and FUB 181 also improved scopolamine-induced learning deficits in mice in a passive avoidance test and the elevated plus-maze test, resp. The effects of clobenpropit were significant only when mice were pretreated with zolantidine but FUB 181 significantly improved without zolantidine. These results suggest that central histaminergic systems are involved in anxiety, and learning, and memory. Further, H3 antagonists such as FUB 181 may be useful as a novel cognitive enhancer.

IT 104076-38-2, Zolantidine

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(histamine **H3-receptor** antagonists effect on

anxiety and learning in mice)

RN 104076-38-2 CAPLUS

CN 2-Benzothiazolamine, N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl] - (9CI)
(CA INDEX NAME)REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 33 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:314934 CAPLUS

DOCUMENT NUMBER: 136:340592

TITLE: Preparation of 4-[4-(piperidin-1-ylcarbonyl)piperidin-
1-ylmethyl]pyridin-2-ylamines as antagonists of
histamine **H3 receptors**INVENTOR(S): Aslanian, Robert G.; Shih, Neng-Yang; Ting, Pauline
C.; Berlin, Michael Y.; Rosenblum, Stuart B.;
McCormick, Kevin D.; Tom, Wing C.; Boyce, Christopher
W.; Mangiaracina, Pietro; Mutahi, Mwangi Wa; Piwinski,
John J.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032893	A2	20020425	WO 2001-US32151	20011015
WO 2002032893	A3	20020822		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2424664	AA	20020425	CA 2001-2424664	20011015
AU 2002015355	A5	20020429	AU 2002-15355	20011015
US 2003045519	A1	20030306	US 2001-978267	20011015
US 6720328	B2	20040413		
BR 2001014754	A	20030701	BR 2001-14754	20011015
EP 1326858	A2	20030716	EP 2001-983968	20011015
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004511553	T2	20040415	JP 2002-536275	20011015
NZ 524857	A	20041224	NZ 2001-524857	20011015
ZA 2003002521	A	20040630	ZA 2003-2521	20030331
NO 2003001744	A	20030614	NO 2003-1744	20030415

US 2004097513 A1 20040520 US 2003-699189 20031031
 PRIORITY APPLN. INFO.: US 2000-240901P P 20001017
 US 2001-978267 A3 20011015
 WO 2001-US32151 W 20011015

OTHER SOURCE(S): MARPAT 136:340592
 ED Entered STN: 26 Apr 2002
 GI




AB The title compds. [I; R1 = (un)substituted aryl, heteroaryl, alkyl, etc.; X = CO, C(NOR3), C(NNR4R5), etc.; M1 = C; M2 = C, N; M3, M4 = C, N; Y = CH2, CO, C(NOH), etc.; Z = alkyl; R2 = (un)substituted 5-6 membered heteroaryl; R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; R5 = H, alkyl, COR4, etc.; R12, R13 = alkyl, OH, alkoxy, F; a, b = 0-2; n, p = 1-3, with the proviso that when M3 and M4 are both N atoms, then p = 2 or 3], useful in treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion), were prepared. E.g., a multi-step synthesis of II which showed Ki of 0.83 nM in H3 receptor binding assay, was given. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compds. I in combination with a H1 receptor antagonist.

IT 58-73-1, Diphenhydramine 469-21-6, Doxylamine
 486-16-8, Carbinoxamine 68844-77-9, Astemizole
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (H1 **receptor** antagonist; preparation of 4-[4-(piperidin-1-ylcarbonyl)piperidin-1-ylmethyl]pyridin-2-ylamines as antagonists of histamine **H3 receptors**)


RN 58-73-1 CAPLUS

CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 469-21-6 CAPLUS

CN Ethanamine, N,N-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 486-16-8 CAPLUS

CN Ethanamine, 2-[(4-chlorophenyl)-2-pyridinylmethoxy]-N,N-dimethyl- (9CI)
(CA INDEX NAME)

RN 68844-77-9 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




IT 416849-52-0P 416849-61-1P 416849-71-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 4-[4-(piperidin-1-ylcarbonyl)piperidin-1-ylmethyl]pyridin-2-ylamines as antagonists of histamine **H3 receptors**)


RN 416849-52-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 416849-61-1 CAPLUS

CN Piperidine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 416849-71-3 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -(6-chloro-3-pyridinyl)-N-hydroxy- (9CI) (CA INDEX NAME)

IT 416849-51-9P 416849-53-1P 416849-54-2P
416849-55-3P 416849-56-4P 416849-57-5P
416849-58-6P 416849-62-2P 416849-63-3P
416849-64-4P 416849-65-5P 416849-66-6P
416849-67-7P 416849-68-8P 416849-69-9P
416849-70-2P 416849-72-4P 416849-73-5P
416849-74-6P 416849-75-7P 416849-76-8P
416849-77-9P 416849-78-0P 416849-79-1P
416849-80-4P 416849-81-5P 416849-82-6P
416849-83-7P 416849-84-8P 416849-85-9P
416849-86-0P 416849-87-1P 416849-91-7P
416849-92-8P 416849-93-9P 416849-94-0P
416849-95-1P 416849-96-2P 416849-97-3P
416849-98-4P 416849-99-5P 416850-00-5P
416850-01-6P 416850-02-7P 416850-04-9P
416850-05-0P 416850-06-1P 416850-07-2P
416850-08-3P 416850-09-4P 416850-10-7P
416850-11-8P 416850-12-9P 416850-13-0P
416850-14-1P 416850-15-2P 416850-16-3P
416850-17-4P 416850-18-5P 416850-20-9P
416850-21-0P 416850-22-1P 416850-23-2P
416850-24-3P 416850-25-4P 416850-26-5P
416850-27-6P 416850-28-7P 416850-31-2P
416850-32-3P 416850-33-4P 416850-34-5P
416850-35-6P 416850-36-7P 416850-37-8P
416850-38-9P 416850-39-0P 416850-40-3P
416850-42-5P 416850-43-6P 416850-44-7P
416850-45-8P 416850-46-9P 416850-47-0P
416850-48-1P 416850-49-2P 416850-50-5P
416850-54-9P 416850-55-0P 416850-56-1P
416850-57-2P 416850-58-3P 416850-59-4P


416850-60-7P 416850-61-8P 416850-62-9P
416850-63-0P 416850-64-1P 416850-65-2P
416850-66-3P 416850-67-4P 416850-68-5P
416850-69-6P 416850-70-9P 416850-73-2P
416850-74-3P 416850-75-4P 416850-76-5P
416850-77-6P 416850-78-7P 416850-80-1P
416850-81-2P 416850-82-3P 416850-83-4P
416850-85-6P 416850-86-7P 416850-87-8P
416850-88-9P 416850-89-0P 416850-92-5P
416850-93-6P 416850-94-7P 416850-95-8P
416850-96-9P 416850-97-0P 416850-98-1P
416850-99-2P 416851-00-8P 416851-01-9P
416851-02-0P 416851-03-1P 416851-04-2P
416851-05-3P 416851-06-4P 416851-07-5P
416851-08-6P 416851-09-7P 416851-10-0P
416851-11-1P 416851-12-2P 416851-13-3P
416851-14-4P 416851-15-5P 416851-16-6P
416851-17-7P 416851-18-8P 416851-19-9P
416851-20-2P 416851-21-3P 416851-22-4P
416851-23-5P 416851-25-7P 416851-27-9P
416851-28-0P 416851-29-1P 416851-30-4P
416851-31-5P 416851-32-6P 416851-34-8P
416851-35-9P 416851-36-0P 416851-37-1P
416851-38-2P 416851-39-3P 416851-40-6P
416851-41-7P 416851-42-8P 416851-43-9P
416851-45-1P 416851-46-2P 416851-47-3P
416851-48-4P 416851-49-5P 416851-50-8P
416851-51-9P 416851-52-0P 416851-53-1P
416851-54-2P 416851-55-3P 416851-56-4P
416851-57-5P 416851-58-6P 416851-59-7P
416851-60-0P 416851-61-1P 416851-62-2P
416851-63-3P 416851-64-4P 416851-65-5P
416851-66-6P 416851-67-7P 416851-68-8P
416851-69-9P 416851-70-2P 416851-71-3P
416851-72-4P 416851-73-5P 416851-74-6P
416851-75-7P 416851-76-8P 416851-77-9P
416851-78-0P 416851-79-1P 416851-80-4P
416851-81-5P 416851-82-6P 416851-84-8P
416851-85-9P 416851-86-0P 416851-87-1P
416851-88-2P 416851-89-3P 416851-90-6P
416851-91-7P 416851-92-8P 416851-93-9P
416851-94-0P 416851-95-1P 416851-96-2P
416851-97-3P 416851-98-4P 416851-99-5P
416852-00-1P 416852-01-2P 416852-02-3P
416852-03-4P 416852-04-5P 416852-05-6P
416852-06-7P 416852-07-8P 416852-08-9P
416852-09-0P 416852-91-0P 416853-58-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of 4-[4-(piperidin-1-ylcarbonyl)piperidin-1-ylmethyl]pyridin-2-ylamines as antagonists of histamine **H3 receptors**)


RN 416849-51-9 CAPLUS

CN Piperidine, 1-[[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(6-fluoro-1,2-benzisoxazol-3-yl)]- (9CI) (CA INDEX NAME)



RN 416849-53-1 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 416849-54-2 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-2-pyridinyl-, (αE)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 416849-55-3 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-2-pyridinyl-, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 416849-56-4 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -(3,5-dichlorophenyl)-N-methoxy- (9CI) (CA INDEX NAME)




RN 416849-57-5 CAPLUS

CN Piperidine, 4-(4-chlorobenzoyl)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 416849-58-6 CAPLUS

CN 4-Piperidinemethanimine, α -(4-chlorophenyl)-N-(1,1-dimethylethoxy)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 416849-62-2 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-N-methoxy- α -2-pyridinyl- (9CI) (CA INDEX NAME)



RN 416849-63-3 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(1S)-1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-N-methoxy- α -2-pyridinyl-, (α E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 416849-64-4 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(1R)-1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-N-methoxy- α -2-pyridinyl-, (α E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 416849-65-5 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(1S)-1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-N-methoxy-α-2-pyridinyl-, (αZ)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 416849-66-6 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-hydroxy-4-piperidinyl]carbonyl]-α-(4-chlorophenyl)-N-methoxy- (9CI) (CA INDEX NAME)




RN 416849-67-7 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-2-methyl-4-piperidinyl]carbonyl]-N-methoxy-α-2-pyridinyl-, (9CI) (CA INDEX NAME)




RN 416849-68-8 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-α-(4-chlorophenyl)-N-methoxy- (9CI) (CA INDEX NAME)




RN 416849-69-9 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[3-(2-amino-4-pyridinyl)propyl]-4-piperidinyl]carbonyl]-N-methoxy-α-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 416849-70-2 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 416849-72-4 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-

piperidinyl]carbonyl]- α -(6-chloro-3-pyridinyl)-N-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 416849-73-5 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -3-pyridinyl- (9CI) (CA INDEX NAME)




RN 416849-74-6 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -(1-oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 416849-75-7 CAPLUS

CN 4-Piperidinemethanimine, α -(5-amino-2-chlorophenyl)-1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 416849-76-8 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-[(4-chlorophenyl)methyl]-N-methoxy- (9CI)
(CA INDEX NAME)



RN 416849-77-9 CAPLUS

CN Carbamic acid, [4-[[4-[[4-[2-(4-chlorophenyl)-1-(methoxyimino)ethyl]-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 416849-78-0 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-[(4-chlorophenyl)methyl]-N-methoxy-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 416849-76-8

CMF C26 H34 Cl N5 O2




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.




RN 416849-79-1 CAPLUS

CN 4-Piperidineethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 416849-80-4 CAPLUS

CN Carbamic acid, [4-[[4-[[4-[2-(4-chlorophenyl)-2-(methoxyimino)ethyl]-1-piperidiny]carbonyl]-1-piperidiny]methyl]-2-pyridiny]-, ethyl ester (9CI) (CA INDEX NAME)



RN 416849-81-5 CAPLUS

CN 4-Piperidineethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -2-pyridinyl- (9CI) (CA INDEX NAME)




RN 416849-82-6 CAPLUS

CN 4-Piperidineethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -2-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 416849-81-5

CMF C25 H34 N6 O2




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 416849-83-7 CAPLUS

CN 4-Piperidinemethanimine, α -[(2-amino-4-pyridinyl)methyl]-1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 416849-84-8 CAPLUS

CN 4-Piperidinemethanimine, α -[(2-amino-4-pyridinyl)methyl]-1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 416849-83-7

CMF C25 H35 N7 O2




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.




RN 416849-85-9 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-4-morpholinyl- α -2-pyridinyl- (9CI) (CA INDEX NAME)




RN 416849-86-0 CAPLUS

CN Piperidine, 4-(4-chlorobenzoyl)-1-[[1-[5-[(dimethylamino)methyl]-2-furanyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 416849-87-1 CAPLUS

CN 4-Piperidinemethanimine, α -(4-chlorophenyl)-1-[[1-[[5-
[(dimethylamino)methyl]-2-furanyl)methyl]-4-piperidinyl]carbonyl]-N-
methoxy- (9CI) (CA INDEX NAME)




RN 416849-91-7 CAPLUS

CN 4-Piperidinemethanimine, α -(4-chlorophenyl)-N-(phenylmethoxy)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 416849-92-8 CAPLUS


CN Acetic acid, [[[4-chlorophenyl][1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-4-piperidinyl]methylenamino]oxy]- (9CI) (CA INDEX NAME)



RN 416849-93-9 CAPLUS


CN 4-Piperidinemethanimine, α -(4-chlorophenyl)-N-(2-methylpropoxy)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

RN 416849-94-0 CAPLUS

CN 4-Piperidinemethanimine, α -(4-chlorophenyl)-N-phenoxy-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


RN 416849-95-1 CAPLUS

CN 4-Piperidinemethanimine, α -(4-chlorophenyl)-N-[(4-fluorophenyl)methoxy]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 416849-96-2 CAPLUS

CN 4-Piperidinemethanimine, α -(4-chlorophenyl)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-N-[[4-(trifluoromethyl)phenyl]methoxy]-(9CI) (CA INDEX NAME)




RN 416849-97-3 CAPLUS

CN Morpholine, 4-[[[[(4-chlorophenyl)1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-4-piperidinyl]methylene]amino]oxy]acetyl]-(9CI) (CA INDEX NAME)




RN 416849-98-4 CAPLUS

CN 4-Piperidinemethanimine, α-(4-chlorophenyl)-N-[(4-chlorophenyl)methoxy]-1-[[1-(4-pyridinylmethyl)-4-piperidiny]carbonyl]-(9CI) (CA INDEX NAME)




RN 416849-99-5 CAPLUS

CN 4-Piperidinemethanimine, α-(4-chlorophenyl)-N-methoxy-1-[[1-[3-(4-pyridinyl)propyl]-4-piperidiny]carbonyl]-(9CI) (CA INDEX NAME)




RN 416850-00-5 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-(4-chlorophenyl)-N-ethoxy- (9CI) (CA INDEX NAME)



RN 416850-01-6 CAPLUS


CN Morpholine, 4-[[[[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-piperidinyl] (4-chlorophenyl)methylene]amino]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 416850-02-7 CAPLUS

CN 4-Piperidinemethanimine, α-(4-chlorophenyl)-N-[2-oxo-2-(1-pyrrolidinyl)ethoxy]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 416850-04-9 CAPLUS
CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -(4-chlorophenyl)-N-(1,1-dimethylethoxy)-(9CI) (CA INDEX NAME)




RN 416850-05-0 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-[1,1'-biphenyl]-4-yl-N-methoxy- (9CI) (CA INDEX NAME)




RN 416850-06-1 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-(2-fluorophenyl)-N-methoxy- (9CI) (CA INDEX NAME)



RN 416850-07-2 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-(2-chlorophenyl)-N-methoxy- (9CI) (CA INDEX NAME)



RN 416850-08-3 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -(4-chlorophenyl)-N-hydroxy-, (α E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 416850-09-4 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -(4-chlorophenyl)-N-hydroxy-, (α Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 416850-10-7 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -(3,5-dimethoxyphenyl)-N-methoxy- (9CI) (CA INDEX NAME)



RN 416850-11-8 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-(4-chlorophenyl)-N-methoxy-, (αZ)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 416850-12-9 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-(4-chlorophenyl)-N-methoxy-, (αE)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 416850-13-0 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -[4-(trifluoromethyl)phenyl]-, (α E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 416850-14-1 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]- α -(4-chlorophenyl)-N-methoxy- (9CI) (CA INDEX NAME)

RN 416850-15-2 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -(2,4-difluorophenyl)-N-methoxy- (9CI) (CA INDEX NAME)


RN 416850-16-3 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -(2,4-difluorophenyl)-N-ethoxy- (9CI) (CA INDEX NAME)




RN 416850-17-4 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -[3,5-bis(trifluoromethyl)phenyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 416850-18-5 CAPLUS

CN Piperidine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-(6-fluoro-1,2-benzisoxazol-3-yl)- (9CI) (CA INDEX NAME)




RN 416850-20-9 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]- α -(2,4-dichlorophenyl)-N-methoxy- (9CI) (CA INDEX NAME)



RN 416850-21-0 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 416850-22-1 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-3-thienyl- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 416850-23-2 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-hydroxy- α -3-pyridinyl- (9CI) (CA INDEX NAME)


RN 416850-24-3 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-hydroxy- α -2-pyridinyl- (9CI) (CA INDEX NAME)


RN 416850-25-4 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -phenyl- (9CI) (CA INDEX NAME)


RN 416850-26-5 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-N-methoxy- α -3-pyridinyl- (9CI) (CA INDEX NAME)

RN 416850-27-6 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-hydroxy- α -2-pyridinyl-, (α E)- (9CI) (CA INDEX NAME)


RN 416850-28-7 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-hydroxy- α -2-pyridinyl-, (α Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

RN 416850-31-2 CAPLUS


CN Piperidine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-isoxazolo[5,4-b]pyridin-3-yl- (9CI) (CA INDEX NAME)



RN 416850-32-3 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-N-methoxy- α -[6-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

RN 416850-33-4 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[1-(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-ethoxy- α -2-pyridinyl- (9CI) (CA INDEX NAME)


RN 416850-34-5 CAPLUS

CN Piperidine, 1-[[1-[1-(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-isoxazolo[5,4-b]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 416850-35-6 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-2-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 416850-36-7 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-N-methoxy-α-2-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 416850-37-8 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-3-isoquinolinyl-N-methoxy- (9CI) (CA INDEX NAME)



RN 416850-38-9 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-

piperidinyl]carbonyl]- α -[3-[(dimethylamino)sulfonyl]phenyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 416850-39-0 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]- α -3-isoquinoliny-N-methoxy- (9CI) (CA INDEX NAME)




RN 416850-40-3 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[1-(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 416850-42-5 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-N-methoxy- α -(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)



RN 416850-43-6 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-N-ethoxy- α -2-pyridinyl- (9CI) (CA INDEX NAME)

RN 416850-44-7 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-2-methyl-4-piperidinyl]carbonyl]-N-ethoxy- α -2-pyridinyl- (9CI) (CA INDEX NAME)


RN 416850-45-8 CAPLUS

CN Piperidine, 4-(4-methoxybenzoyl)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 416850-46-9 CAPLUS


CN Piperidine, 4-(4-methylbenzoyl)-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 416850-47-0 CAPLUS

CN Piperidine, 4-(4-chlorobenzoyl)-1-[[1-[[2-(methylamino)-4-

pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 416850-48-1 CAPLUS

CN 4-Piperidinemethanimine, α -(4-chlorophenyl)-N-methoxy-1-[[1-[(2-methylamino)-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


RN 416850-49-2 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(2,4-difluorobenzoyl)- (9CI) (CA INDEX NAME)




RN 416850-50-5 CAPLUS

CN Piperidine, 4-(4-chlorobenzoyl)-1-[[1-[(4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 416850-54-9 CAPLUS


CN 4-Piperidinemethanimine, 1-[[[1-[[2-[(aminoiminomethyl)amino]-4-thiazolyl]methyl]-4-piperidiny]carbonyl]-α-(4-chlorophenyl)-N-methoxy- (9CI) (CA INDEX NAME)




RN 416850-55-0 CAPLUS

CN 4-Piperidinemethanimine, 1-[[[1-[[2-(aminomethyl)-5-thiazolyl]methyl]-4-piperidiny]carbonyl]-α-(4-chlorophenyl)-N-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 416850-56-1 CAPLUS

CN 4-Piperidinemethanimine, α -(4-chlorophenyl)-N-methoxy-1-[[1-(4-pyridinylmethyl)-4-piperidiny]carbonyl]-, (α Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 416850-57-2 CAPLUS


CN 4-Piperidinemethanimine, α -(4-fluorophenyl)-N-methoxy-1-[[1-(4-pyridinylmethyl)-4-piperidiny]carbonyl]-, (α Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 416850-58-3 CAPLUS
CN 4-Piperidinemethanimine, N-hydroxy- α -phenyl-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-, (α Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 416850-59-4 CAPLUS
CN 4-Piperidinemethanimine, N-methoxy- α -phenyl-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-, (α Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 416850-60-7 CAPLUS
CN 4-Piperidinemethanimine, N-hydroxy- α -phenyl-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-, (α E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 416850-61-8 CAPLUS
CN 4-Piperidinemethanimine, α -(4-chlorophenyl)-N-methoxy-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-, (α E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 416850-62-9 CAPLUS

CN 4-Piperidinemethanimine, α -(4-fluorophenyl)-N-hydroxy-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-, (α E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 416850-63-0 CAPLUS

CN 4-Piperidinemethanimine, α -(4-fluorophenyl)-N-hydroxy-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-, (α Z)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 416850-64-1 CAPLUS


CN 4-Piperidinemethanimine, α -(4-fluorophenyl)-N-methoxy-1-[[1-(4-pyridinylmethyl)-4-piperidiny]carbonyl]-, (α E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 416850-65-2 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]- α -(4-chlorophenyl)-N-methoxy- (9CI) (CA INDEX NAME)



RN 416850-66-3 CAPLUS


CN 4-Piperidinemethanimine, α -(4-chlorophenyl)-N-ethoxy-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-, (α Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 416850-67-4 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -(2,4-dichlorophenyl)-N-methoxy- (9CI) (CA INDEX NAME)



RN 416850-68-5 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -2-pyridinyl-, (α E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 416850-69-6 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -2-pyridinyl- (9CI) (CA INDEX NAME)



RN 416850-70-9 CAPLUS


CN 3-Azetidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -2-pyridinyl-, (α E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 416850-73-2 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-isoxazolo[4,5-b]pyridin-3-yl- (9CI) (CA INDEX NAME)



RN 416850-74-3 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-2-pyridinyl-N-(2,2,2-trifluoroethoxy)-, (αE) - (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 416850-75-4 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-2-pyridinyl-N-(2,2,2-trifluoroethoxy)-, (αZ) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 416850-76-5 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-(6-chloro-2-pyridinyl)-N-methoxy- (9CI) (CA INDEX NAME)




RN 416850-77-6 CAPLUS

CN 4-Piperidinemethanimine, 1-[[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -1H-pyrazol-4-yl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 416850-78-7 CAPLUS


CN Piperidine, 1-[[[1-[(2-amino-4-pyridinyl)methyl]-3-piperidinyl]carbonyl]-4-

(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 416850-80-1 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-cyclohexyl-N-methoxy- (9CI) (CA INDEX NAME)



RN 416850-81-2 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-3-piperidinyl]carbonyl]-N-methoxy-α-2-pyridinyl-, (αZ)- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 416850-82-3 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-3-piperidinyl]carbonyl]-N-methoxy-α-2-pyridinyl-, (αE)- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 416850-83-4 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-(2-quinolinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 416850-85-6 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-N-methoxy-α-2-quinolinyl- (9CI) (CA INDEX NAME)




RN 416850-86-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidiny]carbonyl]-4-[(6-methoxy-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 416850-87-8 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-(6-methoxy-2-pyridinyl)- (9CI)
(CA INDEX NAME)




RN 416850-88-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[(3-hydroxy-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 416850-89-0 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 416850-92-5 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -(3-fluoro-2-pyridinyl)-N-(2,2,2-trifluoroethoxy)-, (α E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 416850-93-6 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -(3-hydroxy-2-pyridinyl)-N-methoxy-, (α E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 416850-94-7 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -(3-hydroxy-2-pyridinyl)-N-methoxy-, (α Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 416850-95-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[(1-methyl-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 416850-96-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(cyclohexylcarbonyl)- (9CI) (CA INDEX NAME)



RN 416850-97-0 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-(1-methyl-1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



RN 416850-98-1 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -(1,6-dihydro-6-oxo-2-pyridinyl)-N-methoxy-, (α E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 416850-99-2 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -(1,6-dihydro-6-oxo-2-pyridinyl)-N-methoxy-, (α Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 416851-00-8 CAPLUS


CN 4-Piperidinol, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 416851-01-9 CAPLUS


CN 4-Piperidinol, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-

4 - [(methoxyimino) - 2-pyridinylmethyl] - (9CI) (CA INDEX NAME)



RN 416851-02-0 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-2-quinoxalinyll- (9CI) (CA INDEX NAME)



RN 416851-03-1 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-4-pyridinyl-, (αZ)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 416851-04-2 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-4-pyridinyl-, (αE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 416851-05-3 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-(2-methylpropoxy)-α-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 416851-06-4 CAPLUS

CN 4-Piperidinemethanimine, α-[(6-amino-2-pyridinyl)methyl]-1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 416851-07-5 CAPLUS


CN 4-Piperidinemethanimine, α-[(6-amino-2-pyridinyl)methyl]-1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- (9CI) (CA INDEX NAME)



RN 416851-08-6 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -2-pyridinyl-, (α E)- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 416851-09-7 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-(1-methylethoxy)- α -2-pyridinyl- (9CI) (CA INDEX NAME)




RN 416851-10-0 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-propoxy- α -2-pyridinyl- (9CI) (CA INDEX NAME)




RN 416851-11-1 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-(4-methyl-2-pyridinyl)-N-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 416851-12-2 CAPLUS

CN 4-Piperidinemethanimine, α-(6-amino-3-pyridinyl)-1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 416851-13-3 CAPLUS

CN Morpholine, 4-[[[[[1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-piperidinyl]-2-pyridinylmethylene]amino]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 416851-14-4 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-phenoxy-α-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 416851-15-5 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 416851-16-6 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 416851-17-7 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 416851-18-8 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 416851-19-9 CAPLUS


CN 4-Piperidinemethanimine, N-methoxy-1-[[1-[(3-methoxy-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 416851-20-2 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -(3-fluoro-2-pyridinyl)-N-methoxy-,
(α E) - (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 416851-21-3 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -(3-fluoro-2-pyridinyl)-N-methoxy-,
(α Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 416851-22-4 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-
[(5-methyl-2-pyridinyl)carbonyl] - (9CI) (CA INDEX NAME)



RN 416851-23-5 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-

[(6-methyl-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 416851-25-7 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -4-pyridinyl- (9CI) (CA INDEX NAME)




RN 416851-27-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[(1-oxido-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 416851-28-0 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 416851-29-1 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- α -[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-N-methoxy- (9CI) (CA INDEX NAME)

RN 416851-30-4 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -(1-oxido-2-pyridinyl)-, (α E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 416851-31-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(pyrazinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 416851-32-6 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -pyrazinyl- (9CI) (CA INDEX NAME)




RN 416851-34-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[(3-fluoro-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 416851-35-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[(3-methyl-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 416851-36-0 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-(3-fluoro-2-pyridinyl)-N-propoxy- (9CI) (CA INDEX NAME)




RN 416851-37-1 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-(3-fluoro-2-pyridinyl)-N-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 416851-38-2 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-(3-fluoro-2-pyridinyl)-N-(2-methylpropoxy)- (9CI) (CA INDEX NAME)




RN 416851-39-3 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-ethoxy-α-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 416851-40-6 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-propoxy-α-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 416851-41-7 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-(1-methylethoxy)-α-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 416851-42-8 CAPLUS

CN 4-Piperidinemethanimine, 1-[[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-(2-methylpropoxy)-α-(3-methyl-2-pyridinyl)-(9CI) (CA INDEX NAME)




RN 416851-43-9 CAPLUS

CN Morpholine, 4-[[[[[1-[[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-piperidinyl](3-methyl-2-pyridinyl)methylene]amino]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 416851-45-1 CAPLUS

CN 4-Piperidinemethanimine, 1-[[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-(3-fluoro-2-pyridinyl)-N-phenoxy-(9CI) (CA INDEX NAME)




RN 416851-46-2 CAPLUS

CN Morpholine, 4-[[[[[1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-piperidinyl](3-fluoro-2-pyridinyl)methylene]amino]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 416851-47-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[(3-fluoro-4-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 416851-48-4 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-(3-fluoro-4-pyridinyl)-N-methoxy- (9CI) (CA INDEX NAME)




RN 416851-49-5 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidiny]carbonyl]-N-methoxy- α -(3-fluoro-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 416851-50-8 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidiny]carbonyl]-N-methoxy- α -(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 416851-51-9 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidiny]carbonyl]-4-[(3-methyl-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 416851-52-0 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidiny]carbonyl]-N-hydroxy- α -phenyl- (9CI) (CA INDEX NAME)




RN 416851-53-1 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]- α -(4-chlorophenyl)-N-hydroxy- (9CI) (CA INDEX NAME)

RN 416851-54-2 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -phenyl- (9CI) (CA INDEX NAME)

RN 416851-55-3 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]- α -(4-fluorophenyl)-N-methoxy- (9CI) (CA INDEX NAME)

RN 416851-56-4 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 416851-57-5 CAPLUS
 CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 416851-58-6 CAPLUS
 CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-α-[1,1'-biphenyl]-4-yl-N-methoxy- (9CI) (CA INDEX NAME)



RN 416851-59-7 CAPLUS
 CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-α-(3,5-dichlorophenyl)-N-methoxy- (9CI) (CA INDEX NAME)




RN 416851-60-0 CAPLUS
 CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-α-(2-fluorophenyl)-N-methoxy- (9CI) (CA INDEX NAME)




RN 416851-61-1 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-alpha-(2-chlorophenyl)-N-methoxy- (9CI) (CA INDEX NAME)




RN 416851-62-2 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-alpha-(3,5-dimethoxyphenyl)-N-methoxy- (9CI) (CA INDEX NAME)



RN 416851-63-3 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-alpha-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 416851-64-4 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-

piperidinyl]carbonyl]- α -(2,4-difluorophenyl)-N-methoxy- (9CI) (CA INDEX NAME)




RN 416851-65-5 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]- α -[3,5-bis(trifluoromethyl)phenyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 416851-66-6 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 416851-67-7 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -3-pyridinyl- (9CI) (CA INDEX NAME)




RN 416851-68-8 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 416851-69-9 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 416851-70-2 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-3-thienyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 416851-71-3 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidyl]carbonyl]-N-methoxy- α -2-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 416851-72-4 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidyl]carbonyl]-N-methoxy- α -(1-oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 416851-73-5 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-α-[(4-chlorophenyl)methyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 416851-74-6 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-α-3-isoquinolinyl-N-methoxy- (9CI) (CA INDEX NAME)



RN 416851-75-7 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-α-[3-[(dimethylamino)sulfonyl]phenyl]-N-methoxy- (9CI) (CA INDEX NAME)



RN 416851-76-8 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-

piperidinyl]carbonyl]-N-methoxy- α -(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 416851-77-9 CAPLUS

CN 4-Piperidinemethanimine, α -(2-amino-5-chlorophenyl)-1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 416851-78-0 CAPLUS

CN 4-Piperidineethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -2-pyridinyl- (9CI) (CA INDEX NAME)




RN 416851-79-1 CAPLUS

CN 4-Piperidinemethanimine, α -[(2-amino-4-pyridinyl)methyl]-1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 416851-80-4 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 416851-81-5 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 416851-82-6 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 416851-84-8 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -4-pyridinyl- (9CI) (CA INDEX NAME)

RN 416851-85-9 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]- α -[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-N-methoxy- (9CI) (CA INDEX NAME)

RN 416851-86-0 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -(1-oxido-2-pyridinyl)- (9CI) (CA INDEX NAME)


RN 416851-87-1 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -pyrazinyl- (9CI) (CA INDEX NAME)



RN 416851-88-2 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 416851-89-3 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-1H-pyrazol-4-yl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 416851-90-6 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidyl]carbonyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 416851-91-7 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidyl]carbonyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 416851-92-8 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-(6-methoxy-2-pyridinyl)- (9CI)
(CA INDEX NAME)




RN 416851-93-9 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-α-(3-hydroxy-2-pyridinyl)-N-methoxy- (9CI)
(CA INDEX NAME)




RN 416851-94-0 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-(1-methyl-1H-pyrrol-2-yl)- (9CI)
(CA INDEX NAME)




RN 416851-95-1 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-α-(1,6-dihydro-6-oxo-2-pyridinyl)-N-methoxy- (9CI) (CA INDEX NAME)




RN 416851-96-2 CAPLUS

CN 4-Piperidinol, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[(methoxyimino)-2-pyridinylmethyl]- (9CI) (CA INDEX NAME)




RN 416851-97-3 CAPLUS

CN 3-Azetidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy-α-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 416851-98-4 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-α-2-benzothiazolyl-N-methoxy- (9CI) (CA INDEX NAME)




RN 416851-99-5 CAPLUS
 CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -2-quinoxaliny- (9CI) (CA INDEX NAME)




RN 416852-00-1 CAPLUS
 CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]- α -(3-fluoro-4-pyridinyl)-N-methoxy- (9CI) (CA INDEX NAME)



RN 416852-01-2 CAPLUS
 CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-ethoxy- α -2-pyridinyl- (9CI) (CA INDEX NAME)




RN 416852-02-3 CAPLUS
 CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]- α -2-pyridinyl-N-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 416852-03-4 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-propoxy- α -2-pyridinyl- (9CI) (CA INDEX NAME)




RN 416852-04-5 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-(2-methylpropoxy)- α -2-pyridinyl- (9CI) (CA INDEX NAME)




RN 416852-05-6 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-(phenylmethoxy)- α -2-pyridinyl- (9CI) (CA INDEX NAME)




RN 416852-06-7 CAPLUS

CN Morpholine, 4-[[[[[1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-piperidinyl]-2-pyridinylmethylene]amino]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 416852-07-8 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-(1-methylethoxy)-α-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 416852-08-9 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-N-phenoxy-α-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 416852-09-0 CAPLUS

CN 4-Piperidinemethanimine, 1-[[4-fluoro-1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-N-methoxy-α-2-pyridinyl-, (αE)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 416852-91-0 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-N-methoxy- α -(2-methyl-4-thiazolyl)-, (αE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 416853-58-2 CAPLUS

CN 4-Piperidinemethanimine, 1-[[[1-[(1R)-1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-N-methoxy- α -2-pyridinyl-, (α Z)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




IT 416853-60-6P 417705-91-0P 417705-92-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-[4-(piperidin-1-ylcarbonyl)piperidin-1-ylmethyl]pyridin-2-ylamines as antagonists of histamine **H3 receptors**)


RN 416853-60-6 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-α-[4-(dimethylamino)phenyl]-N-methoxy- (9CI)
(CA INDEX NAME)



RN 417705-91-0 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-α-(hydroxy-2-pyridinyl)-N-methoxy-, (αE)- (9CI) (CA INDEX NAME)




D1-OH

RN 417705-92-1 CAPLUS

CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]hydroxy-4-piperidinyl]carbonyl]-N-methoxy-α-2-pyridinyl-, (αE)- (9CI)

(CA INDEX NAME)



D1-OH

IT 416852-83-0 416852-86-3 416852-87-4

416852-88-5 416852-90-9


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 4-[4-(piperidin-1-ylcarbonyl)piperidin-1-ylmethyl]pyridin-2-ylamines as antagonists of histamine H3 receptors)

RN 416852-83-0 CAPLUS


CN 4-Piperidinemethanimine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-N-methoxy-2-pyridinyl-, (αE)- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 416852-86-3 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[(6-chloro-3-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 416852-87-4 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-

(2-pyridinylcarbonyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 416849-52-0


CMF C23 H29 N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 416852-88-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(2-amino-5-pyrimidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 416852-90-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(3-amino-4-pyridinyl)methyl]-, monolithium salt (9CI) (CA INDEX NAME)




● Li


IT 138030-54-3P 416852-10-3P 416852-11-4P
 416852-14-7P 416852-18-1P 416852-21-6P
 416852-26-1P 416852-33-0P 416852-35-2P
 416852-43-2P 416852-47-6P 416852-51-2P
 416852-64-7P 416852-65-8P 416852-67-0P
 416852-68-1P 416852-76-1P 416852-77-2P
 416852-78-3P 416852-79-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 4-[4-(piperidin-1-ylcarbonyl)piperidin-1-ylmethyl]pyridin-2-
 ylamines as antagonists of histamine **H3 receptors**)
 RN 138030-54-3 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-(4-pyridinylmethyl)-, ethyl ester (9CI)
 (CA INDEX NAME)



RN 416852-10-3 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 416852-11-4 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]methyl]-, monolithium salt (9CI) (CA INDEX NAME)



● Li

RN 416852-14-7 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-(4-pyridinylmethyl)-, lithium salt (9CI)
(CA INDEX NAME)



● Li


RN 416852-18-1 CAPLUS

CN Carbamic acid, [4-[[4-[[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 416852-21-6 CAPLUS

CN Carbamic acid, [4-[[4-[[4-(2-pyridinylcarbonyl)-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 416852-26-1 CAPLUS

CN Piperidine, 4-(3,5-dichlorobenzoyl)-1-[[1-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 416852-33-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]methyl]-4-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 416852-35-2 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]methyl]-4-hydroxy-, monolithium salt (9CI) (CA INDEX NAME)



● Li


RN 416852-43-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-[bis[(1,1-dimethylethoxy)carbonyl]amino]-5-pyrimidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 416852-47-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-[bis[(1,1-dimethylethoxy)carbonyl]amino]-5-pyrimidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 416852-51-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[3-[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 416852-64-7 CAPLUS

CN Carbamic acid, [4-[[4-[[4-[2-(4-chlorophenyl)-1-hydroxyethyl]-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 416852-65-8 CAPLUS

CN Carbamic acid, [4-[[4-[[4-[(4-chlorophenyl)acetyl]-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 416852-67-0 CAPLUS

CN Carbamic acid, [4-[[4-[[4-[2-(4-chlorophenyl)-2-hydroxyethyl]-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 416852-68-1 CAPLUS

CN Carbamic acid, [4-[[4-[[4-[2-(4-chlorophenyl)-2-oxoethyl]-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 416852-76-1 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[(2-amino-5-pyrimidinyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 416852-77-2 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[(2-amino-5-pyrimidinyl)methyl]-,

monolithium salt (9CI) (CA INDEX NAME)




● Li


RN 416852-78-3 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[(3-amino-4-pyridinyl)methyl]-, ethyl ester
 (9CI) (CA INDEX NAME)



RN 416852-79-4 CAPLUS
 CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



IT **416852-52-3P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of 4-[4-(piperidin-1-ylcarbonyl)piperidin-1-ylmethyl]pyridin-2-ylamines as antagonists of histamine **H3 receptors**)
 RN 416852-52-3 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[3-[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]propyl]- (9CI) (CA INDEX NAME)



L87 ANSWER 34 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:122980 CAPLUS

DOCUMENT NUMBER: 136:183708

TITLE: Preparation of non-imidazole aryloxyalkylamines as histamine **H3 receptor** antagonists

INVENTOR(S): Apodaca, Richard; Carruthers, Nicholas I.; Dvorak, Curt A.; Rudolph, Dale A.; Shah, Chandravadan R.; Xiao, Wei

PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical Inc., USA

SOURCE: PCT Int. Appl., 155 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012214	A2	20020214	WO 2001-US24655	20010806
WO 2002012214	A3	20020620		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2418369	AA	20020214	CA 2001-2418369	20010806
AU 2001084733	A5	20020218	AU 2001-84733	20010806
US 2002065278	A1	20020530	US 2001-922631	20010806
EP 1313721	A2	20030528	EP 2001-963813	20010806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004505960	T2	20040226	JP 2002-518191	20010806
BR 2001013162	A	20040406	BR 2001-13162	20010806
ZA 2003001853	A	20040621	ZA 2003-1853	20030306
ZA 2003001854	A	20040621	ZA 2003-1854	20030306
PRIORITY APPLN. INFO.:			US 2000-223768P	P 20000808
			US 2001-922631	A 20010806
			WO 2001-US24655	W 20010806


OTHER SOURCE(S): MARPAT 136:183708

ED Entered STN: 15 Feb 2002

GI



I



II

AB Title compds. I [Ra-b = alk(en/yn)yl, cycloalkyl; n = 0-4; one of R1-3 = G and the remaining two are H or halo; G = N-containing heterocycle, e.g., piperidinyl, etc.] were prepared For instance, 4-(2-(piperidin-1-yl)ethoxy)benzaldehyde was used to alkylate 1,2,3,4-tetrahydroisoquinoline (ClCH₂CH₂Cl, HOAc, NaBH(OAc)₃, 15 h) to give II. II had K_i = 37 nM for the histamine H₃ receptor. I are useful for treating histamine-mediated conditions.


IT **398473-34-2P**, 1-[3-(4-((Piperidin-1-yl)methyl)phenoxy)propyl]piperidine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; preparation of non-imidazole aryloxyalkylamines as histamine-H₃ receptor antagonists)

RN 398473-34-2 CAPLUS

CN Piperidine, 1-[3-[4-(1-piperidinylmethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




IT **73152-41-7P**, 4-(Piperidin-1-yl)methylphenol

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of non-imidazole aryloxyalkylamines as histamine-H₃ receptor antagonists)

RN 73152-41-7 CAPLUS

CN Phenol, 4-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)




IT 3612-20-2, 1-Benzyl-4-piperidone

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of non-imidazole aryloxyalkylamines as histamine-
H3 receptor antagonists)

RN 3612-20-2 CAPLUS

CN 4-Piperidinone, 1-(phenylmethyl)- (9CI) (CA INDEX NAME)



L87 ANSWER 35 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:122957 CAPLUS

DOCUMENT NUMBER: 136:167285

TITLE: Preparation of aryloxy piperidines as histamine
H3 receptor antagonistsINVENTOR(S): Apodaca, Richard; Carruthers, Nicholas I.; Dvorak,
Curt A.; Shah, Chandravadan R.; Xiao, Wei

PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 155 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012190	A2	20020214	WO 2001-US24660	20010806
WO 2002012190	A3	20020801		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2419036	AA	20020214	CA 2001-2419036	20010806
AU 2001081121	A5	20020218	AU 2001-81121	20010806
US 2002040024	A1	20020404	US 2001-922619	20010806
EP 1311482	A2	20030521	EP 2001-959582	20010806

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2001013161	A	20040406	BR 2001-13161	20010806
JP 2004511438	T2	20040415	JP 2002-518168	20010806
ZA 2003001853	A	20040621	ZA 2003-1853	20030306
ZA 2003001854	A	20040621	ZA 2003-1854	20030306


PRIORITY APPLN. INFO.:

US 2000-223768P	P	20000808
US 2001-922619	A	20010806
WO 2001-US24660	W	20010806

OTHER SOURCE(S): MARPAT 136:167285

ED Entered STN: 15 Feb 2002

GI




AB Title compds. I [X = O; n = 0-3; R5 = alk(en)yl, cycloalkylalkyl, phenylalk(en)yl, alkylcarbonylalkyl; R1-3 = G, W, wherein one of the remaining two is selected from H and halo and the third being H; G = alk(en/yn)yl-N-containing heterocycle, etc.; W = CN, CHO, halo, heterocyclyl, phenoxy, Ph, etc.] were prepared For example, a suspension of 1-isopropylpiperidin-4-ol (preparation given), 4-fluorobenzaldehyde and Cs2CO3 were heated to 100° in DMF for 22 h resulting in the formation of 4-[(1-isopropylpiperidin-4-yl)oxy]benzaldehyde (II). II had Ki = 36 nM for the histamine H3 receptor. I are useful in the treatment of histamine-mediated conditions.

IT **73152-41-7P**, 4-Piperidin-1-ylmethylphenol **397275-85-3P**, [1-[4-((1-Isopropylpiperidin-4-yl)oxy)benzyl]piperidin-4-yl]methanol **397277-27-9P**, 4-[4-((1-Benzylpiperidin-4-yl)oxy)benzyl]morpholine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug; preparation of aryloxypiperidines as histamine **H3** receptor antagonists)


RN 73152-41-7 CAPLUS

CN Phenol, 4-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 397275-85-3 CAPLUS

4-Piperidinemethanol, 1-[[4-[[1-(1-methylethyl)-4-piperidinyl]oxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 397277-27-9 CAPLUS

Morpholine, 4-[[[4-[[1-(phenylmethyl)-4-piperidinyl]oxy]phenyl]methyl]-
(9CI) (CA INDEX NAME)



IT 397275-45-5P, 4-((1-((Cyclopropyl)methyl)piperidin-4-yl)oxy)benzonitrile 397275-65-9P, 1-[4-((1-Isopropylpiperidin-4-yl)oxy)benzyl]piperidine 397275-74-0P, 1-[4-((1-Cyclopentylpiperidin-4-yl)oxy)benzyl]piperidine 397275-78-4P, 1-[4-((1-Isobutylpiperidin-4-yl)oxy)benzyl]piperidine 397275-97-7P, 1-[4-((1-Isopropylpiperidin-4-yl)oxy)benzyl]piperidin-4-ol 397276-05-0P, 1-[4-((1-Isopropylpiperidin-4-yl)oxy)benzyl]-4-benzylpiperidine 397276-49-2P, 4-[4-(4-Benzylidenepiperidin-1-ylmethyl)phenoxy]-1-isopropylpiperidine 397276-70-9P, 1-[4-((1-Cyclohexylpiperidin-4-yl)oxy)benzyl]piperidine 397276-74-3P, 1-[4-((1-Benzylpiperidin-4-yl)oxy)benzyl]piperidine 397276-76-5P, 1-[4-((1-(Cyclohexylmethyl)piperidin-4-yl)oxy)benzyl]piperidine 397276-80-1P, 4-[4-(4-((Piperidin-1-yl)methyl)phenoxy)piperidin-1-yl]butan-2-one 397277-22-4P, 1-[4-(Piperidin-4-yloxy)benzyl]piperidine 397277-34-8P, 4-[4-((1-(Cyclohexylmethyl)piperidin-4-yl)oxy)benzyl]morpholine 397277-42-8P, 1-[4-((1-Propylpiperidin-4-yl)oxy)benzyl]piperidine 397277-45-1P, 1-[4-[1-(1-Methylheptyl)piperidin-4-yloxy]benzyl]piperidine 397277-54-2P, 4-((1-Phenethylpiperidin-4-yl)oxy)benzonitrile 397277-60-0P, 4-((1-Benzylpiperidin-4-yl)oxy)benzonitrile 397277-68-8P, 4-((1-(Cyclohexylmethyl)piperidin-4-yl)oxy)benzonitrile 397277-77-9P, 1-[4-(1-Isopropylpiperidin-4-ylmethoxy)benzyl]piperidine


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; preparation of aryloxypiperidines as histamine **H3** receptor antagonists)


RN 397275-45-5 CAPLUS

CN Benzonitrile, 4-[[1-(cyclopropylmethyl)-4-piperidinyl]oxy] - (9CI) (CA INDEX NAME)




RN 397275-65-9 CAPLUS

CN Piperidine, 1-(1-methylethyl)-4-[4-(1-piperidinylmethyl)phenoxy] - (9CI) (CA INDEX NAME)




RN 397275-74-0 CAPLUS

CN Piperidine, 1-cyclopentyl-4-[4-(1-piperidinylmethyl)phenoxy] - (9CI) (CA INDEX NAME)




RN 397275-78-4 CAPLUS

CN Piperidine, 1-(2-methylpropyl)-4-[4-(1-piperidinylmethyl)phenoxy] - (9CI) (CA INDEX NAME)




RN 397275-97-7 CAPLUS

CN 4-Piperidinol, 1-[[4-[[1-(1-methylethyl)-4-piperidinyl]oxy]phenyl]methyl] - (9CI) (CA INDEX NAME)




RN 397276-05-0 CAPLUS

CN Piperidine, 1-(1-methylethyl)-4-[4-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 397276-49-2 CAPLUS

CN Piperidine, 1-(1-methylethyl)-4-[4-[[4-(phenylmethylene)-1-piperidinyl]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 397276-70-9 CAPLUS

CN Piperidine, 1-cyclohexyl-4-[4-(1-piperidinylmethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 397276-74-3 CAPLUS

CN Piperidine, 1-(phenylmethyl)-4-[4-(1-piperidinylmethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 397276-76-5 CAPLUS

CN Piperidine, 1-(cyclohexylmethyl)-4-[4-(1-piperidinylmethyl)phenoxy]- (9CI)
(CA INDEX NAME)




RN 397276-80-1 CAPLUS

CN 2-Butanone, 4-[4-[4-(1-piperidinylmethyl)phenoxy]-1-piperidinyl]- (9CI)
(CA INDEX NAME)




RN 397277-22-4 CAPLUS

CN Piperidine, 1-[[4-(4-piperidinyl)oxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 397277-34-8 CAPLUS

CN Morpholine, 4-[[4-[[1-(cyclohexylmethyl)-4-piperidinyl]oxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 397277-42-8 CAPLUS

CN Piperidine, 4-[4-(1-piperidinylmethyl)phenoxy]-1-propyl- (9CI) (CA INDEX NAME)




RN 397277-45-1 CAPLUS

CN Piperidine, 1-(1-methylheptyl)-4-[4-(1-piperidinylmethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 397277-54-2 CAPLUS

CN Benzonitrile, 4-[[1-(2-phenylethyl)-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)




RN 397277-60-0 CAPLUS

CN Benzonitrile, 4-[[1-(phenylmethyl)-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)




RN 397277-68-8 CAPLUS

CN Benzonitrile, 4-[[1-(cyclohexylmethyl)-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 397277-77-9 CAPLUS

CN Piperidine, 1-(1-methylethyl)-4-[[4-(1-piperidinylmethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)




IT 2905-56-8, N-Benzylpiperidine

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of aryloxypiperidines as histamine **H3** receptor antagonists)

RN 2905-56-8 CAPLUS

CN Piperidine, 1-(phenylmethyl)- (9CI) (CA INDEX NAME)



L87 ANSWER 36 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:759328 CAPLUS

DOCUMENT NUMBER: 136:96459

TITLE: Histamine **H3**-receptor antagonism
improves memory retention and reverses the cognitive deficit induced by scopolamine in a two-trial place recognition task

AUTHOR(S): Orsetti, Marco; Ghi, Piera; Di Carlo, Giovanni

CORPORATE SOURCE: Dipartimento di Scienze C.A.F. e Farmacologiche,

SOURCE: Universita del Piemonte Orientale, Novara, Italy
Behavioural Brain Research (2001), 124(2), 235-242
CODEN: BBREDI; ISSN: 0166-4328

PUBLISHER: Elsevier Science Ireland Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


ED Entered STN: 18 Oct 2001

AB Several reports have indicated that, under different exptl. conditions, the administration of histamine H3-receptor antagonists exerts procognitive effects by activating central histaminergic transmission. In the present study the action of thioperamide, a H3-receptor blocker, is investigated on consolidation and recall mechanisms of the rat place recognition memory. The animals have been tested on a two-trial delayed comparison paradigm in a Y-maze. Thioperamide enhances the memory retention when administered i.p. post-acquisition (0.7 and 5.0 mg/kg are ineffective, whereas the dose of 2.0 mg/kg improves memory) but does not affect the rat performance when injected 45 min prior to the testing trial. The post-acquisition effect of thioperamide is time-dependent since the administration of the drug 30 min after the end of the training trial has no effect on memory. In addition, thioperamide reverses the amnesia induced by the post-acquisition treatment with 0.02 mg/kg i.p. of scopolamine (SCOP). The procognitive effect of thioperamide is not modified by the contemporary administration of pyrilamine, an histamine H1-receptor antagonist. On the contrary, the blockade of H2-receptors by zolantidine 10 mg/kg reverses both the effect of thioperamide alone and the drug action on the scopolamine-induced memory deficit. The results indicate that the neuronal histamine released in consequence of the post-acquisition thioperamide treatment improves place recognition memory through the activation of postsynaptic H2-receptors.

IT **388111-69-1**, Zolantidine hydrochloride
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(histamine **H3-receptor** antagonism improves memory retention and reverses cognitive deficit induced by scopolamine in a two-trial place recognition task)

RN 388111-69-1 CAPLUS

CN 2-Benzothiazolamine, N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 37 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:571555 CAPLUS

DOCUMENT NUMBER: 131:337220

TITLE: Synthesis and preliminary pharmacological evaluation of some cytosine derivatives

AUTHOR(S): Boido, Caterina Canu; Sparatore, Fabio

CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Università di Genova, Genoa, 3-16132, Italy

SOURCE: Farmaco (1999), 54(7), 438-451
CODEN: FRMCE8; ISSN: 0014-827X

PUBLISHER: Elsevier Science S.A.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 09 Sep 1999


AB Thirty-one N-derivs. of cytisine were prepared to modify the pharmacol. profile and to obtain compds. of potential therapeutic interest either at a peripheral or central level, particularly as nicotinic ligands with improved ability to cross the blood-brain barrier. With the introduction of different kinds of substituents on the basic nitrogen of cytisine a variety of activities were observed, both in vivo (analgesic, dopamine antagonism, antihypertensive, inhibition of stress-induced ulcers, antiinflammatory, protection from PAF-induced mortality, hypoglycemic) and in vitro (pos. cardio-inotropic, β -adrenergic antagonism, α 1- and α 2-antagonism, inhibition of PAF-induced platelet aggregation). Six randomly selected compds. were tested for the ability to recognize a central nicotinic receptor and four of them exhibited K_i values in the range 30-163 nM.

IT 492-02-4P 249906-83-0P 249906-93-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cytisine derivs. and their preliminary pharmacol. evaluation)

RN 492-02-4 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 3,3'-(1,2-ethanediyl)bis[1,2,3,4,5,6-hexahydro-, (1R,1'R,5S,5'S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 249906-83-0 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-(2-phenylethyl)-, (1R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 249906-93-2 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 3,3'-(1,3-propanediyl)bis[1,2,3,4,5,6-hexahydro-, (1R,1'R,5S,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 249907-16-2P 249907-17-3P 249907-28-6P
249907-29-7P 249907-30-0P 249907-33-3P
249907-35-5P 249907-36-6P 249907-37-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of cytosine derivs. and their preliminary pharmacol. evaluation)

RN 249907-16-2 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 3-[(4-fluorophenyl)methyl]-1,2,3,4,5,6-hexahydro-, monohydrochloride, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 249907-17-3 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-[(2,4,6-trimethylphenyl)methyl]-, monohydrochloride, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 249907-28-6 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, dihydrochloride, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 249907-29-7 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-[3-(4-phenyl-1-piperazinyl)propyl]-, dihydrochloride, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 249907-30-0 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-, dihydrochloride, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 249907-33-3 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-[3-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]propyl]-, dihydrochloride, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 249907-35-5 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-[3-[4-(2-pyridinyl)-1-piperazinyl]propyl]-, dihydrochloride, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 249907-36-6 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]-, dihydrochloride, (1R,5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 249907-37-7 CAPLUS

CN Piperazine, 1-(2-furanylcarbonyl)-4-[3-[(1R,5S)-1,5,6,8-tetrahydro-8-oxo-1,5-methano-2H-pyrido[1,2-a][1,5]diazocin-3(4H)-yl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl


IT 78867-61-5P 249906-81-8P 249906-82-9P
249906-84-1P 249906-86-3P 249906-94-3P
249906-95-4P 249906-96-5P 249906-97-6P
249906-98-7P 249906-99-8P 249907-00-4P
249907-01-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of cytosine derivs. and their preliminary pharmacol.
evaluation)

RN 78867-61-5 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-
(phenylmethyl)-, (1R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 249906-81-8 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 3-[(4-
fluorophenyl)methyl]-1,2,3,4,5,6-hexahydro-, (1R,5S)- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 249906-82-9 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-[(2,4,6-trimethylphenyl)methyl]-, (1R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 249906-84-1 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-[2-(4-methoxyphenyl)ethyl]-, (1R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 249906-86-3 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-(3-phenylpropyl)-, (1R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 249906-94-3 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, (1R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 249906-95-4 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-[3-(4-phenyl-1-piperazinyl)propyl]-, (1R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 249906-96-5 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-, (1R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 249906-97-6 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 3-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-1,2,3,4,5,6-hexahydro-, (1R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 249906-98-7 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-[3-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]propyl]-, (1R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 249906-99-8 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-[3-[4-(2-pyridinyl)-1-piperazinyl]propyl]-, (1R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 249907-00-4 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]-, (1R,5S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 249907-01-5 CAPLUS

CN Piperazine, 1-(2-furanylcarbonyl)-4-[3-[(1R,5S)-1,5,6,8-tetrahydro-8-oxo-1,5-methano-2H-pyrido[1,2-a][1,5]diazocin-3(4H)-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 249907-15-1P 249907-18-4P 249907-19-5P
249907-20-8P 249907-27-5P 249907-32-2P
249929-91-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of cytosine derivs. and their preliminary pharmacol.
evaluation)

RN 249907-15-1 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-(phenylmethyl)-, monohydrochloride, (1R,5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 249907-18-4 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-(2-phenylethyl)-, monohydrochloride, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 249907-19-5 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-[2-(4-methoxyphenyl)ethyl]-, monohydrochloride, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 249907-20-8 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-3-(3-phenylpropyl)-, monohydrochloride, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 249907-27-5 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 3,3'-(1,3-propanediyl)bis[1,2,3,4,5,6-hexahydro-, dihydrochloride, (1R,1'R,5S,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 249907-32-2 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 3-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-1,2,3,4,5,6-hexahydro-, dihydrochloride, (1R,5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 249929-91-7 CAPLUS

CN 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, 3,3'-(1,2-ethanediyl)bis[1,2,3,4,5,6-hexahydro-, dihydrochloride, (1R,1'R,5S,5'S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 38 OF 38 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:414527 CAPLUS

DOCUMENT NUMBER: 127:60556

TITLE: Effects of clobenpropit (VUF-9153), a histamine H3-receptor antagonist, on learning and memory, and on cholinergic and monoaminergic systems in mice

AUTHOR(S): Miyazaki, Shuichi; Onodera, Kenji; Imaizumi, Masahiro; Timmerman, Hendrik

CORPORATE SOURCE: Biology Laboratory, Research & Development Division, Yamasa Corporation, Chiba, 288, Japan

SOURCE: Life Sciences (1997), 61(4), 355-361

CODEN: LIFSAK; ISSN: 0024-3205

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English


ED Entered STN: 04 Jul 1997

AB The effects of clobenpropit on a scopolamine-induced learning deficit in the step-through passive avoidance test was studied in mice. Clobenpropit (10 and 20 mg/kg) tended to antagonize the scopolamine-induced learning deficit, and clobenpropit (10 mg/kg) in combination with zolantidine (20 mg/kg), a histamine H2-receptor antagonist, further antagonized the scopolamine-induced effect. This ameliorating effect was antagonized by (R)- α -methylhistamine (20 mg/kg), a histamine H3-receptor agonist, and pyrilamine (20 mg/kg), a histamine H1-receptor antagonist, suggesting that clobenpropit in combination with zolantidine produces an ameliorating effect via histamine H3 receptors and/or histamine H1 receptors. The effects of clobenpropit on cholinergic and monoaminergic systems were also studied. Clobenpropit did not produce any significant effect on these neuronal systems except the activation of the noradrenergic system. The results suggest that the effect of clobenpropit might be partially via activation of the noradrenergic system, and the histaminergic system may play certain important roles in learning and memory.

IT 104076-38-2, Zolantidine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(clobenpropit effect on learning and memory stimulation by)

RN 104076-38-2 CAPLUS
 CN 2-Benzothiazolamine, N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]- (9CI)
 (CA INDEX NAME)



=> □

=> fil reg; d stat que l36; fil capl uspatf toxcenter; s l36
 FILE REGISTRY ENTERED AT 16:12:00 ON 06 JUN 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JUN 2005 HIGHEST RN 851662-51-6
 DICTIONARY FILE UPDATES: 5 JUN 2005 HIGHEST RN 851662-51-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

 *
 * The CA roles and document type information have been removed from *
 * the IDE default display format and the ED field has been added, *
 * effective March 20, 2005. A new display format, IDERL, is now *
 * available and contains the CA role and document type information. *
 *

Crossover limits have been increased. See HELP CROSSOVER for details.







Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

L1 (1757) SEA FILE=CAPLUS ABB=ON WAKEFULNESS/BI
 L2 (13480) SEA FILE=CAPLUS ABB=ON MEMORY, BIOLOGICAL/CT
 L3 (7452) SEA FILE=CAPLUS ABB=ON COGNITION/CW
 L4 (2672) SEA FILE=CAPLUS ABB=ON MENTAL/CW(L) ATTENTION/OBI
 L5 (1385) SEA FILE=CAPLUS ABB=ON SLEEP/OBI(L) (WAKING/OBI OR WAKE/OBI)
 L6 (257) SEA FILE=CAPLUS ABB=ON SLEEPINESS/OBI
 L7 (2816) SEA FILE=CAPLUS ABB=ON L1 OR L5 OR L6
 L8 SEL L7 1- RN : 8252 TERMS

```

L9 (      8252)SEA FILE=REGISTRY ABB=ON  L8
L10      SEL  L3 1- RN :    51186 TERMS  (TERM LIMIT EXCEEDED)
L11 (    51186)SEA FILE=REGISTRY ABB=ON  L10
L12 (      618)SEA FILE=CAPLUS ABB=ON  L2 AND L4
L13      SEL  L12 1- RN :    30814 TERMS
L14 (    30814)SEA FILE=REGISTRY ABB=ON  L13
L15 (    12862)SEA FILE=CAPLUS ABB=ON  L2 NOT L4
L16 (    3950)SEA FILE=CAPLUS RAN=(,1992) ABB=ON  L15 NOT (L1 OR L4 OR L5 OR
      L6)
L17 (    5462)SEA FILE=CAPLUS RAN=(,2001) ABB=ON  L15 NOT L16
L18 (    3450)SEA FILE=CAPLUS ABB=ON  L15 NOT (L16 OR L17)
L19      SEL  L16 1- RN :    9163 TERMS
L20 (    9162)SEA FILE=REGISTRY ABB=ON  L19
L21      SEL  L17 1- RN :    20267 TERMS
L22 (    20267)SEA FILE=REGISTRY ABB=ON  L21
L23      SEL  L18 1- RN :    42655 TERMS
L24 (    42655)SEA FILE=REGISTRY ABB=ON  L23
L25 (    1597)SEA FILE=CAPLUS ABB=ON  L4 NOT (L2 OR L1 OR L3 OR (L5 OR L6))
L26      SEL  L25 1- RN :    27797 TERMS
L27 (    27797)SEA FILE=REGISTRY ABB=ON  L26
L28 (    150742)SEA FILE=REGISTRY ABB=ON  L9 OR L11 OR L14 OR L20 OR L22 OR
      L24 OR L27
L29      STR

```



```

VAR G1=3/6/9/14/20
REP G2=(1-5) C
REP G3=(1-2) CH
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 2
CONNECT IS E1 RC AT 4
CONNECT IS E2 RC AT 25
DEFAULT MLEVEL IS ATOM
GGCAT IS SAT AT 25
DEFAULT ECLEVEL IS LIMITED

```

```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 25


```

```

STEREO ATTRIBUTES: NONE
L30      20417 SEA FILE=REGISTRY SUB=L28 SSS FUL L29
L31      STR

```

*same full file
search*




VAR G1=NH2/49/50/PH/24/54/52/46
 REP G2=(0-1) CH2
 NODE ATTRIBUTES:
 CONNECT IS E2 RC AT 7
 CONNECT IS E2 RC AT 27
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS E6 C AT 28

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 56

STEREO ATTRIBUTES: NONE
 L32 STR

*subset search
 done looking for
 any of the following
 3 str (species)*



VAR G1=60/61/53/15/64/25/27

REP G2=(0-1) CH2

VAR G3=CH2/57

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 7

CONNECT IS E2 RC AT 27

CONNECT IS E2 RC AT 53

CONNECT IS E1 RC AT 60

CONNECT IS E2 RC AT 61

CONNECT IS E1 RC AT 63

DEFAULT MLEVEL IS ATOM

GGCAT IS SAT AT 28

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 41

STEREO ATTRIBUTES: NONE

L33 STR



VAR G1=5/8

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 1

CONNECT IS E2 RC AT 3

CONNECT IS E2 RC AT 6

CONNECT IS E1 RC AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

~~L36~~ 4 SEA FILE=REGISTRY SUB=L30 SSS FUL (L31 OR L32 OR L33)

100.0% PROCESSED 19049 ITERATIONS
SEARCH TIME: 00.00.01

~~4 ANSWERS~~

FILE 'CAPLUS' ENTERED AT 16:12:00 ON 06 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:12:00 ON 06 JUN 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 16:12:00 ON 06 JUN 2005
COPYRIGHT (C) 2005 ACS

L37 20 L36

=> dup rem l37

PROCESSING COMPLETED FOR L37

L38 16 DUP REM L37 (4 DUPLICATES REMOVED)
ANSWERS '1-14' FROM FILE CAPLUS
ANSWERS '15-16' FROM FILE USPATFULL

=> d ibib ed abs hitstr 1-16

L38 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2003:892600 CAPLUS

DOCUMENT NUMBER: 139:381374

TITLE: Preparation of urea derivatives as bombesin
antagonists

INVENTOR(S): Higginbottom, Michael; Kesten, Suzanne Ross;
Lewthwaite, Russell Andrew; Pritchard, Martyn Clive;
Rawson, David James; Schelkun, Robert Michael; Yuen,
Po-Wai

PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA

SOURCE: PCT Int. Appl., 227 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003092670	A1	20031113	WO 2003-IB1686	20030417
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2484582 AA 20031113 CA 2003-2484582 20030417
EP 1501800 A1 20050202 EP 2003-722887 20030417
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
BR 2003009764 A 20050215 BR 2003-9764 20030417
US 2004063643 A1 20040401 US 2003-425758 20030428
PRIORITY APPLN. INFO.: GB 2002-10239 A 20020503
US 2002-398132P P 20020723
WO 2003-IB1686 W 20030417
OTHER SOURCE(S): MARPAT 139:381374
ED Entered STN: 14 Nov 2003
GI




AB R1(CH2)mCR3R4(CH2)nY(CH2)pCO(CH2)qNH(CH2)rR2 [R1 = (un)substituted aryl, heteroaryl, CO2H, CONH2, NH2, OH, alkyl, cycloalkyl; M, n, p, q = 0-2; r = 0-4; Y = (un)substituted NH, CH2; R2 = (un)substituted cycloalkyl, aryl, heteroaryl, aryloxy, alkyl, adamantyl, alkenyl; R3, R4 = H, alkyl; R3R4 = alkylene, heteroalkylene] were prepared for use as bombesin antagonists in treatment of male and female sexual dysfunction, particularly female sexual arousal disorder and male erectile dysfunction. Thus, 2-pyridinylacetonitrile was treated with Br(CH2)5Br to give 1-(2-pyridinyl)cyclohexylacetonitrile which was reduced to the amine, reductively alkylated with 4-HOC6H4CHO, and treated with 2,3-Cl2C6H3NH2 and triphosgene to give the urea I. I has Ki 82 nM for antagonism at the BB1 receptor.

IT **623570-15-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of urea derivs. as bombesin antagonists)

RN 623570-15-0 CAPLUS

CN Benzenemethanamine, 3-[1-(aminomethyl)cyclohexyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 1970:433587 CAPLUS

DOCUMENT NUMBER: 73:33587

TITLE: Potential antiarrhythmics related to 2-phenylethanol diethylaminoethyl ether. II. Pharmacological study

AUTHOR(S): Molimard, Robert; Morin, Robert; Eskenazi, Pierre; Motosso, Francoise; Vigier, Denise

CORPORATE SOURCE: Lab. Jacques Logeais, Issy-les-Moulineaux, Fr.

SOURCE: Chimica Therapeutica (1970), 5(1), 10-15

CODEN: CHTPBA; ISSN: 0009-4374

DOCUMENT TYPE: Journal

LANGUAGE: French

ED Entered STN: 12 May 1984

AB The antiarrhythmic properties of numerous phenylalkoxy alkyl amines were compared on isolated rabbit hearts (lengthening of refractory period) and in rabbits, mice, and rats (protection against aconitine- and CHCl₃-induced fibrillation and against arrhythmia due to coronary ligation). Among the phenylethoxyethylamines, those rings substituted with H, Cl, or Me, such as dimethyl[2-(2-phenylethoxy)ethyl]amine and trip-tolyethoxyethylamine, were most active; however, these compds. were generally neurotoxic. Compds. with unsubstituted amine groups, such as p-chlorophenylethoxyethylamine, were less active and less neurotoxic. Antiarrhythmic activity and neurotoxicity increased with the length of the alkoxy chain, as exemplified by 2-(3-diethylphenylpropoxy)triethylamine and 2-(4-phenylbutoxyethylamine).

IT 27078-39-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antiarrhythmic action of)

RN 27078-39-3 CAPLUS

CN 1-Propanamine, N,N-diethyl-3-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)

Ph- (CH₂)₃-O- (CH₂)₃-NEt₂

L38 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 1957:62160 CAPLUS

DOCUMENT NUMBER: 51:62160

ORIGINAL REFERENCE NO.: 51:11268b-i,11269a-i,11270a-f

TITLE: Preparation and bacteriostatic activity of substituted ureas

AUTHOR(S): Beaver, David J.; Roman, Daniel P.; Stoffel, Paul J.

CORPORATE SOURCE: Monsanto Chem. Co., St. Louis, MO

SOURCE: Journal of the American Chemical Society (1957), 79, 1236-45

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

ED Entered STN: 22 Apr 2001

AB cf. C.A. 49, 924b. The preparation and in vitro bacteriostatic activity of some ureas, carbanilides, and related compds. against *Micrococcus pyrogenes* var. *aureus* are described. The bacteriostatic properties of ureas were remarkably specific in that activity was greatly enhanced or completely lost with slight changes in chemical structure. Activity is drastically reduced by o-substitution regardless of the electronic character of the substituent. Thioureas were invariably less effective than similarly substituted ureas. Bromocarbanilides were less active than the Cl compds. in both ureas and thioureas. Procedure A: PhNCO (11.9 g.) in 50 cc. Et₂O added dropwise to 16.2 g. 3,4-Cl₂C₆H₃NH₂ (I) in 50 cc. Et₂O, the mixture held 2 hrs., and filtered yielded 3,4-dichlorocarbanilide. In the subprocedures the following solvents were used: A2, Skellysolve; A3, C₆H₆; A4, Me₂CO; A5, absolute EtOH; A6, none; A7, none, 4 hrs. at 90°. Procedure B: 3,4-Cl₂C₆H₃NCS (20.4 g.) and 16.2 g. I in 75 cc. absolute EtOH refluxed 1 hr. yielded 3,3',4,4'-tetrachlorothiocarbanilide. Procedure C: PhNCO (11.9 g.) in 400 cc. Et₂O at 20° treated with anhydrous NH₃ yielded phenylurea. Procedure D: 2-Cl₁₀H₇NH₂ (60.0 g.) and 24.0 g. urea heated to 160° and held there 3 hrs. yielded 1,3-di-2-naphthylurea. Procedure E: Cyclohexylamine (60.0 g.) in 800 cc. PhMe treated at 100° with COCl₂ yielded 1,3-dicyclohexylurea. For compds. of the type RNHC(:X)NHR', R, X, R', procedure, % yield, and m.p. are: H, O, 2-Cl₁₀H₇, C, 96.8, 212° (decomposition); H, O, 4-biphenyl, C, 97.0, 209° (decomposition); 1-Cl₁₀H₇, O, 1-Cl₁₀H₇, D, 49.8, 295-6°; 2-Cl₁₀H₇, O, 2-Cl₁₀H₇, D, 86.7, 305-6°; 2-Cl₁₀H₇, O, CH₂CH₂CH₂OMe, A, 80.0, 142.5-3.0°; 1-Cl₁₀H₇, O, cyclohexyl, A, 100.0, 237.0-8.0°; 2-Cl₁₀H₇, O, dicyclohexyl, A, 99.3, 177.3-7.8°; cyclohexyl, O, cyclohexyl, E, 30.2, 226.0-7.0°; dicyclohexyl, O, Et, A, 87.4, 146.8-7.5°; dicyclohexyl, O, dicyclohexyl, E, 36.5, 81.0-1.7°; cyclohexyl, S, Ph, A5, 91.5, 150.1-50.9°; cyclohexyl, S, 4-C₆H₄OEt, B, 74.5, 122.2-3.0°; cyclohexyl, S, 4-Me₂NC₆H₄, B, 91.0, 127.0-7.8°; cyclohexyl, S, 1-Cl₁₀H₇, B, 74.2, 141.8-2.5°; cyclohexyl, S, dicyclohexyl, B, 49.2, 103.2-3.6°; Ph, S, 4-Me₂NC₆H₄, B, 84.2, 154.4-4.8°; Ph, S, 2-Cl₁₀H₇, B, 83.6, 158.2-9.0°; Ph, S, dicyclohexyl, B, 63.7, 86.5-7.3°; Ph, S, 4-C₆H₄OEt, A5, 89.8, 133.9-4.3°; 3,4-Br₂C₆H₃, S, 4-BrC₆H₄, A7, 47.5, 125.0-6.1°. For RC₆H₄NHCONR₁R₂, R, R₁, R₂, procedure, % yield, and m.p. are: H, H, H, C, 61.5, 148.5-9.0°; H, H, CH₂CH₂CH₂NEt₂, A6, 100, 69.5-70.0°; H, H, CH₂CH₂CH₂NHCHMe₂, A2, 58.0, 143.7-4.2°; H, H, CH₂CH₂CH₂OMe, A7, 100.0, 87.5-8.2°; H, H, cyclohexyl, A7, 97.3, 186.3-7.1°; H, H, 2-Cl₁₀H₇, A5, 73.3, 233.0-4.0°; H, cyclohexyl, cyclohexyl, A, 79.4, 180.3-1.3°; H, allyl, allyl, A2, 100.0, 65.5-6.0°; H, PhNHCONHCH₂CH₂CH₂, PhNHCONHCH₂CH₂CH₂, A6, 100, 132° (decomposition); H, Bu, Bu, A6, 98.6, 82.7-3.0°; H, heptyl, heptyl, A, 76.0, -; H, 2-ethylhexyl, 2-ethylhexyl, A7, 93.7, -; H, Ph, Ph, A7, 86.8, 136.0-6.6°; 2-Me, H, cyclohexyl, A, 95.1, 196.1-6.5°; 2-Me, cyclohexyl, cyclohexyl, A, 86.0, 142.2-2.8°; 4-Me, H, cyclohexyl, A, 100.0, 205.2-5.8°; 4-Me, cyclohexyl, cyclohexyl, A, 91.5, 173.4-3.7°; 2-MeO, cyclohexyl, cyclohexyl, A, 100.0, 155.3-6.0°; 2-EtO, H, CH₂CH₂CH₂OMe, A6, 78.0, 86.6-7.2°; 2-EtO, H, 2-Cl₁₀H₇, A, 71.0, 177.5-8.2°; 2-EtO, cyclohexyl, cyclohexyl, A, 65.2, 99.8-100.4°; 4-EtO, H, Et, A, 85.3, 151.9-2.4°; 4-EtO, H, 1-Cl₁₀H₇, A, 97.6, 238.0-9.0°; 4-EtO, H, 2-Cl₁₀H₇, A, 99.3,

237.4-8.0°; 4-EtO, H, cyclohexyl, A, 95.6, 182.6-3.0°; 4-EtO, cyclohexyl, cyclohexyl, A, 91.8, 149.6-50.2°; dodecyl, cyclohexyl, cyclohexyl, A2, 100.0, -; 4-Me2N, 1-ClOH7, H, A, 96.0, 227.5-8.5°; 4-Me2N, 2-ClOH7, H, A, 91.3, 252-3°; 2-Ph, H, Et, A, 88.0, 114.6-15.2°; 2-Ph, cyclohexyl, cyclohexyl, A, 100, 110.0-10.7°; 2-Ph, H, CH2CH2CH2NEt2, A6, 100.0, 76.4-7.0°; 4-Cl, formyl, 2,4-Cl2C6H3, A7, 85.3, 118.5-19.1°; 4-Cl, formyl, 3,4-Cl2C6H3, A7, 63.0, 122.5-3.5°; 4-Cl, allyl, 3,4-Cl2C6H3, A2, 87.2, 151.2-2.0°; 2-MeO, formyl, 2,5-Cl2C6H3, A7, 71.0, 152.5-3.0°. For compds. of the type RC6H4NHCONHC6H4R', R, R' (all procedure A except as noted), % yield, and m.p. are: H, 2-MeO, 84.3, 146.2-6.8°; H, 2-EtO, 94.4, 173.8-4.2°; H, 4-EtO, 100.0, 188.2-8.8°; H, 2-Et, 61.2, 184.9-5.5°; H, 4-Me2N, 94.0, 208.0-8.8°; H, 4-Et2N, 88.8, 178.7-9.3°; H, 2-Ph, 95.7, 173.0-3.6°; H, 4-Ph, 85.5, 240-1°; H, 4-H2N, 78.5, above 400°; H, 4-PhNH, 98.2, 212.8-13.8°; H, 4-Cl, 95.0, 250-1°; 2-MeO, 2,4-Cl2, 99.5, 222.3-3.0°; 4-MeO, 2,4-Cl2, 58.0, 230.0-30.5°; 2-EtO, 4-EtO, 65.2, 146.4-7.0°; 4-EtO, 2-Me, 84.0, 202.0-2.4°; 4-EtO, 4-Me, 100.0, 220.4-1.0°; 4-EtO, 4-Me2N, 91.1, 211.8-12.2°; 4-EtO, dodecyl, A2, 100.0, -; 4-EtO, 2-Ph, 95.8, 194.8-5.4°; 2-Ph, 4-PhNH, 86.8, 155.8-6.2°; 2-Ph, 2-Ph, 74.0, 182.2-2.8°; 4-Ph, 4-Ph, 76.5, 312° (decomposition); 4-Cl, 4-Cl, 98.0, 315-19°; 4-Cl, 2,4-Cl2, 98.0, 253.0-3.8°; 4-Cl, 2,5-Cl2, 83.0, 261.5-2.5°; 3-Cl, 3,4-Br2, 94.0, 208.5-9.0°; 2,4-Cl2, 2,4-Cl2, 97.5, 261-3°. For 3,4-Cl2C6H3NHCONRR', R, R' (all procedure A except as noted), % yield, and m.p. are: H, H, C, 93.7, 155.6-6.3°; H, Et, 100.0, 179.5-80.1°; H, tert-octyl, 100.0, 145.8.6°; H, cyclohexyl, 100.0, 188.0-8.7°; H, 1-ClOH7, 97.0, 265-6°; H, 2-ClOH7, 97.2, 267-8°; H, CH2CH(OH)Me, 100, 152.0-2.8°; H, CH2CH2CH2OH, 98.8, 126.5-8.0°; H, tetrahydrofurfuryl, 100.0, 144.1-4.9°; Et, 4-ClC6H4, 77.0, 116.0-6.8°; allyl, allyl, A2, 100.0, 62.5-3.5°; allyl, iso-Pr, 93.4, 84.0-4.5°; CH2CH2OH, CH2CH2OH, 65.0, 156.8-7.6°; CH2:CClCH2, CH2:CClCH2, 100, 100.7-1.4°; CH2:CClCH2, iso-Pr, 100, 84.7-5.2°; CH2:CClCH2, tert-Bu, 100.0, 93.9-5.0°; CHCl:CHCH2, CHCl:CHCH2, 100.0, 156.0-6.6°; CH2:CClCH2, CH2CH2CH2OMe, A2, 100, -; CH2:CClCH2, Ph, A7, 92.9, 118.7-9.4°; H, CHCl:CClCH2, 61.2, 105.1-5.9°; Bu, Ph, 96.5, 98.5-9.4°; CH2CH2CN, Ph, 89.3, 114.7-15.5°; iso-Pr, MeC.tplbond.C, 71.1, 84.4-5.1°; Ph, Ph, 39.5, 148.3-9.1°; cyclohexyl, cyclohexyl, 98.0, 177.6-8.4°; cyclohexyl, MeCH:CClCH2, 88.7, 160.4-60.8°; allyl, 4-C6H4OEt, 100, -; allyl, 3,4-Cl2C6H3, A2, 87.3, 116.8-17.5°; MeC.tplbond.C, 3,4-Cl2C6H3, 69.0, 145.2-6.0°; Bu, Ph, 96.5, 98.5-9.4°; H, 2-thiazolyl, A4, 99.0, 225° (decomposition). For 3,4-Cl2C6H3NHCONHC6H4R, R, procedure (A unless otherwise noted), % yield, and m.p. are: H, 100, 217.2-7.7°; 4-Me, 100.0, 258.0-9.0°; 2-MeO, 95.2, 173.8-4.3°; 4-MeO, 93.5, 233.1-4.0°; 4-Me2N, 95.0, 229.6-30.4°; 4-H2N, A3, 96.0, above 360°; dodecyl, A7, 98.0, -; 2-Ph, 91.6, 183.3-4.1°; 4-Ph, 84.5, 233.0-4.0°; 2-Cl, 87.0, 220.0-20.6°; 3-Cl, 91.5, 210.7-11.3°; 4-Cl, 88.0, 255.2-56.2°; 2,4-Cl2, 97.3, 238.5-9.2°; 2,5-Cl2, 94.2, 242.2-2.6°; 3,4-Cl2, 100.0, 281-2°; 3,4,5-Cl3, 100.0, 308-10°; 3-Cl-4-HO, 95.4, 237.4-8.0°; 3,5-Cl2-4-HO, 92.4, 272-3°; 3-Br, 100.0, 208.5-9.2°; 4-PhNH, 100, 208.8-9.5°; 4-HO, A3, 82.5, 213.8-14.5°; 4-NO2, 95.3, 294-5°; 4-sulfamyl, A4, 83.6, 258.5-9.5°; 4-(2-thiazolesulfamyl), A4, 82.8, 271-2°; 4-(2-pyrimidinesulfamyl), A4, 79.0, 290° (decomposition). For RC6H4NHC:XR', R, X, R', procedure, % yield, and m.p. are: H, O, morpholino, A, 74.5, 159.3-60.0°; H, S, morpholino, B, 72.6,


132.6-3.4°; H, O, 2-methyl-1-piperidyl, A, 94.5, 115.4-16.0°; H, O, 1,2-dihydro-2,2,4-trimethyl-1-quinolyl, A, 71.0, 125.5-6.2°; H, O, 1,2-dihydro-6-ethoxy-2,2,4-trimethyl-1-quinolyl, A, 94.2, 146.6-7.0°; H, O, 1,2-dihydro-6-phenyl-2,2,4-trimethyl-1-quinolyl, A, 40.5, 148.0-9.1°; 4-MeO, O, morpholino, A2, 95.7, 124.5-5.0°; 2-Cl, O, morpholino, A2, 93.8, 132.2-2.8°; 3-Cl, O, morpholino, A2, 98.3, 129.7-30.3°; 4-Cl, O, 4-morpholino, A2, 91.4, 200.8-1.4°; 3,4-Cl2, O, morpholino, A, 90.0, 157.1-7.8°; 3,4-Cl2, S, morpholino, B, 96.8, 197.5-8.1°; 3,4-Cl2, O, 1-piperidyl, A, 100.0, 175.0-5.8°; 3,4-Cl2, O, 2-methyl-1-piperidyl, A2, 97.5, 171.4-1.9°; 3,4-Cl2, O, 3-methyl-1-piperidyl, A, 56.5, 115.7-6.7°; 3,4-Cl2, O, 4-methyl-1-piperidyl, A2, 92.5, 144.0-4.8°; 3,4-Cl2, O, 1-pyrrolidyl, A, 97.8, 176.8-7.4°; 3,4-Cl2, O, 2-pyrrolidon-1-yl, A, 89.3, 151.8-2.7°; 3,4-Cl2, O, 3,4-Cl2, 2-thiono-1-pyridyl, A4, 90.5, 171.9-2.8°; 3,4-Cl2, S, 2-thiono-1-pyrrolidyl, A7, 52.6, 126.7-7.2°; 3,4-Cl2, O, 3-methylpyrazin-5-on-1-yl, A4, 62.3, 228.0-9.0°; 3,4-Cl2, O, 2,4,6-trimethyl-1-piperidyl, A, 85.5, 135.3-6.1°; 3,4-Cl2, O, 1-decahydroquinolyl, A, 99.7, 160.5-1.4°; 3,4-Cl2, O, 2-decahydroisoquinolyl, A, 90.4, 144.0-5.0°; 3,4-Cl2, O, 1,2-dihydro-6-ethoxy-2,2,4-trimethyl-1-quinolyl, A, 54.0, 139.3-40.2°. For 3,4-Cl2C6H3NHCSNRR', R, R', procedure, % yield, and m.p. are: H, CH2CH2CH2OH, A2, 99.0, 34-5°; H, 4-ClC6H4, B, 82.0, 154.2-4.9°; H, 3-ClC6H4, B, 75.5, 119.5-20.5°; H, Ph, B, 99.0, 136.1-7.0°; H, 3-BrC6H6, A7, 74.6, 107.5-8.3°; H, 3,4-Cl2C6H3, B, 94.5, 162.6-3.5°; H, 2-thenyl, A, 99.0, 153.2-4.1°; iso-Pr, allyl, A2, 93.4, 80.8-1.6°; iso-Pr, MeC.tplbond.C, A2, 88.7, 77.2-7.8°. Procedures are given for new compds. 3,4-Cl2C6H3XC6H4R, for which X, R, % yield, and m.p. follow: CONH, 3,4-d-Cl2, 86.5, 232.6-3.3°; CSNH, 4-Cl, 77.0, 144.5-5.3°; CONH, 4-Cl, 80.0, 167.3-8.1°; CH2NH, 4-Cl, 18.5, 169.0-0.5°; NHCH2, 4-Cl, 18.0, 122.3-3.1°; NHCO, 4-Cl, 73.3, 176.6-7.4°; N:CH, 3,4-Cl2, 86.5, 132.3-3.0°; N:CH, 4-Cl, 81.0, 103.7-4.4°; NHCH2CO, 4-Cl, 80.0, 182.5-3.7°; NHCOCH2CONH, 3,4-Cl2, 28.7, 227.8-8.6; CH:CHCOCH:CH, 3,4-Cl2, 59.3, 202.1-2.8°; NHCOCNH, 3,4-Cl2, 27.3, 228.2-9.1°; NHC(:NH)NH, 3,4-Cl2, 74.0, 181.1-2.0°; NHCOCH:CHCONH, 3,4-Cl2, 85.0, 227-9°; NHCO2CH2CH2OCONH, 3,4-Cl2, 79.3, 217.3-18.0°; NHCONH(CH2)4NHCONH, 3,4-Cl2, 100.0, 197.2-8.2°; NHCOC6H4 CONH-o, 3,4-Cl2, 71.8, 256-7°; NHCONHC6H4NHCONH-p, 3,4-Cl2, 94.3, above 360°; NHCONHCH2, 3,4-Cl2, 90.0, 194.7-5.8°; CH2NHCONH, 4-Cl, 88.8, 213.2-13.7°; NHCO2C6H4O2CNH-p, 3,4-Cl2, 84.5, 279-80°; NHSONH, 3,4-Cl2, 70.6, 49.5-50.2°; NHCO2CH2CH2SCH2CH2OCONH, 3,4-Cl2, 87.3, 141.4-2.5°; CONHCONHCO, 3,4-Cl2, 70.0, 199.6-200.4°; NHCSNHNHCSNH, 3,4-Cl2, 89.9, 169° (decomposition); NHCONHNHCONH, 3,4-Cl2, 88.8, 233-4°; NHCONHNH, H, 97.8, 172.2-3.1°; NHCO2(CH2)4OCONH, 3,4-Cl2, 86.0, 170.9-1.8°; CCl3CH:, 3,4-Cl2, 74.9, 101.3-2.1°; NHCH:N, 3,4-Cl2, 73.0, 158.3-9.1°; NHCO2, 4-Cl, 88.8, 149.5-50.7°; NHCO2, 3,4-Cl, 91.5, 148.1-9.1°. I (162.1 g.) at 75-80° treated dropwise with 60.0 g. MeC.tplbond.CBr, the slurry held 3 hrs. at 85°, cooled, neutralized at 20° (ice bath) with 30 g. NaOH in 500 cc. H2O, the oil extracted with Et2O, and the extract fractionated yielded N-(2-propynyl)-3,4-dichloroaniline, b7 152.7-3.4°, nD25 1.5991. I treated with CH2:CHCH2Cl and the product held 18 hrs. at 80-5° yielded N-allyl-3,4-dichloroaniline, b7.5 159.0-61.0, nD25 1.5859. EtOAc (1 l.) saturated with COCl2, treated at reflux during 2-3 hrs. with 324 g. I in 1.5 l. EtOAc under a flow of COCl2, the solution held 1 hr. at reflux, 1.5 l. EtOAc distilled at atmospheric pressure, and the remaining EtOAc removed under a gradually increasing

vacuum yielded 90.5% 3,4-dichlorophenyl isocyanate, b10.5 116.7-18.1°, m. 40-1°. H₂O (350 cc) containing 58.0 cc. 38% HCl treated during 30 min. at 10-15° with 80.0 g. CCl₄, the cooling bath removed, 128.0 g. I in 400 cc. PhMe added during 30-60 min., the product held 3 hrs. at 85°, filtered, and the PhMe layer separated and fractionated yielded 95.1% 3,4-dichlorophenyl isothiocyanate, b7.0 134.8-5.9°. 3,4-Br₂C₆H₃NH₂ by the same method yielded 86.5% crude 3,4-dibromophenyl isothiocyanate.

IT 99759-00-9, Urea, 1-(3-diethylaminopropyl)-3-phenyl-
(and its bacteriostatic activity)

RN 99759-00-9 CAPLUS

CN Urea, N-[3-(diethylamino)propyl]-N'-phenyl- (9CI) (CA INDEX NAME)



L38 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 1939:29745 CAPLUS

DOCUMENT NUMBER: 33:29745

ORIGINAL REFERENCE NO.: 33:4199f-i

TITLE: Urethans as local anesthetics. V. Alkyl
γ-diethylaminopropylcarbamates

AUTHOR(S): Shriner, R. L.; Hickey, J. H.

SOURCE: Journal of the American Chemical Society (1939), 61,
888-9

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable


ED Entered STN: 16 Dec 2001

AB cf. C. A. 33, 169.5. γ-Bromopropylphthalimide (I) (50 g.) and 32 g. Et₂NH, refluxed 8 hrs., give γ-diethylaminopropylphthalimide (II), a brown oil, whose HCl salt (56% yield) m. 144-5°. If the reaction product containing II (after removal of excess Et₂NH) is directly hydrolyzed with HCl (boiling 2 hrs. after filtering off the I), there results 48% of γ-diethylaminopropylamine (III), b. 167-70°, d₂₀ 0.8283, n_D 1.4437; phenylthiourea, m. 116-16.5°. Treating a paste of 10 g. III and 8 g. K₂CO₃ in 100 cc. Et₂O and a little H₂O with an alkyl chloroformate in Et₂O with cooling and allowing the mixture to stand 20 hrs. at room temperature give 65-70% of the following alkyl γ-diethylaminopropylcarbamates (values are given for d₂₀, n_D and s (solubility in g./100 g. H₂O at 25°)): Me b₉ 125-7°, d. 0.9713, n 1.4535, s ∞ Et, b₉ 138°, d. 0.9631, n 1.4515, s 12.5; Pr b₁₁ 147-9°, d. 0.9479, n 1.4520, s 5; Bu b₁₁ 158-61°, d. 0.9318, n 1.4519, s 0.9; iso-Bu b₈ 144-7°, d. 0.9310, n 1.4504, s 1.1; Am b₉₋₁₀ 159-63°, d. 0.9304, n 1.4531, s 0.5; iso-Am, b₂ 139-43°, d. 0.9286, n 1.4575, s 0.6; hexyl b₁₀ 172-6°, d. 0.9241, n 1.4540, s 0.2. The pharmacol. data show that the toxicity increases with increase in length of the alkyl group (from 300 to 40 mg./kg. mice on intravenous injection for Me to hexyl); no topical anesthesia was shown until the hexyl derivative was reached; no regular variations in injection anesthesia occur; all these urethans are irritating to some extent.

IT 99759-00-9, Urea, 1-(3-diethylaminopropyl)-3-phenyl-
(preparation of)

RN 99759-00-9 CAPLUS

CN Urea, N-[3-(diethylamino)propyl]-N'-phenyl- (9CI) (CA INDEX NAME)



L38 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:389962 CAPLUS

DOCUMENT NUMBER: 135:266626

TITLE: Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists

AUTHOR(S): Meier, G.; Apelt, J.; Reichert, U.; Grassmann, S.; Ligneau, X.; Elz, S.; Leurquin, F.; Ganellin, C. R.; Schwartz, J.-C.; Schunack, W.; Stark, H.

CORPORATE SOURCE: Institut fur Pharmazie, Freie Universitat Berlin, Berlin, 14195, Germany

SOURCE: European Journal of Pharmaceutical Sciences (2001), 13(3), 249-259

CODEN: EPSCED; ISSN: 0928-0987

PUBLISHER: Elsevier Science Ireland Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 30 May 2001

AB The reference compds. for histamine H3-receptor antagonists carry as a common feature an imidazole moiety substituted in the 4-position. Very recently novel ligands lacking an imidazole ring have been described possessing a N-containing non-aromatic heterocycle instead. In this study we investigated whether imidazole replacement, favorably by a piperidine moiety, is generally applicable to different structural classes of reference compds., e.g., thioperamide, carboperamide, clobenpropit, FUB 181, ciproxifan, etc. While replacement led to a loss of affinity for many of the compds., it was successfully applied to some ether derivs. The piperidine analogs of FUB 181 and ciproxifan, 3-(4-chlorophenyl)propyl 3-piperidinopropyl ether hydrogen oxalate and cyclopropyl 4-(3-piperidinopropoxy)phenyl methanone hydrogen maleate, almost maintained in vitro affinities, pKi values of 7.8 and 8.4, resp., and showed high potency in vivo after p.o. administration (ED50 values of 1.6 and 0.18 mg/kg, resp.).

IT 362665-85-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists)


RN 362665-85-8 CAPLUS

CN 1-Propanamine, N,N-diethyl-3-(3-phenylpropoxy)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 27078-39-3


CMF C16 H27 N O



CM 2

CRN 144-62-7

CMF C2 H2 O4



REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:781497 CAPLUS

DOCUMENT NUMBER: 137:262957

TITLE: Preparation of aryloxyalkylamines as histamine H3 receptor modulators

INVENTOR(S): Schwartz, Jean-Charles; Arrang, Jean-Michel; Garbarg, Monique; Lecomte, Jeanne-Marie; Ligneau, Xavier; Schunack, Walter G.; Stark, Holger; Ganellin, Charon Robin; Leurquin, Fabien; Sigurd, Elz

PATENT ASSIGNEE(S): Societe Civile Bioprojet, Fr.

SOURCE: PCT Int. Appl., 195 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006254	A2	20000210	WO 1999-EP5744	19990729
WO 2000006254	A3	20000504		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 978512	A1	20000209	EP 1998-401944	19980729
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
EP 982300	A2	20000301	EP 1998-403351	19981231
EP 982300	A3	20000308		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
CA 2321881	AA	20000210	CA 1999-2321881	19990729
AU 9955119	A1	20000221	AU 1999-55119	19990729
EP 1100503	A2	20010523	EP 1999-941543	19990729
EP 1100503	B1	20040922		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002521463	T2	20020716	JP 2000-562103	19990729
AT 276751	E	20041015	AT 1999-941543	19990729
US 2004220225	A1	20041104	US 2004-856838	20040601


PRIORITY APPLN. INFO.:

EP 1998-401944	A 19980729
EP 1998-403351	A 19981231
WO 1999-EP5744	W 19990729
US 2001-622199	A3 20010531

OTHER SOURCE(S): MARPAT 137:262957

ED Entered STN: 14 Oct 2002

GI



AB The title non-imidazole compds. I [wherein n = 2-8; m = 0-5; X = O, S; R¹, R² = alkyl, cycloalkyl; NR¹R² = (unsatd.) N-containing ring, substituted piperazino; R³ = halo, alkyl, cycloalkyl, CF₃, aryl, alkoxy, aryloxy, NO₂, CHO, alkanoyl, aroyl, aralkanoyl, amino, carboxamido, cyano, alkoximino, alkenyl, alkynyl, etc.; and their pharmaceutically acceptable salts, hydrates, polymorphic crystalline structures, optical isomers, racemates, diastereoisomers, and enantiomers] were prepared as antagonists and/or agonists of the histamine H₃-receptors. Thus, 1-[3-(4-cyanophenoxy)propyl]piperidine hydrogen oxalate (general preparation given) increased telemethylhistamine in mice with ED₅₀ = 0.20 mg/kg orally. I are useful for the treatment of central nervous system disorders, in particular Alzheimer's disease, mood and attention alterations, cognitive deficits in psychiatric pathologies, obesity, vertigo, and motion sickness (no data).


IT 27078-39-3P 99759-00-9P 362665-85-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(H₃ receptor modulator; preparation of aryloxyalkylamines as histamine H₃ receptor modulators)


RN 27078-39-3 CAPLUS

CN 1-Propanamine, N,N-diethyl-3-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)



RN 99759-00-9 CAPLUS

CN Urea, N-[3-(diethylamino)propyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 362665-85-8 CAPLUS

CN 1-Propanamine, N,N-diethyl-3-(3-phenylpropoxy)-, ethanedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 27078-39-3


CMF C16 H27 N O



CM 2

CRN 144-62-7

CMF C2 H2 O4



L38 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1989:202699 CAPLUS

DOCUMENT NUMBER: 110:202699

TITLE: Color recording material and color imaging method

INVENTOR(S): Shiba, Keisuke; Takahashi, Toshiro; Inoue, Akiyuki

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 43 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 63205653	A2	19880825	JP 1987-37797	19870223
PRIORITY APPLN. INFO.:			JP 1987-37797	19870223

ED Entered STN: 26 May 1989

AB In a color recording material possessing a photosensitive layer containing a Ag halide emulsion and a color coupler(s) on a support, a contrast-improving agent or its precursor which gives color image(s) with $\gamma_{\text{max}} \geq 3$ is incorporated in the material. Color image formation is effected by development in the presence of contrast promoters.


IT 99759-00-9

RL: PROC (Process)

(contrast promoter, photog. development in presence of)

RN 99759-00-9 CAPLUS

CN Urea, N-[3-(diethylamino)propyl]-N'-phenyl- (9CI) (CA INDEX NAME)



L38 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1988:429986 CAPLUS

DOCUMENT NUMBER: 109:29986

TITLE: Color photographic paper for rapid development with color photographic developers containing no benzyl

alcohol
 INVENTOR(S): Asami, Masahiro; Yagihara, Morio
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 29 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62275250	A2	19871130	JP 1986-39467	19860225
JP 62275251	A2	19871130	JP 1986-43452	19860228
JP 06056485	B4	19940727		
JP 62275252	A2	19871130	JP 1986-43453	19860228
JP 62275253	A2	19871130	JP 1986-43455	19860228
PRIORITY APPLN. INFO.:			JP 1986-19110	A1 19860130

ED Entered STN: 22 Jul 1988


AB The color photog. paper is given an amino compound to enable it to be developed within 2.5 min in a color photog. developer containing essentially no benzyl alc. The amino compound such as BuN(CH₂CH₂OH)₂ is included in ≥1 photosensitive layer and/or nonphotosensitive layer of the color photog. paper.

IT 99759-00-9

RL: DEV (Device component use); USES (Uses)
 (color photog. paper containing, for rapid development with color developer containing no benzyl alc.)

RN 99759-00-9 CAPLUS

CN Urea, N-[3-(diethylamino)propyl]-N'-phenyl- (9CI) (CA INDEX NAME)



L38 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1987:565395 CAPLUS

DOCUMENT NUMBER: 107:165395

TITLE: Preparation of photographic photosensitive materials

INVENTOR(S): Tachibana, Noriiku; Ueda, Eiichi; Masuda, Kosaku

PATENT ASSIGNEE(S): Konishiroku Photo Industry Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62056952	A2	19870312	JP 1985-196913	19850906
PRIORITY APPLN. INFO.:			JP 1985-196913	19850906

ED Entered STN: 31 Oct 1987

AB Photog. materials are prepared by coating a support with photog. layers containing hydrophilic colloids in which low mol. weight gelatin and a polymer latex are contained. The photog. layers are coated uniformly, exhibit good phys. properties, and the materials containing them show good photog. and

developing properties. Thus, a Ag halide gelatin emulsion with added Nikkol CCD-4 (collagen peptide; average mol. weight 400) (I) and poly(Et acrylate)) latex (II) was coated on baryta paper, and a gelatin solution containing I and II was then coated thereon to give a photog. material. The emulsion and protective layers had no cissing and foam, and the material showed good photog. properties.

IT 99759-00-9
 RL: USES (Uses)
 (photog. hydrophilic colored layer containing)
 RN 99759-00-9 CAPLUS
 CN Urea, N-[3-(diethylamino)propyl]-N'-phenyl- (9CI) (CA INDEX NAME)




L38 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1987:625933 CAPLUS
 DOCUMENT NUMBER: 107:225933
 TITLE: Ultrahigh-contrast photographic image formation
 INVENTOR(S): Kagami, Kenji; Tamura, Noriyuki
 PATENT ASSIGNEE(S): Oriental Photo Industrial Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62050829	A2	19870305	JP 1985-191256	19850830
PRIORITY APPLN. INFO.:			JP 1985-191256	19850830

ED Entered STN: 12 Dec 1987

AB The title image is formed by exposing a photosensitive material consisting of a support coated with ≥ 1 Ag halide emulsion layers containing ≥ 50 mol% AgBr and RNHNHCOR1 (I; R = aryl; R1 = H, Ph, C1-3 alkyl) and with hydrophilic colloid layers containing I and developing in the presence of R2R3NZZ1CONHR4 (R2, R3 = alkyl, R2-R3 may form a cycle with O, S, NR5; R4 = alkyl, arylene; R5 = alkyl, acyl; Z = alkylene; Z1 = NH, O) or its salts. Thus formed image had high relative sensitivity and γ value.

IT 99759-00-9
 RL: USES (Uses)
 (photog. developer containing, for ultrahigh-contrast image)
 RN 99759-00-9 CAPLUS
 CN Urea, N-[3-(diethylamino)propyl]-N'-phenyl- (9CI) (CA INDEX NAME)



L38 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1986:505677 CAPLUS

DOCUMENT NUMBER: 105:105677
 TITLE: High-contrast development of silver halide photographic material
 INVENTOR(S): Okutsu, Eiichi; Watase, Kazumi
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60218642	A2	19851101	JP 1984-76163	19840416
US 4863830	A	19890905	US 1988-225665	19880729
PRIORITY APPLN. INFO.:			JP 1984-76163	A 19840416
			US 1985-723416	A1 19850415

ED Entered STN: 19 Sep 1986

AB A method of developing an exposed Ag halide photog. material in the presence of a hydrazine derivative comprises using a developer of pH 10.5-12.3 in which (1) a developing agent, (2) ≥ 0.25 mol/L of sulfite, and (3) a compound of the formula RR_1NZR_2 (I: R, R_1 = alkyl or R and R_1 may be combined to form a ring; R_2 = alkyl, aryl, heterocyclic ring; Z = alkylene; Z_1 = CONH, OCONH, NHCONH, NHCO₂, CO₂, OCO, CO, NHCO, SO₂NH, NHSO₂, SO₂, O) are incorporated. In spite of its relatively low pH, the developer enables high-contrast development aided by the hydrazine derivative which works at pH ≥ 12 and has little Ag strain. Thus, 1-formyl-[2,4-[2-(2,4-di-tert-pentylphenoxy)butylamide]phenyl] hydrazide was added to a Ag(Br,Cl) emulsion prepared in presence of a Rh salt (0.3 μ in average size) and coated on a film support. By developing the film with a black-and-white developer with pH 11.4 and containing I [R, R_1 = Et; R_2 = Ph; Z = (CH₂)₃; Z_1 = -NHCONH-], a high-contrast image was obtained.


IT 99759-00-9

RL: USES (Uses)

(high-contrast photog. development of silver halide materials in presence of hydrazine derivative and)

RN 99759-00-9 CAPLUS

CN Urea, N-[3-(diethylamino)propyl]-N'-phenyl- (9CI) (CA INDEX NAME)



L38 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1986:43107 CAPLUS

DOCUMENT NUMBER: 104:43107

TITLE: Silver halide photographic material

INVENTOR(S): Kameoka, Kimitaka; Inagaki, Yoshio; Inoe, Nobuaki

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60140340	A2	19850725	JP 1983-248913	19831228
JP 04002935	B4	19920121		
PRIORITY APPLN. INFO.:			JP 1983-248913	19831228
ED Entered STN: 08 Feb 1986				
GI				



AB A Ag halide photog. material comprises a support bearing ≥ 1 photosensitive Ag halide emulsion layer and contains in ≥ 1 of the emulsion layers or other coated layers an amine derivative in addition to a compound of general formula $R(NH)2ZR1$ [R = aryl; $R1$ = H, aryl, alkyl, alkoxy, aryloxy; Z = carbonyl, sulfonyl, sulfoxy, phosphoryl, (N-substituted)imino]. The material provides an ultrahigh contrast neg. image useful for lithog. by use of a stable processing composition. Thus, a monodisperse Ag(Br,Cl,I) emulsion containing $Rh\ 2.7 + 10^{-7}$ mol/mol Ag was prepared and chemical sensitized with Au + S. The emulsion containing a sensitizing dye, 5-methylbenzotriazole, 4-hydroxy-6-methyl-1,3,3a,7-tetrazaindene, poly(Et acrylate), I, and 2-diethylaminoethanol (II) was coated on a poly(ethylene terephthalate) support to form a lithog. film. The film was then sensitometrically exposed and developed by using a stabilized developer composition containing hydroquinone,

4,4-diethyl-1-phenyl-3-pyrazolidone, and a large amount of Na_2SO_3 to form a dot image which was shown to have high sensitivity, high contrast, and high quality and blackness as compared to a control not employing II along with I.


IT 99759-00-9

RL: USES (Uses)

(lith photog. film containing hydrazine derivative and, for high-contrast images)

RN 99759-00-9 CAPLUS

CN Urea, N-[3-(diethylamino)propyl]-N'-phenyl- (9CI) (CA INDEX NAME)



L38 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1970:403585 CAPLUS

DOCUMENT NUMBER: 73:3585

TITLE: Potential antiarrhythmics related to 2-phenylethanol diethylaminoethyl ether. I. Synthesis

AUTHOR(S): Maillard, Jacques; Langlois, Michel; Meingan, Jean P.; Remond, Georges; Jolly, Raymond

CORPORATE SOURCE: Lab. Jacques Logealis, Issay-les-Moulineaux, Fr.

SOURCE: Chimica Therapeutica (1970), 5(1), 1-9
 CODEN: CHTPBA; ISSN: 0009-4374

DOCUMENT TYPE: Journal

LANGUAGE: French

ED Entered STN: 12 May 1984

GI For diagram(s), see printed CA Issue.

AB Antiarrhythmic aminoalkyl phenylalkyl ethers (I), where n is 2 or 3, R is alkyl or (R₂N =) piperidino; R₁ is alkylene, substituted alkylene, or OCH₂CH₂; and R₃ and (or) R₄ is H, Cl, Me, alkoxy, CF₃, or NH₂, were prepared by treating a 1-dialkylamino-2-chloroalkane with a substituted 2-phenylalkanol Na derivs. I may be converted into its nitro and amino derivs.

IT 27078-39-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 27078-39-3 CAPLUS

CN 1-Propanamine, N,N-diethyl-3-(3-phenylpropoxy) - (9CI) (CA INDEX NAME)

Ph-(CH₂)₃-O-(CH₂)₃-NEt₂

L38 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1960:91741 CAPLUS

DOCUMENT NUMBER: 54:91741

ORIGINAL REFERENCE NO.: 54:17408g-i,17409a-e

TITLE: Relation between chemical structure and local anesthetic action. Potentiation by transformation of barbiturates of local anesthetic action into basic aryl ureas

AUTHOR(S): Chiti, W.

CORPORATE SOURCE: Lab. IBIS, Florence, Italy

SOURCE: Farmaco, Edizione Scientifica (1960), 15, 114-25
 CODEN: FRPSAX; ISSN: 0430-0920

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

ED Entered STN: 22 Apr 2001

AB Adding dropwise with cooling 10.8 g. EtCOCl in 50 cc. C₆H₆ to 28 g. o-ClC₆H₄NH₂ in 100 cc. C₆H₆, refluxing the mixture 1 h., cooling, filtering, drying the filtrate, evaporating in vacuo, taking the residue up in H₂O, extracting with Et₂O, drying, evaporating, distilling at 105-35°/18-20 mm., mixing the distillate with 3 vols. P₂O₅, and distilling gave ochlorophenyl isocyanate, b₄₃ 114-15°. Treating 28 g. p-ClC₆H₄NH₂ and 10.8 g. EtCOCl as described gave (on distillation) p-chlorophenylurethane, b. 66-8° (ligroine), which, distilled with P₂O₅ gave p-chlorophenyl isocyanate (I) b₄₅ 115-17°. Mixing 11.9 g. Ph isocyanate and 11.6 g. Et₂NCH₂CH₂NH₂ in 30 cc. MePh at room temperature, diluting with 50 cc. Et₂O, extracting with dilute HCl, precipitating with Na₂CO₃, extracting the oil with Et₂O, washing, drying, evaporating to dryness, and allowing to stand a few days gave a waxy material of N-(γ-diethylaminoethyl)-N'-phenylurea (II), solidifying at 35°. II was also prepared by dropping the Ph isocyanate into the diamine with a solvent (with stirring), heating 1 h. at 100°, taking up in dilute HCl, and precipitating with Na₂CO₃. Dissolving II in HCl in EtOH, evaporating to dryness, dissolving in H₂O, and adding a saturated solution of

picric acid gave II picrate, m. 149° (boiling H₂O). Distilling II at 16-20 mm. and 195-200° and dissolving the distillate in cold EtOH gave a residue of N,N'-diphenylurea, m. 233-5° (boiling EtOH). The method described gave (from equimolar amts. of Ph isocyanate and Et₂NCH₂CH₂CH₂NH₂) N-(β-diethylaminopropyl)-N'-phenylurea (III), m. 62-5° (ligroine); picrate m. 154-6°. By the same method (in MePh) were prepared: N-(β-diethylaminoethyl)-N'-(p-tolyl)urea (IV), m. 54° (ligroine); N-(β-diethylaminoethyl)-N'-(o-tolyl)urea (V), m. 78-80°; N-(β-diethylaminoethyl)-N'-(2,4-dimethylphenyl)urea, m. 70-2° (ligroine); N-(γ-diethylaminopropyl)-N'-(2,4-dimethylphenyl)urea, m. 69-70° (ligroine); N-(β-diethylaminoethyl)-N'-(p-chlorophenyl)urea, m. 94-6° (ligroine), and N-(β-diethylaminoethyl)-N'-(o-chlorophenyl)urea, m. 58-60° (ligroine). Adding to 23.5 g. II in 200 cc. MePh dropwise 9.8 g. diethylmalonyl chloride in 20 cc. MePh, heating 1 h., decanting the solution from the oily deposit, extracting the solution

with dilute HCl, and evaporating the acid extract to dryness gave 1-(β-diethylaminoethyl)-3-phenyl-5,5-diethylmalonylurea-HCl, m. 189° (BuOH). Adding to 25 g. III in 150 cc. MePh 31.8 g. anhydrous Na₂CO₃ and then dropwise with ice cooling 19.7 g. diethylmalonyl chloride in 50 cc. MePh, stirring 2 h. at room temperature, heating 8 h. on a water bath,


cooling, filtering, extracting the MePh solution with dilute HCl, washing the extract

with MePh, evaporating to dryness, dissolving the residue in BuOH, adding Et₂O, and drying the precipitate formed at 110° gave 1-(γ-diethylamino-propyl)-3-phenyl-5,5-diethylmalonylurea-HCl, m. 15960°; picrate m. 154°. The same method was applied to IV; the HCl salt (requiring a few days to crystallize from BuOH) gave 1-(β-diethylaminoethyl)-3-(p-tolyl)-5,5-diethylmalonylurea-HCl, m. 179-81° (iso-PrOH). V gave the o-tolyl analog, m. 219-21° (iso-BuOH). Also prepared were 1-(β-diethylaminoethyl)-3-(2,4-dimethylphenyl)-5,5-diethylmalonylurea-HCl, m. 170° (iso-PrOH); 1-(γ-diethylaminopropyl)-3-(2,4-dimethylphenyl)-5,5-diethylmalonylurea-HCl, m. 157-8° (iso-PrOH); 1-(β-diethylaminoethyl)-3-(p-chlorophenyl)-5,5-diethylmalonylurea-HCl, m. 153-5° (iso-PrOH); and the o-chlorophenyl analog, m. 220° (iso-PrOH). While the local anesthetic action of the barbitals derivs. was not marked, that of the corresponding urea derivs. was still inferior.

IT 99759-00-9, Urea, 1-(3-diethylaminopropyl)-3-phenyl-
(preparation of)

RN 99759-00-9 CAPLUS

CN Urea, N-[3-(diethylamino)propyl]-N'-phenyl- (9CI) (CA INDEX NAME)



L38 ANSWER 15 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2004:83187 USPATFULL

TITLE: Bombesin antagonists

INVENTOR(S): Higginbottom, Michael, Sandwich, UNITED KINGDOM
Kesten, Suzanne Ross, Ann Arbor, MI, UNITED STATES
Lewthwaite, Russell Andrew, Sandwich, UNITED KINGDOM
Pritchard, Martyn Clive, Sandwich, UNITED KINGDOM
Rawson, David James, Sandwich, UNITED KINGDOM

PATENT ASSIGNEE(S): Schelkun, Robert Michael, Ann Arbor, MI, UNITED STATES
Yuen, Po-Wai, Ann Arbor, MI, UNITED STATES
Pfizer Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004063643	A1	20040401
APPLICATION INFO.:	US 2003-425758	A1	20030428 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-10239	20020503
	US 2002-398132P	20020723 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5369	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Compounds of formula (I): ##STR1##	

and their salts, solvates, prodrugs, etc., wherein the substituents have the values mentioned herein, are bombesin antagonists, which have utility in a variety of therapeutic areas including male and female sexual dysfunction, particularly female sexual dysfunction (FSD) especially wherein the FSD is female sexual arousal disorder (FSAD) and male erectile dysfunction (MED)


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 623570-15-0P

(preparation of urea derivs. as bombesin antagonists)

RN 623570-15-0 USPATFULL

CN Benzenemethanamine, 3-[1-(aminomethyl)cyclohexyl]-N,N-dimethyl-,
dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L38 ANSWER 16 OF 16 USPATFULL on STN

ACCESSION NUMBER: 89:74090 USPATFULL

TITLE: Process for hard tone development of silver halide
photographic light-sensitive material

INVENTOR(S): Okutsu, Eiichi, Kanagawa, Japan
Watase, Kazumi, Kanagawa, Japan

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Kanagawa, Japan (non-U.S.
corporation)

NUMBER	KIND	DATE
--------	------	------

 PATENT INFORMATION: US 4863830 19890905
 APPLICATION INFO.: US 1988-225665 19880729 (7)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1985-723416, filed on 15
 Apr 1985, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1984-76163	19840416
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Schilling, Richard L.	
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak & Seas	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	714	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for hard tone development of a silver halide photographic light-sensitive material is described, comprising developing an imagewise exposed negative type silver halide photographic light-sensitive material in the presence of hydrazine, using a developing solution comprising (1) a developing agent, (2) 0.25 mol/l or more of sulfite and (3) a compound represented by the general formula (I) and having a pH value of 10.5 to 12.3: ##STR1## wherein R.sub.1 and R.sub.2 represent each an alkyl group of R.sub.1 and R.sub.2 may form a ring by linking each other, R.sub.3 represents an alkyl group, an aryl group or a heterocyclic group, and R.sub.1, R.sub.2 and R.sub.3 may have substituents, A represents an alkylene group which may be substituted, and X represents --CONH--, --OCONH--, --NHCONH--, --NHCOO--, --COO--, --OCO--, --CO--, --NHCO--, --SO.sub.2 NH--, --NHSO.sub.2 --, --SO.sub.2 --or --O--.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99759-00-9

(high-contrast photog. development of silver halide materials in presence of hydrazine derivative and)

RN 99759-00-9 USPATFULL

CN Urea, N-[3-(diethylamino)propyl]-N'-phenyl- (9CI) (CA INDEX NAME)



=> fil beil; s 136

FILE BEILSTEIN ENTERED AT 16:12:24 ON 06 JUN 2005

COPYRIGHT (c) 2005 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE RELOADED ON OCTOBER 20, 2002

FILE LAST UPDATED ON APRIL 21, 2005

FILE COVERS 1771 TO 2004.

*** FILE CONTAINS 9,218,366 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query.

Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For more detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *

NEW


* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.
* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

L39 2 L36

=> d ide allref l39 1-2; fil cao; s l36

L39 ANSWER 1 OF 2 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN

Beilstein Records (BRN):	2730958
Beilstein Pref. RN (BPR):	99759-00-9
CAS Reg. No. (RN):	99759-00-9
Chemical Name (CN):	N-(3-diethylamino-propyl)-N'-phenyl-urea
Autonom Name (AUN):	1-(3-diethylamino-propyl)-3-phenyl-urea
Molec. Formula (MF):	C14 H23 N3 O
Molecular Weight (MW):	249.36
Lawson Number (LN):	14131, 3027, 2826, 1762
Compound Type (CTYPE):	isocyclic
Constitution ID (CONSID):	2470784
Tautomer ID (TAUTID):	2628008
Beilstein Citation (BSO):	4-12-00-00763, 5-12
Entry Date (DED):	1989/07/11
Update Date (DUPD):	1992/06/02



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	4
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	2
DED	Entry Date	1
DUPD	Update Date	1
CDER	Chemical Derivative	1
MP	Melting Point	2

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	2
RXREA	Substance is Reaction Reactant	1
RXPRO	Substance is Reaction Product	1

All References:


ALLREF

1. Chiti, Farmaco Ed.Sci., CODEN: FRPSAX, 15, <1960>, 114,122
2. Beaver et al., J.Amer.Chem.Soc., CODEN: JACSAT, 79, <1957>, 1236,1242, J.Org.Chem., CODEN: JOCEAH, 24, <1959>, 1676

L39 ANSWER 2 OF 2 BEILSTEIN COPYRIGHT 2005 BEILSTEIN MDL on STN

Beilstein Records (BRN): 2452356
 Beilstein Pref. RN (BPR): 27078-39-3
 CAS Reg. No. (RN): 27078-39-3
 Chemical Name (CN): 3-(diethylamino)propyl 3-phenylpropyl ether
 Autonom Name (AUN): diethyl-<3-(3-phenyl-propoxy)-propyl>-amine
 Molec. Formula (MF): C16 H27 N O
 Molecular Weight (MW): 249.40

Lawson Number (LN):	5246, 3131, 2826
Compound Type (CTYPE):	isocyclic
Constitution ID (CONSID):	2234019
Tautomer ID (TAUTID):	2337018
Beilstein Citation (BSO):	5-06
Entry Date (DED):	1989/07/05
Update Date (DUPD):	2002/04/29



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	3
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
DED	Entry Date	1
DUPD	Update Date	1
BP	Boiling Point	1
CDER	Chemical Derivative	1
XREF	Crossfile Reference	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	2
RXPRO	Substance is Reaction Product	2

All References:

ALLREF


1. Meier, Galina; Apelt, Joachim; Reichert, Ulrich; Grassmann, Sven; Ligneau, Xavier; Elz, Sigurd; Leurquin, Fabien; Ganellin, C. Robin; Schwartz, Jean-Charles; Schunack, Walter; Stark, Holger, Eur.J.Pharm.Sci., CODEN: EPSCED, 13(3), <2001>, 249 - 260; BABS-6316934
2. Maillard, J. et al., Chim.Ther., CODEN: CHTPBA, 5, <1970>, 1-9

13098-68-5	13114-83-5	13142-26-2	13142-50-2	13142-82-0
13143-07-2	13208-22-5	13252-26-1	13256-73-0	13262-48-1
14628-79-6	15093-49-9	15093-54-6	15863-25-9	15863-28-2
16655-17-7	16655-18-8	16655-19-9	16655-20-2	16655-21-3
16655-24-6	17738-59-9	18981-89-0	18981-90-3	18982-71-3
18982-72-4	18982-73-5	18982-74-6	19010-53-8	20049-73-4
20461-04-5	25417-47-4	27098-56-2	28478-77-5	33102-63-5
35640-08-5	36034-83-0	36903-84-1	38044-61-0	38045-03-3
38045-04-4	42160-05-4	49755-03-5	52625-27-1	52696-84-1
53723-87-8	54405-33-3	55268-52-5	55346-81-1	56661-50-8
57883-93-9	58351-66-9	72802-48-3	73953-75-0	76958-90-2
82200-77-9	87919-21-9	87919-26-4	87919-35-5	89609-46-1
91025-98-8	91430-53-4	92961-10-9	95533-58-7	95745-38-3
95766-89-5	96462-93-0	96463-04-6	96463-81-9	96583-27-6
97028-41-6	97194-12-2	98588-80-8	99357-01-4	99357-18-3
99360-34-6	99514-07-5	99759-00-9	99979-42-7	
99982-04-4	100123-93-1	100398-88-7	100614-62-8	100614-70-8
100615-32-5	100623-41-4	100726-75-8	100793-82-6	100793-83-7
100800-79-1	100865-63-2	100957-93-5	101081-76-9	101095-38-9
101112-22-5	101273-10-3	101273-20-5	101423-59-0	101423-78-3
101446-85-9	101574-01-0	101578-08-9	101578-25-0	101936-00-9
101955-46-8	102081-10-7	102184-51-0	102314-60-3	102318-23-0
102319-56-2	102375-14-4	102883-21-6	102888-03-9	102899-11-6
102953-22-0	103151-81-1	103395-38-6	103754-47-8	103862-76-6
104116-14-5	105908-83-6	105912-49-0	106472-18-8	106472-37-1
106522-45-6	106737-64-8	107774-89-0	107776-97-6	107917-40-8
108238-76-2	108757-40-0	108841-82-3	108923-28-0	108971-40-0
108975-29-7	109245-35-4	109471-29-6	109596-88-5	109614-17-7
109614-81-5	109693-58-5	109726-56-9	109806-11-3	110145-13-6
110145-14-7	110146-17-3	110244-04-7	110245-41-5	110332-08-6
110375-77-4	112442-84-9	113491-87-5	113863-42-6	114160-59-7
114160-73-5	114888-86-7	115049-58-6	115293-14-6	120547-68-4
120582-37-8	121975-58-4	122703-48-4	124157-70-6	131977-06-5
132346-16-8	133044-01-6			

IT **99759-00-9**

RN 99759-00-9 CAOLD

CN Urea, N-[3-(diethylamino)propyl]-N'-phenyl- (9CI) (CA INDEX NAME)



=> fil hom

FILE 'HOME' ENTERED AT 16:13:16 ON 06 JUN 2005

=>

FILE 'CAOLD' ENTERED AT 16:13:00 ON 06 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.


New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L40 2 L36

=> diall hitstr l40 1-2

L40 ANSWER 1 OF 2 CAOLD COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: CA54:17408g CAOLD
TITLE: relation between chemical structure and local anesthetic action-potential by transformation of barbiturates of local anesthetic action into basic aryl ureas
AUTHOR NAME: Chiti, Walter
INDEX TERM: 104-12-1 2621-80-9 4559-89-1 14574-55-1
99759-00-9 107057-85-2 107057-86-3 108012-33-5
108013-40-7 108236-72-2 109813-44-7 112248-78-9 114329-07-6
114330-93-7 114585-29-4 115000-37-8 115272-94-1 119150-17-3
119185-31-8 124162-85-2 132465-59-9
IT 99759-00-9
RN 99759-00-9 CAOLD
CN Urea, N-[3-(diethylamino)propyl]-N'-phenyl- (9CI) (CA INDEX NAME)



L40 ANSWER 2 OF 2 CAOLD COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: CA51:11268b CAOLD
TITLE: preparation and bacteriostatic activity of substituted ureas
AUTHOR NAME: Beaver, David J.; Roman, D. P.; Stoffel, P. J.
INDEX TERM: 101-20-2 102-36-3 607-56-7 722-03-2 886-59-9
1219-99-4 1677-30-1 1756-43-0 1932-37-2 1967-26-6
2008-73-3 2302-14-9 2327-02-8 2353-25-5 2387-23-7
2448-04-6 2589-21-1 2617-72-3 2680-85-5 3035-41-4
3185-71-5 4300-34-9 4300-43-0 4345-85-1 4559-92-6
4575-37-5 5006-82-6 5109-07-9 5441-80-5 5663-04-7
5765-54-8 5779-20-4 6299-42-9 6335-93-9 6950-84-1
10141-46-5 10220-13-0 10286-79-0 13041-45-7 13041-52-6






=> d stat que 171; d his full

```

L19      1757 SEA FILE=CAPLUS ABB=ON WAKEFULNESS/BI
L21      13480 SEA FILE=CAPLUS ABB=ON MEMORY, BIOLOGICAL/CT
L22      7452 SEA FILE=CAPLUS ABB=ON COGNITION/CW
L23      2672 SEA FILE=CAPLUS ABB=ON MENTAL/CW(L) ATTENTION/OBI
L24      1385 SEA FILE=CAPLUS ABB=ON SLEEP/OBI(L) (WAKING/OBI OR WAKE/OBI)
L25      257 SEA FILE=CAPLUS ABB=ON SLEEPINESS/OBI
L27      2816 SEA FILE=CAPLUS ABB=ON L19 OR L24 OR L25
L28      TRANSFER L27 1- RN : 8252 TERMS
L29      8252 SEA FILE=REGISTRY ABB=ON L28
L30      TRANSFER L22 1- RN : 51186 TERMS (TERM LIMIT EXCEEDED)
L31      51186 SEA FILE=REGISTRY ABB=ON L30
L33      618 SEA FILE=CAPLUS ABB=ON L21 AND L23
L34      TRANSFER L33 1- RN : 30814 TERMS
L35      30814 SEA FILE=REGISTRY ABB=ON L34
L36      12862 SEA FILE=CAPLUS ABB=ON L21 NOT L23
L39      3950 SEA FILE=CAPLUS RAN=(,1992) ABB=ON L36 NOT (L19 OR L23 OR L24
OR L25)
L40      5462 SEA FILE=CAPLUS RAN=(,2001) ABB=ON L36 NOT L39
L41      3450 SEA FILE=CAPLUS ABB=ON L36 NOT (L39 OR L40)
L42      TRANSFER L39 1- RN : 9163 TERMS
L43      9162 SEA FILE=REGISTRY ABB=ON L42
L44      TRANSFER L40 1- RN : 20267 TERMS
L45      20267 SEA FILE=REGISTRY ABB=ON L44
L46      TRANSFER L41 1- RN : 42655 TERMS
L47      42655 SEA FILE=REGISTRY ABB=ON L46
L48      1597 SEA FILE=CAPLUS ABB=ON L23 NOT (L21 OR L19 OR L22 OR (L24 OR
L25))
L49      TRANSFER L48 1- RN : 27797 TERMS
L50      27797 SEA FILE=REGISTRY ABB=ON L49
L51      150742 SEA FILE=REGISTRY ABB=ON L29 OR L31 OR L35 OR L43 OR L45 OR
L47 OR L50
L53      STR

```

G1~Ak
1 25



VAR G1=3/6/9/14/20

REP G2=(1-5) C

REP G3=(1-2) CH

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 2

CONNECT IS E1 RC AT 4

CONNECT IS E2 RC AT 25

DEFAULT MLEVEL IS ATOM

GGCAT IS SAT AT 25

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:



RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L55 20417 SEA FILE=REGISTRY SUB=L51 SSS FUL L53

L66 STR



VAR G1=11/32/36/34

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 13

CONNECT IS E1 RC AT 35

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 36

STEREO ATTRIBUTES: NONE

L67 STR



VAR G1=9/21

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 11

CONNECT IS E1 RC AT 12


CONNECT IS E1 RC AT 23

CONNECT IS E1 RC AT 24

DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 22


STEREO ATTRIBUTES: NONE
L68 STR



REP G1=(0-1) C
VAR G2=11/13
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
L69 STR



VAR G1=NH2/CY/9/11
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 7
CONNECT IS E2 RC AT 14
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE
L71 5921 SEA FILE=REGISTRY SUB=L55 SSS FUL (L66 OR L67 OR L68 OR L69)

100.0% PROCESSED 18726 ITERATIONS
SEARCH TIME: 00.00.01

5921 ANSWERS

(FILE 'HOME' ENTERED AT 12:06:49 ON 06 JUN 2005)

FILE 'CAPLUS' ENTERED AT 12:07:35 ON 06 JUN 2005

SET LINE 250
SET DETAIL OFF
E US2003-622199/AP,PRN 25
SET LINE LOGIN
SET DETAIL LOGIN

FILE 'STNGUIDE' ENTERED AT 12:08:04 ON 06 JUN 2005

FILE 'CAPLUS' ENTERED AT 12:09:30 ON 06 JUN 2005

L1 2934 SEA ABB=ON SCHWARTZ J?/AU
L2 126 SEA ABB=ON ARRANG J?/AU
L3 113 SEA ABB=ON L1 AND L2
L4 136 SEA ABB=ON GARBARG M?/AU
L5 50 SEA ABB=ON L3 AND L4
L6 1113 SEA ABB=ON LECOMTE J?/AU
E LE COMTE J/AU
L7 2 SEA ABB=ON LE COMTE J?/AU
L8 14 SEA ABB=ON L5 AND (L6 OR L7)
D SCAN TI
L9 4 SEA ABB=ON LIGAND#/TI AND L8
SEL RN

FILE 'REGISTRY' ENTERED AT 12:11:23 ON 06 JUN 2005

L10 530 SEA ABB=ON (106243-16-7/BI OR 75614-87-8/BI OR 10041-02-8/BI
OR 1009-11-6/BI OR 102-29-4/BI OR 102676-60-8/BI OR 102676-61-9
/BI OR 103-72-0/BI OR 104-98-3/BI OR 106-44-5/BI OR 106-47-8/BI
OR 106-94-5/BI OR 106-95-6/BI OR 106-96-7/BI OR 107-82-4/BI
OR 1070-83-3/BI OR 1072-95-3/BI OR 1073-72-9/BI OR 1074-59-5/BI
OR 108-88-3/BI OR 109293-16-5/BI OR 110-78-1/BI OR 111-36-4/BI
OR 1119-51-3/BI OR 1137-42-4/BI OR 119507-55-0/BI OR 122246-22
-4/BI OR 123-07-9/BI OR 123-08-0/BI OR 127607-62-9/BI OR
129378-52-5/BI OR 13103-80-5/BI OR 131056-82-1/BI OR 132740-43-
3/BI OR 13518-55-3/BI OR 13939-69-0/BI OR 141-82-2/BI OR
142-62-1/BI OR 14267-92-6/BI OR 142688-48-0/BI OR 1476-23-9/BI
OR 149647-72-3/BI OR 150-76-5/BI OR 15020-57-2/BI OR 152028-81-
4/BI OR 152029-84-0/BI OR 152029-85-1/BI OR 152030-49-4/BI OR
157135-85-8/BI OR 1609-86-5/BI OR 1611-65-0/BI OR 16545-68-9/BI
OR 1667-11-4/BI OR 170651-15-7/BI OR 174095-02-4/BI OR
174095-03-5/BI OR 174095-08-0/BI OR 174095-09-1/BI OR 174095-16
-0/BI OR 174095-17-1/BI OR 174095-22-8/BI OR 174095-23-9/BI OR
174583-09-6/BI OR 177708-10-0/BI OR 177708-14-4/BI OR 178056-76
-3/BI OR 1795-48-8/BI OR 180306-92-7/BI OR 180307-01-1/BI OR
182068-99-1/BI OR 182069-00-7/BI OR 182069-04-1/BI OR 182069-05
-2/BI OR 182069-10-9/BI OR 182069-11-0/BI OR 183155-86-4/BI OR
183155-87-5/BI OR 183155-96-6/BI OR 183155-97-7/BI OR 183155-98
-8/BI OR 183155-99-9/BI OR 183156-00-5/BI OR 184020-25-5/BI OR
184020-26-6/BI OR 184020-31-3/BI OR 184020-32-4/BI OR 184020-38
-0/BI OR 184020-39-1/BI OR 184020-45-9/BI OR 184020-46-0/BI OR
184020-52-8/BI OR 184020-53-9/BI OR 184020-57-3/BI OR 184020-58
-4/BI OR 184020-64-2/BI OR 184020-65-3/BI OR 184020-67-5/BI OR
184020-68-6/BI OR 184020-71-1/BI OR 184020-72-2/BI OR 184020-76
-6/BI OR 184020-77-7/BI OR 184020-83-5/BI OR 184020-84-6/BI OR
184020-89-1/BI OR 184020-90-4/BI OR 184020-95-9/BI OR 184020-96
-0/BI OR 184021-01-0/BI OR 184021-02-1/BI OR 184021-08-7/BI OR

184021-09-8/BI OR 184021-17-8/BI OR 184021-18-9/BI OR 184021-28
-1/BI OR 184021-29-2/BI OR 184021-35-0/BI OR
L11 417 SEA ABB=ON L10 AND N/ELS AND RSD/FA
L12 1325 SEA ABB=ON PIPERIDINOPROPYL
L13 0 SEA ABB=ON L11 AND L12
L14 834672 SEA ABB=ON PIPERIDIN?
L15 4 SEA ABB=ON L11 AND L14
D SCAN

FILE 'CAPLUS' ENTERED AT 12:16:08 ON 06 JUN 2005
L16 13 SEA ABB=ON L8 AND H3/OBI
D SCAN

FILE 'STNGUIDE' ENTERED AT 12:16:39 ON 06 JUN 2005

FILE 'LCA' ENTERED AT 12:26:54 ON 06 JUN 2005
L17 0 SEA ABB=ON WAKEFULNESS
L18 3 SEA ABB=ON WAKEFULNESS
D SCAN

FILE 'CAPLUS' ENTERED AT 12:27:35 ON 06 JUN 2005
L19 1757 SEA ABB=ON WAKEFULNESS/BI
L20 9 SEA ABB=ON (L1 OR L2 OR L4 OR (L6 OR L7)) AND L19
D SCAN
E MEMORY, BIOLOGICAL+ALL/CT
E COGNITION ENHANCERS+ALL/CT
L21 13480 SEA ABB=ON MEMORY, BIOLOGICAL/CT
L22 7452 SEA ABB=ON COGNITION/CW
L23 2672 SEA ABB=ON MENTAL/CW(L) ATTENTION/OBI
L24 1385 SEA ABB=ON SLEEP/OBI(L) (WAKING/OBI OR WAKE/OBI)
L25 257 SEA ABB=ON SLEEPINESS/OBI
L26 23239 SEA ABB=ON (L19 OR (L21 OR L22 OR L23 OR L24 OR L25))

FILE 'REGISTRY' ENTERED AT 12:32:30 ON 06 JUN 2005

FILE 'CAPLUS' ENTERED AT 12:32:41 ON 06 JUN 2005

FILE 'REGISTRY' ENTERED AT 12:33:27 ON 06 JUN 2005
L*** DEL TRA L26 1- RN : 50628 TERMS

FILE 'REGISTRY' ENTERED AT 12:33:27 ON 06 JUN 2005

FILE 'CAPLUS' ENTERED AT 12:36:53 ON 06 JUN 2005
L27 2816 SEA ABB=ON L19 OR L24 OR L25

FILE 'REGISTRY' ENTERED AT 12:38:49 ON 06 JUN 2005

FILE 'CAPLUS' ENTERED AT 12:39:02 ON 06 JUN 2005
L28 TRA L27 1- RN : 8252 TERMS

FILE 'REGISTRY' ENTERED AT 12:40:03 ON 06 JUN 2005
L29 8252 SEA ABB=ON L28

FILE 'CAPLUS' ENTERED AT 12:41:10 ON 06 JUN 2005

FILE 'REGISTRY' ENTERED AT 12:41:50 ON 06 JUN 2005
L30 TRA L22 1- RN : 51186 TERMS

FILE 'REGISTRY, REGISTRY' ENTERED AT 12:41:50 ON 06 JUN 2005
L31 51186 SEA ABB=ON L30

FILE 'CAPLUS' ENTERED AT 12:45:37 ON 06 JUN 2005

L32 FILE 'REGISTRY' ENTERED AT 12:46:16 ON 06 JUN 2005
TRA L23 1- RN : 50646 TERMS

FILE 'REGISTRY' ENTERED AT 12:46:16 ON 06 JUN 2005

L33 FILE 'CAPLUS' ENTERED AT 12:47:05 ON 06 JUN 2005
618 SEA ABB=ON L21 AND L23

FILE 'REGISTRY' ENTERED AT 12:47:20 ON 06 JUN 2005

L34 FILE 'CAPLUS' ENTERED AT 12:47:20 ON 06 JUN 2005
TRA L33 1- RN : 30814 TERMS

L35 FILE 'REGISTRY' ENTERED AT 12:47:44 ON 06 JUN 2005
30814 SEA ABB=ON L34

L36 FILE 'CAPLUS' ENTERED AT 12:49:49 ON 06 JUN 2005
12862 SEA ABB=ON L21 NOT L23

FILE 'REGISTRY' ENTERED AT 12:50:05 ON 06 JUN 2005

FILE 'CAPLUS' ENTERED AT 12:50:05 ON 06 JUN 2005

L37 FILE 'REGISTRY' ENTERED AT 12:51:45 ON 06 JUN 2005
TRA L36 1- RN : 50460 TERMS

FILE 'REGISTRY' ENTERED AT 12:51:46 ON 06 JUN 2005

L38 FILE 'CAPLUS' ENTERED AT 12:52:30 ON 06 JUN 2005
12828 SEA ABB=ON L36 NOT (L19 OR L23 OR L24 OR L25)
D L38 AN 4000, 9000

L39 3950 SEA RAN=(,1992) ABB=ON L36 NOT (L19 OR L23 OR L24 OR L25)

L40 5462 SEA RAN=(,2001) ABB=ON L36 NOT L39

L41 3450 SEA ABB=ON L36 NOT (L39 OR L40)

FILE 'REGISTRY' ENTERED AT 12:55:02 ON 06 JUN 2005

L42 FILE 'CAPLUS' ENTERED AT 12:55:02 ON 06 JUN 2005
TRA L39 1- RN : 9163 TERMS

L43 FILE 'REGISTRY' ENTERED AT 12:56:01 ON 06 JUN 2005
9162 SEA ABB=ON L42

L44 FILE 'CAPLUS' ENTERED AT 12:57:00 ON 06 JUN 2005
TRA L40 1- RN : 20267 TERMS

L45 FILE 'REGISTRY' ENTERED AT 12:58:12 ON 06 JUN 2005
20267 SEA ABB=ON L44

FILE 'STNGUIDE' ENTERED AT 13:00:14 ON 06 JUN 2005

FILE 'REGISTRY' ENTERED AT 13:04:31 ON 06 JUN 2005

L46 FILE 'CAPLUS' ENTERED AT 13:04:31 ON 06 JUN 2005
TRA L41 1- RN : 42655 TERMS

FILE 'REGISTRY' ENTERED AT 13:05:21 ON 06 JUN 2005

L47 42655 SEA ABB=ON L46

FILE 'STNGUIDE' ENTERED AT 13:09:28 ON 06 JUN 2005

FILE 'CAPLUS' ENTERED AT 13:15:55 ON 06 JUN 2005

L48 1597 SEA ABB=ON L23 NOT (L21 OR L19 OR L22 OR (L24 OR L25))

FILE 'REGISTRY' ENTERED AT 13:16:37 ON 06 JUN 2005

FILE 'CAPLUS' ENTERED AT 13:16:37 ON 06 JUN 2005

L49 TRA L48 1- RN : 27797 TERMS

FILE 'REGISTRY' ENTERED AT 13:17:18 ON 06 JUN 2005

L50 27797 SEA ABB=ON L49

L51 150742 SEA ABB=ON L29 OR L31 OR L35 OR L43 OR L45 OR L47 OR L50

L52 STR

L53 STR L52

L54 50 SEA SUB=L51 SSS SAM L53

L55 20417 SEA SUB=L51 SSS FUL L53

SAVE TEMP L55 SEA199FULL/A

FILE 'CAPLUS' ENTERED AT 13:57:26 ON 06 JUN 2005

L56 268141 SEA ABB=ON L55

L57 3062 SEA ABB=ON (L19 OR (L21 OR L22 OR L23 OR L24 OR L25)) AND L56

L58 1265 SEA ABB=ON H3/OBI(L)RECEPTOR#/OBI

L59 72 SEA ABB=ON L57 AND L58

L60 180 SEA ABB=ON L56 AND L19

L61 1507 SEA ABB=ON L56 AND L21

L62 1385 SEA ABB=ON L56 AND L22

L63 579 SEA ABB=ON L56 AND L23

L64 151 SEA ABB=ON L56 AND L24

L65 59 SEA ABB=ON L56 AND L25

FILE 'REGISTRY' ENTERED AT 14:07:25 ON 06 JUN 2005

L66 STR

L67 STR

L68 STR

L69 STR

L70 50 SEA SUB=L55 SSS SAM (L66 OR L67 OR L68 OR L69)

L71 5921 SEA SUB=L55 SSS FUL (L66 OR L67 OR L68 OR L69)

SAVE TEMP L71 SEA199SUB1/A

FILE 'CAPLUS' ENTERED AT 14:17:36 ON 06 JUN 2005

L72 5 SEA ABB=ON WAKEFULLNESS/OBI

L73 34331 SEA ABB=ON L71

L74 879 SEA ABB=ON L73 AND (L19 OR (L21 OR L22 OR L23 OR L24 OR L25))

L75 37 SEA ABB=ON L74 AND L58

L76 39 SEA ABB=ON L73 AND L19

L77 352 SEA ABB=ON L73 AND L21

L78 491 SEA ABB=ON L73 AND L22

L79 215 SEA ABB=ON L73 AND L23

L80 36 SEA ABB=ON L73 AND L24

L81 22 SEA ABB=ON L73 AND L25

L82 3357 SEA ABB=ON (L19 AND (L21 OR L22 OR L23 OR L24 OR L25)) OR
(L21 AND (L22 OR L23 OR L24 OR L25)) OR (L22 AND (L23 OR L24
OR L25)) OR (L23 AND (L24 OR L25)) OR (L24 AND L25)

L83 224 SEA ABB=ON L82 AND L73

L84 0 SEA ABB=ON L19 AND L21 AND L22 AND L23 AND L24 AND L25

L85 D QUE
5 SEA ABB=ON (L19 OR L24 OR L25) AND L21 AND L22 AND L23
L86 2 SEA ABB=ON L85 AND L73
D QUE NOS L75

FILE 'REGISTRY' ENTERED AT 14:21:39 ON 06 JUN 2005
D STAT QUE L71

FILE 'CAPLUS' ENTERED AT 14:21:39 ON 06 JUN 2005
D QUE NOS L86
D QUE NOS L75
L87 38 SEA ABB=ON L86 OR L75
D IBIB ED ABS HITSTR L87 1-38
D STAT QUE L71

FILE HOME

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Jun 2005 VOL 142 ISS 24
FILE LAST UPDATED: 5 Jun 2005 (20050605/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 3, 2005 (20050603/UP).

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JUN 2005 HIGHEST RN 851662-51-6
DICTIONARY FILE UPDATES: 5 JUN 2005 HIGHEST RN 851662-51-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *

* effective March 20, 2005. A new display format, IDERL, is now *
 * available and contains the CA role and document type information. *
 *

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>


FILE LCA
 LCA IS A STATIC LEARNING FILE

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE
 SUBSTANCE IDENTIFICATION.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
 substance identification.

```
=> => d stat que l36; d his full
L1 (      1757)SEA FILE=CAPLUS ABB=ON  WAKEFULNESS/BI
L2 (     13480)SEA FILE=CAPLUS ABB=ON  MEMORY, BIOLOGICAL/CT
L3 (      7452)SEA FILE=CAPLUS ABB=ON  COGNITION/CW
L4 (     2672)SEA FILE=CAPLUS ABB=ON  MENTAL/CW(L) ATTENTION/OBI
L5 (     1385)SEA FILE=CAPLUS ABB=ON  SLEEP/OBI(L) (WAKING/OBI OR WAKE/OBI)
L6 (      257)SEA FILE=CAPLUS ABB=ON  SLEEPINESS/OBI
L7 (     2816)SEA FILE=CAPLUS ABB=ON  L1 OR L5 OR L6
L8          SEL  L7 1- RN :      8252 TERMS
L9 (     8252)SEA FILE=REGISTRY ABB=ON  L8
L10         SEL  L3 1- RN :     51186 TERMS (TERM LIMIT EXCEEDED)
L11 (    51186)SEA FILE=REGISTRY ABB=ON  L10
L12 (      618)SEA FILE=CAPLUS ABB=ON  L2 AND L4
L13         SEL  L12 1- RN :     30814 TERMS
L14 (    30814)SEA FILE=REGISTRY ABB=ON  L13
L15 (    12862)SEA FILE=CAPLUS ABB=ON  L2 NOT L4
L16 (     3950)SEA FILE=CAPLUS RAN=(,1992) ABB=ON  L15 NOT (L1 OR L4 OR L5 OR
L6)
L17 (     5462)SEA FILE=CAPLUS RAN=(,2001) ABB=ON  L15 NOT L16
L18 (     3450)SEA FILE=CAPLUS ABB=ON  L15 NOT (L16 OR L17)
L19         SEL  L16 1- RN :      9163 TERMS
L20 (     9162)SEA FILE=REGISTRY ABB=ON  L19
L21         SEL  L17 1- RN :     20267 TERMS
L22 (    20267)SEA FILE=REGISTRY ABB=ON  L21
L23         SEL  L18 1- RN :     42655 TERMS
L24 (    42655)SEA FILE=REGISTRY ABB=ON  L23
L25 (     1597)SEA FILE=CAPLUS ABB=ON  L4 NOT (L2 OR L1 OR L3 OR (L5 OR L6))
L26         SEL  L25 1- RN :     27797 TERMS
L27 (    27797)SEA FILE=REGISTRY ABB=ON  L26
L28 (   150742)SEA FILE=REGISTRY ABB=ON  L9 OR L11 OR L14 OR L20 OR L22 OR
L24 OR L27
L29         STR
```



VAR G1=3/6/9/14/20

REP G2=(1-5) C

REP G3=(1-2) CH

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 2

CONNECT IS E1 RC AT 4

CONNECT IS E2 RC AT 25

DEFAULT MLEVEL IS ATOM

GGCAT IS SAT AT 25

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L30 20417 SEA FILE=REGISTRY SUB=L28 SSS FUL L29


L31 STR



VAR G1=NH2/49/50/PH/24/54/52/46
 REP G2=(0-1) CH2
 NODE ATTRIBUTES:
 CONNECT IS E2 RC AT 7
 CONNECT IS E2 RC AT 27
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS E6 C AT 28

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 56

STEREO ATTRIBUTES: NONE
 L32 STR



VAR G1=60/61/53/15/64/25/27

REP G2=(0-1) CH2

VAR G3=CH2/57

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 7

CONNECT IS E2 RC AT 27

CONNECT IS E2 RC AT 53

CONNECT IS E1 RC AT 60

CONNECT IS E2 RC AT 61

CONNECT IS E1 RC AT 63

DEFAULT MLEVEL IS ATOM

GGCAT IS SAT AT 28

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 41

STEREO ATTRIBUTES: NONE

L33 STR



VAR G1=5/8

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 1

CONNECT IS E2 RC AT 3

CONNECT IS E2 RC AT 6

CONNECT IS E1 RC AT 12
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L36 4 SEA FILE=REGISTRY SUB=L30 SSS FUL (L31 OR L32 OR L33)

100.0% PROCESSED 19049 ITERATIONS
 SEARCH TIME: 00.00.01

4 ANSWERS

(FILE 'HOME' ENTERED AT 15:56:31 ON 06 JUN 2005)

FILE 'REGISTRY' ENTERED AT 15:57:06 ON 06 JUN 2005

D SAVED

ACT SEA199FULL/A

```

L1 ( 1757)SEA ABB=ON WAKEFULNESS/BI
L2 ( 13480)SEA ABB=ON MEMORY, BIOLOGICAL/CT
L3 ( 7452)SEA ABB=ON COGNITION/CW
L4 ( 2672)SEA ABB=ON MENTAL/CW(L)ATTENTION/OBI
L5 ( 1385)SEA ABB=ON SLEEP/OBI(L) (WAKING/OBI OR WAKE/OBI)
L6 ( 257)SEA ABB=ON SLEEPINESS/OBI
L7 ( 2816)SEA ABB=ON L1 OR L5 OR L6
L8 SEL L7 1- RN : 8252 TERMS
L9 ( 8252)SEA ABB=ON L8
L10 SEL L3 1- RN : 51186 TERMS (TERM LIMIT EXCEEDED)
L11 ( 51186)SEA ABB=ON L10
L12 ( 618)SEA ABB=ON L2 AND L4
L13 SEL L12 1- RN : 30814 TERMS
L14 ( 30814)SEA ABB=ON L13
L15 ( 12862)SEA ABB=ON L2 NOT L4
L16 ( 3950)SEA RAN=(,1992) ABB=ON L15 NOT (L1 OR L4 OR L5 OR L6)
L17 ( 5462)SEA RAN=(,2001) ABB=ON L15 NOT L16
L18 ( 3450)SEA ABB=ON L15 NOT (L16 OR L17)
L19 SEL L16 1- RN : 9163 TERMS
L20 ( 9162)SEA ABB=ON L19
L21 SEL L17 1- RN : 20267 TERMS
L22 ( 20267)SEA ABB=ON L21
L23 SEL L18 1- RN : 42655 TERMS
L24 ( 42655)SEA ABB=ON L23
L25 ( 1597)SEA ABB=ON L4 NOT (L2 OR L1 OR L3 OR (L5 OR L6))
L26 SEL L25 1- RN : 27797 TERMS
L27 ( 27797)SEA ABB=ON L26
L28 ( 150742)SEA ABB=ON L9 OR L11 OR L14 OR L20 OR L22 OR L24 OR L27
L29 STR
L30 20417 SEA SUB=L28 SSS FUL L29
-----
L31 STR
L32 STR L31
L33 STR
L34 0 SEA SSS SAM (L31 OR L32 OR L33)
L35 0 SEA SUB=L30 SSS SAM (L31 OR L32 OR L33)

```

L36 4 SEA SUB=L30 SSS FUL (L31 OR L32 OR L33)
SAVE TEMP L36 SEA199SUB2/A
D STAT QUE
D LC 1-4

FILE 'REGISTRY' ENTERED AT 16:12:00 ON 06 JUN 2005
D STAT QUE L36

L37 FILE 'CAPLUS, USPATFULL, TOXCENTER' ENTERED AT 16:12:00 ON 06 JUN 2005
20 SEA ABB=ON L36
L38 16 DUP REM L37 (4 DUPLICATES REMOVED)
ANSWERS '1-14' FROM FILE CAPLUS
ANSWERS '15-16' FROM FILE USPATFULL
D IBIB ED ABS HITSTR 1-16

L39 FILE 'BEILSTEIN' ENTERED AT 16:12:24 ON 06 JUN 2005
2 SEA ABB=ON L36
D IDE ALLREF L39 1-2

L40 FILE 'CAOLD' ENTERED AT 16:13:00 ON 06 JUN 2005
2 SEA ABB=ON L36
D IALL HITSTR L40 1-2

FILE 'HOME' ENTERED AT 16:13:16 ON 06 JUN 2005

FILE 'CAOLD' ENTERED AT 16:13:29 ON 06 JUN 2005
D L40 PAGE 1
D L40 PAGE 2
D STAT QUE L36

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JUN 2005 HIGHEST RN 851662-51-6
DICTIONARY FILE UPDATES: 5 JUN 2005 HIGHEST RN 851662-51-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer

to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Jun 2005 VOL 142 ISS 24
FILE LAST UPDATED: 5 Jun 2005 (20050605/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 2 Jun 2005 (20050602/PD)
FILE LAST UPDATED: 2 Jun 2005 (20050602/ED)
HIGHEST GRANTED PATENT NUMBER: US6901606
HIGHEST APPLICATION PUBLICATION NUMBER: US2005120451
CA INDEXING IS CURRENT THROUGH 2 Jun 2005 (20050602/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 2 Jun 2005 (20050602/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2005

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE TOXCENTER

FILE COVERS 1907 TO 31 May 2005 (20050531/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TOXCENTER has been enhanced with new files segments and search fields. See HELP CONTENT for more information.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary. See <http://www.nlm.nih.gov/mesh/> and http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html for a description of changes.

FILE BEILSTEIN
FILE RELOADED ON OCTOBER 20, 2002
FILE LAST UPDATED ON APRIL 21, 2005

FILE COVERS 1771 TO 2004.

FILE CONTAINS 9,218,366 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For more detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *

NEW

- * PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.
- * NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

FILE CAOLD
FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=>

This Page Blank (uspto)